FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Joshi, SK Lee, L Lovett, DH Kang, H Kim, HT Delgado, C Liu, XH AF Joshi, Sunil K. Lee, Lawrence Lovett, David H. Kang, Heejae Kim, Hubert T. Delgado, Cynthia Liu, Xuhui TI Novel intracellular N-terminal truncated matrix metalloproteinase-2 isoform in skeletal muscle ischemia-reperfusion injury SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE matrix metalloproteinase-2; N-terminal truncated matrix metalloproteinase-2; skeletal muscle; hindlimb ischemia-reperfusion injury; hypoxia ID FOCAL CEREBRAL-ISCHEMIA; KAPPA-B INHIBITOR; TOLL-LIKE; PYRROLIDINE DITHIOCARBAMATE; ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; CARDIAC ISCHEMIA; MURINE HINDLIMB; UP-REGULATION; EXPRESSION AB Ischemia-reperfusion injury (IRI) occurs when blood returns to tissues following a period of ischemia. Reintroduction of blood flow results in the production of free radicals and reactive oxygen species that damage cells. Skeletal muscle IRI is commonly seen in orthopedic trauma patients. Experimental studies in other organ systems have elucidated the importance of extracellular and intracellular matrix metalloproteinase-2 (MMP-2) isoforms in regulating tissue damage in the setting of oxidant stress resulting from IRI. Although the extracellular full-length isoform of MMP-2 (FL-MMP-2) has been previously studied in the setting of skeletal muscle IRI, studies investigating the role of the N-terminal truncated isoform (NTT-MMP-2) in this setting are lacking. In this study, we first demonstrated significant increases in FL- and NTT-MMP-2 gene expression in C2C12 myoblast cells responding to re-oxygenation following hypoxia in vitro. We then evaluated the expression of FL- and NTT-MMP-2 in modulating skeletal muscle IRI using a previously validated murine model. NTT-MMP-2, but not FL-MMP-2 expression was significantly increased in skeletal muscle following IRI. Moreover, the expression of toll-like receptors (TLRs) -2 and -4, IL-6, OAS-1A, and CXCL1 was also significantly up-regulated following IRI. Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. This data suggests that NTT-MMP-2, but not FL-MMP-2, is the major isoform of MMP-2 involved in skeletal muscle IRI. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:502-509, 2016. C1 [Joshi, Sunil K.; Lee, Lawrence; Lovett, David H.; Kang, Heejae; Kim, Hubert T.; Delgado, Cynthia; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Joshi, Sunil K.; Lovett, David H.; Delgado, Cynthia] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kim, Hubert T.; Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. RP Liu, XH (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.; Liu, XH (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. EM Liux@orthosurg.ucsf.edu FU Veterans Affairs Rehabilitation Research and Development Merit Review [RX000195] FX Grant sponsor: Veterans Affairs Rehabilitation Research and Development Merit Review; Grant number: RX000195. NR 49 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2016 VL 34 IS 3 BP 502 EP 509 DI 10.1002/jor.22992 PG 8 WC Orthopedics SC Orthopedics GA DF5UT UT WOS:000371418700015 PM 26213293 ER PT J AU Burke, RE Whitfield, EA Hittle, D Min, SJ Levy, C Prochazka, AV Coleman, EA Schwartz, R Ginde, AA AF Burke, Robert E. Whitfield, Emily A. Hittle, David Min, Sung-joon Levy, Cari Prochazka, Allan V. Coleman, Eric A. Schwartz, Robert Ginde, Adit A. TI Hospital Readmission From Post-Acute Care Facilities: Risk Factors, Timing, and Outcomes SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Post-acute care; readmission; care transition ID SKILLED NURSING FACILITIES; PROSPECTIVE-PAYMENT SYSTEM; QUALITY-OF-CARE; POSTACUTE CARE; HOME RESIDENTS; OLDER-ADULTS; GEOGRAPHIC-VARIATION; FUNCTIONAL OUTCOMES; THERAPY INTENSITY; POSTHOSPITAL CARE AB Objectives: Hospital discharges to post-acute care (PAC) facilities have increased rapidly. This increase may lead to more hospital readmissions from PAC facilities, which are common and poorly understood. We sought to determine the risk factors and timing for hospital readmission from PAC facilities and evaluate the impact of readmission on patient outcomes. Design: Retrospective analysis of Medicare Current Beneficiary Survey (MCBS) from 2003-2009. Setting: The MCBS is a nationally representative survey of beneficiaries matched with claims data. Participants: Community-dwelling beneficiaries who were hospitalized and discharged to a PAC facility for rehabilitation. Intervention/Exposure: Potential readmission risk factors included patient demographics, health utilization, active medical conditions at time of PAC admission, and PAC characteristics. Measurements: Hospital readmission during the PAC stay, return to community residence, and all-cause mortality. Results: Of 3246 acute hospitalizations followed by PAC facility stays, 739 (22.8%) included at least 1 hospital readmission. The strongest risk factors for readmission included impaired functional status (HR 4.78, 95% CI 3.21-7.10), markers of increased acuity such as need for intravenous medications in PAC (1.63, 1.39-1.92), and for-profit PAC ownership (1.43, 1.21-1.69). Readmitted patients had a higher mortality rate at both 30 days (18.9% vs 8.6%, P <. 001) and 100 days (39.9% vs 14.5%, P <. 001) even after adjusting for age, comorbidities, and prior health care utilization (30 days: OR 2.01, 95% CI 1.60-2.54; 100 days: OR 3.79, 95% CI 3.13-4.59). Conclusions: Hospital readmission from PAC facilities is common and associated with a high mortality rate. Readmission risk factors may signify inadequate transitional care processes or a mismatch between patient needs and PAC resources. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine. C1 [Burke, Robert E.; Whitfield, Emily A.; Levy, Cari; Prochazka, Allan V.] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Hittle, David; Min, Sung-joon; Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Schwartz, Robert] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Hosp Med Sect, 1055 Clermont St, Denver, CO 80220 USA. EM Robert.Burke5@va.gov RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017 FU NIA NIH HHS [R03 AG050885] NR 58 TC 7 Z9 7 U1 7 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAR 1 PY 2016 VL 17 IS 3 BP 249 EP 255 DI 10.1016/j.jamda.2015.11.005 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DE9IK UT WOS:000370950000012 PM 26715357 ER PT J AU Zhao, K Craig, JR Cohen, NA Adappa, ND Khalili, S Palmer, JN AF Zhao, Kai Craig, John R. Cohen, Noam A. Adappa, Nithin D. Khalili, Sammy Palmer, James N. TI Sinus irrigations before and after surgeryVisualization through computational fluid dynamics simulations SO LARYNGOSCOPE LA English DT Article DE Nasal irrigation; computational fluid dynamics; modeling; sinus surgery; sinusitis; frontal; maxillary; sphenoid; head position ID NASAL AIR-FLOW; CHRONIC RHINOSINUSITIS; ODORANT TRANSPORT; PARANASAL SINUSES; HUMAN NOSE; OLFACTION; DELIVERY; SURGERY; PENETRATION; MODEL AB Objectives/HypothesisTopical sinus irrigations play a critical role in the management of sinonasal disease, and the improvement in irrigant penetration into the sinuses postoperatively greatly contributes to the success of endoscopic sinus surgery. Prior investigations on postoperative sinus irrigations have been mostly limited to cadaver studies, which are labor intensive and do not capture the full dynamics of the flows. A pilot study was conducted to investigate the impact of surgery on sinus irrigation through computational fluid dynamics (CFD) simulations. Study DesignRetrospective computational study. MethodsPre- and postoperative computed tomography (CT) scans were obtained on a patient who underwent standard endoscopic surgeries for all sinuses, including a Draf III frontal sinusotomy. CT-based pre- and postoperative CFD models then simulated irrigations of 120 mL saline per nostril at 12 mL/s (typical of Sinugator) and 60 mL/s (SinusRinse Bottle), in two head positions: face parallel and at a 45 degrees angle to the ground. ResultsOverall, surgery most significantly improved frontal sinus irrigation, but surprisingly resulted in less maxillary and ethmoid sinuses penetration. This may due to the partial removal of the septum during the Draf III, causing most fluid to exit prematurely across the resected septum. Higher flow rate slightly improved ethmoid sinus irrigation, but resulted in less preoperative contralateral maxillary sinus penetration. ConclusionsCFD modeling of sinonasal irrigations is a novel technique for evaluating irrigant penetration of individual sinus cavities. It may prove useful in determining the optimal degree of surgery or the ideal irrigation strategy to allow for maximal and targeted sinus irrigant penetration. C1 [Zhao, Kai] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA. [Craig, John R.; Cohen, Noam A.; Adappa, Nithin D.; Khalili, Sammy; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhao, K (reprint author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA.; Palmer, JN (reprint author), Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA. EM zhao.1949@osu.edu; james.palmer@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU NIH NIDCD [R01 DC013626] FX This work was supported by NIH NIDCD R01 DC013626 to K.Z. NR 24 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD MAR PY 2016 VL 126 IS 3 BP E90 EP E96 DI 10.1002/lary.25666 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA DF3KM UT WOS:000371242800001 PM 26467934 ER PT J AU Konadhode, RR Pelluru, D Shiromani, PJ AF Konadhode, Roda Rani Pelluru, Dheeraj Shiromani, Priyattam J. TI Unihemispheric Sleep: An Enigma for Current Models of Sleep-Wake Regulation SO SLEEP LA English DT Editorial Material ID SLOW-WAVE SLEEP; GABA RELEASE; MAMMALIAN SLEEP; LOCUS-COERULEUS; WAKING CYCLE; MCH NEURONS; REM-SLEEP; FUR SEALS; DISCHARGE; STATE C1 [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Behav Sci, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Shiromani, PJ (reprint author), Med Univ S Carolina, Dept Psychiat, Ralph H Johnson VA Med Ctr, 114 Doughty St, Charleston, SC 29425 USA. EM shiroman@musc.edu FU BLRD VA [I01 BX000798]; NINDS NIH HHS [NS084477, R01 NS052287, NS079940, NS052287] NR 50 TC 0 Z9 0 U1 12 U2 17 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 491 EP 494 AR PII sp-00020-16 DI 10.5665/sleep.5508 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800001 PM 26856898 ER PT J AU Fields, BG Behari, PP McCloskey, S True, G Richardson, D Thomasson, A Korom-Djakovic, D Davies, K Kuna, ST AF Fields, Barry G. Behari, Pratima Pathak McCloskey, Susan True, Gala Richardson, Diane Thomasson, Arwin Korom-Djakovic, Danijela Davies, Keith Kuna, Samuel T. TI Remote Ambulatory Management of Veterans with Obstructive Sleep Apnea SO SLEEP LA English DT Article DE obstructive sleep apnea; telemedicine; home sleep testing; auto-titrating positive airway pressure ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSIS; POLYSOMNOGRAPHY; TELEMEDICINE; TELEHEALTH; ADHERENCE; CARE; AUTOTITRATION; VALIDATION AB Study Objectives: Despite significant medical sequelae of obstructive sleep apnea (OSA), the condition remains undiagnosed and untreated in many affected individuals. We explored the feasibility of a comprehensive, telemedicine-based OSA management pathway in a community-based Veteran cohort. Methods: This prospective, parallel-group randomized pilot study assessed feasibility of a telemedicine-based pathway for OSA evaluation and management in comparison to a more traditional, in-person care model. The study included 60 Veterans at the Philadelphia Veterans Affairs Medical Center and two affiliated community-based outpatient clinics. Telemedicine pathway feasibility, acceptability, and outcomes were assessed through a variety of quantitative (Functional Outcomes of Sleep Questionnaire, dropout rates, positive airway pressure [PAP] adherence rates, participant satisfaction ratings) and qualitative (verbal feedback) metrics. Results: There was no significant difference in functional outcome changes, patient satisfaction, dropout rates, or objectively measured PAP adherence between groups after 3 months of treatment. Telemedicine participants showed greater improvement in mental health scores, and their feedback was overwhelmingly positive. Conclusions: Our pilot study suggests that telemedicine-based management of OSA patients is feasible in terms of patient functional outcomes and overall satisfaction with care. Future studies should include larger populations to further elucidate these findings while assessing provider-and patient-related cost effectiveness. C1 [Fields, Barry G.] Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA. [Fields, Barry G.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30030 USA. [Behari, Pratima Pathak; McCloskey, Susan; True, Gala; Richardson, Diane; Thomasson, Arwin; Korom-Djakovic, Danijela; Davies, Keith; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Thomasson, Arwin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Fields, BG (reprint author), Atlanta Vet Affairs Med Ctr, Sleep Med Ctr, 250 N Arcadia Ave, Decatur, GA 30030 USA. EM barry.fields@va.gov FU VISN 4 Competitive Pilot Project Fund FX This was not an industry supported study. Financial support was provided by VISN 4 Competitive Pilot Project Fund. The authors have indicated no financial conflicts of interest. NR 40 TC 5 Z9 5 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 501 EP 509 AR PII sp-00254-15 DI 10.5665/sleep.5514 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800004 PM 26446115 ER PT J AU Stone, KL Blackwell, TL Ancoli-Israel, S Barrett-Connor, E Bauer, DC Cauley, JA Ensrud, KE Hoffman, AR Mehra, R Stefanick, ML Varosy, PD Yaffe, K Redline, S AF Stone, Katie L. Blackwell, Terri L. Ancoli-Israel, Sonia Barrett-Connor, Elizabeth Bauer, Douglas C. Cauley, Jane A. Ensrud, Kristine E. Hoffman, Andrew R. Mehra, Reena Stefanick, Marcia L. Varosy, Paul D. Yaffe, Kristine Redline, Susan CA Osteoporotic Fractures Men MrOS St TI Sleep Disordered Breathing and Risk of Stroke in Older Community-Dwelling Men SO SLEEP LA English DT Article DE stroke; sleep disordered breathing; nocturnal hypoxemia ID OSTEOPOROTIC FRACTURES; INSULIN-RESISTANCE; ISCHEMIC-STROKE; APNEA; SCALE; DETERMINANTS; ASSOCIATION; UPDATE; HEALTH; MROS AB Study Objectives: Men with sleep disordered breathing (SDB) may be at increased stroke risk, due to nocturnal hypoxemia, sleep loss or fragmentation, or other mechanisms. We examined the association of SDB with risk of incident stroke in a large cohort of older men. Methods: Participants were 2,872 community-dwelling men (mean age 76 years) enrolled in the MrOS Sleep Study, which gathered data from 2003 to 2005 at six clinical sites in the Unites States. SDB predictors (obstructive apnea-hypopnea index, apnea-hypopnea index, central apnea index, and nocturnal hypoxemia) were measured using overnight polysomnography. Incident stroke over an average follow-up of 7.3 years was centrally adjudicated by physician review of medical records. Results: One hundred fifty-six men (5.4%) had a stroke during follow-up. After adjustment for age, clinic site, race, body mass index, and smoking status, older men with severe nocturnal hypoxemia (>= 10% of the night with SpO(2) levels below 90%) had a 1.8-fold increased risk of incident stroke compared to those without nocturnal hypoxemia (relative hazard = 1.83; 95% confidence interval 1.12-2.98; P trend = 0.02). Results were similar after further adjustment for other potential covariates and after excluding men with a history of stroke. Other indices of SDB were not associated with incident stroke. Conclusions: Older men with severe nocturnal hypoxemia are at significantly increased risk of incident stroke. Measures of overnight oxygen saturation may better identify older men at risk for stroke than measures of apnea frequency. C1 [Stone, Katie L.; Blackwell, Terri L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Stone, Katie L.; Blackwell, Terri L.] San Francisco Coordinating Ctr, San Francisco, CA 94158 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. [Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Hoffman, Andrew R.; Stefanick, Marcia L.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Palo Alto, CA 94304 USA. [Mehra, Reena] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Sleep Ctr,Neurol Inst, Cleveland, OH 44106 USA. [Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. RP Stone, KL (reprint author), San Francisco Coordinating Ctr, Res Inst, Calif Pacific Med Ctr, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA. EM kstone@sfcc-cpmc.net RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408; Mehra, Reena/0000-0002-6222-2675 FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; National Heart, Lung, and Blood Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839, R01 HL089467]; K 24 grant [AG031155]; ResMed, Inc; Philips Respironics; ResMed Foundation FX This was not an industry supported study. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The National Heart, Lung, and Blood Institute (NHLBI) provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr Yaffe received funding from K 24 grant AG031155. The measurement of inflammation markers was funded by the NHLBI, grant number R01 HL089467. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the decision to submit the manuscript for publication. Dr. Stone has consulted for Merck. Dr. Ancoli-Israel is a consultant for Merck and Purdue University. Dr. Redline's institution has received grant funding from ResMed, Inc, Philips Respironics, and ResMed Foundation and equipment from them for use in NIH studies. The other authors have indicated no financial conflicts of interest. Analysis was performed at California Pacific Medical Center, Research Institute. NR 29 TC 1 Z9 1 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 531 EP 540 AR PII sp-00349-15 DI 10.5665/sleep.5520 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800007 PM 26943468 ER PT J AU Lyamin, OI Lapierre, JL Kosenko, PO Kodama, T Bhagwandin, A Korneva, SM Peever, JH Mukhametov, LM Siegel, JM AF Lyamin, Oleg I. Lapierre, Jennifer L. Kosenko, Peter O. Kodama, Tohru Bhagwandin, Adhil Korneva, Svetlana M. Peever, John H. Mukhametov, Lev M. Siegel, Jerome M. TI Monoamine Release during Unihemispheric Sleep and Unihemispheric Waking in the Fur Seal SO SLEEP LA English DT Article DE unihemispheric sleep; norepinephrine; histamine; serotonin; acetylcholine; fur seal; marine mammals ID SLOW-WAVE SLEEP; BASAL FOREBRAIN NEURONS; SEROTONERGIC NEURONS; WAKE CYCLE; ACETYLCHOLINE-RELEASE; NUCLEUS BASALIS; WAKEFULNESS; HYPOCRETIN; HISTAMINE; CATAPLEXY AB Study Objectives: Our understanding of the role of neurotransmitters in the control of the electroencephalogram (EEG) has been entirely based on studies of animals with bilateral sleep. The study of animals with unihemispheric sleep presents the opportunity of separating the neurochemical substrates of waking and sleep EEG from the systemic, bilateral correlates of sleep and waking states. Methods: The release of histamine (HI), norepinephrine (NE), and serotonin (5HT) in cortical and subcortical areas (hypothalamus, thalamus and caudate nucleus) was measured in unrestrained northern fur seals (Callorhinus ursinus) using in vivo microdialysis, in combination with, polygraphic recording of EEG, electrooculogram, and neck electromyogram. Results: The pattern of cortical and subcortical HI, NE, and 5HT release in fur seals is similar during bilaterally symmetrical states: highest in active waking, reduced in quiet waking and bilateral slow wave sleep, and lowest in rapid eye movement (REM) sleep. Cortical and subcortical HI, NE, and 5HT release in seals is highly elevated during certain waking stimuli and behaviors, such as being sprayed with water and feeding. However, in contrast to acetylcholine (ACh), which we have previously studied, the release of HI, NE, and 5HT during unihemispheric sleep is not lateralized in the fur seal. Conclusions: Among the studied neurotransmitters most strongly implicated in waking control, only ACh release is asymmetric in unihemispheric sleep and waking, being greatly increased on the activated side of the brain. C1 [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Lyamin, Oleg I.; Mukhametov, Lev M.] RAS, Severtsov Inst Ecol & Evolut, Moscow 117901, Russia. [Lyamin, Oleg I.; Kosenko, Peter O.; Korneva, Svetlana M.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow, Russia. [Lapierre, Jennifer L.; Peever, John H.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada. [Kosenko, Peter O.] Southern Fed Univ, Rostov Na Donu, Russia. [Kodama, Tohru] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Tokyo 113, Japan. [Bhagwandin, Adhil] Univ Witwatersrand, Fac Hlth Sci, Sch Anat Sci, Johannesburg, South Africa. RP Siegel, JM (reprint author), Univ Calif Los Angeles, VA GLAHS Sepulveda, Neurobiol Res 151A3, 16111 Plummer St North Hills, Los Angeles, CA 91343 USA. EM jsiegel@ucla.edu FU National Science Foundation [0919929]; National Institute of Health [MH064109, DA034748]; Russian Fund for Basic Research [13-04-01704, 14-04-32075]; Medical Research Service of the Dept. of Veterans Affairs; Utrish Dolphinarium Ltd.; National Science and Engineering Council of Canada; Canadian Institutes of Health Research FX This was not an industry supported study. This study was supported by grants from National Science Foundation (0919929), National Institute of Health MH064109, DA034748, Russian Fund for Basic Research (13-04-01704, 14-04-32075), Medical Research Service of the Dept. of Veterans Affairs, Utrish Dolphinarium Ltd., National Science and Engineering Council of Canada, and Canadian Institutes of Health Research. The authors have indicated no financial conflicts of interest. This study was performed at the University of California Los Angeles, Los Angeles, USA and Severtsov Institute of Ecology and Evolution, Moscow, Russia. NR 39 TC 2 Z9 2 U1 7 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 625 EP 636 AR PII sp-00454-15 DI 10.5665/sleep.5540 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800017 PM 26715233 ER PT J AU Chiao, E Stier, EA AF Chiao, Elizabeth Stier, Elizabeth A. TI Prevalence of anal human papillomavirus infection and anal human papillomavirus-related disorders in women: a systematic review REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Chiao, Elizabeth] Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Stier, Elizabeth A.] Boston Med Ctr, Dept Obstet & Gynecol, Boston, MA USA. RP Chiao, E (reprint author), Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. EM echiao@bcm.edu NR 3 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAR PY 2016 VL 214 IS 3 BP 411 EP 412 DI 10.1016/j.ajog.2015.10.917 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DF0JC UT WOS:000371024100049 PM 26522860 ER PT J AU Luo, SX Huang, EJ AF Luo, Sarah X. Huang, Eric J. TI Dopaminergic Neurons and Brain Reward Pathways From Neurogenesis to Circuit Assembly SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Review ID ENTERIC NERVOUS-SYSTEM; TGF-BETA SUPERFAMILY; EMBRYONIC STEM-CELLS; GROWTH-FACTOR-BETA; SURVIVAL IN-VIVO; SONIC-HEDGEHOG; VENTRAL MIDBRAIN; BASAL GANGLIA; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA AB Midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta and ventral tegmental area regulate extrapyramidal movement and important cognitive functions, including motivation, reward associations, and habit learning. Dysfunctions in DA neuron circuitry have been implicated in several neuropsychiatric disorders, including addiction and schizophrenia, whereas selective degeneration of DA neurons in substantia nigra pars compacta is a key neuropathological feature in Parkinson disease. Efforts to understand these disorders have focused on dissecting the underlying causes, as well as developing therapeutic strategies to replenish dopamine deficiency. In particular, the promise of cell replacement therapies for clinical intervention has led to extensive research in the identification of mechanisms involved in DA neuron development. It is hoped that a comprehensive understanding of these mechanisms will Lead to therapeutic strategies that improve the efficiency of DA neuron production, engraftment, and function. This review provides a comprehensive discussion on how Wnta-catenin and sonic hedgehog Smoothened signaling mechanisms control the specification and expansion of DA progenitors and the differentiation of DA neurons. We also discuss how mechanisms involving transforming growth factor-beta and transcriptional cofactor homeodomain interacting protein kinase 2 regulate the survival and maturation of DA neurons in early postnatal life. These results not only reveal fundamental mechanisms regulating DA neuron development, but also provide important insights to their potential contributions to neuropsychiatric and neurodegenerative diseases. C1 [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA. [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA USA. RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM eric.huang2@ucsf.edu OI Huang, Eric/0000-0002-5381-3801 FU NIH [OD010927, OD011915]; Department of Veterans Affairs [BX001108, BX001625]; Singapore Agency for Science, Technology, and Research (A*STAR) Scholar Program; University of California San Francisco Graduate Education in Medical Sciences (GEMS) Scholar Award FX Supported by NIH grants OD010927 and OD011915; the Department of Veterans Affairs grants BX001108 and BX001625 (E.J.H.); the Singapore Agency for Science, Technology, and Research (A*STAR) Scholar Program (S.X.L.); and the University of California San Francisco Graduate Education in Medical Sciences (GEMS) Scholar Award (S.X.L.). NR 100 TC 9 Z9 9 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2016 VL 186 IS 3 BP 478 EP 488 DI 10.1016/j.ajpath.2015.09.023 PG 11 WC Pathology SC Pathology GA DE9WY UT WOS:000370991800003 PM 26724386 ER PT J AU Cholerton, B Larson, EB Quinn, JF Zabetian, CP Mata, IF Keene, CD Flanagan, M Crane, PK Grabowski, TJ Montine, KS Montine, TJ AF Cholerton, Brenna Larson, Eric B. Quinn, Joseph F. Zabetian, Cyrus P. Mata, Ignacio F. Keene, C. Dirk Flanagan, Margaret Crane, Paul K. Grabowski, Thomas J. Montine, Kathleen S. Montine, Thomas J. TI Precision Medicine Clarity for the Complexity of Dementia SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Review ID ALZHEIMERS ASSOCIATION GUIDELINES; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID TAU; PARKINSONS-DISEASE; NATIONAL INSTITUTE; NEUROPATHOLOGIC ASSESSMENT; COHORT; BRAIN; BETA; RECOMMENDATIONS AB Three key elements to precision medicine are stratification by risk, detection of pathophysiological processes as early as possible (even before clinical presentation), and alignment of mechanism of action of intervention(s) with an individual's molecular driver(s) of disease. Used for decades in the management of some rare diseases and now gaining broad currency in cancer care, a precision medicine approach is beginning to be adapted to cognitive impairment and dementia. This review focuses on the application of precision medicine to address the clinical and biological complexity of two common neurodegenerative causes of dementia: Alzheimer disease and Parkinson disease. C1 [Cholerton, Brenna] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Mata, Ignacio F.; Grabowski, Thomas J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Keene, C. Dirk; Flanagan, Margaret; Montine, Kathleen S.; Montine, Thomas J.] Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Grabowski, Thomas J.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Zabetian, Cyrus P.; Mata, Ignacio F.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA. EM tmontine@uw.edu RI Keene, Christopher/N-1806-2015 FU NIH [P50 AG005136, P50 NS062684, R01 AG042437, R01 NS065070, U01 AG006781]; Office of Research and Development Medical Research Service, Department of Veterans Affairs; Nancy and Buster Alvord Endowment FX Supported by NIH grants P50 AG005136 (T.J.M., C.D.K., T.J.G.), P50 NS062684 (T.J.M., C.P.Z., J.F.Q., T.J.G.), R01 AG042437 (P.K.C.), R01 NS065070 (C.P.Z.), and U01 AG006781 (E.B.L.); the Office of Research and Development Medical Research Service, Department of Veterans Affairs (C.P.Z., J.F.Q.); and the Nancy and Buster Alvord Endowment (T.J.M.). NR 56 TC 7 Z9 7 U1 4 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2016 VL 186 IS 3 BP 500 EP 506 DI 10.1016/j.ajpath.2015.12.001 PG 7 WC Pathology SC Pathology GA DE9WY UT WOS:000370991800005 PM 26724389 ER PT J AU Benfield, J Maknojia, A Epstein, F AF Benfield, Jon Maknojia, Asif Epstein, Franklin TI Progressive Paraplegia from Spinal Cord Stimulator Lead Fibrotic Encapsulation A Case Report SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Epidural Electrode; Dorsal Myelopathy; Epidural Scar Tissue; Paraplegia; Spinal Cord Stimulator ID REGIONAL PAIN SYNDROME; MYELOPATHY SECONDARY; SCAR TISSUE; FOLLOW-UP; ELECTRODE; COMPLICATIONS; EXPERIENCE; HARDWARE; SURGERY AB Ten years after placement of a spinal cord stimulator (SCS) and resolution of pain, this patient presented with progressive paraplegia, worsening thoracic radicular pain at the same dermatome level of the electrodes, and bowel and bladder incontinence. Computed tomographic myelogram confirmed thoracic spinal cord central canal stenosis at the level of electrodes. After removal of the fibrotic tissue and electrodes, the patient had resolution of his thoracic radicular pain and a return of his pre-SCS pain and minimal neurologic and functional return. To the authors' knowledge, no studies have been identified with thoracic SCS lead fibrosis in the United States causing permanent paraplegia. Only one other case has been reported in Madrid, Spain. Patients with SCS presenting with loss of pain relief, new-onset radicular or neuropathic pain in same dermatome(s) as SCS electrodes, worsening neuromuscular examination, or new bladder or bowel incontinence need to be evaluated for complications regarding SCS implantation causing spinal stenosis and subsequent cord compression to avoid permanent neurologic deficits. C1 [Benfield, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. [Maknojia, Asif] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. [Epstein, Franklin] Audie L Murphy Vet Affairs Hosp, Dept Surg, San Antonio, TX USA. RP Benfield, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. NR 21 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2016 VL 95 IS 3 BP E30 EP E33 DI 10.1097/PHM.0000000000000411 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DE9LJ UT WOS:000370958700001 PM 26495817 ER PT J AU Krenek, M Lyons, R Simpson, TL AF Krenek, Marketa Lyons, Robert Simpson, Tracy L. TI Degree of correspondence between daily monitoring and retrospective recall of alcohol use among men and women with comorbid AUD and PTSD SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID TIMELINE FOLLOW-BACK; ECOLOGICAL MOMENTARY ASSESSMENT; POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; VOICE RESPONSE IVR; DRINKING PATTERNS; CONSUMPTION; RELIABILITY; TECHNOLOGY; INSTRUMENT AB Background and ObjectivesThe majority of studies that have identified good correspondence between daily monitoring and retrospective recall of alcohol use have included participants who are relatively stable, are moderate drinkers, report abstinence, and are not diagnosed with comorbid disorders. The current study examined degree of correspondence between alcohol use that was reported daily via interactive voice response (IVR) telephone monitoring and retrospectively using an abbreviated Form-90 (Form-35) covering the same 35-day time period. MethodsParticipants were 54 men and women with comorbid alcohol dependence and posttraumatic stress disorder (PTSD) who reported drinking during the time period. ResultsResults indicated that participants reported more drinking days via IVR. Correspondence was strong between the reporting methods for aggregate-level alcohol use variables, including presence/absence of drinking days and heavy drinking days and standard drinks, and associations increased for weeks closer to the assessment date for drinking days and heavy drinking days. Day-to-day agreement was moderate for drinking days and heavy drinking days, though there was large between-person variability in correspondence between reporting methods. Post-hoc analyzes suggested that men and participants who drink more tend to have lower correspondence between assessment methods. Discussion and ConclusionsOverall, findings partially replicated previous research and extend our knowledge of alcohol assessment in a comorbid sample. Scientific SignificanceFindings highlight the importance of considering the influence that moderating variables have on reporting of alcohol use. (Am J Addict 2016;25:145-151) C1 [Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. [Lyons, Robert] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Krenek, M (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM marketa.krenek@va.gov FU National Institute on Alcohol Abuse and Alcoholism [1 R21 AA 17130-01]; Department of Defense CDMRP [11152009, W81XWH-BAA-11-1]; NIH/NIAAA [R01 AA 020252-01] FX This work was supported, in part by a grant from the National Institute on Alcohol Abuse and Alcoholism (1 R21 AA 17130-01) awarded to Tracy L. Simpson, PhD and Department of Defense CDMRP grant (11152009, W81XWH-BAA-11-1).; This work also supported in part by a grant from NIH/NIAAA (R01 AA 020252-01). NR 31 TC 1 Z9 1 U1 5 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD MAR PY 2016 VL 25 IS 2 BP 145 EP 151 DI 10.1111/ajad.12342 PG 7 WC Substance Abuse SC Substance Abuse GA DF3IV UT WOS:000371238400011 PM 26824635 ER PT J AU Bamman, MM Wick, TM Carmona-Moran, CA Bridges, SL AF Bamman, Marcas M. Wick, Timothy M. Carmona-Moran, Carlos A. Bridges, S. Louis, Jr. TI Exercise Medicine for Osteoarthritis: Research Strategies to Maximize Effectiveness SO ARTHRITIS CARE & RESEARCH LA English DT Review ID TRANSDERMAL DRUG-DELIVERY; TOTAL HIP-ARTHROPLASTY; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; CLUSTER-ANALYSIS; OLDER-ADULTS; INFLAMMATION; HEALTH; TRIAL; METAANALYSIS C1 [Bamman, Marcas M.] Univ Alabama Birmingham, Ctr Exercise Med & Comprehens Arthrit, Musculoskeletal Bone & Autoimmun Ctr, Birmingham, AL 35294 USA. [Bamman, Marcas M.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Ctr Exercise Med, BioMatrix Engn & Regenerat Med Ctr, Birmingham, AL 35294 USA. [Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Comprehens Arthrit Musculoskeletal Bone & Autoimm, Birmingham, AL 35294 USA. [Carmona-Moran, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Bamman, MM (reprint author), Univ Alabama Birmingham, 966 McCallum Bldg,1720 Second Ave South, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU NIH [RO1-HD-084124] FX Drs. Bamman and Bridges' work was supported by the NIH (grant RO1-HD-084124). NR 42 TC 0 Z9 0 U1 3 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2016 VL 68 IS 3 BP 288 EP 291 DI 10.1002/acr.22680 PG 4 WC Rheumatology SC Rheumatology GA DF0VG UT WOS:000371056700002 PM 26239196 ER PT J AU Barrera, TL Szafranski, DD Ratcliff, CG Garnaat, SL Norton, PJ AF Barrera, Terri L. Szafranski, Derek D. Ratcliff, Chelsea G. Garnaat, Sarah L. Norton, Peter J. TI An Experimental Comparison of Techniques: Cognitive Defusion, Cognitive Restructuring, and in-vivo Exposure for Social Anxiety SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY LA English DT Article DE Cognitive defusion; cognitive restructuring; exposure; social anxiety disorder ID THOUGHTS; THERAPY AB Background: One of the primary differences between Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) for anxiety is the approach to managing negative thoughts. CBT focuses on challenging the accuracy of dysfunctional thoughts through cognitive restructuring exercises, whereas ACT attempts to foster acceptance of such thoughts through cognitive defusion exercises. Previous research suggests that both techniques reduce the distress associated with negative thoughts, though questions remain regarding the benefit of these techniques above and beyond exposure to feared stimuli. Aims: In the present study, we conducted a brief experimental intervention to examine the utility of cognitive defusion + in-vivo exposure, cognitive restructuring + in-vivo exposure, and in-vivo exposure alone in reducing the impact of negative thoughts in patients with social anxiety disorder. Method: All participants completed a brief public speaking exposure and those in the cognitive conditions received training in the assigned cognitive technique. Participants returned a week later to complete a second exposure task and self-report measures. Results: All three conditions resulted in similar decreases in discomfort related to negative thoughts. ANOVA models failed to find an interaction between change in accuracy or importance and assignment to condition in predicting decreased distress of negative thoughts. Conclusions: These preliminary results suggest that changes in perceived importance and accuracy of negative thoughts may not be the mechanisms by which cognitive defusion and cognitive restructuring affect distress in the short-term. C1 [Barrera, Terri L.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Barrera, Terri L.] South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Szafranski, Derek D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Ratcliff, Chelsea G.] Univ Houston, Houston, TX 77004 USA. [Garnaat, Sarah L.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Norton, Peter J.] Monash Univ, Clayton, Vic 3800, Australia. RP Barrera, TL (reprint author), VA HSR&D Houston Ctr Excellence MEDVAMC 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM terrib@bcm.edu FU University of Houston; Department of Veterans Affairs South Central Mental Illness Research Education and Clinical Center (MIRECC); Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This research was supported by an internal grant from the University of Houston. The research was supported in part by the Department of Veterans Affairs South Central Mental Illness Research Education and Clinical Center (MIRECC), and the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US Government. Conflict of Interest Statement: The authors declare they have no conflicts of interest to report. NR 6 TC 0 Z9 0 U1 8 U2 19 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1352-4658 EI 1469-1833 J9 BEHAV COGN PSYCHOTH JI Behav. Cognit. Psychther. PD MAR PY 2016 VL 44 IS 2 BP 249 EP 254 DI 10.1017/S1352465814000630 PG 6 WC Psychology, Clinical SC Psychology GA DE8AA UT WOS:000370857000011 PM 25683574 ER PT J AU Singh, JA Shah, N Edwards, NL AF Singh, Jasvinder A. Shah, Nipam Edwards, N. Lawrence TI A cross-sectional internet-based patient survey of the management strategies for gout SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Gout; Cherry extract; Cherry juice; Complementary medicine; Allopurinol; Febuxostat; Internet study; Survey; Natural supplements; Diet modification ID QUALITY-OF-LIFE; PURINE-RICH FOODS; MEDICAL CONDITIONS; RISK-FACTORS; CARE; HEALTH; ADHERENCE; MEN; HYPERURICEMIA; BARRIERS AB Background: Almost half of the patients with gout are not prescribed urate-lowering therapy (ULT) by their health care provider and > 50 % use complementary and alternative therapies. Diet modification is popular among gout patients due to known associations of certain foods with gout flares. The interplay of the use of dietary supplements, diet modification, and ULT adherence in gout patients is not known. Despite the recent interest in diet and supplements, there are limited data on their use. Our objective was to assess ULT use and adherence and patient preference for non-pharmacological interventions by patients with gout, using a cross-sectional survey. Methods: People who self-reported physician-diagnosed gout during their visit to a gout website (http://gouteducation.org) were invited to participate in a brief anonymous cross-sectional Internet survey between 08/11/2014 to 04/14/2015 about the management of their gout. The survey queried ULT prescription, ULT adherence, the use of non-pharmacological interventions (cherry extract, diet modification) and the likelihood of making a lifelong diet modification for gout management. Results: A total of 499 respondents with a mean age 56.3 years were included; 74 % were males and 74 % were White. Of these, 57 % (285/499) participants were prescribed a ULT for gout, of whom 88 % (251/285) were currently taking ULT. Of those using ULT, 78 % (97/251) reported ULT adherence > 80 %. Gender, race, and age were not significantly associated with the likelihood of receiving a ULT prescription or ULT adherence > 80 %. Fifty-six percent of patients with gout preferred ULT as a lifelong treatment for gout, 24 % preferred cherry extract and 16 % preferred diet modification (4 % preferred none). Men had significantly lower odds of preferring ULT as the lifelong treatment choice for gout vs. other choices (p = 0.03). We found that 38.3 % participants were highly motivated to make a lifelong dietary modification to improve their gout (score of 9-10 on a 0-10 likelihood scale). Older age was significantly associated with high level of willingness to modify diet (p = 0.02). Conclusion: We found that only 57 % of gout patients reported being prescribed ULT. 40 % of gout patients preferred non-pharmacological interventions such as cherry extract and diet modification for gout management. The latter finding requires further investigation. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. NR 37 TC 0 Z9 0 U1 5 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD MAR 1 PY 2016 VL 16 AR 90 DI 10.1186/s12906-016-1067-3 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DF1RO UT WOS:000371117100002 PM 26931313 ER PT J AU Mor, V Joyce, NR Cote, DL Gidwani, RA Ersek, M Levy, CR Faricy-Anderson, KE Miller, SC Wagner, TH Kinosian, BP Lorenz, KA Shreve, ST AF Mor, Vincent Joyce, Nina R. Cote, Danielle L. Gidwani, Risha A. Ersek, Mary Levy, Cari R. Faricy-Anderson, Katherine E. Miller, Susan C. Wagner, Todd H. Kinosian, Bruce P. Lorenz, Karl A. Shreve, Scott T. TI The rise of concurrent care for veterans with advanced cancer at the end of life SO CANCER LA English DT Article DE end-of-life care; hospices; neoplasms; palliative care; veterans ID HOSPICE ELIGIBILITY CRITERIA; PALLIATIVE CARE; MEDICARE; QUALITY; COSTS; ASSOCIATION; OUTCOMES; BENEFIT AB BACKGROUNDUnlike Medicare, the Veterans Health Administration (VA) health care system does not require veterans with cancer to make the terrible choice between receipt of hospice services or disease-modifying chemotherapy/radiation therapy. For this report, the authors characterized the VA's provision of concurrent care, defined as days in the last 6 months of life during which veterans simultaneously received hospice services and chemotherapy or radiation therapy. METHODSThis retrospective cohort study included veteran decedents with cancer during 2006 through 2012 who were identified from claims with cancer diagnoses. Hospice and cancer treatment were identified using VA and Medicare administrative data. Descriptive statistics were used to characterize the changes in concurrent care, hospice, palliative care, and chemotherapy or radiation treatment. RESULTSThe proportion of veterans receiving chemotherapy or radiation therapy remained stable at approximately 45%, whereas the proportion of veterans who received hospice increased from 55% to 68%. The receipt of concurrent care also increased during this time from 16.2% to 24.5%. The median time between hospice initiation and death remained stable at around 21 days. Among veterans who received chemotherapy or radiation therapy in their last 6 months of life, the median time between treatment termination and death ranged from 35 to 40 days. There was considerable variation between VA medical centers in the use of concurrent care (interquartile range, 16%-34% in 2012). CONCLUSIONSConcurrent receipt of hospice and chemotherapy or radiation therapy increased among veterans dying from cancer without reductions in the receipt of cancer therapy. This approach reflects the expansion of hospice services in the VA with VA policy allowing the concurrent receipt of hospice and antineoplastic therapies. (c) 2015 American Cancer Society. C1 [Mor, Vincent; Joyce, Nina R.; Cote, Danielle L.; Faricy-Anderson, Katherine E.; Miller, Susan C.] Providence Vet Hlth Adm VA Med Ctr, Ctr Innovat, Providence, RI USA. [Mor, Vincent; Miller, Susan C.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Joyce, Nina R.] Harvard Univ, Sch Med, Dept Hlth Policy, Boston, MA USA. [Gidwani, Risha A.; Wagner, Todd H.] VA Palo Alto Healthcare Syst, VA Hlth Econ Resource Ctr, Palo Alto, CA USA. [Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] VA Palo Alto Healthcare Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Ersek, Mary; Kinosian, Bruce P.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA. [Ersek, Mary] US Dept Vet Affairs, Natl Performance Reporting & Outcomes Measurement, Washington, DC USA. [Levy, Cari R.] Eastern Colorado VA Healthcare Syst, Denver, CO USA. [Faricy-Anderson, Katherine E.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Kinosian, Bruce P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Shreve, Scott T.] US Dept Vet Affairs, Hosp & Palliat Care Program, Washington, DC USA. [Shreve, Scott T.] Penn State Coll Med, Hershey, PA USA. RP Mor, V (reprint author), 121 South Main St,Box G-121-6, Providence, RI 02912 USA. EM vincent_mor@brown.edu FU US Department of Veterans Affairs [IIR 12-121]; Merit Review Award from Health Services Research and Development Service FX This work was supported by a Merit Review Award (IIR 12-121) from the Health Services Research and Development Service, US Department of Veterans Affairs. NR 21 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAR 1 PY 2016 VL 122 IS 5 BP 782 EP 790 DI 10.1002/cncr.29827 PG 9 WC Oncology SC Oncology GA DF2IP UT WOS:000371166300019 PM 26670795 ER PT J AU Rogal, SS Yan, P Rimland, D Lo Re, V Al-Rowais, H Fried, L Butt, AA AF Rogal, Shari S. Yan, Peng Rimland, David Lo Re, Vincent, III Al-Rowais, Hind Fried, Linda Butt, Adeel A. CA Erchives Elect Retrieved Cohort TI Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE CKD; HCV; Progressive CKD ID VIRUS-INFECTION; RENAL-DISEASE; UNITED-STATES; ASSOCIATION; VETERANS; RISK; FIBROSIS; SURVIVAL; THERAPY; COHORT AB We aimed to assess the incidence and progression of chronic kidney disease (CKD) following hepatitis C virus (HCV) seroconversion. This retrospective cohort study included Veterans with a confirmed HCV seroconversion between 2001 and 2014 and Veterans with negative HCV testing over the same time period. The outcomes included development of advanced CKD (eGFR < 60 mL/min/1.73 m(2) on two separate occasions at least 90 days apart, plus a a parts per thousand yen10 mL/min/1.73 m(2) decline from baseline) and progressive CKD (decline in eGFR of a parts per thousand yen30 mL/min/1.73 m(2) from baseline). Multivariable Cox proportional hazards models were used to evaluate the association between HCV and incident advanced and progressive CKD. The final cohort consisted of 71,528 Veterans, including 2589 with recently seroconverted HCV. Over a mean follow-up of 6 years, 36 % of patients with and 31 % without HCV developed advanced CKD (p < 0.001), and 35 % of patients with vs. 26 % without HCV developed progressive CKD (p < 0.001). After controlling for traditional risk factors, recently seroconverted HCV+ patients were significantly less likely to develop advanced CKD (HR 0.86; 95 % CI 0.79, 0.92), and HCV status was not significantly associated with progressive CKD (HR 0.93; 95 % CI 0.86, 1.00). Factors associated with developing advanced and progressive CKD included older age, female sex, diabetes, hypertension, development of cirrhosis, and substance abuse. In this cohort of newly infected US Veterans, HCV infection was associated with decreased incidence of advanced and unchanged risk of progressive CKD, suggesting a larger role for traditional risk factors in the development of CKD after HCV seroconversion. C1 [Rogal, Shari S.; Yan, Peng; Fried, Linda; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Rogal, Shari S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Al-Rowais, Hind] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. [Fried, Linda; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. RP Rogal, SS (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.; Rogal, SS (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. EM rogalss@upmc.edu FU Gilead Sciences; AbbVie FX Dr. Butt reports grants (to the institution) from Gilead Sciences and AbbVie. Dr. Rogal reports a grant (to the institution) from Gilead Sciences. The other authors report no conflict of interest related to the submitted work. NR 33 TC 1 Z9 1 U1 49 U2 49 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2016 VL 61 IS 3 BP 930 EP 936 DI 10.1007/s10620-015-3918-z PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE9KT UT WOS:000370957000035 PM 26526451 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Impaired Visual Acuity in Older Adults US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID INTRAOCULAR-LENS IMPLANTATION; RANDOMIZED CONTROLLED-TRIAL; EYE CATARACT-SURGERY; MACULAR DEGENERATION; UNITED-STATES; CONTRAST SENSITIVITY; HEALTH-STATUS; PEOPLE; FALLS; RISK AB DESCRIPTION Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults. METHODS The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration. POPULATION This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems. RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM chair@uspstf.net OI Phillips, William/0000-0003-2802-4349 FU Agency for Healthcare Research and Quality (AHRQ) FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 31 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 1 PY 2016 VL 315 IS 9 BP 908 EP 914 DI 10.1001/jama.2016.0763 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DF1DB UT WOS:000371077500021 ER PT J AU Barnett, ML Mehrotra, A Frolkis, JP Spinks, M Steiger, C Hehir, B Greenberg, JO Singh, H AF Barnett, Michael L. Mehrotra, Ateev Frolkis, Joseph P. Spinks, Melissa Steiger, Casey Hehir, Brandon Greenberg, Jeffrey O. Singh, Hardeep TI Implementation Science Workshop: Implementation of an Electronic Referral System in a Large Academic Medical Center SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE health information technology; program evaluation; primary care; implementation science ID HEALTH-CARE; FOLLOW-UP; GENERAL-PRACTITIONERS; PATIENT-SAFETY; SPECIALTY CARE; UNITED-STATES; COMMUNICATION; MODEL; RECORDS; NEIGHBORHOOD C1 [Barnett, Michael L.; Frolkis, Joseph P.; Greenberg, Jeffrey O.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. [Steiger, Casey; Hehir, Brandon; Greenberg, Jeffrey O.] Brigham & Womens Phys Org, Boston, MA USA. [Spinks, Melissa] Par8o Inc, Newton, MA USA. [Barnett, Michael L.; Mehrotra, Ateev] Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA. [Singh, Hardeep] Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA. RP Barnett, ML (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA. EM mlb748@mail.harvard.edu FU AHRQ HHS [R01 HS022087, R01HS022087]; PHS HHS [T32-HP10251] NR 53 TC 0 Z9 0 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2016 VL 31 IS 3 BP 343 EP 352 DI 10.1007/s11606-015-3516-y PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DF2HE UT WOS:000371162400023 PM 26556594 ER PT J AU Newell, J Yesavage, JA Taylor, JL Kraemer, HC Munro, CA Friedman, L Rosenberg, PB Madore, M Chao, SZ Devanand, DP Drye, LT Mintzer, JE Pollock, BG Porsteinsson, AP Schneider, LS Shade, DM Weintraub, D Lyketsos, CG Noda, A AF Newell, Jeffery Yesavage, Jerome A. Taylor, Joy L. Kraemer, Helena C. Munro, Cynthia A. Friedman, Leah Rosenberg, Paul B. Madore, Michelle Chao, Steven Z. Devanand, D. P. Drye, Lea T. Mintzer, Jacobo E. Pollock, Bruce G. Porsteinsson, Anton P. Schneider, Lon S. Shade, David M. Weintraub, Daniel Lyketsos, Constantine G. Noda, Art CA CitAD Res Grp TI Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Agitation; Sedation; Citalopram ID DEMENTIA; AGGRESSION; CLINICIAN; TRIAL AB Background: We found a benefit of citalopram for agitation in the Citalopram for Agitation in Alzheimer's Disease study (CitAD), and wondered if this was mediated by a sedative effect. CitAD was a randomized, placebo-controlled, double-blind, parallel group trial conducted at 8 academic centers in the United States and Canada from August 2009 to January 2013. One hundred sixty-two participants with probable Alzheimer's disease (AD) and clinically significant agitation were analyzed in this study. Participants received a psychosocial intervention and were randomized to receive either citalopram or placebo (approximately half assigned to each group). Participants were rated on the Neurobehavioral Rating Scale Agitation subscale and measures of sedation (i.e., fatigue and somnolence). Methods: Using the MacArthur Foundation procedures for documenting a mediator effect, we performed a secondary analysis examining whether sedation mediates the effect of treatment on agitation outcome. Results: We found a statistically significant mediating effect of sedation on agitation outcomes, but the magnitude of the effect was small, only explaining 11% of the variance in agitation, with a significant, but modest effect size of 0.16 (95% CI: 0.08 to 0.22). Conclusions: The benefit of citalopram was partly due to sedation but largely due to other mechanisms of action. Published by Elsevier Ltd. C1 [Newell, Jeffery] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. [Yesavage, Jerome A.; Taylor, Joy L.; Madore, Michelle; Chao, Steven Z.] Dept Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA. [Yesavage, Jerome A.; Taylor, Joy L.; Kraemer, Helena C.; Friedman, Leah; Madore, Michelle; Noda, Art] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Yesavage, Jerome A.; Chao, Steven Z.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Sch Med, Baltimore, MD 21205 USA. [Devanand, D. P.] New York State Psychiat Inst & Hosp, Div Geriatr Psychiat, New York, NY 10032 USA. [Devanand, D. P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Drye, Lea T.; Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Mintzer, Jacobo E.] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC 29401 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Pollock, Bruce G.] Univ Toronto, CAMH, Campbell Inst, Toronto, ON M5S 2S1, Canada. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Dept Vet Affairs, Philadelphia, PA 19104 USA. RP Yesavage, JA (reprint author), Palo Alto VA Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA. EM yesavage@stanford.edu FU NIA and NIMH [R01AG031348]; NIH [AG05142, P50]; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); Medical Research Service of Department of Veterans Affairs FX This work was supported by NIA and NIMH, R01AG031348 and in part by NIH P50, AG05142 (USC, LSS). and by the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and the Medical Research Service of the Department of Veterans Affairs. The funding sources had a role in in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. NR 15 TC 2 Z9 2 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD MAR PY 2016 VL 74 BP 17 EP 21 DI 10.1016/j.jpsychires.2015.12.005 PG 5 WC Psychiatry SC Psychiatry GA DE8RS UT WOS:000370905000004 PM 26736036 ER PT J AU Peralta, CA Bibbins-Domingo, K Vittinghoff, E Lin, F Fornage, M Kopp, JB Winkler, CA AF Peralta, Carmen A. Bibbins-Domingo, Kirsten Vittinghoff, Eric Lin, Feng Fornage, Myriam Kopp, Jeffrey B. Winkler, Cheryl A. TI APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; AFRICAN-AMERICANS; VARIANTS ASSOCIATE; RACIAL-DIFFERENCES; UNITED-STATES; RISK; MICROALBUMINURIA; INSUFFICIENCY; NEPHROPATHY; PROGRESSION AB Variants in the APOL1 gene are associated with kidney disease in blacks. We examined associations of APOL1 with incident albuminuria and kidney function decline among 3030 young adults with preserved GFR in the Coronary Artery Risk Development in Young Adults (CARDIA) study. eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio were measured at scheduled examinations. Participants were white (n=1700), high-risk black (two APOL1 risk alleles, n=176), and low-risk black (zero/one risk allele, n=1154). Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m(2), and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6-22.1) for high-risk blacks, 7.8 (6.4-9.4) for low-risk blacks, and 3.9 (3.1-4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks and 2.32 (1.73-3.13) for low-risk blacks. Adjustment for risk factors attenuated the difference between low-risk blacks and whites (odds ratio 1.21, 95% confidence interval 0.86-1.71). After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites. Low-risk blacks also had a faster yearly eGFRcys decline compared with whites, but this difference was attenuated after adjustment for risk factors and socioeconomic position. In conclusion, blacks with two APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, whereas disparities between low-risk blacks and whites were related to differences in traditional risk factors. C1 [Peralta, Carmen A.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Vittinghoff, Eric; Lin, Feng] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Kopp, Jeffrey B.] NIDDK, Kidney Dis Branch, Bethesda, MD 20892 USA. [Winkler, Cheryl A.] Leidos Biomed Inc, Basic Res Lab, Ctr Canc Res, Natl Canc Inst,Frederick Natl Lab, Frederick, MD USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R03-DK095877-03]; Robert Wood Johnson Harold Amos Program; NIDDK Intramural Research Program; National Cancer Institute, National Institutes of Health (NIH) [HHSN26120080001E]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]; [R01-DK078124]; [P60006902]; [K24-DK103992] FX C.P. is funded by grant 5R03-DK095877-03 from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Robert Wood Johnson Harold Amos Program.; K.B.D. was funded by R01-DK078124, P60006902 and K24-DK103992.; J.B.K. was supported by the NIDDK Intramural Research Program. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract HHSN26120080001E.; The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.; The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an infra-agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. NR 23 TC 8 Z9 8 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2016 VL 27 IS 3 BP 887 EP 893 DI 10.1681/ASN.2015020124 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DF1LN UT WOS:000371101400024 PM 26180129 ER PT J AU Sun, C Molineros, JE Looger, LL Zhou, XJ Kim, K Okada, Y Ma, JY Qi, YY Kim-Howard, X Motghare, P Bhattarai, K Adler, A Bang, SY Lee, HS Kim, TH Kang, YM Suh, CH Chung, WT Park, YB Choe, JY Shim, SC Kochi, Y Suzuki, A Kubo, M Sumida, T Yamamoto, K Lee, SS Kim, YJ Han, BG Dozmorov, M Kaufman, KM Wren, JD Harley, JB Shen, N Chua, KH Zhang, H Bae, SC Nath, SK AF Sun, Celi Molineros, Julio E. Looger, Loren L. Zhou, Xu-jie Kim, Kwangwoo Okada, Yukinori Ma, Jianyang Qi, Yuan-yuan Kim-Howard, Xana Motghare, Prasenjeet Bhattarai, Krishna Adler, Adam Bang, So-Young Lee, Hye-Soon Kim, Tae-Hwan Kang, Young Mo Suh, Chang-Hee Chung, Won Tae Park, Yong-Beom Choe, Jung-Yoon Shim, Seung Cheol Kochi, Yuta Suzuki, Akari Kubo, Michiaki Sumida, Takayuki Yamamoto, Kazuhiko Lee, Shin-Seok Kim, Young Jin Han, Bok-Ghee Dozmorov, Mikhail Kaufman, Kenneth M. Wren, Jonathan D. Harley, John B. Shen, Nan Chua, Kek Heng Zhang, Hong Bae, Sang-Cheol Nath, Swapan K. TI High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry SO NATURE GENETICS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MULTIPLE AUTOIMMUNE-DISEASES; GENOME-WIDE ASSOCIATION; CD226 GLY307SER ASSOCIATION; PRIMARY SJOGRENS-SYNDROME; WILLIAMS-BEUREN SYNDROME; CHINESE HAN POPULATION; TFII-I; SUSCEPTIBILITY LOCI; CLINICAL-FEATURES AB Systemic lupus erythematosus (SLE) has a strong but incompletely understood genetic architecture. We conducted an association study with replication in 4,478 SLE cases and 12,656 controls from six East Asian cohorts to identify new SLE susceptibility loci and better localize known loci. We identified ten new loci and confirmed 20 known loci with genome-wide significance. Among the new loci, the most significant locus was GTF2IRDI-GTF21 at 7q11.23 (rs73366469, P-meta = 3.75 x 10(-117), odds ratio (OR) = 2.38), followed by DEF6, IL128, TCF7, TERT, CD226, PCNXL3, RASGRP1, SYNGR1 and SIGLEC6. We identified the most likely functional variants at each locus by analyzing epigenetic marks and gene expression data. Ten candidate variants are known to alter gene expression in cis or in trans. Enrichment analysis highlights the importance of these loci in B cell and T cell biology. The new loci, together with previously known loci, increase the explained heritability of SLE to 24%. The new loci share functional and ontological characteristics with previously reported loci and are possible drug targets for SLE therapeutics. C1 [Sun, Celi; Molineros, Julio E.; Kim-Howard, Xana; Motghare, Prasenjeet; Bhattarai, Krishna; Adler, Adam; Wren, Jonathan D.; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Looger, Loren L.] Janelia Res Campus, Howard Hughes Med Inst, Ashburn, VA USA. [Zhou, Xu-jie; Qi, Yuan-yuan; Zhang, Hong] Peking Univ, Hosp 1, Inst Nephrol, Key Lab Renal Dis,Minist Hlth China,Div Renal, Beijing 100871, Peoples R China. [Zhou, Xu-jie; Qi, Yuan-yuan; Zhang, Hong] Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing 100871, Peoples R China. [Kim, Kwangwoo; Bang, So-Young; Lee, Hye-Soon; Kim, Tae-Hwan; Bae, Sang-Cheol] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo, Japan. [Okada, Yukinori] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan. [Ma, Jianyang; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Rheumatol, Shanghai 200030, Peoples R China. [Kang, Young Mo] Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea. [Suh, Chang-Hee] Ajou Univ Hosp, Dept Rheumatol, Suwon, South Korea. [Chung, Won Tae] Dong A Univ Hosp, Dept Internal Med, Busan, South Korea. [Park, Yong-Beom] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea. [Choe, Jung-Yoon] Daegu Catholic Univ Hosp, Dept Internal Med, Daegu, South Korea. [Shim, Seung Cheol] Chungnam Natl Univ Hosp, Daejeon Rheumatoid & Degenerat Arthrit Ctr, Daejeon, South Korea. [Kochi, Yuta; Suzuki, Akari; Yamamoto, Kazuhiko] RIKEN, Ctr Integrat Med Sci, Lab Autoimmune Dis, Yokohama, Kanagawa, Japan. [Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Yokohama, Kanagawa, Japan. [Sumida, Takayuki] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki, Japan. [Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan. [Lee, Shin-Seok] Chonnam Natl Univ Hosp, Dept Rheumatol, Gwangju, South Korea. [Kim, Young Jin; Han, Bok-Ghee] Korea Natl Inst Hlth, Osong, South Korea. [Dozmorov, Mikhail] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Shen, Nan] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH 45229 USA. [Chua, Kek Heng] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.; Bae, SC (reprint author), Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. EM scbae@hanyang.ac.kr; naths@omrf.org OI Suh, Chang-Hee/0000-0001-6156-393X FU Korea Center for Disease Control and Prevention at the Korea National Institute of Health; Ministry of Health and Welfare, Republic of Korea; US National Institutes of Health [AR060366, MD007909, AI103399, AI024717, AI083194, AI107176, TR001425, HG008666, HG006828]; US Department of Defense [PR094002]; US Department of Veterans Affairs; National Basic Research Program of China (973 program) [2014CB541902]; Research Fund of Beijing Municipal Science and Technology for the Outstanding PhD Program [20121000110]; National Natural Science Foundation of China [81200524, 81230072]; High-Impact Research Ministry of Education, Malaysia [UM.C/625/1/HIR/MoE/E000044-20001]; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [HI13C2124] FX We are grateful to the affected and unaffected individuals who participated in this study. We thank the research assistants, coordinators and physicians who helped in the recruitment of subjects, including the individuals in the coordinating projects. A part of the Korean control data was provided from the Korean Biobank Project supported by the Korea Center for Disease Control and Prevention at the Korea National Institute of Health. Genomic DNA from similar to 100 Korean patients with SLE was obtained from the Korean National Biobank at Wonkwang University Hospital, which is supported by the Ministry of Health and Welfare, Republic of Korea.; This work was supported by grants from the US National Institutes of Health (AR060366, MD007909, AI103399, AI024717, AI083194, AI107176, TR001425, HG008666 and HG006828), the US Department of Defense (PR094002), the US Department of Veterans Affairs, the National Basic Research Program of China (973 program) (2014CB541902), the Research Fund of Beijing Municipal Science and Technology for the Outstanding PhD Program (20121000110), the National Natural Science Foundation of China (81200524, 81230072) and High-Impact Research Ministry of Education Grant UM.C/625/1/HIR/MoE/E000044-20001, Malaysia. This study was also supported by a grant from the Korea Healthcare Technology R&D Project (HI13C2124), Ministry for Health and Welfare, Republic of Korea. NR 57 TC 14 Z9 15 U1 4 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD MAR PY 2016 VL 48 IS 3 BP 323 EP 330 DI 10.1038/ng.3496 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA DE8QW UT WOS:000370902600018 PM 26808113 ER PT J AU Kosheleva, E Spadoni, AD Strigo, IA Buchsbaum, MS Simmons, AN AF Kosheleva, Elena Spadoni, Andrea D. Strigo, Irina A. Buchsbaum, Monte S. Simmons, Alan N. TI Faking Bad: The Neural Correlates of Feigning Memory Impairment SO NEUROPSYCHOLOGY LA English DT Article DE fMRI; test of memory malingering; anterior cingulate cortex; mild traumatic brain injury; feigning ID TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; ANTERIOR CINGULATE; TEST-PERFORMANCE; WORKING-MEMORY; DECEPTION; ACTIVATION; CORTEX; LIE AB Objective: The detection of malingering in cognitive performance is a challenge in clinical and legal environments. Neuroimaging may provide an objective method for delineation of malingering. Method: A heterogeneous with concern of gender and racial-ethnic identity of 22 healthy volunteers completed the Tombaugh Test of Memory Malingering during an fMRI scan. Subjects were either instructed to perform optimally (not feigning) or to perform "as if they had a mild traumatic brain injury with memory impairment" (feigning). Results: A voxel-based multiple regression analysis revealed that during correct responses there was greater activation in the superior and medial prefrontal cortex during the feigning versus the not-feigning responses. Conclusions: This finding suggests that falsified memory performance requires greater activation of cognitive control networks to determine a correct selection. C1 [Kosheleva, Elena; Spadoni, Andrea D.; Simmons, Alan N.] San Diego Vet Affairs Hlth Care Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Kosheleva, Elena; Spadoni, Andrea D.; Buchsbaum, Monte S.; Simmons, Alan N.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Strigo, Irina A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Strigo, Irina A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Simmons, AN (reprint author), San Diego VA, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM ansimmons@ucsd.edu RI strigo, irina/L-9882-2016 OI strigo, irina/0000-0002-8799-716X FU Department of Veterans Affairs [I01-CX-000715-01, I01-CX-000816-01, 1 IK2 CX000864-01]; VA Center of Excellence in Stress and Mental Health FX This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research. Salary was supported by Department of Veterans Affairs via Merit Grant I01-CX-000715-01 to Alan N. Simmons; Grant I01-CX-000816-01 to Irina A. Strigo; Career Development Grant 1 IK2 CX000864-01 to Andrea D. Spadoni; and the VA Center of Excellence in Stress and Mental Health to Alan N. Simmons, Elena Kosheleva, and Andrea D. Spadoni. NR 46 TC 0 Z9 0 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD MAR PY 2016 VL 30 IS 3 BP 377 EP 384 DI 10.1037/neu0000251 PG 8 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA DF0ZS UT WOS:000371068800012 PM 26765340 ER PT J AU Patel, AK Newcomb, CW Liesegang, TL Pujari, SS Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Sen, HN Artornsombudh, P Kothari, S Kempen, JH AF Patel, Apurva K. Newcomb, Craig W. Liesegang, Teresa L. Pujari, Siddharth S. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Sen, H. Nida Artornsombudh, Pichaporn Kothari, Srishti Kempen, John H. CA Systemic Immunosuppressive Therapy TI Risk of Retinal Neovascularization in Cases of Uveitis SO OPHTHALMOLOGY LA English DT Article ID INFLAMMATORY OCULAR NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; POSTERIOR UVEITIS; PARS PLANITIS; DISC NEOVASCULARIZATION; OPTIC DISC; RETINOPATHY; PATHOGENESIS; MECHANISMS AB Purpose: To evaluate the risk of and risk factors for retinal neovascularization (NV) in cases of uveitis. Design: Retrospective cohort study. Participants: Patients with uveitis at 4 US academic ocular inflammation subspecialty practices. Methods: Data were ascertained by standardized chart review. Prevalence data analysis used logistic regression. Incidence data analysis used survival analysis with time-updated covariates where appropriate. Main Outcome Measures: Prevalence and incidence of NV. Results: Among uveitic eyes of 8931 patients presenting for initial evaluation, 106 of 13 810 eyes had NV (prevalence = 0.77%, 95% confidence interval [CI], 0.60-0.90). Eighty-eight more eyes developed NV over 26 465 eye-years (incidence, 0.33%/eye-year; 95% CI, 0.27-0.41). Factors associated with incident NV include age <35 years compared with >35 years (adjusted hazard ratio [aHR], 2.4; 95% CI, 1.5-3.9), current cigarette smoking (aHR, 1.9; 95% CI, 1.1-3.4), and systemic lupus erythematosus (aHR, 3.5, 95% CI, 1.1-11). Recent diagnosis of uveitis was associated with an increased incidence of NV (compared with patients diagnosed >5 years ago, aHR, 2.4 [95% CI, 1.1-5.0] and aHR, 2.6 [95% CI, 1.2-6.0] for diagnosis within <1 year vs. 1-5 years, respectively). Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (aHR, 5.2; 95% CI, 2.5-11), and panuveitis (aHR, 4.3; 95% CI, 2.0-9.3) were associated with a similar degree of increased NV incidence. Active (aHR, 2.1, 95% CI, 1.2-3.7) and slightly active (aHR, 2.4, 95% CI, 1.3-4.4) inflammation were associated with an increased incidence of NV compared with inactive inflammation. Neovascularization incidence also was increased with retinal vascular occlusions (aHR, 10, 95% CI, 3.0-33), retinal vascular sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13). Diabetes mellitus was associated with a somewhat increased incidence of retinal NV (aHR, 2.3, 95% CI, 1.1-4.9), and systemic hypertension (aHR 1.5, 95% CI, 0.89-2.4) was associated with nonsignificantly increased NV incidence. Results were similar in sensitivity analyses excluding the small minority of patients with diabetes mellitus. Conclusions: Retinal NV is a rare complication of uveitis, which occurs more frequently in younger patients, smokers, and those with intermediate/posterior/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflammation. Inflammation and retinal NV likely are linked; additional studies are needed to further elucidate this connection. (C) 2016 by the American Academy of Ophthalmology. C1 [Patel, Apurva K.; Artornsombudh, Pichaporn; Kothari, Srishti; Kempen, John H.] Univ Penn, Scheie Eye Inst, Ophthalmol, Philadelphia, PA 19104 USA. [Newcomb, Craig W.; Kempen, John H.] Univ Penn, Scheie Eye Inst, Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Scheie Eye Inst, Ocular Inflammat Serv, Philadelphia, PA 19104 USA. [Patel, Apurva K.] Retina Northwest PC, Portland, OR USA. [Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Internal Med, Portland, OR 97201 USA. [Pujari, Siddharth S.] Om Eye Care Hosp, Belgaum, Karnataka, India. [Pujari, Siddharth S.; Foster, C. Stephen; Artornsombudh, Pichaporn; Kothari, Srishti] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Ophthalmol, New York, NY 10029 USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Med, New York, NY 10029 USA. [Nussenblatt, Robert B.; Sen, H. Nida] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.; Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. [Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Safety Harbor, FL USA. [Artornsombudh, Pichaporn] Chulalongkorn Univ, Div Ophthalmol, Naval Med Dept, Royal Thai Navy,Dept Ophthalmol,Fac Med,Somdech P, Bangkok, Thailand. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu FU National Eye Institute [EY014943]; Research to Prevent Blindness (RPB); Paul and Evanina Mackall Foundation; Lois Pope Life Foundation; RPB James S. Adams Special Scholar Award; R.P.B. Harrington Special Scholar Award; Research to Prevent Blindness Senior Scientific Investigator Award; intramural funds of the National Eye Institute; Department of Veterans' Affairs FX Supported primarily by National Eye Institute Grant EY014943 (J.H.K.). Additional support was provided by Research to Prevent Blindness (RPB), the Paul and Evanina Mackall Foundation, and the Lois Pope Life Foundation. J.H.K. was an RPB James S. Adams Special Scholar Award recipient, J.E.T. was an R.P.B. Harrington Special Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. G.A.L.-C. was previously supported by and RBN and HNS continues to be supported by intramural funds of the National Eye Institute. E.B.S. receives support from the Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of this manuscript. NR 32 TC 1 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD MAR PY 2016 VL 123 IS 3 BP 646 EP 654 DI 10.1016/j.ophtha.2015.10.056 PG 9 WC Ophthalmology SC Ophthalmology GA DE4UQ UT WOS:000370626300042 PM 26686964 ER PT J AU Chen, Y Seepersaud, R Bensing, BA Sullam, PM Rapoport, TA AF Chen, Yu Seepersaud, Ravin Bensing, Barbara A. Sullam, Paul M. Rapoport, Tom A. TI Mechanism of a cytosolic O-glycosyltransferase essential for the synthesis of a bacterial adhesion protein SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE O-glycosylation; bacterial adhesin; crystal structure; Ser/Thr-rich repeats; enzymatic mechanism ID CELLULOSE-BINDING DOMAIN; RICH REPEAT PROTEINS; ACCESSORY SEC LOCUS; WALL TEICHOIC-ACID; STREPTOCOCCUS-GORDONII; STAPHYLOCOCCUS-AUREUS; SURFACE PROTEIN; LINKED GLYCOSYLATION; GLCNAC TRANSFERASE; ENZYMATIC ANALYSIS AB O-glycosylation of Ser and Thr residues is an important process in all organisms, which is only poorly understood. Such modification is required for the export and function of adhesin proteins that mediate the attachment of pathogenic Gram-positive bacteria to host cells. Here, we have analyzed the mechanism by which the cytosolic O-glycosyltransferase GtfA/B of Streptococcus gordonii modifies the Ser/Thr-rich repeats of adhesin. The enzyme is a tetramer containing two molecules each of GtfA and GtfB. The two subunits have the same fold, but only GtfA contains an active site, whereas GtfB provides the primary binding site for adhesin. During a first phase of glycosylation, the conformation of GtfB is restrained by GtfA to bind substrate with unmodified Ser/Thr residues. In a slow second phase, GtfB recognizes residues that are already modified with N-acetylglucosamine, likely by converting into a relaxed conformation in which one interface with GtfA is broken. These results explain how the glycosyltransferase modifies a progressively changing substrate molecule. C1 [Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Rapoport, TA (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.; Rapoport, TA (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.; Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Sullam, PM (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA. EM paul.sullam@ucsf.edu; tom_rapoport@hms.harvard.edu FU National Institute of General Medical Sciences from the National Institutes of Health (NIH) [P41 GM103403]; DOE Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]; Howard Hughes Medical Institute (HHMI)-Helen Hay Whitney Foundation fellowship; NIH [GM052586]; Department of Veterans Affairs, NIH [R01-AI041513, R01-AI106987]; Northern California Institute for Research and Education FX We thank the staff at the Advanced Photon Source of the Northeastern Collaborative Access Team (NE-CAT) beamline for help with data collection; Phil Jeffrey (Princeton University), Surajit Banerjee (NE-CAT), and Simon Jenni (Harvard Medical School) for help with crystallographic data merging and anisotropy correction; and Stephen Harrison for advice on initial backbone tracing. NE-CAT is supported by National Institute of General Medical Sciences Grant P41 GM103403 from the National Institutes of Health (NIH). This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Y.C. was supported by a Howard Hughes Medical Institute (HHMI)-Helen Hay Whitney Foundation fellowship. The work in the T.A.R. laboratory was supported by NIH Grant GM052586. T.A.R. is an HHMI Investigator. P.M.S. is supported by the Department of Veterans Affairs, NIH Grants R01-AI041513 and R01-AI106987, and the Northern California Institute for Research and Education. NR 53 TC 2 Z9 2 U1 6 U2 17 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 1 PY 2016 VL 113 IS 9 BP E1190 EP E1199 DI 10.1073/pnas.1600494113 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2WG UT WOS:000371204500011 PM 26884191 ER PT J AU Toledo, JB Gopal, P Raible, K Irwin, DJ Brettschneider, J Sedor, S Waits, K Boluda, S Grossman, M Van Deerlin, VM Lee, EB Arnold, SE Duda, JE Hurtig, H Lee, VMY Adler, CH Beach, TG Trojanowski, JQ AF Toledo, Jon B. Gopal, Pallavi Raible, Kevin Irwin, David J. Brettschneider, Johannes Sedor, Samantha Waits, Kayla Boluda, Susana Grossman, Murray Van Deerlin, Vivianna M. Lee, Edward B. Arnold, Steven E. Duda, John E. Hurtig, Howard Lee, Virginia M. -Y. Adler, Charles H. Beach, Thomas G. Trojanowski, John Q. TI Pathological alpha-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology SO ACTA NEUROPATHOLOGICA LA English DT Article DE Alzheimer disease; Parkinson disease; Dementia with Lewy bodies; Neuropathology; Diagnosis; Classification ID SPORADIC PARKINSONS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; ASSOCIATION GUIDELINES; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA; NATIONAL INSTITUTE; DONATION PROGRAM; DEMENTIA; BRAIN; BODIES AB We investigated the distribution patterns of Lewy body-related pathology (LRP) and the effect of coincident Alzheimer disease (AD) pathology using a data-driven clustering approach that identified groups with different LRP pathology distributions without any diagnostic or researcher's input in two cohorts including: Parkinson disease patients without (PD, n = 141) and with AD (PD-AD, n = 80), dementia with Lewy bodies subjects without AD (DLB, n = 13) and demented subjects with AD and LRP pathology (Dem-AD-LB, n = 308). The Dem-AD-LB group presented two LRP patterns, olfactory-amygdala and limbic LRP with negligible brainstem pathology, that were absent in the PD groups, which are not currently included in the DLB staging system and lacked extracranial LRP as opposed to the PD group. The Dem-AD-LB individuals showed relative preservation of substantia nigra cells and dopamine active transporter in putamen. PD cases with AD pathology showed increased LRP. The cluster with occipital LRP was associated with non-AD type dementia clinical diagnosis in the Dem-AD-LB group and a faster progression to dementia in the PD groups. We found that (1) LRP pathology in Dem-AD-LB shows a distribution that differs from PD, without significant brainstem or extracranial LRP in initial phases; (2) coincident AD pathology is associated with increased LRP in PD indicating an interaction; (3) LRP and coincident AD pathology independently predict progression to dementia in PD, and (4) evaluation of LRP needs to acknowledge different LRP spreading patterns and evaluate substantia nigra integrity in the neuropathological assessment and consider the implications of neuropathological heterogeneity for clinical and biomarker characterization. C1 [Toledo, Jon B.; Gopal, Pallavi; Raible, Kevin; Irwin, David J.; Brettschneider, Johannes; Sedor, Samantha; Waits, Kayla; Boluda, Susana; Van Deerlin, Vivianna M.; Lee, Edward B.; Lee, Virginia M. -Y.; Trojanowski, John Q.] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Irwin, David J.; Grossman, Murray; Arnold, Steven E.; Hurtig, Howard] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Brettschneider, Johannes] Univ Ulm, Dept Clin Neuroanat & Neurol, D-89069 Ulm, Germany. [Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Adler, Charles H.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. [Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA. RP Toledo, JB (reprint author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. EM jtoledo@mail.med.upenn.edu OI Toledo, Jon/0000-0003-4366-9268 FU NIH grants [AG05136, AG006781]; Morris K Udall Center for Parkinson's disease Research Core grants [P50 NS053488, NS062684]; National Institute of Neurological Disorders and Stroke (National Brain and Tissue Resource for Parkinson's Disease and Related Disorders) [U24 NS072026]; National Institute on Aging (Arizona Alzheimer's Disease Core Center) [P30 AG19610]; Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; [NS088341] FX This study was supported by NIH grants: AG05136, AG006781 and Morris K Udall Center for Parkinson's disease Research Core grants P50 NS053488 and NS062684. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. DJI is supported by NS088341. Finally, we thank our patients and their families for making this research possible. NR 47 TC 7 Z9 7 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAR PY 2016 VL 131 IS 3 BP 393 EP 409 DI 10.1007/s00401-015-1526-9 PG 17 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DE7LG UT WOS:000370817600005 PM 26721587 ER PT J AU Acharjee, S Teo, KK Jacobs, AK Hartigan, PM Barn, K Gosselin, G Tanguay, JF Maron, DJ Kostuk, WJ Chaitman, BR Mancini, GBJ Spertus, JA Dada, MR Bates, ER Booth, DC Weintraub, WS O'Rourke, RA Boden, WE AF Acharjee, Subroto Teo, Koon K. Jacobs, Alice K. Hartigan, Pamela M. Barn, Kulpreet Gosselin, Gilbert Tanguay, Jean-Francois Maron, David J. Kostuk, William J. Chaitman, Bernard R. Mancini, G. B. John Spertus, John A. Dada, Marcin R. Bates, Eric R. Booth, David C. Weintraub, William S. O'Rourke, Robert A. Boden, William E. TI Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial SO AMERICAN HEART JOURNAL LA English DT Article ID ELEVATION MYOCARDIAL-INFARCTION; ARTERY-DISEASE; GENDER-DIFFERENCES; CONSERVATIVE TREATMENT; UNSTABLE ANGINA; SEX-DIFFERENCES; YENTL-SYNDROME; HEART-DISEASE; MANAGEMENT; MEN AB Objectives To determine whether sex-based differences exist in clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in patients with stable coronary artery disease. Background A prior pre-specified unadjusted analysis from COURAGE showed that women randomized to PCI had a lower rate of death or myocardial infarction during a median 4.6-year follow-up with a trend for interaction with respect to sex. Methods We analyzed outcomes in 338 women (15%) and 1949 men (85%) randomized to PCI plus OMT versus OMT alone after adjustment for relevant baseline characteristics. Results There was no difference in treatment effect by sex for the primary end point (death or myocardial infarction; HR, 0.89; 95% CI, 0.77-1.03 for women and HR, 1.02, 95% CI 0.96-1.10 for men; P for interaction = .07). Although the event rate was low, a trend for interaction by sex was nonetheless noted for hospitalization for heart failure, with only women, but not men, assigned to PCI experiencing significantly fewer events as compared to their counterparts receiving OMT alone (HR, 0.59; 95% CI, 0.40-0.84, P < .001 for women and HR, 0.86; 95% CI, 0.74-1.01, P = .47 for men; P for interaction = .02). Both sexes randomized to PCI experienced significantly reduced need for subsequent revascularization (HR, 0.72; 95% CI, 0.62-0.83, P < .001 for women; HR, 0.84; 95% CI, 0.79-0.89, P < .001 for men; P for interaction = .02) with evidence of a sex-based differential treatment effect. Conclusion In this adjusted analysis of the COURAGE trial, there were no significant differences in treatment effect on major outcomes between men and women. However, women assigned to PCI demonstrated a greater benefit as compared to men, with a reduction in heart failure hospitalization and need for future revascularization. These exploratory observations require further prospective study. C1 [Acharjee, Subroto] Einstein Med Ctr Philadelphia, Philadelphia, PA USA. [Teo, Koon K.] Master Univ, Hamilton Gen Hosp, Hamilton, ON, Canada. [Jacobs, Alice K.] Boston Med Ctr, Boston, MA USA. [Hartigan, Pamela M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Barn, Kulpreet] Geisinger Med Ctr, Danville, PA 17822 USA. [Gosselin, Gilbert; Tanguay, Jean-Francois] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada. [Chaitman, Bernard R.] St Louis Univ, Sch Med, St Louis, MT USA. [Mancini, G. B. John] Vancouver Hosp, Vancouver, BC, Canada. [Mancini, G. B. John] Hlth Sci Ctr, Vancouver, BC, Canada. [Spertus, John A.] Mid Amer Heart Inst, Kansas City, MO USA. [Dada, Marcin R.] Hartford Hosp, Hartford, CT 06115 USA. [Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Booth, David C.] Univ Kentucky, Med Ctr, Lexington, KY USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Weintraub, William S.] Ctr Outcomes Res, Newark, DE USA. [O'Rourke, Robert A.] South Texas Vet Hlth Care Syst, Audie Murphy Campus, San Antonio, TX USA. [Boden, William E.] Albany Med Coll, Stratton VA Med Ctr, Albany, NY 12208 USA. RP Boden, WE (reprint author), Samuel S Stratton VA Med Ctr, 113 Holland Ave, Albany, NY 12208 USA. EM william.boden@va.gov FU Amgen Merck Canada; Sanofi; Astra Zeneca; Gilead FX Dr GB John Mancini: <$10,000 grant, honoraria, speakers bureau: Amgen Merck Canada, Sanofi, Astra Zeneca.; Dr John Spertus: owns the copyright to the Seattle Angina Questionnaire, consultant for United Healthcare, St. Jude Medical, Abbott Vascular and Genentech, research grant from Gilead. NR 32 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAR PY 2016 VL 173 BP 108 EP 117 DI 10.1016/j.ahj.2015.07.020 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DE7HO UT WOS:000370806800014 PM 26920603 ER PT J AU Levey, AS Bilous, R Shlipak, MG AF Levey, Andrew S. Bilous, Rudy Shlipak, Michael G. TI CKD and Diabetes: What Can We Learn From Their Similarities and Differences? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; PROGRESSION; PREVENTION; PREDICTION; COMMUNITY; HEALTH; MODEL; CARE C1 [Levey, Andrew S.] Tufts Med Ctr, Boston, MA USA. [Bilous, Rudy] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Levey, AS (reprint author), Tufts Med Ctr, William B Schwartz Div Nephrol, Box 391,800 Washington St, Boston, MA 02111 USA. EM alevey@tuftsmedicalcenter.org NR 21 TC 0 Z9 0 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2016 VL 67 IS 3 BP 360 EP 363 DI 10.1053/j.ajkd.2015.12.003 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA DE5UM UT WOS:000370698100008 PM 26916373 ER PT J AU Bhasin, B Velez, JCQ AF Bhasin, Bhavna Velez, Juan Carlos Q. TI Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Polyuria; water diuresis; solute excretion; urinary osmoles; hypernatremia ID NEPHROGENIC DIABETES-INSIPIDUS; SALT WASTING SYNDROME; OSMOTIC DIURESIS; DIFFERENTIAL-DIAGNOSIS; HYPERNATREMIA; HYPONATREMIA; THERAPY; VASOPRESSIN; MECHANISMS; CLEARANCE AB Polyuria, defined as daily urine output in excess of 3.0 to 3.5 L/d, can occur due to solute or water diuresis. Solute-induced polyuria can be seen in hospitalized patients after a high solute load from exogenous protein administration or following relief of urinary obstruction. Similar clinical scenarios are rarely encountered in the outpatient setting. We describe a case of polyuria due to high solute ingestion and excessive water intake leading to a mixed picture of solute and water diuresis. Restriction of the daily solute load and water intake resulted in complete resolution of polyuria. Determination of the daily excreted urinary osmoles may yield important clues to the cause of polyuria and should be included in the routine workup of polyuria. (C) 2016 by the National Kidney Foundation, Inc. C1 [Bhasin, Bhavna; Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Nephrol Sect, Charleston, SC USA. RP Bhasin, B (reprint author), 96 Jonathan Lucas St,Clinical Sci Bldg, Charleston, SC 29425 USA. EM bhasinb@musc.edu RI Velez, Juan Carlos/N-3782-2016 NR 30 TC 2 Z9 2 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2016 VL 67 IS 3 BP 507 EP 511 DI 10.1053/j.ajkd.2015.10.021 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA DE5UM UT WOS:000370698100025 PM 26687922 ER PT J AU Montgomery, AE Dichter, ME Thomasson, AM Roberts, CB AF Montgomery, Ann E. Dichter, Melissa E. Thomasson, Arwin M. Roberts, Christopher B. TI Services Receipt Following Veteran Outpatients' Positive Screen for Homelessness SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MENTAL-ILLNESS; SEXUAL TRAUMA; RISK; VIOLENCE; GENDER; IRAQ AB Introduction: The Veterans Health Administration seeks to reduce homelessness among Veterans by identifying, and providing prevention and supportive services to, patients with housing concerns. The objectives of this study were to assess the proportion of Veterans Health Administration patients who received homeless or social work services within 6 months of a positive screen for homelessness or risk in the Veterans Health Administration and the demographic and clinical characteristics that predicted services utilization. Methods: Data were from a cohort of 27,403 Veteran outpatients who screened positive for homelessness or risk between November 1, 2012 and January 31, 2013. During 2013, AORs were calculated using a mixed-effects logistic regression to estimate the likelihood of patients' receipt of VHA homeless or social work services based on demographic and clinical characteristics. Results: The majority of patients received services within 6 months post-screening; predictors of services utilization varied by gender. Among women, diagnosis of drug abuse and psychosis predicted receipt of services, being unmarried increased the odds of using services among those screening positive for homelessness, and a diagnosis of post-traumatic stress disorder increased the odds of receiving services for at-risk women. Among men, being younger, unmarried, not service-connected/Medicaideligible, and having a medical or behavioral health condition predicted receipt of services. Conclusions: Receipt of housing support services among Veterans post-homelessness screening differs by patient demographic and clinical characteristics. Future research should investigate the role that primary and secondary prevention interventions play in Veterans' resolution of risk for homelessness and experience of homelessness. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Montgomery, Ann E.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Dichter, Melissa E.; Thomasson, Arwin M.; Roberts, Christopher B.] US Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Thomasson, Arwin M.] Hosp Univ Penn, Penn Transplant Inst, 3400 Spruce St, Philadelphia, PA 19104 USA. RP Montgomery, AE (reprint author), 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM ann.montgomery2@va.gov FU U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans; Center for Health Equity Research and Promotion FX The contents of this article do not necessarily represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. This study was funded by the U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans, and Center for Health Equity Research and Promotion. NR 26 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 336 EP 343 DI 10.1016/j.amepre.2015.06.035 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300009 PM 26564329 ER PT J AU Campbell, JA Walker, RJ Egede, LE AF Campbell, Jennifer A. Walker, Rebekah J. Egede, Leonard E. TI Associations Between Adverse Childhood Experiences, High-Risk Behaviors, and Morbidity in Adulthood SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RETROSPECTIVE COHORT; MENTAL-HEALTH; STATES; DISEASE; DISPARITIES; MORTALITY; IMPACT; DEATH; URBAN; US AB Introduction: Adverse childhood experiences (ACEs) are associated with early mortality and morbidity. This study evaluated the association among ACEs, high-risk health behaviors, and comorbid conditions, as well as the independent effect of ACE components. Methods: Data were analyzed on 48,526 U.S. adults from five states in the 2011 Behavioral Risk Factor Surveillance System survey. Exposures included psychological, physical, and sexual forms of abuse as well as household dysfunction such as substance abuse, mental illness, violence, and incarceration. Main outcome measures included risky behaviors and morbidity measures, including binge drinking, heavy drinking, current smoking, high-risk HIV behavior, obesity, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by poor health, and use of special equipment because of disability. Multiple logistic regression assessed the independent relationship between ACE score categories and risky behaviors/comorbidities in adulthood, and assessed the independent relationship between individual ACE components and risky behaviors/comorbid conditions in adulthood controlling for covariates. Results: A total of 55.4% of respondents reported at least one ACE and 13.7% reported four or more ACEs. An ACE score >= 4 was associated with increased odds for binge drinking, heavy drinking, smoking, risky HIV behavior, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by health, and use of special equipment because of disability. In addition, the individual components had different effects on risky behavior and comorbidities. Conclusions: In addition to having a cumulative effect, individual ACE components have differential relationships with risky behaviors, morbidity, and disability in adulthood after controlling for important confounders. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Campbell, Jennifer A.; Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease (Principal Investigator, Leonard Egede) [K24DK093699-02] FX This study was supported by grant K24DK093699-02 from The National Institute of Diabetes and Digestive and Kidney Disease (Principal Investigator, Leonard Egede). LEE obtained funding for the study. JAC, RJW, and LEE designed the study and acquired, analyzed, and interpreted data. JAC, RJW, and LEE developed analysis, contributed to interpretation, and critically revised the manuscript for important intellectual content. All authors approved the final manuscript. This article represents the views of the authors and not those of NIH, Veterans Health Administration, or Health Services Research & Development. NR 38 TC 6 Z9 6 U1 7 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 344 EP 352 DI 10.1016/j.amepre.2015.07.022 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300010 PM 26474668 ER PT J AU Thrift, AP El-Serag, HB AF Thrift, Aaron P. El-Serag, Hashem B. TI Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID UNITED-STATES; BARRETTS-ESOPHAGUS; CIGARETTE-SMOKING; AFRICAN-AMERICANS; RISK; WHITES; TRENDS C1 [Thrift, Aaron P.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. RP Thrift, AP (reprint author), Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. NR 16 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 330 EP 332 DI 10.1016/j.cgh.2015.10.028 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700007 PM 26528803 ER PT J AU Kang, XY Zhao, LN Leung, F Luo, H Wang, LM Wu, J Guo, XY Wang, XP Zhang, LH Hui, N Tao, Q Jia, H Liu, ZG Chen, ZQ Liu, JJ Wu, KC Fan, DM Pan, YL Guo, XG AF Kang, Xiaoyu Zhao, Lina Leung, Felix Luo, Hui Wang, Limei Wu, Ji Guo, Xiaoyang Wang, Xiangping Zhang, Linhui Hui, Na Tao, Qin Jia, Hui Liu, Zhiguo Chen, Zhangqin Liu, Junjun Wu, Kaichun Fan, Daiming Pan, Yanglin Guo, Xuegang TI Delivery of Instructions via Mobile Social Media App Increases Quality of Bowel Preparation SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Colon Cancer Screening; Bowel Preparation; ADR ID ADENOMA DETECTION RATE; COLORECTAL-CANCER; COLONOSCOPY PREPARATION; PATIENT EDUCATION; VALIDATION; RISK; RECOMMENDATIONS; INDICATORS; SOCIETY; IMPACT AB BACKGROUND & AIMS: Bowel preparation is closely linked to the quality of colonoscopy. We investigated whether delivery of instructions via a social media app increases the quality of colonoscopy by improving adequacy of bowel preparation. METHODS: We performed a prospective study at 3 endoscopic centers in China of 770 colonoscopy outpatients (18-80 years old) with convenient access to Wechat (a widely used mobile social media app) from May through November 2014. Patients were randomly assigned to groups that received standard education along with delivery of interactive information via Wechat (n = 387) or standard education (controls, n = 383). The primary outcome was proportion of patients with adequate bowel preparation (Ottawa score <6). Secondary outcomes included rates of adenoma detection and cecal intubation, cecal intubation time, rates of incomplete compliance with instructions, and patient willingness to repeat bowel preparation. RESULTS: Demographic features were comparable between the groups. A higher proportion of patients in the group that received social media instruction had adequate bowel preparation than the control group (82.2% vs 69.5%, P < .001). Among patients with successful colonoscopies, the group that received social media instruction had lower mean total and segmental Ottawa scores (P < .05). A higher proportion of patients receiving social media instruction also had cecal intubation (97.2% vs 93.2% in controls, P = .014) and were found to have adenomas (18.6% vs 12.0% in controls, P = .012). CONCLUSIONS: Instruction via a mobile social media app, in conjunction with regular instruction, increases subjective measures of adequacy of bowel preparation. Use of the app significantly increased the proportion of patients with successful cecal intubation and in whom adenomas were detected, indicating increased quality of colonoscopy. ClinicalTrials.gov number: NCT02140827 C1 [Kang, Xiaoyu; Luo, Hui; Guo, Xiaoyang; Wang, Xiangping; Zhang, Linhui; Hui, Na; Tao, Qin; Jia, Hui; Liu, Zhiguo; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. [Zhao, Lina] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian 710032, Shaanxi, Peoples R China. [Leung, Felix] VA Greater Los Angeles Healthcare Syst, Sepulveda ACC, North Hill, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wang, Limei; Chen, Zhangqin] Shaanxi Second Peoples Hosp, Dept Gastroenterol, Xian, Peoples R China. [Wu, Ji; Liu, Junjun] Chancheng Cent Hosp Foshan, Dept Gastroenterol, Foshan, Peoples R China. RP Pan, YL; Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. EM yanglinpan@hotmail.com; xuegangguo@gmail.com FU National Natural Science Foundation of China [81172288, 81370585] FX Supported in part by the National Natural Science Foundation of China (81172288 and 81370585). NR 23 TC 5 Z9 5 U1 5 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 429 EP + DI 10.1016/j.cgh.2015.09.038 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700021 PM 26492848 ER PT J AU Khan, A Kanwal, F AF Khan, Anam Kanwal, Fasiha TI Treatment of Alcohol Use Disorders: Benchmarking Houston, Texas, and Philadelphia, Pennsylvania Reply SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter C1 [Khan, Anam] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kanwal, Fasiha] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Kanwal, Fasiha] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Kanwal, Fasiha] Texas Med Ctr Digest Dis Ctr, Houston, TX USA. [Kanwal, Fasiha] Dan L Duncan Canc Ctr, Houston, TX USA. RP Khan, A (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 487 EP 488 DI 10.1016/j.cgh.2015.12.010 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700037 PM 26689902 ER PT J AU Park, JJ Wong, DK Wahed, AS Lee, WM Feld, JJ Terrault, N Khalili, M Sterling, RK Kowdley, KV Bzowej, N Lau, DT Kim, WR Smith, C Carithers, RL Torrey, KW Keith, JW Levine, DL Traum, D Ho, S Valiga, ME Johnson, GS Doo, E Lok, ASF Chang, KM AF Park, Jang-June Wong, David K. Wahed, Abdus S. Lee, William M. Feld, Jordan J. Terrault, Norah Khalili, Mandana Sterling, Richard K. Kowdley, Kris V. Bzowej, Natalie Lau, Daryl T. Kim, W. Ray Smith, Coleman Carithers, Robert L. Torrey, Keith W. Keith, James W. Levine, Danielle L. Traum, Daniel Ho, Suzanne Valiga, Mary E. Johnson, Geoffrey S. Doo, Edward Lok, Anna S. F. Chang, Kyong-Mi CA Hepatitis B Res Network TI Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B SO GASTROENTEROLOGY LA English DT Article DE HBRN; LPS; IFN; IL10 ID IMMUNE-RESPONSE; VIRAL-HEPATITIS; SUSTAINED RESPONSE; PROGRAMMED DEATH-1; HBV INFECTION; E-ANTIGEN; PATHOGENESIS; ETHNICITY; GENOTYPE; THERAPY AB BACKGROUND & AIMS: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). METHODS: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyteassociated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. RESULTS: Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3(+)CD127(-) regulatory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg- patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyteassociated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg+ than HBeAg- patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. CONCLUSIONS: HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell-based immune signatures for clinical phenotypes. These findings suggest additional T-cell-independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation. C1 [Park, Jang-June; Torrey, Keith W.; Keith, James W.; Levine, Danielle L.; Traum, Daniel; Ho, Suzanne; Valiga, Mary E.; Chang, Kyong-Mi] Philadelphia Corporal Michael J Crescenz VA Med C, Philadelphia, PA USA. [Park, Jang-June; Torrey, Keith W.; Keith, James W.; Levine, Danielle L.; Traum, Daniel; Ho, Suzanne; Valiga, Mary E.; Chang, Kyong-Mi] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Wong, David K.; Feld, Jordan J.] Univ Toronto, Toronto, ON, Canada. [Wahed, Abdus S.; Johnson, Geoffrey S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Lee, William M.] Univ Texas Southwestern, Dallas, TX USA. [Terrault, Norah; Khalili, Mandana] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sterling, Richard K.] Virginia Commonwealth Univ, Richmond, VA USA. [Kowdley, Kris V.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Bzowej, Natalie] Calif Pacific Med Ctr, San Francisco, CA USA. [Lau, Daryl T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Kim, W. Ray] Mayo Clin, Rochester, MN USA. [Smith, Coleman] Univ Minnesota, Minneapolis, MN USA. [Carithers, Robert L.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Doo, Edward] NIDDK, NIH, Bethesda, MD 20892 USA. [Lok, Anna S. F.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Chang, KM (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.; Chang, KM (reprint author), Univ Penn, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM kmchang@mail.med.upenn.edu OI Wahed, Abdus/0000-0001-6911-7221; Wong, David/0000-0002-3310-3538 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U01, DK 082843, DK082863, DK082864, DK082866, DK082867, DK082871, U01 DK082872, DK082874, DK082919, DK082923, DK082927, DK082943, U01 DK082944]; NIDDK [A-DK-3002-001]; intramural program, NIDDK, National Institutes of Health (NIH); Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases) [P30DK50306]; Immunology Center (NIH Public Health Service Research Grant) [M01-RR00040]; Immunology Center (VA Merit Review) [BX000649, UL1TR000058]; NCATS (National Center for Advancing Translational Sciences, NIH) [UL1TR000058]; CTSA [UL1TR000004, UL1RR024986]; Clinical and Translational Science Award [CTSA] [UL1TR001111]; Gilead Sciences, Inc.; Roche Molecular Systems through the NIDDK; NIH [UO-1DK082866, R01-AI-47519]; Philadelphia VA Medical Research; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases [P30DK50306]; Molecular Biology and Cell Culture Core Facilities; NIH Public Health Service Research Grant [M01-RR00040]; Office of Research and Development, Department of Veterans Affairs FX The HBRN was funded by a U01 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to the following investigators Lewis R. Roberts, MB, ChB, PhD (DK 082843), Anna Suk-Fong Lok, MD (DK082863), Steven H. Belle, PhD, MScHyg (DK082864), Kyong-Mi Chang, MD (DK082866), Michael W. Fried, MD (DK082867), Adrian M. Di Bisceglie, MD (DK082871), William M. Lee, MD (U01 DK082872), Harry L. A. Janssen, MD, PhD (DK082874), Daryl T.-Y. Lau, MD, MPH (DK082919), Richard K. Sterling, MD, MSc (DK082923), Steven-Huy B. Han, MD (DK082927), Robert C. Carithers, MD (DK082943), Norah A. Terrault, MD, MPH (U01 DK082944), an interagency agreement with NIDDK: Lilia M. Ganova-Raeva, PhD (A-DK-3002-001) and support from the intramural program, NIDDK, National Institutes of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong-Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01-RR00040, VA Merit Review BX000649), Richard K. Sterling, MD, MSc (UL1TR000058, NCATS (National Center for Advancing Translational Sciences, NIH), Norah A. Terrault, MD, MPH (CTSA grant number UL1TR000004), Michael W. Fried, MD (Clinical and Translational Science Award [CTSA] grant number UL1TR001111), and Anna Suk-Fong Lok (CTSA grant number UL1RR024986). Additional support was provided by Gilead Sciences, Inc. and Roche Molecular Systems via a cooperative research and development agreement through the NIDDK. This study was supported by NIH grants UO-1DK082866 and R01-AI-47519; the Philadelphia VA Medical Research; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306 and its Molecular Biology and Cell Culture Core Facilities; the NIH Public Health Service Research Grant M01-RR00040. This material is based on work supported in part by the Office of Research and Development, Department of Veterans Affairs and with the resources and the use of facilities at the Philadelphia Corporal Michael J. Crescenz VA Medical Center. The contents of this work do not represent the views of the Department of Veterans Affairs or the United States Government. NR 52 TC 9 Z9 12 U1 3 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2016 VL 150 IS 3 BP 684 EP + DI 10.1053/j.gastro.2015.11.050 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE5CH UT WOS:000370648100029 PM 26684441 ER PT J AU Kahi, CJ Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Robertson, DJ Rex, DK AF Kahi, Charles J. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Robertson, Douglas J. Rex, Douglas K. TI Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer SO GASTROENTEROLOGY LA English DT Article DE Colonoscopy; Colorectal Neoplasms; Surveillance ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES; COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL EXCISION; RADICAL SURGERY AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance. C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA. EM ckahi2@iu.edu NR 124 TC 9 Z9 9 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2016 VL 150 IS 3 BP 758 EP + DI 10.1053/j.gastro.2016.01.001 PG 22 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE5CH UT WOS:000370648100034 PM 26892199 ER PT J AU Kahi, CJ Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Robertson, DJ Rex, DK AF Kahi, Charles J. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Robertson, Douglas J. Rex, Douglas K. TI Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES; COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL EXCISION; RADICAL SURGERY AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance. C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Boland, C. Richard] Baylor Univ, Med Ctr Dallas, Dallas, TX USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA. EM ckahi2@iu.edu NR 123 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2016 VL 83 IS 3 BP 489 EP U273 DI 10.1016/j.gie.2016.01.020 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1AU UT WOS:000370359000002 PM 26802191 ER PT J AU Cadoni, S Leung, FW AF Cadoni, Sergio Leung, Felix W. TI Discrepancy in the classification of water immersion from water exchange colonoscopy Response SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter ID CONTROLLED-TRIAL; CECAL INTUBATION; AIR INSUFFLATION; INFUSION C1 [Cadoni, Sergio] St Barbara Hosp, Digest Endoscopy Unit, Iglesias, CI, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Iglesias, CI, Italy. NR 9 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2016 VL 83 IS 3 BP 677 EP 678 DI 10.1016/j.gie.2015.11.012 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1AU UT WOS:000370359000058 PM 26897057 ER PT J AU Stockdale, SE Tang, LQ Pudilo, E Lucas-Wright, A Chung, BW Horta, M Masongsong, Z Jones, F Belin, TR Sherbourne, C Wells, K AF Stockdale, Susan E. Tang, Lingqi Pudilo, Esmeralda Lucas-Wright, Anna Chung, Bowen Horta, Mariana Masongsong, Zoe Jones, Felica Belin, Thomas R. Sherbourne, Cathy Wells, Kenneth TI Sampling and Recruiting Community-Based Programs Using Community-Partnered Participation Research SO HEALTH PROMOTION PRACTICE LA English DT Article DE CBPR; depression; anxiety ID RANDOMIZED CONTROLLED-TRIAL; QUALITY IMPROVEMENT; PRIMARY-CARE; AFRICAN-AMERICANS; DEPRESSION; INTERVENTION; SERVICES; DISPARITIES; PREVALENCE; ENGAGEMENT AB The inclusion of community partners in participatory leadership roles around statistical design issues like sampling and randomization has raised concerns about scientific integrity. This article presents a case study of a community-partnered, participatory research (CPPR) cluster-randomized, comparative effectiveness trial to examine implications for study validity and community relevance. Using study administrative data, we describe a CPPR-based design and implementation process for agency/ program sampling, recruitment, and randomization for depression interventions. We calculated participation rates and used cross-tabulation to examine balance by intervention status on service sector, location, and program size and assessed differences in potential populations served. We achieved 51.5% agency and 89.6% program participation rates. Programs in different intervention arms were not significantly different on service sector, location, or program size. Participating programs were not significantly different from eligible, nonparticipating programs on community characteristics. We reject claims that including community members in research design decisions compromises scientific integrity. This case study suggests that a CPPR process can improve implementation of a community-grounded, rigorous randomized comparative effectiveness trial. C1 [Stockdale, Susan E.; Chung, Bowen; Belin, Thomas R.; Wells, Kenneth] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Stockdale, Susan E.; Tang, Lingqi] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tang, Lingqi; Pudilo, Esmeralda; Masongsong, Zoe; Wells, Kenneth] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Lucas-Wright, Anna; Jones, Felica] Healthy African Amer Families II, Los Angeles, CA USA. [Lucas-Wright, Anna] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Chung, Bowen; Sherbourne, Cathy; Wells, Kenneth] RAND Corp, Santa Monica, CA USA. [Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Horta, Mariana] Princeton Univ, Princeton, NJ 08544 USA. [Belin, Thomas R.; Wells, Kenneth] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Stockdale, SE (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer Ave,Bldg 25,Room A103, Sepulveda, CA 91343 USA. EM susan.stockdale@va.gov NR 35 TC 1 Z9 1 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD MAR PY 2016 VL 17 IS 2 BP 254 EP 264 DI 10.1177/1524839915605059 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE6WF UT WOS:000370774400012 PM 26384926 ER PT J AU Osborn, KE Shytle, RD Frontera, AT Soble, JR Schoenberg, MR AF Osborn, Katie E. Shytle, R. Douglas Frontera, Alfred T. Soble, Jason R. Schoenberg, Mike R. TI Addressing Potential Role of Magnesium Dyshomeostasis to Improve Treatment Efficacy for Epilepsy: A Reexamination of the Literature SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Review DE magnesium; seizure; epilepsy; epileptogenesis; metal ion; electrolyte imbalance; ketogenic diet ID ASPARTATE-INDUCED SEIZURES; SECONDARY HYPOCALCEMIA; KETOGENIC DIET; FAMILIAL HYPOMAGNESEMIA; ANTIEPILEPTIC DRUGS; REFRACTORY EPILEPSY; CHILDHOOD EPILEPSY; AMERICAN-ACADEMY; DOUBLE-BLIND; DEFICIENCY AB Magnesium (Mg2+) is an abundant mineral in the body serving many biochemical functions. Magnesium supplementation has been shown to raise seizure threshold in animal and human studies, but the etiological contribution of magnesium deficiency to the onset and maintenance of epilepsy, as well as the degree to which it impacts antiepileptic drug efficacy, remains poorly understood. This may be due, at least in part, to the inherent limitations of commonly used serum levels as a measure of functional magnesium status, as well as insufficient data regarding relative bioavailabilities of various magnesium salts and chelates for use with humans. To date, I randomized clinical trial has been conducted assessing Mg2+ supplementation in epilepsy, and findings yielded promising results. Yet a notable dearth in the literature remains, and more studies are needed. To better understand the potential role of magnesium deficiency as a causal factor in epilepsy, more convenient and accurate measurement methods should to be developed and employed in randomized, controlled trials of oral magnesium supplementation in epilepsy. Findings from such studies have the potential to facilitate far-reaching clinical and economic improvements in epilepsy treatment standards. C1 [Osborn, Katie E.; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Psychiat & Behav Neurosci, Tampa, FL USA. [Osborn, Katie E.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Shytle, R. Douglas; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL USA. [Frontera, Alfred T.; Schoenberg, Mike R.] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL 33620 USA. [Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Psychiat & Behav Neurosci, 3515 E Fletcher Ave, Tampa, FL 33613 USA.; Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Neurol, 3515 E Fletcher Ave, Tampa, FL 33613 USA.; Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Neurosurg, 3515 E Fletcher Ave, Tampa, FL 33613 USA. EM mschoenb@health.usf.edu NR 66 TC 0 Z9 0 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-2700 EI 1552-4604 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD MAR PY 2016 VL 56 IS 3 BP 260 EP 265 DI 10.1002/jcph.626 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DD8GB UT WOS:000370162700002 PM 26313363 ER PT J AU Qin, LM Bouchard, R Pugazhenthi, S AF Qin, LiMei Bouchard, Ron Pugazhenthi, Subbiah TI Regulation of cyclic AMP response element-binding protein during neuroglial interactions SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; CREB; human neuroprogenitor cells; microglia; neuroinflammation; signal transduction ID MEDIATED DOWN-REGULATION; NECROSIS-FACTOR-ALPHA; HIPPOCAMPAL NEUROGENESIS; DIFFERENTIAL REGULATION; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; BCL-2 PROMOTER; CELLS; TRANSCRIPTION AB Communications between neurons and glial cells play an important role in regulating homeostasis in the central nervous system. cAMP response element-binding protein (CREB), a transcription factor, is down-regulated by neurotoxins, which are known to be released by activated glial cells. To determine the role of CREB signaling in neuroglial interactions, we used three neuroglial coculture models consisting of human neuroprogenitor cell (NPC)-derived neurons and human microglia. Conditioned medium from the Abeta (A)-activated microglia decreased CREB phosphorylation and brain-derived neurotrophic factor promoter activity (47%), whereas the same medium induced (p<0.01) the promoter of CXCL10, a chemokine, in NPC-derived neuron-rich cultures. These effects were reversed when microglia were exposed to A in the presence of minocycline, an anti-inflammatory agent. The expression of CREB targets, including brain-derived neurotrophic factor, synapsin-1, and BIRC3 decreased by 50-65% (p<0.01) in neurons isolated by laser capture microdissection in close proximity of microglia in neuroglial mixed cultures. Neuronal survival actively modulated microglial behavior when neurons and microglia were cocultured side-by-side on semicircles of ACLAR membrane. Neuronal injury, caused by the over-expression of dominant negative form of CREB, exacerbated A-mediated microglial activation, whereas CREB over-expression resulted in decreased microglial activation. Decreases in the levels of neuronal markers were observed when NPCs were differentiated in the presence of proinflammatory cytokines IL-1, tumor necrosis factor , or IL-6. Instead, the NPCs differentiated into a glial phenotype, and these effects were more pronounced in the presence of tumor necrosis factor . Our findings suggest that CREB down-regulation is an important component of defective neuroglial communications in the brain during neuroinflammation. C1 [Qin, LiMei; Bouchard, Ron; Pugazhenthi, Subbiah] Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO USA. [Bouchard, Ron; Pugazhenthi, Subbiah] Univ Colorado Denver, Dept Med, Aurora, CO USA. RP Pugazhenthi, S (reprint author), Univ Colorado, Denver VA Med Ctr, Anschutz Med Campus,Mail Stop 8106, Aurora, CO 80045 USA.; Pugazhenthi, S (reprint author), Univ Colorado, Dept Med, Anschutz Med Campus,Mail Stop 8106, Aurora, CO 80045 USA. EM subbiah.pugazhenthi@ucdenver.edu FU Veterans Administration [NEUD-004-07F] FX This work was carried out with the use of resources and facilities at the Denver VA Medical Center. This study was supported by Merit Review grant NEUD-004-07F from the Veterans Administration (to S.P.). RT-PCR analysis was performed at the University of Colorado Cancer Center Core Facility. Digital deconvolution microscopy was carried out at the VA Microscopy Core Facility. Authors declare that there is no conflict of interest associated with this manuscript. NR 42 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2016 VL 136 IS 5 BP 918 EP 930 DI 10.1111/jnc.13497 PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DE5BT UT WOS:000370646500004 PM 26677139 ER PT J AU Samantaray, S Das, A Matzelle, DC Yu, SP Wei, L Varma, A Ray, SK Banik, NL AF Samantaray, Supriti Das, Arabinda Matzelle, Denise C. Yu, Shan P. Wei, Ling Varma, Abhay Ray, Swapan K. Banik, Naren L. TI Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE acute spinal cord injury; calpain; estrogen; estrogen receptors; gliosis; neuroprotection ID APOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-VESSELS; RECEPTOR-ALPHA; UP-REGULATION; NEUROPROTECTIVE AGENT; FUNCTIONAL RECOVERY; SIGNAL-TRANSDUCTION; CALPAIN INHIBITORS; CORTICAL-NEURONS AB Spinal cord injury (SCI) is a debilitating condition with neurological deficits and loss of motor function that, depending on the severity, may lead to paralysis. The only treatment currently available is methylprednisolone, which is widely used and renders limited efficacy in SCI. Therefore, other therapeutic agents must be developed. The neuroprotective efficacy of estrogen in SCI was studied with a pre-clinical and pro-translational perspective. Acute SCI was induced in rats that were treated with low doses of estrogen (1, 5, 10, or 100g/kg) and compared with vehicle-treated injured rats or laminectomy control (sham) rats at 48h post-SCI. Changes in gliosis and other pro-inflammatory responses, expression and activity of proteolytic enzymes (e.g., calpain, caspase-3), apoptosis of neurons in SCI, and cell death were monitored via Western blotting and immunohistochemistry. Negligible pro-inflammatory responses or proteolytic events and very low levels of neuronal death were found in sham rats. In contrast, vehicle-treated SCI rats showed profound pro-inflammatory responses with reactive gliosis, elevated expression and activity of calpain and caspase-3, elevated Bax:Bcl-2 ratio, and high levels of neuronal death in lesion and caudal regions of the injured spinal cord. Estrogen treatment at each dose reduced pro-inflammatory and proteolytic activities and protected neurons in the caudal penumbra in acute SCI. Estrogen treatment at 10g was found to be as effective as 100g in ameliorating the above parameters in injured animals. Results from this investigation indicated that estrogen at a low dose could be a promising therapeutic agent for treating acute SCI. C1 [Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA. [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA. [Banik, Naren L.] Ralph H Johnson Vet Adm, Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA. EM baniknl@musc.edu FU NIH [R01-NS31622, R01 NS45967]; Veterans Administration [1IOBX00126 and 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015-P-01, SCIRF-2015-P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program FX This work was supported in part by funding from NIH (R01-NS31622 and R01 NS45967); Veterans Administration (1IOBX00126 and 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015-P-01, SCIRF-2015-P-04, and SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. Kelly Guyton for her valuable contribution to this work. Authors declare no conflict of interests. NR 73 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2016 VL 136 IS 5 BP 1064 EP 1073 DI 10.1111/jnc.13464 PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DE5BT UT WOS:000370646500016 PM 26662641 ER PT J AU Panchal, N Zide, M AF Panchal, Neeraj Zide, Michael TI The Parkland 12-Minute Checklist Tracheotomy SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article AB Purpose: To validate the surgical time and propose a new checklist or algorithm to execute a tracheotomy within 12 minutes with optimal outcomes. Materials and Methods: The authors designed and implemented a checklist method for tracheotomy based on 6 consecutive patients with respiratory failure and prolonged intubation in a medical intensive care unit. The primary outcome variable was surgical time for a tracheotomy performed by a fifth-or sixth-year resident under the supervision of the senior author (M.Z.). Results: Six consecutive patients undergoing tracheotomy (mean, 48 yr; range, 24 to 55 yr; 4 men and 2 women) were included in the study. The average time recorded from the incision to correct insertion of the tracheotomy tube and confirmation of carbon dioxide return by the anesthesiologist was 10.66 minutes (range, 8 to 12 minutes). Conclusion: This checklist facilitates the execution of a time-efficient and safe tracheotomy in less than 12 minutes. (C) 2016 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 74: 556-561, 2016 C1 [Panchal, Neeraj] Univ Texas Southwestern, Parkland Mem Hosp, Dallas, TX USA. [Panchal, Neeraj] Univ Penn, Dept Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA. [Panchal, Neeraj] Philadelphia Vet Affairs Med Ctr, Dept Oral & Maxillofacial Surg, Philadelphia, PA USA. [Zide, Michael] Univ Texas SW Med Ctr Dallas, Div Oral & Maxillofacial Surg, Parkland Mem Hosp, Dallas, TX 75390 USA. RP Panchal, N (reprint author), 3400 Spruce St,5 White Bldg, Philadelphia, PA 19104 USA. EM neeraj.panchal@uphs.upenn.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAR PY 2016 VL 74 IS 3 BP 556 EP 561 DI 10.1016/j.joms.2015.10.022 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DE1FX UT WOS:000370373300023 PM 26657394 ER PT J AU Mukherjee, R AF Mukherjee, Rupak TI Forewarned is forearmed: Benefits of remote ischemic preconditioning SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material ID ISOLATED RAT-HEART; REPERFUSION INJURY; SEVOFLURANE; ISOFLURANE; PROTECTION; MYOCARDIUM C1 [Mukherjee, Rupak] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Div Cardiothorac Surg, MSC 777,114 Doughty St,Ste 338, Charleston, SC 29426 USA. EM mukherr@musc.edu FU NIA NIH HHS [AG036954]; RRD VA [I21 RX001707] NR 14 TC 1 Z9 1 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2016 VL 151 IS 3 BP 786 EP 787 DI 10.1016/j.jtcvs.2015.10.089 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DD9KR UT WOS:000370244700051 PM 26628358 ER PT J AU Barshes, NR Pisimisis, G Kougias, P AF Barshes, Neal R. Pisimisis, George Kougias, Panos TI Compartment syndrome of the foot associated with a delayed presentation of acute limb ischemia SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID FASCIOTOMY; ANKLE AB Compartment syndrome of the leg is a well-recognized complication known to follow urgent revascularization done for acute limb ischemia, but compartment syndrome of the foot has not been reported after the ischemia-reperfusion sequence. Herein we report a case of foot fasciotomy done for compartment syndrome that occurred after urgent revascularization. We suggest that foot fasciotomies should be considered in particular circumstances of acute lower leg ischemia, such as infrapopliteal thromboembolic events, prolonged ischemia, and persistent or worsening foot symptoms that follow revascularization and calf fasciotomies. C1 [Barshes, Neal R.; Pisimisis, George; Kougias, Panos] Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Div Vasc & Endovasc Surg, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr,Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 16 TC 1 Z9 1 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAR PY 2016 VL 63 IS 3 BP 819 EP 822 DI 10.1016/j.jvs.2015.01.043 PG 4 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DE6YI UT WOS:000370780400037 PM 25752690 ER PT J AU Ford, JM AF Ford, Judith M. TI Studying auditory verbal hallucinations using the RDoC framework SO PSYCHOPHYSIOLOGY LA English DT Article DE RDoC; Agency; Auditory verbal hallucinations; EEG; ERP; N1 ID COROLLARY DISCHARGE; SPEECH PRODUCTION; SCHIZOPHRENIA; CORTEX; SYMPTOMS; INITIATION; RESPONSES; TALKING; SOUNDS; BRAIN AB In this paper, I explain why I adopted a Research Domain Criteria (RDoC) approach to study the neurobiology of auditory verbal hallucinations (AVH), or voices. I explain that the RDoC construct of agency fits well with AVH phenomenology. To the extent that voices sound nonself, voice hearers lack a sense of agency over the voices. Using a vocalization paradigm like those used with nonhuman primates to study mechanisms subserving the sense of agency, we find that the auditory N1 ERP is suppressed during vocalization, that EEG synchrony preceding speech onset is related to N1 suppression, and that both are reduced in patients with schizophrenia. Reduced cortical suppression is also seen across multiple psychotic disorders and in clinically high-risk youth, but it is not related to AVH. The motor activity preceding talking and connectivity between frontal and temporal lobes during talking have both proved sensitive to AVH, suggesting neural activity and connectivity associated with intentions to act may be a better way to study agency and predictions based on agency. C1 [Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Ford, JM (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.; Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.Ford@ucsf.edu FU Department of Veterans Affairs [I01CX000497]; National Institute of Mental Health [MH-58262] FX This work was supported by grants to JMF from Department of Veterans Affairs (I01CX000497) and National Institute of Mental Health (MH-58262). I would like to thank all of my coauthors of the work discussed in this paper. Special thanks go to Daniel H. Mathalon for ongoing inspiration and intellectual guidance, Brian J. Roach for making it all happen and his inspired data analysis, John Sweeney and his team for collecting data with our paradigm at his BSNIP site at the University of Illinois in Chicago, James Reilly for the heritability analysis of the BSNIP data, Jun Wang for his MRI-guided source analysis of the BSNIP data, Chi-Ming Chen for his analysis of the intracranial data, Veronica Perez for her analysis of the data from the clinical high-risk sample, Theda Heinks for her work on the pitch perturbation paradigm, Kevin Sitek for his work on the naturalistic formant variation analysis, Vanessa Palzes for her work on the button press paradigms, and to all the patients and their families for participating in this research. NR 64 TC 8 Z9 8 U1 5 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD MAR PY 2016 VL 53 IS 3 SI SI BP 298 EP 304 DI 10.1111/psyp.12457 PG 7 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DE2VL UT WOS:000370485200003 PM 26877116 ER PT J AU Cochran, G Gordon, AJ Field, C Bacci, J Dhital, R Ylioja, T Stitzer, M Kelly, T Tarter, R AF Cochran, Gerald Gordon, Adam J. Field, Craig Bacci, Jennifer Dhital, Ranjita Ylioja, Thomas Stitzer, Maxine Kelly, Thomas Tarter, Ralph TI Developing a framework of care for opioid medication misuse in community pharmacy SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Opioid misuse; Adherence; Medication management; Qualitative research ID RANDOMIZED CONTROLLED-TRIAL; BRIEF ALCOHOL INTERVENTIONS; GENERAL-PRACTICE; NONMEDICAL USE; DRUG-USE; THERAPY MANAGEMENT; CLINICAL-TRIAL; SETTINGS; HEALTH; PAIN AB Background: Prescription opioid misuse is a major public health concern in the US. Few resources exist to support community pharmacists engaging patients who misuse or are at risk for misuse. Objectives: This report describes the results of the execution of the ADAPT-ITT model (a model for modifying evidence-based behavioral interventions to new populations and service settings) to guide the development of a behavioral health framework for opioid medication misuse in the community pharmacy setting. Methods: Pharmacy, addiction, intervention, and treatment experts were convened to attend a one-day meeting to review the empirical knowledgebase and discuss adapting the screening, brief intervention, and referral to treatment (SBIRT) protocol for addressing opioid medication misuse in community pharmacy. Qualitative data gathered from the meeting were analyzed by 2 independent coders in a 2-cycle process using objective coding schemes. Percentage of agreement and Cohen's Kappa were calculated to assess coder agreement. Results: First-cycle coding identified 4 distinct themes, with coder percentage of agreement ranging from 93.5 to 99.6% and with Kappa values between 0.81 and 0.93. Second-cycle coding identified 10 sub-themes, with coder percentage of agreement ranging from 83 to 99.8% and with Kappa values between 0.58 and 0.93. Identified themes and sub-themes encompassed patient identification, intervention, prevention, and referral to treatment. Conclusions: Focus of screening efforts in the emerging model should capitalize on pharmacists' knowledge of medication management. Screening likewise should be multidimensional in order to facilitate patient-centered interventions that activate additional disciplines able to interface with patients at risk or involved in medication misuse. (C) 2016 Elsevier Inc. All rights reserved. C1 [Cochran, Gerald; Ylioja, Thomas] Univ Pittsburgh, Sch Social Work, 4200 Fifth Ave, Pittsburgh, PA 15260 USA. [Cochran, Gerald; Kelly, Thomas] Univ Pittsburgh, Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15213 USA. [Gordon, Adam J.] Univ Pittsburgh, Dept Med, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Univ Dr C 151-C, Pittsburgh, PA 15240 USA. [Field, Craig] Univ Texas El Paso, Dept Psychol, El Paso, TX 79968 USA. [Bacci, Jennifer] Univ Pittsburgh, Sch Pharm, 501 Terrace St, Pittsburgh, PA 15213 USA. [Dhital, Ranjita] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, James Clerk Maxwell Bldg,57 Waterloo Rd, London SE1 8WA, England. [Stitzer, Maxine] Johns Hopkins Med, Behav Pharmacol Res Unit, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA. RP Cochran, G (reprint author), Univ Pittsburgh, Sch Social Work, 4200 Fifth Ave, Pittsburgh, PA 15260 USA. EM gcochran@pitt.edu FU Staunton Farm Foundation FX This project was supported by a grant from the Staunton Farm Foundation, which had no involvement in the conceptualization, execution, or submission of this work. NR 49 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD MAR-APR PY 2016 VL 12 IS 2 BP 293 EP 301 DI 10.1016/j.sapharm.2015.05.001 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DE1NB UT WOS:000370392600007 PM 26048710 ER PT J AU Walker, M El-Serag, HB Sada, Y Mittal, S Ying, J Duan, Z Richardson, P Davila, JA Kanwal, F AF Walker, M. El-Serag, H. B. Sada, Y. Mittal, S. Ying, J. Duan, Z. Richardson, P. Davila, J. A. Kanwal, F. TI Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID FATTY LIVER-DISEASE; PRIMARY-CARE PROVIDERS; UNITED-STATES; HEPATITIS-C; CARCINOMA; FIBROSIS; SURVEILLANCE; PROGNOSIS; POPULATION; ARTICLE AB BackgroundMost clinical practice guidelines recommend screening for HCC in patients with cirrhosis. However, patients with compensated cirrhosis are often asymptomatic and may remain unrecognised for years. AimsTo determine the extent to which cirrhosis is unrecognised in a US Veteran population with HCC, and to evaluate the association between lack of cirrhosis recognition and stage of HCC at diagnosis. MethodsWe reviewed the electronic medical records of a random sample of HCC cases diagnosed in the national Veterans Affairs system between 2005 and 2011. We conducted multivariable analyses adjusting for patients' demographics, comorbidity, aetiology of underlying disease and healthcare utilisation including HCC surveillance. ResultsOf 1201 patients with HCC and cirrhosis, 24.6% had unrecognised cirrhosis prior to HCC diagnosis. Older patients [>65 years, odds ratio (OR) 2.32], African Americans (OR 1.93), patients with alcoholic or NAFLD liver disease (OR 1.69 and 4.77 respectively), HIV (OR 3.02), and fewer comorbidities (Deyo 0 vs. 3, OR 2.42) had significantly higher odds of having unrecognised cirrhosis than comparison groups. Furthermore, patients with unrecognised cirrhosis were 6.5 times more likely to have advanced stage HCC at diagnosis. The effect of cirrhosis recognition on HCC stage remained significant after adjusting for pre-specified covariates (OR 3.37). ConclusionsIn one quarter of patients, cirrhosis was unrecognised prior to HCC diagnosis, and this group was significantly more likely to have advanced stage HCC. These findings emphasise the importance of timely evaluation for cirrhosis in at-risk populations as a critical step to improving outcomes for patients with HCC. C1 [Walker, M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [El-Serag, H. B.; Sada, Y.; Mittal, S.; Ying, J.; Duan, Z.; Richardson, P.; Davila, J. A.; Kanwal, F.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effect & Safety IQuESt, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. [El-Serag, H. B.; Mittal, S.; Kanwal, F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, H. B.; Mittal, S.; Kanwal, F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Hepatol, Houston, TX 77030 USA. [Sada, Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hematol & Oncol, Houston, TX 77030 USA. [Richardson, P.; Davila, J. A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Davila, JA; Kanwal, F (reprint author), Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effect & Safety IQuESt, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM jdavila@bcm.edu; fasiha.kanwal@va.gov FU National Cancer Institute [R01 CA160738]; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This material is based upon work supported by the National Cancer Institute (R01 CA160738, PI: Davila), and in part by the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413). NR 31 TC 3 Z9 3 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAR PY 2016 VL 43 IS 5 BP 621 EP 630 DI 10.1111/apt.13505 PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA DD5QU UT WOS:000369980000007 PM 26784271 ER PT J AU Bergman, J Ballon-Landa, E Lorenz, KA Saucedo, J Saigal, CS Bennett, CJ Litwin, MS AF Bergman, Jonathan Ballon-Landa, Eric Lorenz, Karl A. Saucedo, Josemanuel Saigal, Christopher S. Bennett, Carol J. Litwin, Mark S. TI Community-Partnered Collaboration to Build an Integrated Palliative Care Clinic: The View From Urology SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE adult; attitude of health personnel; delivery of health care; integrated; interviews as topic; palliative care; patient care team; patient preference; physician's role; physicians; psychology; quality improvement; quality of health care; terminal care; urology ID END-OF-LIFE; ADVANCED CANCER; SUPPORTIVE CARE; QUALITY; HEALTH; INTERVENTION; PROVIDERS; ATTITUDES; OUTCOMES; PROJECT AB Background: We partnered with patients, families, and palliative care clinicians to develop an integrated urology-palliative care clinic for patients with metastatic cancer. We assessed clinician satisfaction with a multidisciplinary palliative care clinic model. Methods: We conducted semi-structured interviews with 18 clinicians who practice in our integrated clinic. We analyzed transcripts using a multistage, cutting-and-sorting technique in an inductive approach based on grounded theory analysis. Finally, we administered a validated physician job satisfaction survey. Results: Clinicians found that referring a patient to palliative care in the urology clinic was feasible and appropriate. Patients were receptive to supportive care, and clinicians perceived that quality of care improved following the intervention. Conclusion: An integrated, patient-centered model for individuals with advanced urologic malignancies is feasible and well received by practitioners. C1 [Bergman, Jonathan; Saucedo, Josemanuel; Saigal, Christopher S.; Bennett, Carol J.; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. [Bergman, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90024 USA. [Bergman, Jonathan; Lorenz, Karl A.; Saigal, Christopher S.; Bennett, Carol J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ballon-Landa, Eric] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA. [Ballon-Landa, Eric] UC Irvine Sch Med, Irvine, CA USA. [Lorenz, Karl A.; Saigal, Christopher S.] RAND Corp, Santa Monica, CA USA. [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. EM jbergman@mednet.ucla.edu RI Kausar, Nadia/D-7414-2016 NR 34 TC 1 Z9 1 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAR PY 2016 VL 33 IS 2 BP 164 EP 170 DI 10.1177/1049909114555156 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD8TW UT WOS:000370200800009 PM 25326489 ER PT J AU Reinke, LF Feemster, LC Backhus, LM Gylys-Colwell, I Au, DH AF Reinke, Lynn F. Feemster, Laura C. Backhus, Leah M. Gylys-Colwell, Ina Au, David H. TI Assessment and Management of Symptoms for Outpatients Newly Diagnosed With Lung Cancer SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE lung cancer; newly diagnosed; symptom assessment; management ID OBSTRUCTIVE PULMONARY-DISEASE; EARLY PALLIATIVE CARE; ADULTS RECEIVING TREATMENT; HOME NURSING-CARE; OF-LIFE CARE; PROGNOSTIC INFORMATION; DISTRESS; COMMUNICATION; INTERVENTION; PREFERENCES AB Rationale: Little is known about symptom assessment around the time of lung cancer diagnosis. The purpose of this pilot study was to assess symptoms within 2 months of diagnosis and the frequency with which clinicians addressed symptoms among a cohort of veterans (n = 20) newly diagnosed with lung cancer. We administered questionnaires and then reviewed medical records to identify symptom assessment and management provided by subspecialty clinics for 6 months following diagnosis. Results: Half (50%) of the patients were diagnosed with early-stage non-small-cell lung cancer (NSCLC), stage I or II. At baseline, 45% patients rated their overall symptoms as severe. There were no significant differences in symptoms among patients with early- or late-stage NSCLC or small-cell lung cancer. Of the 212 clinic visits over 6 months, 70.2% occurred in oncology. Clinicians most frequently addressed pain although assessment differed by clinic. Conclusions: Veterans with newly diagnosed lung cancer report significant symptom burden. Despite ample opportunities to address patients' symptoms, variations in assessment exist among subspecialty services. Coordinated approaches to symptom assessment are likely needed among patients newly diagnosed with lung cancer. C1 [Reinke, Lynn F.; Feemster, Laura C.; Backhus, Leah M.; Gylys-Colwell, Ina; Au, David H.] Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv R&D, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Feemster, Laura C.; Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Backhus, Leah M.] Univ Washington, Sch Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA. RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv R&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM reinkl@uw.edu RI Kausar, Nadia/D-7414-2016 FU Office of Nursing Services from United States (US) Department of Veterans Affairs [NRI-01-001] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported a pilot project award from the Office of Nursing Services, #NRI-01-001 from the United States (US) Department of Veterans Affairs. NR 31 TC 2 Z9 2 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAR PY 2016 VL 33 IS 2 BP 178 EP 183 DI 10.1177/1049909114557635 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD8TW UT WOS:000370200800011 PM 25376224 ER PT J AU Sharma, A Albergotti, WG Duvvuri, U AF Sharma, Arun Albergotti, W. Greer Duvvuri, Umamaheswar TI Applications of Evolving Robotic Technology for Head and Neck Surgery SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE head and neck; head and neck cancer; robotic surgery; transoral robotic surgery; thyroid ID SQUAMOUS-CELL CARCINOMA; CANCER AB Objective: Assess the use and potential benefits of a new robotic system for transoral radical tonsillectomy, transoral supraglottic laryngectomy, and retroauricular thyroidectomy in a cadaver dissection. Methods: Three previously described robotic procedures (transoral radical tonsillectomy, transoral supraglottic laryngectomy, and retroauricular thyroidectomy) were performed in a cadaver using the da Vinci Xi Surgical System. Surgical exposure and access, operative time, and number of collisions were examined objectively. Results: The new robotic system was used to perform transoral radical tonsillectomy with dissection and preservation of glossopharyngeal nerve branches, transoral supraglottic laryngectomy, and retroauricular thyroidectomy. There was excellent exposure without any difficulties in access. Robotic operative times (excluding set-up and docking times) for the 3 procedures in the cadaver were 12.7, 14.3, and 21.2 minutes (excluding retroauricular incision and subplatysmal elevation), respectively. No robotic arm collisions were noted during these 3 procedures. The retroauricular thyroidectomy was performed using 4 robotic ports, each with 8 mm instruments. Conclusions: The use of updated and evolving robotic technology improves the ease of previously described robotic head and neck procedures and may allow surgeons to perform increasingly complex surgeries. C1 [Sharma, Arun] So Illinois Univ, Div Otolaryngol Head & Neck Surg, Springfield, IL USA. [Albergotti, W. Greer; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Head & Neck Robot Surg,Eye & Ear Inst, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Head & Neck Robot Surg,Eye & Ear Inst, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs, Biomedical and Laboratory Science Research and Development group FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part from funds from the Department of Veterans Affairs, Biomedical and Laboratory Science Research and Development group. This works does not reflect the views of the Department of Veterans Affairs or the US government. NR 15 TC 1 Z9 2 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD MAR PY 2016 VL 125 IS 3 BP 207 EP 212 DI 10.1177/0003489415606448 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DD6YN UT WOS:000370070800004 PM 26391091 ER PT J AU Pearce, EN Lee, SL Magner, RW Garber, JR Campion, FX Leung, AM AF Pearce, Elizabeth N. Lee, Stephanie L. Magner, Richard Weissjames Garber, Jeffrey R. Campion, F. X. Leung, Angela M. TI Unique obstacles to establishing thyroid cancer registries SO JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY LA English DT Letter C1 [Pearce, Elizabeth N.; Lee, Stephanie L.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02215 USA. [Pearce, Elizabeth N.; Garber, Jeffrey R.] Harvard Vanguard Med Associates, Div Endocrine, Boston, MA USA. [Magner, Richard Weissjames] Sanofi Co, Med Affairs Genzyme Corp, Cambridge, MA USA. [Garber, Jeffrey R.] Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA USA. [Campion, F. X.] Harvard Med Sch, Dept Populat Med, Boston, MA USA. [Campion, F. X.] Harvard Vanguard Med Associates, Dept Internal Med, Boston, MA USA. [Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA USA. RP Leung, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. EM AMLeung@mednet.ucla.edu FU NIH [K23HD068552]; Genzyme Corporation FX Supported by NIH K23HD068552 (AML). Some funds to support pilot efforts were provided by Genzyme Corporation as an Investigator Sponsored Study. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-6237 J9 J CLIN TRANSL ENDOCR JI J. Clin. Transl. ENdocrinol. PD MAR PY 2016 VL 3 BP 12 EP 13 DI 10.1016/j.jcte.2015.12.003 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ER8QX UT WOS:000399087900003 ER PT J AU Haynes, PL Kelly, M Warner, L Quan, SF Krakow, B Bootzin, RR AF Haynes, Patricia L. Kelly, Monica Warner, Lesley Quan, Stuart F. Krakow, Barry Bootzin, Richard R. TI Cognitive Behavioral Social Rhythm Group Therapy for Veterans with posttraumatic stress disorder, depression, and sleep disturbance: Results from an open trial SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Veterans; Post-traumatic stress disorder; Depression; Insomnia; Cognitive behavioral therapy ID ADMINISTERED PTSD SCALE; RANDOMIZED CONTROLLED-TRIAL; CIRCADIAN-RHYTHMS; MAJOR DEPRESSION; PSYCHOLOGICAL TREATMENTS; COMORBID INSOMNIA; IMAGERY REHEARSAL; MENTAL-DISORDERS; VIETNAM VETERANS; COMBAT VETERANS AB Introduction: Cognitive Behavioral Social Rhythm Therapy (CBSRT) is a group psychotherapy tailored for Veterans with Posttraumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and sleep disturbances. The aims of this study were to introduce and present initial outcomes of Cognitive Behavioral Social Rhythm Therapy (CBSRT), a 12-week skills group therapy designed to improve sleep and mood by reducing chaotic or isolated lifestyles in Veterans with PTSD. Methods: Twenty-four male Veterans with at least moderate PTSD and MDD participated in this open trial. Main outcomes were the daily sleep diary for sleep disturbances, the Clinician-Administered PTSD Scale (CAPS) for PTSD, and the Hamilton Depression Rating scale for MDD. Results: Veterans improved on all measures (a) with large within subject effects on PTSD symptoms, MDD symptoms, and sleep quality, and (b) with 46-58% of the sample receiving clinically significant benefits on MDD and PTSD symptoms respectively. The consistency of social rhythms was associated with the average reduction in global CAPS scores over time. Only 13% of participants dropped-out of the group therapy prematurely suggesting that this new group therapy is relatively well-tolerated by Veterans. Limitations: Future research that employs a control condition is necessary to establish efficacy of CBSRT. Conclusions: Data from this initial pilot study demonstrate that CBSRT may be an effective group treatment option for Veterans presenting with all three symptom complaints. These data also suggest that daily routine may be an important mechanism to consider in the treatment of PTSD symptoms comorbid with depression. (C) 2015 Elsevier B.V. All rights reserved. C1 [Haynes, Patricia L.] Univ Arizona, Dept Hlth Promot Sci, 1295 N Martin Ave,POB 245209, Tucson, AZ 85724 USA. [Haynes, Patricia L.; Kelly, Monica; Warner, Lesley; Bootzin, Richard R.] Univ Arizona, Dept Psychiat, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Haynes, Patricia L.; Kelly, Monica; Warner, Lesley] Southern Arizona VA Hlth Care Syst, 3601 S 6th Ave,116B, Tucson, AZ 85723 USA. [Haynes, Patricia L.; Kelly, Monica; Bootzin, Richard R.] Univ Arizona, Dept Psychol, 1503 E Univ Blvd, Tucson, AZ 85721 USA. [Quan, Stuart F.] Univ Arizona, Dept Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Quan, Stuart F.] Harvard Univ, Div Sleep Med, Sch Med, 164 Longwood Ave, Boston, MA 02115 USA. [Krakow, Barry] Maimonides Sleep Arts & Sci, 6739 Acad Rd NE Suite 380, Albuquerque, NM 87109 USA. [Warner, Lesley] VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Haynes, PL (reprint author), Univ Arizona, Dept Hlth Promot Sci, 1295 N Martin Ave,POB 245209, Tucson, AZ 85724 USA. EM thaynes@email.arizona.edu FU American Sleep Medicine Foundation Career Development Grant [37-CA-06]; Institute for Mental Health Research Pilot Award FX This project was supported by the American Sleep Medicine Foundation Career Development Grant (Grant #37-CA-06) and the Institute for Mental Health Research Pilot Award. The authors gratefully acknowledge the assistance of Marta Williamson, Valerie Scheller, Sacha Brown, and Suzanne Perkins. Dr. Haynes, Ms. Kelly, and Ms. Warner are no longer affiliated with the Southern Arizona VA Health Care System. NR 94 TC 3 Z9 3 U1 12 U2 33 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAR 1 PY 2016 VL 192 BP 234 EP 243 DI 10.1016/j.jad.2015.12.012 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DB8UG UT WOS:000368791600032 PM 26748739 ER PT J AU Garcia, HA McGeary, CA Finley, EP McGeary, DD Ketchum, NS Peterson, AL AF Garcia, Hector A. McGeary, Cindy A. Finley, Erin P. McGeary, Donald D. Ketchum, Norma S. Peterson, Alan L. TI The influence of trauma and patient characteristics on provider burnout in VA post-traumatic stress disorder specialty programmes SO PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE LA English DT Article DE burnout; Veterans Health Administration; post-traumatic stress disorder; malingering; personality disorders ID COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH PROVIDERS; COMPASSION SATISFACTION; BEHAVIORAL THERAPY; JOB BURNOUT; VETERANS; RECOMMENDATIONS; DISSEMINATION; PROFESSIONALS; FATIGUE AB ObjectiveProlonged exposure (PE) and cognitive processing therapy (CPT) - post-traumatic stress disorder (PTSD) treatments now available at the Veterans Health Administration (VHA) - expose the provider to graphic traumatic material. Little is known about the impact of traumatic material on VHA providers. The purpose of this study was to examine the relationship between trauma content, patient characteristics, and burnout among VHA PTSD Clinical Team (PCT) providers. It was hypothesized that trauma content and patient characteristics would significantly predict burnout in this population. DesignThis cross-sectional study consisted of 137 participants. The sample was mostly female (67%), Caucasian (non-Hispanic; 81%), and married (70%) with a mean age of 44.3years (SD=11.3). MethodsParticipants completed an electronic survey that assessed demographics, patient characteristics (i.e., anger, personality disorder, malingering), trauma content characteristics (e.g., killing of women and children) as well as burnout as measured by the Maslach Burnout Inventory-General Survey (MBI-GS; Maslach etal., 1996, Burnout inventory manual. Palo Alto: Consulting Psychologist Press). ResultsOver half of the study population reported being bothered by trauma content; however, trauma content did not predict burnout. Treating patients with personality disorders and suspected malingering predicted burnout in PCT providers. High numbers (77%) reported perceiving that emotional exhaustion impacted the quality of care they provided. ConclusionThese findings suggest an important role of burnout assessment, prevention, and treatment strategies at the VHA. C1 [Garcia, Hector A.; Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Garcia, Hector A.; McGeary, Cindy A.; McGeary, Donald D.; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ketchum, Norma S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Garcia, HA (reprint author), Frank Tejeda Outpatient Clin, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Hector.Garcia2@va.gov OI Finley, Erin/0000-0003-4497-7721 FU Practice Based Research Network, The University of Texas Health Science Center at San Antonio FX The research was supported in part by the Practice Based Research Network, The University of Texas Health Science Center at San Antonio. NR 43 TC 3 Z9 3 U1 4 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1476-0835 EI 2044-8341 J9 PSYCHOL PSYCHOTHER-T JI Psychol. Psychother.-Theory Res. Pract. PD MAR PY 2016 VL 89 IS 1 BP 66 EP 81 DI 10.1111/papt.12057 PG 16 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DB9KE UT WOS:000368834000005 PM 25643839 ER PT J AU Han, SJ Jang, HS Kim, JI Lipschutz, JH Park, KM AF Han, Sang Jun Jang, Hee-Seong Kim, Jee In Lipschutz, Joshua H. Park, Kwon Moo TI Unilateral nephrectomy elongates primary cilia in the remaining kidney via reactive oxygen species SO SCIENTIFIC REPORTS LA English DT Article ID INDUCED FUNCTIONAL INJURY; HEPATOCYTE GROWTH-FACTOR; MAPK KINASE ACTIVATION; ISCHEMIA/REPERFUSION INJURY; OXIDATIVE STRESS; EPITHELIAL-CELLS; ISCHEMIC-INJURY; CILIOGENESIS; CYSTOGENESIS; HYPERTROPHY AB The length of primary cilia is associated with normal cell and organ function. In the kidney, the change of functional cilia length/mass is associated with various diseases such as ischemia/reperfusion injury, polycystic kidney disease, and congenital solitary kidney. Here, we investigate whether renal mass reduction affects primary cilia length and function. To induce renal mass reduction, mice were subjected to unilateral nephrectomy (UNx). UNx increased kidney weight and superoxide formation in the remaining kidney. Primary cilia were elongated in proximal tubule cells, collecting duct cells and parietal cells of the remaining kidney. Mn(III) Tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP), an antioxidant, reduced superoxide formation in UNx-mice and prevented the elongation of primary cilia. UNx increased the expression of phosphorylated ERK, p21, and exocyst complex members Sec8 and Sec10, in the remaining kidney, and these increases were prevented by MnTMPyP. In MDCK, a kidney tubular epithelial cell line, cells, low concentrations of H2O2 treatment elongated primary cilia. This H2O2-induced elongation of primary cilia was also prevented by MnTMPyP treatment. Taken together, these data demonstrate that kidney compensation, induced by a reduction of renal mass, results in primary cilia elongation, and this elongation is associated with an increased production of reactive oxygen species (ROS). C1 [Han, Sang Jun; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Daegu 700422, South Korea. [Han, Sang Jun; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, BK Project 21, Daegu 700422, South Korea. [Kim, Jee In] Keimyung Univ, Sch Med, Dept Mol Med, Daegu 705717, South Korea. [Kim, Jee In] Keimyung Univ, Sch Med, MRC, Daegu 705717, South Korea. [Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. RP Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, Dept Anat, Daegu 700422, South Korea.; Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, BK Project 21, Daegu 700422, South Korea. EM kmpark@knu.ac.kr FU National Research Foundation of Korea (NRF) - Korea government (MEST) [NRF-2014R1A11049549]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C2011] FX This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A11049549) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare (HI14C2011), Republic of Korea. NR 31 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 29 PY 2016 VL 6 AR 22281 DI 10.1038/srep22281 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF1OO UT WOS:000371109300002 PM 26923764 ER PT J AU Knight, EM Ruiz, HH Kim, SH Harte, JC Hsieh, W Glabe, C Klein, WL Attie, AD Buettner, C Ehrlich, ME Gandy, S AF Knight, Elysse M. Ruiz, Henry H. Kim, Soong Ho Harte, Jessica C. Hsieh, Wilson Glabe, Charles Klein, William L. Attie, Alan D. Buettner, Christoph Ehrlich, Michelle E. Gandy, Sam TI Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1 SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Alzheimer's disease; Amyloid beta; Metabolic; Insulin; Glucose; Transgenic model ID AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E RECEPTOR; QUANTITATIVE TRAIT LOCUS; TRANSGENIC MOUSE MODEL; INSULIN-RESISTANCE; A-BETA; DIABETES-MELLITUS; LR11/SORLA EXPRESSION; RETROMER COMPLEX; DISEASE AB Introduction: Insulin resistance and type 2 diabetes mellitus (T2D) are associated with increased risk for cognitive impairment, Alzheimer's disease (AD) and vascular dementia. SORCS1 encodes a protein-sorting molecule genetically linked to both T2D and AD. The association of SORCS1 with both AD and T2D is sexually dimorphic in humans, with both disease associations showing more robust effects in females. Based on published evidence that manipulation of the mouse genome combining multiple genes related to cerebral amyloidosis, to T2D, or both, might provide novel mouse models with exacerbated amyloid and/or diabetes phenotypes, we assessed memory, glucose homeostasis, and brain biochemistry and pathology in male and female wild-type, Sorcs1 -/-, APP/PSEN1, and Sorcs1 -/- X APP/PSEN1 mice. Results: Male mice with either the APP/PSEN1 or Sorcs1 -/- genotype displayed earlier onset and persistent impairment in both learning behavior and glucose homeostasis. Unlike prior examples in the literature, the behavioral and metabolic abnormalities in male mice were not significantly exacerbated when the two disease model mice (Sorcs1 -/- models T2D; APP/PSEN1 models AD) were crossed. However, female Sorcs1 -/- X APP/PSEN1 mice exhibited worse metabolic dysfunction than Sorcs1 -/- knockout mice and worse memory than wild-type mice. The deletion of Sorcs1 from APP/PSEN1 mutant mice led to no obvious changes in brain levels of total or oligomeric amyloid-beta (A beta) peptide. Conclusions: In general, unexpectedly, there was a trend for gene targeting of Sorcs1-/- to partially mitigate, not exacerbate, the metabolic and amyloid pathologies. These results indicate that crossing AD model mice and T2D model mice may not always cause exacerbation of both the amyloidosis phenotype and the metabolic phenotype and highlight the unexpected pitfalls of creating mixed models of disease. C1 [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Ehrlich, Michelle E.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Ruiz, Henry H.; Hsieh, Wilson; Buettner, Christoph] Icahn Sch Med Mt Sinai, Dept Med, Diabet Obes & Metab Inst, New York, NY 10029 USA. [Glabe, Charles] Univ Calif Irvine, Irvine, CA 92697 USA. [Klein, William L.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA. [Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Glabe, Charles] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia. [Glabe, Charles] King Abdulaziz Univ, King Fahd Med Res Ctr, Expt Biochem Unit, Jeddah 21413, Saudi Arabia. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.; Gandy, S (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. EM samuel.gandy@mssm.edu RI Faculty of, Sciences, KAU/E-7305-2017 FU BLRD VA [I01 BX000348]; NIA NIH HHS [R34 AG049649, P50 AG005138, U01 AG046170]; NIAAA NIH HHS [AA023416, R01 AA023416]; NIDDK NIH HHS [DK074873, DK082724, DK083568, K08 DK074873, R03 DK082724]; NINDS NIH HHS [NS075685, R01 NS075685]; RRD VA [I01 RX000684] NR 70 TC 2 Z9 2 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD FEB 25 PY 2016 VL 4 AR 16 DI 10.1186/s40478-016-0282-y PG 15 WC Neurosciences SC Neurosciences & Neurology GA DE7SE UT WOS:000370836200001 PM 26916443 ER PT J AU Pott, GB Tsurudome, M Bamfo, N Goalstone, ML AF Pott, Gregory B. Tsurudome, Mark Bamfo, Nadia Goalstone, Marc L. TI ERK2 and Akt are negative regulators of insulin and Tumor Necrosis Factor-alpha stimulated VCAM-1 expression in rat aorta endothelial cells SO JOURNAL OF INFLAMMATION-LONDON LA English DT Article DE Atherosclerosis; Inflammation; ERK2; Akt; RNAi; Insulin; TNF alpha; VCAM-1 ID ADHESION MOLECULE-1 EXPRESSION; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; CARDIOVASCULAR-DISEASE; SURFACE EXPRESSION; RESISTANCE; DIFFERENTIATION; INFLAMMATION; MONOCYTE AB Background: Diabetes is quickly becoming the most widespread disorder in the Western world. Among the most prevalent effects of diabetes is atherosclerosis, which in turn is driven in part by inflammation. Both insulin and Tumor Necrosis Factor-alpha (TNF alpha) increase the presence of Vascular Cellular Adhesion Molecule-1 (VCAM-1) expression. The aim of this study is to determine the effects of downregulating Extracellular signal-Regulated Kinase-2 (ERK2) and Akt on insulin and TNF alpha-stimulated VCAM-1 expression. Methods: Here we begin to define the relationships between ERK2 and Akt regulation of insulin and TNF alpha-stimulated VCAM-1 expression in Rat Arterial Endothelial Cells (RAEC) by transfecting RAEC with ERK2 and Akt RNA interference (RNAi) and then treating these cells with insulin (10 nM) or TNF alpha (10 ng/mL) alone or in combination. Results: Western blot analyses, flow cytometry and confocal microscopy were used to determine changes in VCAM-1 expression within the above-stated parameters. Cells transfected with ERK2 or Akt RNAi plasmids increased insulin and TNF alpha-stimulated VCAM-1 total protein expression significantly (P < 0.05) greater than that seen in mock transfected cells and expressed cell surface VCAM-1 greater than that seen in mock transfected cells as indicated by flow cytometry and confocal microscopy. Nevertheless, the decrease of both kinases did not increase insulin or TNF alpha-stimulated VCAM-1 expression above that seen when one or the other RNAi was present. Conclusions: Taken together, our results demonstrate that ERK2 and Akt may be negative regulators of insulin and TNF-alpha stimulated VCAM-1 and that their loss or down regulation might upregulate VCAM-1 expression and contribute to vascular disease. C1 [Pott, Gregory B.; Tsurudome, Mark; Bamfo, Nadia; Goalstone, Marc L.] Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, 12801 East 17th Ave Mail Stop 8106, Aurora, CO 80045 USA. [Goalstone, Marc L.] Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, 1055 Clermont St Mail Stop 151, Denver, CO 80220 USA. RP Goalstone, ML (reprint author), Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, 12801 East 17th Ave Mail Stop 8106, Aurora, CO 80045 USA.; Goalstone, ML (reprint author), Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, 1055 Clermont St Mail Stop 151, Denver, CO 80220 USA. EM Marc.Goalstone@va.gov FU Research Service of the Department of Veterans Affairs FX This work was supported by the Research Service of the Department of Veterans Affairs (to M.L.G.), in which Dr. Goalstone is a recipient of a VA Merit Review Award. We would like to thank Ron Bouchard for his excellent work in confocal microscopy and Harsh Pratap for his beneficial assistance with our flow cytometry measurements. The flow cytometer is equipment associated with the Mucosal and Vaccine Research Colorado (MAVRC). NR 25 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-9255 J9 J INFLAMM-LOND JI J. Inflamm.-Lond. PD FEB 25 PY 2016 VL 13 AR 6 DI 10.1186/s12950-016-0115-6 PG 9 WC Immunology SC Immunology GA DF1WR UT WOS:000371130600001 PM 26917991 ER PT J AU Paul-Emile, K Smith, AK Lo, B Fernandez, A AF Paul-Emile, Kimani Smith, Alexander K. Lo, Bernard Fernandez, Alicia TI Dealing with Racist Patients SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Paul-Emile, Kimani] Fordham Univ, Sch Law, New York, NY 10023 USA. [Lo, Bernard] Greenwall Fdn, New York, NY USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Fernandez, Alicia] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Paul-Emile, K (reprint author), Fordham Univ, Sch Law, New York, NY 10023 USA. NR 3 TC 2 Z9 2 U1 1 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 25 PY 2016 VL 374 IS 8 BP 708 EP 711 DI 10.1056/NEJMp1514939 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DE6BB UT WOS:000370716600004 PM 26933847 ER PT J AU Yang, N Friedl, A AF Yang, Ning Friedl, Andreas TI Syndecan-1-Induced ECM Fiber Alignment Requires Integrin alpha v beta 3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains SO PLOS ONE LA English DT Article ID CELL-SURFACE PROTEOGLYCAN; BREAST-CARCINOMA CELLS; EXTRACELLULAR-MATRIX; FIBRONECTIN MATRIX; CANCER CELLS; 3-DIMENSIONAL MATRICES; BETA-3 INTEGRINS; ACTIN-FILAMENTS; NUCLEAR SHAPE; BINDING-SITE AB Expression of the cell surface proteoglycan syndecan-1 (Sdc1) is frequently induced in stromal fibroblasts of invasive breast carcinomas. We have recently identified a correlation between stromal Sdc1 expression and extracellular matrix (ECM) fiber alignment, both in vitro and in vivo. ECMs derived from Sdc1-positive human mammary fibroblasts (HMF) showed an aligned fiber architecture, which contrasted markedly with the more random fiber arrangement in the ECM produced by Sdc1-negative HMFs. We further demonstrated that aligned fiber architecture promotes the directional migration and invasion of breast carcinoma cells. To decipher the molecular mechanisms governing the formation of an aligned, invasion-permissive ECM, a series of Sdc1 mutants was introduced into HMF. We found that both the ectodomain and heparan sulfate chains of Sdc1 were required for full activity of Sdc1 in regulating ECM alignment, while transmembrane and cytoplasmic domains were dispensable. Sdc1 regulates the activities of several integrins via its ectodomain. Integrins are key players in the assembly of fibronectin-rich ECM. In addition, integrins are capable of regulating cell morphology and cell shape and orientation may affect ECM architecture. Therefore, we investigated the role of integrins in Sdc1-mediated ECM fiber alignment. Sdc1-overexpressing HMF gained an enhanced spindle-shaped morphology when cultured in an overconfluent state under conditions permissive for ECM production, which was partially reversed by siRNA-mediated silencing of beta 3 integrin expression. Moreover, suppression of alpha v beta 3 integrin activity by a function-blocking antibody or beta 3 knockdown largely abolished the aligned ECM fiber architecture and consequently the invasion-permissive properties of the ECM induced by Sdc1. The results suggest that Sdc1 may modulate fibronectin fibrillogenesis and/or alter cell morphology during ECM production through alpha v beta 3 integrin, thereby mediating ECM fiber alignment. Understanding the mechanisms governing ECM organization may lead to the development of novel stroma-targeted therapy for breast cancer, aiming at converting an invasion-permissive to an invasion-restrictive microenvironment. C1 [Yang, Ning; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. [Friedl, Andreas] UW Carbone Canc Ctr, Madison, WI USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.; Friedl, A (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.; Friedl, A (reprint author), UW Carbone Canc Ctr, Madison, WI USA. EM afriedl@wisc.edu FU National Cancer Institute [R01 CA107012-06]; NIH/NCI [R01 CA107012] FX This work was supported by the National Cancer Institute, R01 CA107012-06 (http://www.cancer.gov). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by NIH/NCI grant R01 CA107012. The authors are grateful to other members of the Friedl lab, especially Kristy Key Meyer, for help with experiments. The authors also thank the University of Wisconsin Carbone Cancer Center (P30 CA014520 40) for use of its facilities and Flow Cytometry Laboratory. The contents do not represent the views of the Dept. of Veterans Affairs or the United States Government. NR 81 TC 1 Z9 1 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 24 PY 2016 VL 11 IS 2 AR e0150132 DI 10.1371/journal.pone.0150132 PG 25 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2IA UT WOS:000371164700069 PM 26909794 ER PT J AU Chen, JS Sprague, BL Klabunde, CN Tosteson, ANA Bitton, A Onega, T MacLean, CD Harris, K Schapira, MM Haas, JS AF Chen, Jane S. Sprague, Brian L. Klabunde, Carrie N. Tosteson, Anna N. A. Bitton, Asaf Onega, Tracy MacLean, Charles D. Harris, Kimberly Schapira, Marilyn M. Haas, Jennifer S. CA PROSPR Population-Based Res Optim TI Take the money and run? Redemption of a gift card incentive in a clinician survey SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article DE Survey methods; Provider surveys ID SURVEY RESPONSE RATES; PHYSICIANS; BREAST AB Background: Clinician surveys provide critical information about many facets of health care, but are often challenging to implement. Our objective was to assess use by participants and non-participants of a prepaid gift card incentive that could be later reclaimed by the researchers if unused. Methods: Clinicians were recruited to participate in a mailed or online survey as part of a study to characterize women's primary health care provider attitudes towards breast and cervical cancer screening guidelines and practices (n = 177). An up-front incentive of a $50 gift card to a popular online retailer was included with the study invitation. Clinicians were informed that the gift card would expire if it went unused after 4 months. Outcome measures included use of gift cards by participants and non-participants and comparison of hypothetical costs of different incentive strategies. Results: 63.5 % of clinicians who responded to the survey used the gift card, and only one provider who didn't participate used the gift card (1.6 %). Many of those who participated did not redeem their gift cards (36.5 % of respondents). The price of the incentives actually claimed totaled $3700, which was less than half of the initial outlay. Since some of the respondents did not redeem their gift cards, the cost of incentives was less than it might have been if we had provided a conditional incentive of $50 to responders after they had completed the survey. Conclusions: Redeemable online gift card codes may provide an effective way to motivate clinicians to participate in surveys. C1 [Chen, Jane S.; Bitton, Asaf; Harris, Kimberly; Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. [Bitton, Asaf; Haas, Jennifer S.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Sprague, Brian L.; MacLean, Charles D.] Univ Vermont, Burlington, VT USA. [Tosteson, Anna N. A.; Onega, Tracy] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Lebanon, NH USA. [Klabunde, Carrie N.] NIH, Off Director, Off Dis Prevent, Bethesda, MD USA. [Haas, Jennifer S.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Schapira, Marilyn M.] Univ Penn, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chen, Jane S.] Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.; Haas, JS (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM jhaas@partners.org FU [U54 CA163307]; [U54 CA 163313]; [U54 CA163303] FX The authors thank the participating PROSPR Research Centers for the data they have provided for this study. A list of the PROSPR investigators and contributing research staff are provided at: http://healthcaredelivery.cancer.gov/prospr/. (Grant numbers U54 CA163307, U54 CA 163313, U54 CA163303). NR 9 TC 1 Z9 1 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD FEB 24 PY 2016 VL 16 AR 25 DI 10.1186/s12874-016-0126-2 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DE7SH UT WOS:000370836500002 PM 26911445 ER PT J AU Lau, KM Madden, E Neylan, TC Seal, KH Maguen, S AF Lau, Karen M. Madden, Erin Neylan, Thomas C. Seal, Karen H. Maguen, Shira TI Assessing for mild TBI among Iraq and Afghanistan veterans: Outcomes of injury severity and neurological factors SO BRAIN INJURY LA English DT Article DE veterans; injury severity markers; nausea; neurologic symptoms; Traumatic brain injury ID TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL SYMPTOM INVENTORY; POSTCONCUSSION SYNDROME; CLINICAL MANAGEMENT; HEAD-INJURY; MILITARY; DIAGNOSIS; MANIFESTATIONS; CLASSIFICATION; PERFORMANCE AB Objective: To investigate injury severity markers and neurological symptoms associated with clinician-confirmed mild traumatic brain injury (TBI) among Iraq and Afghanistan veterans. Setting: Department of Veterans Affairs (VA) medical centre and five affiliated community-based outpatient clinics. Participants: Three hundred and fifty Iraq and Afghanistan veterans with positive initial VA TBI screens between 1 April 2007 and 1 June 2010 and clinician-confirmed TBI status by 1 December 2010. Methods: Retrospective-cohort study of medical record data. Main measures included clinician-confirmed TBI status, injury severity markers (e.g. loss of consciousness (LOC), post-traumatic amnesia (PTA) or confusion/disorientation) and neurological symptoms. Results: Among veterans who screened positive on the initial VA TBI and then received a clinician evaluation, 60% were confirmed to have a TBI diagnosis. Veterans reporting at least one LOC, confusion or PTA were almost 18-times more likely to receive a confirmed TBI diagnosis. Odds of clinician-confirmed TBI were 2.5-3-times greater among those who endorsed dizziness, poor coordination, headaches, nausea, vision problems and/or irritability, compared to those not endorsing these symptoms. Nausea had greatest utility for confirming a TBI. Conclusions: Identification of neurologic symptoms that most contribute to a clinician-confirmed diagnosis of TBI has potential for streamlining detection of TBI and symptoms needed for treatment. C1 [Lau, Karen M.; Madden, Erin; Neylan, Thomas C.; Seal, Karen H.; Maguen, Shira] San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. [Neylan, Thomas C.; Seal, Karen H.; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Lau, KM (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM karen.lau2@va.gov FU Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program; VA Health Sciences Research and Development (HSR&D) Career Development 475 Award FX This research was supported by a Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program (Maguen) and VA Health Sciences Research and Development (HSR&D) Career Development 475 Award (Maguen). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. NR 37 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD FEB 23 PY 2016 VL 30 IS 3 BP 287 EP 294 DI 10.3109/02699052.2015.1089601 PG 8 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DG9QM UT WOS:000372418900006 PM 26910483 ER PT J AU Anderson, RI Lopez, MF Becker, HC AF Anderson, Rachel I. Lopez, Marcelo F. Becker, Howard C. TI Stress-Induced Enhancement of Ethanol Intake in C57BL/6J Mice with a History of Chronic Ethanol Exposure: Involvement of Kappa Opioid Receptors SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Article DE ethanol; stress; kappa opioid receptor; dynorphin; mice ID CORTICOTROPIN-RELEASING-FACTOR; COCAINE PLACE PREFERENCE; ANXIETY-LIKE BEHAVIOR; CENTRAL AMYGDALA; ALCOHOL-DRINKING; INDUCED REINSTATEMENT; INDUCED INCREASES; CENTRAL NUCLEUS; SOCIAL STRESS; SALVINORIN-A AB Our laboratory has previously demonstrated that daily forced swim stress (FSS) prior to ethanol drinking sessions facilitates enhanced ethanol consumption in mice with a history of chronic intermittent ethanol (CIE) vapor exposure without altering ethanol intake in air -exposed controls. Because both stress and chronic ethanol exposure have been shown to activate the dynorphin/kappa opioid receptor (KOR) system, the present study was designed to explore a potential role for KORs in modulating stress effects on ethanol consumption in the CIE model of dependence and relapse drinking. After stable baseline ethanol intake was established in adult male C57BU6J mice, subjects received chronic intermittent exposure (16 h/day x 4 days/week) to ethanol vapor (CIE group) or air (CTL group). Weekly cycles of inhalation exposure were alternated with 5 -day limited access drinking tests (1 h access to 15% ethanol). Experiment 1 compared effects of daily FSS and KOR activation on ethanol consumption. CIE and CTL mice were either exposed to FSS (10 min), the KOR agonist U50,488 (5 mg/kg), or a vehicle injection (non stressedcondition) prior to each daily drinking session during test weeks. FSS selectively increased drinking in CIE mice. U50,488 mimicked this effect in CIE mice, but also increased drinking in CTL mice. Experiment 2 assessed effects of KOR blockade on stress induced drinking in CIE and CTL mice. Stressed and non stressed mice were administered the short -acting KOR antagonist LY2444296 (0 or 5 mg/kg) 30 min prior to each drinking session during test weeks. FSS selectively increased ethanol consumption in CIE mice, an effect that was abolished by LY2444296 pretreatment. In Experiment 3, CIE and CTL mice were administered one of four doses of U50,488 (0, 1.25, 2.5, 5.0 mg/kg) 1 h prior to each daily drinking test (in lieu of FSS). All doses of U50,488 increased ethanol consumption in both CIE and CTL mice. The U50,488 induced increase in drinking was blocked by LY2444296. Our results demonstrate that the KOR system contributes to the stress enhancement of ethanol intake in mice with a history of chronic ethanol exposure. C1 [Anderson, Rachel I.; Lopez, Marcelo F.; Becker, Howard C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anderson, Rachel I.; Lopez, Marcelo F.; Becker, Howard C.] Charleston Alcohol Res Ctr, Charleston, SC USA. [Becker, Howard C.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Anderson, RI (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.; Anderson, RI (reprint author), Charleston Alcohol Res Ctr, Charleston, SC USA. EM andersor@musc.edu OI Anderson, Rachel/0000-0002-6671-4810 FU NIH/NIAAA [U01 AA014095, P50 AA010761, U01 AA020929, T32 AA007474, F32 AA023700] FX This work was supported by NIH/NIAAA grants to HCB (U01 AA014095, P50 AA010761) and MFL (U01 AA020929). RIA was supported by NIH/NIAAA grants T32 AA007474 and F32 AA023700. Thanks to Chelsea Johnson, Rebecca Kritschil, and Anne Olsen for technical assistance. NR 60 TC 3 Z9 3 U1 1 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD FEB 23 PY 2016 VL 10 AR 45 DI 10.3389/fncel.2016.00045 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DE5FH UT WOS:000370656100001 PM 26941607 ER PT J AU Nagae, LM Honce, JM Tanabe, J Shelton, E Sillau, SH Berman, BD AF Nagae, Lidia M. Honce, Justin M. Tanabe, Jody Shelton, Erika Sillau, Stefan H. Berman, Brian D. TI Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes SO FRONTIERS IN NEUROANATOMY LA English DT Article DE Parkinson disease; motor subtypes; diffusion tensor imaging; basal ganglia ID SUBSTANTIA-NIGRA; MOTOR SUBTYPES AB Diffusion tensor imaging (DTI) of the substantia nigra has shown promise in detecting and quantifying neurodegeneration in Parkinson disease (PD). It remains unknown, however, whether differences in microstructural changes within the basal ganglia underlie PD motor subtypes. We investigated microstructural changes within the basal ganglia of mild to moderately affected PD patients using DTI and sought to determine if microstructural changes differ between the tremor dominant (TD) and postural instability/gait difficulty (PIGD) subtypes. Fractional anisotropy, mean diffusivity, radial, and axial diffusivity were obtained from bilateral caudate, putamen, globus pallidus, and substantia nigra of 21 PD patients (12 TD and 9 PIGD) and 20 age-matched healthy controls. T-tests and ANOVA methods were used to compare PD patients, subtypes, and controls, and Spearman correlations tested for relationships between DTI and clinical measures. We found our cohort of PD patients had reduced fractional anisotropy within the substantia nigra and increased mean and radial diffusivity within the substantia nigra and globus pallidus compared to controls, and that changes within those structures were largely driven by the PIGD subtype. Across all PD patients fractional anisotropy within the substantia nigra correlated with disease stage, while in PIGD patients increased diffusivity within the globus pallidus correlated with disease stage and motor severity. We conclude that PIGD patients have more severely affected microstructural changes within the substantia nigra compared to TD, and that microstructural changes within the globus pallidus may be particularly relevant for the manifestation of the PIGD subtype. C1 [Nagae, Lidia M.; Honce, Justin M.; Tanabe, Jody; Berman, Brian D.] Univ Colorado, Dept Biol, Anschutz Med Campus, Aurora, CO USA. [Shelton, Erika; Sillau, Stefan H.; Berman, Brian D.] Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA. [Berman, Brian D.] Denver VA Med Ctr, Neurol Sect, Denver, CO USA. RP Berman, BD (reprint author), Univ Colorado, Dept Biol, Anschutz Med Campus, Aurora, CO USA.; Berman, BD (reprint author), Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA.; Berman, BD (reprint author), Denver VA Med Ctr, Neurol Sect, Denver, CO USA. EM brian.berman@ucdenver.edu FU NIH/NCATS Colorado CTSI Grant [KL2 TR001080]; University of Colorado Department of Neurology; University of Colorado Center for NeuroScience FX This work was supported by NIH/NCATS Colorado CTSI Grant Number KL2 TR001080, the University of Colorado Department of Neurology, and the University of Colorado Center for NeuroScience. NR 30 TC 3 Z9 3 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5129 J9 FRONT NEUROANAT JI Front. Neuroanat. PD FEB 23 PY 2016 VL 10 AR 17 DI 10.3389/fnana.2016.00017 PG 9 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA DE5AI UT WOS:000370642000001 PM 26941615 ER PT J AU Maertens, JA Raad, II Marr, KA Patterson, TF Kontoyiannis, DP Cornely, OA Bow, EJ Rahav, G Neofytos, D Aoun, M Baddley, JW Giladi, M Heinz, WJ Herbrecht, R Hope, W Karthaus, M Lee, DG Lortholary, O Morrison, VA Oren, I Selleslag, D Shoham, S Thompson, GR Lee, M Maher, RM Schmitt-Hoffmann, AH Zeiher, B Ullmann, AJ AF Maertens, Johan A. Raad, Issam I. Marr, Kieren A. Patterson, Thomas F. Kontoyiannis, Dimitrios P. Cornely, Oliver A. Bow, Eric J. Rahav, Galia Neofytos, Dionysios Aoun, Mickael Baddley, John W. Giladi, Michael Heinz, Werner J. Herbrecht, Raoul Hope, William Karthaus, Meinolf Lee, Dong-Gun Lortholary, Olivier Morrison, Vicki A. Oren, Ilana Selleslag, Dominik Shoham, Shmuel Thompson, George R., III Lee, Misun Maher, Rochelle M. Schmitt-Hoffmann, Anne-Hortense Zeiher, Bernhardt Ullmann, Andrew J. TI Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial SO LANCET LA English DT Article ID PHARMACODYNAMIC TARGET DETERMINATION; LIPOSOMAL AMPHOTERICIN-B; CELL TRANSPLANT PATIENTS; MYCOSES STUDY-GROUP; EUROPEAN-ORGANIZATION; PULMONARY ASPERGILLOSIS; CLINICAL-PRACTICE; THERAPY; INFECTIONS; CANCER AB Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1: 1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of -1.0% (95% CI -7.8 to 5.7). Because the upper bound of the 95% CI (5.7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0.122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0.016), eye disorders (39 [15%] vs 69 [27%]; p=0.002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0.037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p<0.001). Interpretation Isavuconazole was non-inferior to voriconazole for the primary treatment of suspected invasive mould disease. Isavuconazole was well tolerated compared with voriconazole, with fewer study-drug-related adverse events. Our results support the use of isavuconazole for the primary treatment of patients with invasive mould disease. C1 [Maertens, Johan A.] Katholieke Univ Leuven, Univ Ziekenhuizen Leuven, Dept Hematol, Louvain, Belgium. [Raad, Issam I.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA. [Marr, Kieren A.; Shoham, Shmuel] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Marr, Kieren A.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. [Neofytos, Dionysios] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA. [Cornely, Oliver A.] Univ Cologne, ZKS Koln Ctr Integrated Oncol CIO Koln Bonn, Cologne Excellence Cluster Cellular Stress Respon, Dept Internal Med,Clin Trials Ctr Cologne,German, D-50931 Cologne, Germany. [Bow, Eric J.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada. [Bow, Eric J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada. [Bow, Eric J.] CancerCare Manitoba, Infect Control Serv, Winnipeg, MB, Canada. [Rahav, Galia] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Rahav, Galia] Tel Aviv Univ, Sackler Sch Med, Ramat Gan, Israel. [Aoun, Mickael] Inst Jules Bordet, Div Infect Dis, B-1000 Brussels, Belgium. [Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL USA. [Baddley, John W.] Vet Affairs Med Ctr, Birmingham, AL USA. [Giladi, Michael] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Infect Dis Unit, IL-69978 Tel Aviv, Israel. [Giladi, Michael] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Heinz, Werner J.] Univ Wurzburg, Med Ctr, D-97070 Wurzburg, Germany. [Herbrecht, Raoul] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France. [Herbrecht, Raoul] Univ Strasbourg, Strasbourg, France. [Hope, William] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England. [Karthaus, Meinolf] Klinikum Neuperlach, Klin Hamatol & Onkol, Munich, Germany. [Lee, Dong-Gun] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea. [Lortholary, Olivier] Univ Paris 05, Ctr Infectiol Necker Pasteur, Hop Necker Enfants Malades, IHU Imagine, Paris, France. [Lortholary, Olivier] Inst Pasteur, Ctr Natl Reference Mycoses Invas & Antifong, Paris, France. [Morrison, Vicki A.] Univ Minnesota, Minneapolis, MN USA. [Morrison, Vicki A.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Oren, Ilana] Rambam Hlth Care Campus, Infect Dis Unit, Haifa, Israel. [Oren, Ilana] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. [Selleslag, Dominik] Algemeen Ziekenhuis St Jan, Brugge, Belgium. [Thompson, George R., III] Univ Calif Davis, Med Ctr, Davis, CA 95616 USA. [Lee, Misun; Maher, Rochelle M.; Zeiher, Bernhardt] Astellas Pharma Global Dev, Northbrook, IL USA. [Schmitt-Hoffmann, Anne-Hortense] Basilea Pharmaceut Int, Basel, Switzerland. [Ullmann, Andrew J.] Univ Wurzburg, Dept Internal Med 2, Infect Dis, Oderdurrbacher Str 6, D-97080 Wurzburg, Germany. RP Ullmann, AJ (reprint author), Univ Wurzburg, Dept Internal Med 2, Infect Dis, Oderdurrbacher Str 6, D-97080 Wurzburg, Germany. EM andrew.ullmann@uni-wuerzburg.de OI Patterson, Thomas /0000-0002-9513-7127; Heinz, Werner/0000-0002-7833-9202; Herbrecht, Raoul/0000-0002-9381-4876; Hope, William/0000-0001-6187-878X FU Astellas Pharma Global Development FX Isavuconazole was co-developed by Astellas Pharma US and Basilea Pharmaceutica International. We acknowledge the contributions of the medical director of the SECURE trial, Neddie Zadeikis (Astellas Pharma Global Development during the conduct of the study) in the design and conduct of the study. Editorial assistance was provided by Radhika Bhatia, of Envision Scientific Solutions, funded by Astellas Pharma Global Development. NR 32 TC 53 Z9 53 U1 15 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD FEB 20 PY 2016 VL 387 IS 10020 BP 760 EP 769 DI 10.1016/S0140-6736(15)01159-9 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DE1WU UT WOS:000370418000035 PM 26684607 ER PT J AU Baxi, SM Scherzer, R Greenblatt, RM Minkoff, H Sharma, A Cohen, M Young, MA Abraham, AG Shlipak, MG AF Baxi, Sanjiv M. Scherzer, Rebecca Greenblatt, Ruth M. Minkoff, Howard Sharma, Anjali Cohen, Mardge Young, Mary A. Abraham, Alison G. Shlipak, Michael G. CA Womens Interagency HIV Study TI Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV SO AIDS LA English DT Article DE adverse drug effect; HIV; kidney function; pharmacokinetics; tenofovir; Women's Interagency HIV Study ID DISOPROXIL FUMARATE; INFECTED PATIENTS; RENAL TOXICITY; INCOMPLETE REVERSIBILITY; ANTIRETROVIRAL ACTIVITY; PLASMA-CONCENTRATIONS; CLINICAL-TRIALS; PHASE I/II; PHARMACOKINETICS; ALAFENAMIDE AB Objective:Tenofovir disoproxil fumarate is a commonly used antiretroviral drug, but risk factors for tenofovir (TFV)-associated kidney disease are not fully understood. We used intensive pharmacokinetic studies in a cohort of HIV-infected women on TFV-based therapy to study the relationship between TFV exposure and subsequent kidney function.Design:This is a nested study within the Women's Interagency HIV Study, a multicenter, prospective cohort of HIV-infected women. Participants on TFV-based therapy underwent 24-h intensive pharmacokinetic sampling after witnessed dose. Kidney function was measured over the succeeding 7 years by serum creatinine [estimated glomerular filtration rate calculated by serum creatinine (eGFRcr)].Methods:Multivariable linear mixed models evaluated the relationship of baseline TFV area under the-time concentration curves (AUCs) with subsequent changes in kidney function. Covariates included age, diabetes, hypertension, race, BMI, ritonavir use, duration of TFV exposure, current CD4(+) cell count, and HIV viral load.Results:Of the 105 participants, persons within the highest baseline TFV AUC tertile had significantly lower eGFRcr compared with those in the lowest tertile (meanstandard error: 80 +/- 4.3 vs. 104 +/- 2.5ml/min per 1.73m(2), P<0.0001). By year 7, this difference widened (72 +/- 4.9 vs. 105 +/- 2.9, P<0.0001). After multivariable adjustment, TFV AUC in the highest tertile remained associated with lower eGFRcr relative to values in the lowest tertile at both baseline (-15ml/min per 1.73m(2), P=0.0047) and year 7 (-23ml/min per 1.73m(2), P=0.0002).Conclusion:Through intensive TFV pharmacokinetic sampling, we found a strong association between greater TFV exposure and subsequent decline in kidney function. Variations in TFV drug exposure may partially account for subsequent nephrotoxicity in persons infected with HIV. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Baxi, Sanjiv M.; Scherzer, Rebecca; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Baxi, Sanjiv M.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Scherzer, Rebecca; Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Greenblatt, Ruth M.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Minkoff, Howard] Suny Downstate Med Ctr, Div Infect Dis, Brooklyn, NY 11203 USA. [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Cohen, Mardge] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Div Infect Dis, Chicago, IL USA. [Young, Mary A.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Abraham, Alison G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Baxi, SM (reprint author), Univ Calif San Francisco, Div Infect Dis, 513 Parnassus Ave,Room S380, San Francisco, CA 94143 USA. EM sanjiv.baxi@ucsf.edu FU Bronx WIHS [U01-AI-035004]; Brooklyn WIHS [U01-AI-031834]; Chicago WIHS [U01-AI-034993]; Metropolitan Washington WIHS [U01-AI-034994]; Connie Wofsy Women's HIV Study, Northern California [U01-AI-034989, R01 AI 65233]; WIHS Data Management and Analysis Center [U01-AI-042590]; Southern California WIHS [U01-HD-032632]; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Cancer Institute (NCI); National Institute on Drug Abuse (NIDA); National Institute on Mental Health (NIMH); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Deafness and other Communication Disorders (NIDCD); NIH Office of Research on Women's Health; UCSF CTSA [UL1-TR000004]; UCSF Traineeship in AIDS Prevention Studies [US National Institutes of Health (NIH)] [T32 MH-19105]; National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR) [P30-AI027763]; US NIH National Institute on Aging [2R01AG03485306] FX WIHS (Principal Investigators): Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen), U01-AI-034993; Metropolitan Washington WIHS (Mary Young), U01-AI-034994; Connie Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien) U01-AI-034989; and R01 AI 65233 (NIAID/NIH, P.I. Greenblatt); WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Alexandra Levine and Marek Nowicki), U01-HD-032632 (WIHS I-WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA). S.M.B. is supported by the UCSF Traineeship in AIDS Prevention Studies [US National Institutes of Health (NIH) T32 MH-19105]. This research was also supported by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR), P30-AI027763 (Principal Investigators Paul Volberding and Warner Greene). M.G.S. and R.S. by the US NIH National Institute on Aging grant 2R01AG03485306. NR 43 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD FEB 20 PY 2016 VL 30 IS 4 BP 609 EP 617 DI 10.1097/QAD.0000000000000958 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DC7ST UT WOS:000369421400009 PM 26558723 ER PT J AU Scheckel, C Drapeau, E Frias, MA Park, CY Fak, J Zucker-Scharff, I Kou, Y Haroutunian, V Ma'ayan, A Buxbaum, JD Darnell, RB AF Scheckel, Claudia Drapeau, Elodie Frias, Maria A. Park, Christopher Y. Fak, John Zucker-Scharff, Ilana Kou, Yan Haroutunian, Vahram Ma'ayan, Avi Buxbaum, Joseph D. Darnell, Robert B. TI Regulatory consequences of neuronal ELAV-like protein binding to coding and non-coding RNAs in human brain SO ELIFE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; DIFFERENTIAL EXPRESSION ANALYSIS; GAP-43 GENE-EXPRESSION; RO 60-KDA AUTOANTIGEN; MESSENGER-RNA; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; PC12 CELLS; HITS-CLIP; PARKINSON-DISEASE AB Neuronal ELAV-like (nELAVL) RNA binding proteins have been linked to numerous neurological disorders. We performed crosslinking-immunoprecipitation and RNAseq on human brain, and identified nELAVL binding sites on 8681 transcripts. Using knockout mice and RNAi in human neuroblastoma cells, we showed that nELAVL intronic and 3' UTR binding regulates human RNA splicing and abundance. We validated hundreds of nELAVL targets among which were important neuronal and disease-associated transcripts, including Alzheimer's disease (AD) transcripts. We therefore investigated RNA regulation in AD brain, and observed differential splicing of 150 transcripts, which in some cases correlated with differential nELAVL binding. Unexpectedly, the most significant change of nELAVL binding was evident on non-coding Y RNAs. nELAVL/Y RNA complexes were specifically remodeled in AD and after acute UV stress in neuroblastoma cells. We propose that the increased nELAVL/Y RNA association during stress may lead to nELAVL sequestration, redistribution of nELAVL target binding, and altered neuronal RNA splicing. C1 [Scheckel, Claudia; Frias, Maria A.; Park, Christopher Y.; Fak, John; Zucker-Scharff, Ilana; Darnell, Robert B.] Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA. [Scheckel, Claudia; Frias, Maria A.; Park, Christopher Y.; Fak, John; Zucker-Scharff, Ilana; Darnell, Robert B.] Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA. [Drapeau, Elodie; Kou, Yan; Buxbaum, Joseph D.] Seaver Autism Ctr Res & Treatment, New York, NY USA. [Drapeau, Elodie; Haroutunian, Vahram; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Park, Christopher Y.; Darnell, Robert B.] New York Genome Ctr, New York, NY USA. [Kou, Yan; Ma'ayan, Avi] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, LINCS Data Integrat & Coordinat Ctr BD2K, Mt Sinai Knowledge Management Ctr Illuminating Dr, New York, NY 10029 USA. [Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Haroutunian, Vahram] James J Peters VA Med Ctr, New York, NY USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth Inst, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. RP Darnell, RB (reprint author), Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA.; Darnell, RB (reprint author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.; Buxbaum, JD (reprint author), Seaver Autism Ctr Res & Treatment, New York, NY USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Darnell, RB (reprint author), New York Genome Ctr, New York, NY USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Mindich Child Hlth Inst, New York, NY 10029 USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. EM buxbaum@mssm.edu; darnelr@rockefeller.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU EMBO; SNF; Seaver Foundation; National Institutes of Health [ADRC AG005138, AG02219, HHSN27120130031C, R01GM098316, U54CA189201, U54HL127624, NS34389]; G Harold and Leila Y. Mathers Foundation; Simons Foundation; Howard Hughes Medical Institute FX EMBO Long-Term Fellowship Claudia Scheckel; SNF Early and Advanced Postdoc Mobility Fellowship Claudia Scheckel; Seaver Foundation Graduate Fellowship Yan Kou; National Institutes of Health ADRC AG005138 Vahram Haroutunian; National Institutes of Health AG02219 Vahram Haroutunian; National Institutes of Health HHSN27120130031C Vahram Haroutunian; National Institutes of Health R01GM098316 Avi Ma'ayan; National Institutes of Health U54CA189201 Avi Ma'ayan; National Institutes of Health U54HL127624 Avi Ma'ayan; G Harold and Leila Y. Mathers Foundation Joseph D Buxbaum; National Institutes of Health ADRC AG005138 Joseph D Buxbaum; National Institutes of Health NS081706 Robert B Darnell; Simons Foundation Robert B Darnell; National Institutes of Health NS34389 Robert B Darnell; Howard Hughes Medical Institute Robert B Darnell NR 112 TC 8 Z9 8 U1 0 U2 2 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD FEB 19 PY 2016 VL 5 AR e10421 DI 10.7554/eLife.10421 PG 35 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DG2EX UT WOS:000371880400001 ER PT J AU Li, CW Menconi, F Osman, R Mezei, M Jacobson, EM Concepcion, E David, CS Kastrinsky, DB Ohlmeyer, M Tomer, Y AF Li, Cheuk Wun Menconi, Francesca Osman, Roman Mezei, Mihaly Jacobson, Eric M. Concepcion, Erlinda David, Chella S. Kastrinsky, David B. Ohlmeyer, Michael Tomer, Yaron TI Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE cell surface protein; endocrinology; major histocompatibility complex (MHC); peptides; small molecule; structural model; thyroid; thyroid hormone; thyroglobulin; thyroiditis ID MYELIN BASIC-PROTEIN; HLA-DR; TRANSGENIC MICE; GRAVES-DISEASE; HASHIMOTOS-THYROIDITIS; THYROGLOBULIN PEPTIDES; MULTIPLE-SCLEROSIS; UNITED-STATES; L-THYROXINE; CEPHARANTHINE AB We previously showed that an HLA-DR variant containing arginine at position 74 of the DR1 chain (DR1-Arg74) is the specific HLA class II variant conferring risk for autoimmune thyroid diseases (AITD). We also identified 5 thyroglobulin (Tg) peptides that bound to DR1-Arg74. We hypothesized that blocking the binding of these peptides to DR1-Arg74 could block the continuous T-cell activation in thyroiditis needed to maintain the autoimmune response to the thyroid. The aim of the current study was to identify small molecules that can block T-cell activation by Tg peptides presented within DR1-Arg74 pockets. We screened a large and diverse library of compounds and identified one compound, cepharanthine that was able to block peptide binding to DR1-Arg74. We then showed that Tg.2098 is the dominant peptide when inducing experimental autoimmune thyroiditis (EAT) in NOD mice expressing human DR1-Arg74. Furthermore, cepharanthine blocked T-cell activation by thyroglobulin peptides, in particular Tg.2098 in mice that were induced with EAT. For the first time we identified a small molecule that can block Tg peptide binding and presentation to T-cells in autoimmune thyroiditis. If confirmed cepharanthine could potentially have a role in treating human AITD. C1 [Li, Cheuk Wun; Menconi, Francesca; Jacobson, Eric M.; Concepcion, Erlinda; Tomer, Yaron] Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. [Osman, Roman; Mezei, Mihaly; Kastrinsky, David B.; Ohlmeyer, Michael] Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. [David, Chella S.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA. [Tomer, Yaron] Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu FU National Institutes of Health from NIDDK [DK061659, DK073681]; NIAID [T32 AI007605]; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants DK061659 and DK073681 from the NIDDK (to Y. T.) and Grant T32 AI007605 from the NIAID (to C. W. L.). This material is based upon work supported in part by the Department of Veterans Affairs. The authors declare that they have no conflicts of interest with the contents of this article. NR 66 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 19 PY 2016 VL 291 IS 8 BP 4079 EP 4090 DI 10.1074/jbc.M115.694687 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DF4RQ UT WOS:000371338400033 PM 26703475 ER PT J AU Li, J Brock, J Jack, B Mittman, B Naylor, M Sorra, J Mays, G Williams, MV AF Li, Jing Brock, Jane Jack, Brian Mittman, Brian Naylor, Mary Sorra, Joanna Mays, Glen Williams, Mark V. CA Project ACHIEVE Team TI Project ACHIEVE - using implementation research to guide the evaluation of transitional care effectiveness SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Transitional care; Implementation research; Comparative effectiveness; Patient centered ID HOSPITAL READMISSIONS; PUBLIC-HEALTH; FRAMEWORK; DISCHARGE; INTERVENTION; QUALITY; TRIAL; REHOSPITALIZATION; PROGRAM; SCIENCE AB Background: Poorly managed hospital discharges and care transitions between health care facilities can cause poor outcomes for both patients and their caregivers. Unfortunately, the usual approach to health care delivery does not support continuity and coordination across the settings of hospital, doctors' offices, home or nursing homes. Though complex efforts with multiple components can improve patient outcomes and reduce 30-day readmissions, research has not identified which components are necessary. Also we do not know how delivery of core components may need to be adjusted based on patient, caregiver, setting or characteristics of the community, or how system redesign can be accelerated. Methods/design: Project ACHIEVE focuses on diverse Medicare populations such as individuals with multiple chronic diseases, patients with low health literacy/numeracy and limited English proficiency, racial and ethnic minority groups, low-income groups, residents of rural areas, and individuals with disabilities. During the first phase, we will use focus groups to identify the transitional care outcomes and components that matter most to patients and caregivers to inform development and validation of assessment instruments. During the second phase, we will evaluate the comparative effectiveness of multi-component care transitions programs occurring across the U.S. Using a mixed-methods approach for this evaluation, we will study historical (retrospective) and current and future (prospective) groups of patients, caregivers and providers using site visits, surveys, and clinical and claims data. In this natural experiment observational study, we use a fractional factorial study design to specify comparators and estimate the individual and combined effects of key transitional care components. Discussion: Our study will determine which evidence-based transitional care components and/or clusters most effectively produce patient and caregiver desired outcomes overall and among diverse patient and caregiver populations in different healthcare settings. Using the results, we will develop concrete, actionable recommendations regarding how best to implement these strategies. Finally, this work will provide tools for hospitals, community-based organizations, patients, caregivers, clinicians and other stakeholders to help them make informed decisions about which strategies are most effective and how best to implement them in their communities. C1 [Li, Jing] Univ Kentucky, Ctr Hlth Serv Res, Lexington, KY USA. [Li, Jing] Univ Kentucky, Internal Med, Lexington, KY USA. [Brock, Jane] Care Transit Theme Support Ctr, Englewood, CO USA. [Jack, Brian] Boston Univ, Sch Med, Family Med, Boston, MA 02118 USA. [Mittman, Brian] Kaiser Permanente, Res & Evaluat, Pasadena, CA USA. [Mittman, Brian] VA Ctr Implementat Practice & Res, US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mittman, Brian] Univ Calif Los Angeles, Sch Med, Clin Translat Sci Inst, Los Angeles, CA USA. [Naylor, Mary] Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Sorra, Joanna] Westat Corp, Washington, DC USA. [Mays, Glen] Univ Kentucky, Natl Coordinating Ctr Publ Hlth Serv & Syst Res, Lexington, KY USA. [Williams, Mark V.] Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. RP Williams, MV (reprint author), Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. EM mark.will@uky.edu FU Patient Centered Outcomes Research Institute (PCORI), U.S [TC-1403-14049] FX Support for this research was provided by Contract No. TC-1403-14049, Patient Centered Outcomes Research Institute (PCORI), U.S. NR 33 TC 2 Z9 2 U1 6 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD FEB 19 PY 2016 VL 16 AR 70 DI 10.1186/s12913-016-1312-y PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DE1SK UT WOS:000370406500001 PM 26896024 ER PT J AU Asch, DA Pauly, MV Muller, RW AF Asch, David A. Pauly, Mark V. Muller, Ralph W. TI Asymmetric Thinking about Return on Investment SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Asch, David A.; Muller, Ralph W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.; Pauly, Mark V.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Asch, DA (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.; Asch, DA (reprint author), Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.; Asch, DA (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 18 PY 2016 VL 374 IS 7 BP 606 EP 608 DI 10.1056/NEJMp1512297 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DD9ER UT WOS:000370229000005 PM 26886519 ER PT J AU Keating, J Judy, R Newton, A Singhal, S AF Keating, Jane Judy, Ryan Newton, Andrew Singhal, Sunil TI Near-infrared operating lamp for intraoperative molecular imaging of a mediastinal tumor SO BMC MEDICAL IMAGING LA English DT Article DE Intraoperative imaging; Cancer; Near-infrared; Indocyanine green; Mediastinal tumors AB Background: Near-Infrared (NIR) intraoperative molecular imaging is a new diagnostic modality utilized during cancer surgery for the identification of tumors, metastases and lymph nodes. Surgeons typically use headlamps during an operation to increase visible light; however, these light sources are not adapted to function simultaneously with NIR molecular imaging technology. Here, we design a NIR cancelling headlamp and utilize it during surgery to assess whether intraoperative molecular imaging of mediastinal tumors is possible. Methods: A NIR cancelling headlamp was designed and tested using NIR spectroscopy preoperatively. Next, a 46 year-old-female was referred to the thoracic surgery clinic for a 5.8 cm mediastinal mass noted on chest x-ray. Prior to surgery, she was given intravenous indocyanine green (ICG). Then, the prototype headlamp was used in conjunction with our intraoperative molecular imaging device. The tumor was imaged both in vivo and following resection prior to pathological examination. Results: NIR spectroscopy confirmed NIR light excitation of the unfiltered headlamp and the absence of NIR emitted light after addition of the filter. Next, in vivo imaging confirmed fluorescence of the tumor, but also demonstrated a significant amount of NIR background fluorescence emanating from the unfiltered headlamp. During imaging with the filtered headlamp, we again demonstrated a markedly fluorescent tumor but with a reduced false positive NIR signal. Final pathology was well-differentiated thymoma with negative surgical margins. Conclusions: NIR intraoperative molecular imaging using a systemic injection of intravenous ICG was successful in localizing a thymoma. Additionally, a simple design and implementation of a NIR cancelling headlamp reduces false positive NIR fluorescence. C1 [Keating, Jane] Univ Penn, Dept Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. RP Keating, J (reprint author), Univ Penn, Dept Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM janejkeating@gmail.com FU [NIH R01 CA163256] FX Funding for the clinical trial in which this case report was involved was provided by grant NIH R01 CA163256. NR 11 TC 0 Z9 0 U1 4 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2342 J9 BMC MED IMAGING JI BMC Med. Imag. PD FEB 17 PY 2016 VL 16 AR 15 DI 10.1186/s12880-016-0120-5 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DE0LK UT WOS:000370316200001 PM 26883511 ER PT J AU Wang, J Bi, WN Zhao, W Varghese, M Koch, RJ Walker, RH Chandraratna, RA Sanders, ME Janesick, A Blumberg, B Ward, L Ho, L Pasinetti, GM AF Wang, Jun Bi, Weina Zhao, Wei Varghese, Merina Koch, Rick J. Walker, Ruth H. Chandraratna, Roshantha A. Sanders, Martin E. Janesick, Amanda Blumberg, Bruce Ward, Libby Ho, Lap Pasinetti, Giulio M. TI Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease SO ONCOTARGET LA English DT Article DE brain bioavailable; dopaminergic; nuclear receptor related-1 protein; Parkinson's disease; retinoid X receptor; Gero-target ID CILIARY NEUROTROPHIC FACTOR; ORPHAN NUCLEAR RECEPTOR; GENE-EXPRESSION; TYROSINE-HYDROXYLASE; CANCER PREVENTION; DOPAMINE CELLS; NEURONS; TRANSCRIPTION; SURVIVAL; ACID AB Parkinson's disease (PD) is one of the most common movement disorders, and currently there is no effective treatment that can slow disease progression. Preserving and enhancing DA neuron survival is increasingly regarded as the most promising therapeutic strategy for treating PD. IRX4204 is a second generation retinoid X receptor (RXR) agonist that has no cross reactivity with retinoic acid receptors, farnesoid X receptor, liver X receptors or peroxisome proliferator-activated receptor PPAR.. We found that IRX4204 promotes the survival and maintenance of nigral dopaminergic (DA) neurons in a dose-dependent manner in primary mesencephalic cultures. Brain bioavailability studies demonstrate that IRX4204 can cross the blood brain barrier and reach the brain at nM concentration. Oral administration of IRX4204 can activate nuclear receptor Nurr1 downstream signaling in the substantia nigra (SN) and attenuate neurochemical and motor deficits in a rat model of PD. Our study suggests that IRX4204 represents a novel, potent and selective pharmacological means to activate cellular RXR-Nurr1 signaling and promote SN DA neuron survival in PD prevention and/or treatment. C1 [Wang, Jun; Bi, Weina; Zhao, Wei; Varghese, Merina; Ward, Libby; Ho, Lap; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Koch, Rick J.; Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Chandraratna, Roshantha A.; Sanders, Martin E.] Io Therapeut Inc, Santa Ana, CA USA. [Janesick, Amanda; Blumberg, Bruce] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA USA. [Janesick, Amanda; Blumberg, Bruce] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Pasinetti, GM (reprint author), Geriatr Res Educ & Clin Ctr, Bronx, NY USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU Io Therapeutics, Inc. FX This study was funded by Io Therapeutics, Inc., and we thank Drs. Chandraratna and Sanders for providing the IRX4204 compound for the study herein described. NR 46 TC 1 Z9 1 U1 1 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7469 EP 7479 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900011 PM 26862735 ER PT J AU Edderkaoui, M Xu, SP Chheda, C Morvaridi, S Hu, RW Grippo, PJ Mascarinas, E Principe, DR Knudsen, B Xue, J Habtezion, A Uyeminami, D Pinkerton, KE Pandol, SJ AF Edderkaoui, Mouad Xu, Shiping Chheda, Chintan Morvaridi, Susan Hu, Robert W. Grippo, Paul J. Mascarinas, Emman Principe, Daniel R. Knudsen, Beatrice Xue, Jing Habtezion, Aida Uyeminami, Dale Pinkerton, Kent E. Pandol, Stephen J. TI HDAC3 mediates smoking-induced pancreatic cancer SO ONCOTARGET LA English DT Article DE smoking; HDAC; pancreatic cancer ID EPITHELIAL-MESENCHYMAL TRANSITION; STELLATE CELLS; HISTONE DEACETYLASES; STEM-CELLS; T-CELLS; DIFFERENTIATION; INTERLEUKIN-6; MACROPHAGES; PROGRESSION; STATISTICS AB Smoking is a major risk factor for developing pancreatic adenocarcinoma (PDAC); however, little is known about the mechanisms involved. Here we employed a genetic animal model of early stages of PDAC that overexpresses oncogenic Kras in the pancreas to investigate the mechanisms of smoking-induced promotion of the disease in vivo. We confirmed the regulation of the interactions between the tumor microenvironment cells using in vitro cellular systems. Aerial exposure to cigarette smoke stimulated development of pancreatic intraepithelial neaoplasia (PanIN) lesions associated with a tumor microenvironment-containing features of human PDAC including fibrosis, activated stellate cells, M2-macrophages and markers of epithelial-mesenchymal transition (EMT). The pro-cancer effects of smoking were prevented by Histone Deacetylase HDAC I/II inhibitor Saha. Smoking decreased histone acetylation associated with recruitment of and phenotypic changes in macrophages; which in turn, stimulated survival and induction of EMT of the pre-cancer and cancer cells. The interaction between the cancer cells and macrophages is mediated by IL-6 produced under the regulation of HDAC3 translocation to the nucleus in the cancer cells. Pharmacological and molecular inhibitions of HDAC3 decreased IL-6 levels in cancer cells. IL-6 stimulated the macrophage phenotype change through regulation of the IL-4 receptor level of the macrophage. This study demonstrates a novel pathway of interaction between cancer cells and tumor promoting macrophages involving HDAC3 and IL-6. It further demonstrates that targeting HDAC3 prevents progression of the disease and could provide a strategy for treating the disease considering that the HDAC inhibitor we used is FDA approved for a different disease. C1 [Edderkaoui, Mouad; Chheda, Chintan; Morvaridi, Susan; Hu, Robert W.; Knudsen, Beatrice; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Edderkaoui, Mouad; Chheda, Chintan; Morvaridi, Susan; Hu, Robert W.; Knudsen, Beatrice; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA. [Edderkaoui, Mouad; Xu, Shiping; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Edderkaoui, Mouad; Xu, Shiping; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Xu, Shiping] Peoples Liberat Army Gen Hosp, Nanlou Div, Dept Gastroenterol, Beijing, Peoples R China. [Grippo, Paul J.; Mascarinas, Emman; Principe, Daniel R.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Grippo, Paul J.; Mascarinas, Emman; Principe, Daniel R.] Univ Illinois, Dept Med, Chicago, IL USA. [Xue, Jing; Habtezion, Aida] Stanford Univ, Dept Med, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA. [Uyeminami, Dale; Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA. RP Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA.; Edderkaoui, M (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.; Edderkaoui, M (reprint author), Univ Calif Los Angeles, Los Angeles, CA USA. EM mouad.edderkaoui@cshs.org FU NIAAA [K01 AA019996, P50AA011999]; Hirshberg Foundation; NCI [P01CA163200]; Department of Veterans Affairs FX This work was supported by the NIAAA grant K01 AA019996 and the Hirshberg Foundation Award (to ME), the NCI grant P01CA163200, the NIAAA grant P50AA011999 and the Department of Veterans Affairs (to SJP). NR 41 TC 2 Z9 2 U1 2 U2 4 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7747 EP 7760 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900030 PM 26745602 ER PT J AU Prasad, R Kappes, JC Katiyar, SK AF Prasad, Ram Kappes, John C. Katiyar, Santosh K. TI Inhibition of NADPH oxidase 1 activity and blocking the binding of cytosolic and membrane-bound proteins by honokiol inhibit migratory potential of melanoma cells SO ONCOTARGET LA English DT Article DE honokiol; melanoma; NADPH oxidase; cell migration; imaging ID IN-VIVO; CANCER CELLS; PHOSPHORYLATION; GROWTH; NOX1; SRC; EPIDEMIOLOGY; ACTIVATION; TRANSITION; EXPRESSION AB Overexpression of NADPH oxidase 1 (Nox1) in melanoma cells is often associated with increased migration/metastasis rate. To develop effective treatment options, we have examined the effect of honokiol, a phytochemical from Magnolia plant, on the migratory potential of human melanoma cell lines (A375, Hs294t, SK-Mel119 and SK-Mel28) and assessed whether Nox1 is the target. Using an in vitro cell migration assay, we observed that treatment of different melanoma cell lines with honokiol for 24 h resulted in a dose-dependent inhibition of cell migration that was associated with reduction in Nox1 expression and reduced levels of oxidative stress. Treatment of cells with N-acetyl-L-cysteine, an anti-oxidant, also inhibited the migration of melanoma cells. Treatment of cells with diphenyleneiodonium chloride, an inhibitor of Nox1, significantly decreased the migration ability of Hs294t and SK-Mel28 cells. Further, we examined the effect of honokiol on the levels of core proteins (p22(phox) and p47(phox)) of the NADPH oxidase complex. Treatment of Hs294t and SK-Mel28 cells with honokiol resulted in accumulation of the cytosolic p47(phox) protein and decreased levels of the membrane-bound p22(phox) protein, thus blocking their interaction and inhibiting Nox1 activation. Our in vivo bioluminescence imaging data indicate that oral administration of honokiol inhibited the migration/extravasation and growth of intravenously injected melanoma cells in internal body organs, such as liver, lung and kidney in nude mice, and that this was associated with an inhibitory effect on Nox1 activity in these internal organs/tissues. C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA. [Kappes, John C.; Katiyar, Santosh K.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA. [Kappes, John C.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA.; Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. EM skatiyar@uab.edu FU National Institutes of Health (NIH,) National Cancer Institute [CA166883]; Veterans Administration Merit Review Award [1I01BX001410]; Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR) [P30-AI-27767] FX This work was supported by a grant from the National Institutes of Health (NIH, CA166883) National Cancer Institute (to S.K. Katiyar) and the Veterans Administration Merit Review Award (1I01BX001410) to S.K. Katiyar. The research also used the facilities supported by of the Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR), P30-AI-27767. NR 31 TC 1 Z9 2 U1 2 U2 6 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7899 EP 7912 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900041 PM 26760964 ER PT J AU Miglioretti, DL Lange, J van den Broek, JJ Lee, CI van Ravesteyn, NT Ritley, D Kerlikowske, K Fenton, JJ Melnikow, J de Koning, HJ Hubbard, RA AF Miglioretti, Diana L. Lange, Jane van den Broek, Jeroen J. Lee, Christoph I. van Ravesteyn, Nicolien T. Ritley, Dominique Kerlikowske, Karla Fenton, Joshua J. Melnikow, Joy de Koning, Harry J. Hubbard, Rebecca A. TI Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening A Modeling Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID UNITED-STATES; TOMOSYNTHESIS; RISK; ACCURACY; OBESITY; TRIAL AB Background: Estimates of risk for radiation-induced breast cancer from mammography screening have not considered variation in dose exposure or diagnostic work-up after abnormal screening results. Objective: To estimate distributions of radiation-induced breast cancer incidence and mortality from digital mammography screening while considering exposure from screening and diagnostic mammography and dose variation among women. Design: 2 simulation-modeling approaches. Setting: U.S. population. Patients: Women aged 40 to 74 years. Intervention: Annual or biennial digital mammography screening from age 40, 45, or 50 years until age 74 years. Measurements: Lifetime breast cancer deaths averted (benefits) and radiation-induced breast cancer incidence and mortality (harms) per 100 000 women screened. Results: Annual screening of 100 000 women aged 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 deaths (CI, 11 to 23), relative to 968 breast cancer deaths averted by early detection from screening. Women exposed at the 95th percentile were projected to develop 246 cases of radiation-induced breast cancer leading to 32 deaths per 100 000 women. Women with large breasts requiring extra views for complete examination (8% of population) were projected to have greater radiation-induced breast cancer risk (266 cancer cases and 35 deaths per 100 000 women) than other women (113 cancer cases and 15 deaths per 100 000 women). Biennial screening starting at age 50 years reduced risk for radiation-induced cancer 5-fold. Limitation: Life-years lost from radiation-induced breast cancer could not be estimated. Conclusion: Radiation-induced breast cancer incidence and mortality from digital mammography screening are affected by dose variability from screening, resultant diagnostic work-up, initiation age, and screening frequency. Women with large breasts may have a greater risk for radiation-induced breast cancer. C1 [Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, One Shields Ave,Med Sci Bldg 1C,Room 144, Davis, CA 95616 USA. [Lange, Jane] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [van den Broek, Jeroen J.; van Ravesteyn, Nicolien T.; de Koning, Harry J.] Erasmus MC Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands. [Lee, Christoph I.] Univ Washington, Sch Med, Dept Radiol, 825 Eastlake Ave East,G3-200, Seattle, WA 98109 USA. [Ritley, Dominique; Fenton, Joshua J.; Melnikow, Joy] Univ Calif Davis, Ctr Hlth Care Policy & Res, 2103 Stockton Blvd, Sacramento, CA 95817 USA. [Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. [Hubbard, Rebecca A.] Univ Penn, Dept Biostat & Epidemiol, 604 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RP Miglioretti, DL (reprint author), Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, One Shields Ave,Med Sci Bldg 1C,Room 144, Davis, CA 95616 USA. EM dmiglioretti@ucdavis.edu FU Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, National Cancer Institute FX Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, National Cancer Institute. NR 42 TC 9 Z9 9 U1 2 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 205 EP + DI 10.7326/M15-1241 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300011 PM 26756460 ER PT J AU Nelson, HD O'Meara, ES Kerlikowske, K Balch, S Miglioretti, D AF Nelson, Heidi D. O'Meara, Ellen S. Kerlikowske, Karla Balch, Steven Miglioretti, Diana TI Factors Associated With Rates of False-Positive and False -Negative Results From Digital Mammography Screening: An Analysis of Registry Data SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID SERVICES TASK-FORCE; BREAST-CANCER RISK; UNITED-STATES; COMMUNITY PRACTICE; HORMONE-THERAPY; WOMEN; TOMOSYNTHESIS; US; DENSITY; RECOMMENDATION AB Background: Women screened with digital mammography may receive false-positive and false-negative results and subsequent imaging and biopsies. How these outcomes vary by age, time since the last screening, and individual risk factors is unclear. Objective: To determine factors associated with false-positive and false-negative digital mammography results, additional imaging, and biopsies among a general population of women screened for breast cancer. Design: Analysis of registry data. Setting: Participating facilities at 5 U.S. Breast Cancer Surveillance Consortium breast imaging registries with linkages to pathology databases and tumor registries. Patients: 405 191 women aged 40 to 89 years screened with digital mammography between 2003 and 2011. A total of 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening. Measurements: Rates of false-positive and false-negative results and recommendations for additional imaging and biopsies from a single screening round; comparisons by age, time since the last screening, and risk factors. Results: Rates of false-positive results (121.2 per 1000 women [95% Cl, 105.6 to 138.7]) and recommendations for additional imaging (124.9 per 1000 women [Cl, 109.3 to 142.3]) were highest among women aged 40 to 49 years and decreased with increasing age. Rates of false-negative results (1.0 to 1.5 per 1000 women) and recommendations for biopsy (15.6 to 17.5 per 1000 women) did not differ greatly by age. Results did not differ by time since the last screening. False-positive rates were higher for women with risk factors, particularly family history of breast cancer; previous benign breast biopsy result; high breast density; and, for younger women, low body mass index. Limitations: Confounding by variation in patient-level characteristics and outcomes across registries and regions may have been present. Some factors, such as numbers of first- and second-degree relatives with breast cancer and diagnoses associated with previous benign biopsy results, were not examined. Conclusion: False-positive mammography results and additional imaging are common, particularly for younger women and those with risk factors, whereas biopsies occur less often. Rates of false-negative results are low. C1 [Nelson, Heidi D.] Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA. [O'Meara, Ellen S.; Balch, Steven] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [Kerlikowske, Karla] VAMC 111A1, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Miglioretti, Diana] Univ Calif Davis, 1 Shields Ave,Med Sci 1C,Room 145, Davis, CA 95616 USA. RP Nelson, HD (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA. EM nelsonh@ohsu.edu FU Agency for Healthcare Research and Quality; National Cancer Institute FX Agency for Healthcare Research and Quality and National Cancer Institute. NR 42 TC 12 Z9 12 U1 0 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 226 EP + DI 10.7326/M15-0971 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300013 PM 26756902 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP LeFevre, M AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. LeFevre, Michael CA US Preventive Serv Task Force TI Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement (Retracted article. See vol. 164, pg. 448, 2016) SO ANNALS OF INTERNAL MEDICINE LA English DT Article; Retracted Publication ID CARCINOMA IN-SITU; DIGITAL MAMMOGRAPHY; FILM MAMMOGRAPHY; TOMOSYNTHESIS; WOMEN; DENSITY; RISK; RACE; AGE; OVERDIAGNOSIS AB Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer. Methods: The USPSTF reviewed the evidence on the following: effectiveness of breast cancer screening in reducing breast cancer-specific and all-cause mortality, as well as the incidence of advanced breast cancer and treatment-related morbidity; harms of breast cancer screening; test performance characteristics of digital breast tomosynthesis as a primary screening strategy; and adjunctive screening in women with increased breast density. In addition, the USPSTF reviewed comparative decision models on optimal starting and stopping ages and intervals for screening mammography; how breast density, breast cancer risk, and comorbidity level affect the balance of benefit and harms of screening mammography; and the number of radiation-induced breast cancer cases and deaths associated with different screening mammography strategies over the course of a woman's lifetime. Population: This recommendation applies to asymptomatic women aged 40 years or older who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Recommendations: The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. (B recommendation) The decision to start screening mammography in women prior to age 50 years should be an individual one. Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging (MRI), DBT, or other methods in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. [LeFevre, Michael] Univ Missouri, Columbia, MO USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. FU U.S. Congress mandates that the Agency for Healthcare Research and Quality FX The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF. NR 59 TC 68 Z9 69 U1 5 U2 22 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 279 EP + DI 10.7326/M15-2886 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300018 PM 26757170 ER PT J AU Hon, YY Lin, EE Tian, X Yang, Y Sun, H Swenson, ER Taveira-Dasilva, AM Gladwin, MT Machado, RF AF Hon, Yuen Yi Lin, Elaina E. Tian, Xin Yang, Yang Sun, He Swenson, Erik R. Taveira-Dasilva, Angelo M. Gladwin, Mark T. Machado, Roberto F. TI Increased consumption and vasodilatory effect of nitrite during exercise SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE nitrite store; incremental exercise test; pharmacokinetics; hemodynamics; vasodilation ID DIETARY NITRATE SUPPLEMENTATION; OXIDE PRODUCTION; BLOOD-FLOW; MITOCHONDRIAL RESPIRATION; XANTHINE-OXIDASE; OXYGEN-UPTAKE; O-2 COST; L-NAME; CAPACITY; HUMANS AB This study investigated the effects of aerobic-to-anaerobic exercise on nitrite stores in the human circulation and evaluated the effects of systemic nitrite infusion on aerobic and anaerobic exercise capacity and hemodynamics. Six healthy volunteers were randomized to receive sodium nitrite or saline for 70 min in two separate occasions in an exercise study. Subjects cycled on an upright electronically braked cycle ergometer 30 min into the infusion according to a ramp protocol designed to attain exhaustion in 10 min. They were allowed to recover for 30 min thereafter. The changes of whole blood nitrite concentrations over the 70-min study period were analyzed by pharmacokinetic modeling. Longitudinal measurements of hemodynamic and clinical variables were analyzed by fitting nonparametric regression spline models. During exercise, nitrite consumption/elimination rate was increased by similar to 137%. Cardiac output (CO), mean arterial pressure (MAP), and pulmonary artery pressure (PAP) were increased, but smaller elevation of MAP and larger increases of CO and PAP were found during nitrite infusion compared with placebo control. The higher CO and lower MAP during nitrite infusion were likely attributed to vasodilation and a trend toward decrease in systemic vascular resistance. In contrast, there were no significant changes in mean pulmonary artery pressures and pulmonary vascular resistance. These findings, together with the increased consumption of nitrite and production of iron-nitrosyl-hemoglobin during exercise, support the notion of nitrite conversion to release NO resulting in systemic vasodilatation. However, at the dosing used in this protocol achieving micromolar plasma concentrations of nitrite, exercise capacity was not enhanced, as opposed to other reports using lower dosing. C1 [Hon, Yuen Yi] Clin Ctr Pharm Dept, NIH, Bethesda, MD USA. [Lin, Elaina E.; Gladwin, Mark T.; Machado, Roberto F.] NHLBI, Vasc Med Branch, Bldg 10, Bethesda, MD 20892 USA. [Tian, Xin; Yang, Yang] NHLBI, Off Biostat Res, Bldg 10, Bethesda, MD 20892 USA. [Sun, He] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Taveira-Dasilva, Angelo M.] NHLBI, Cardiovasc & Pulm Branch, Bldg 10, Bethesda, MD 20892 USA. RP Machado, RF (reprint author), Univ Illinois, Sect Pulm Crit Care Med Sleep & Allergy, 840 S Wood St,Rm 920-N,Clin Sci Bldg,MC 719, Chicago, IL 60612 USA. EM machador@uic.edu FU Intramural Research Program of Clinical Center Pharmacy Department; National Heart, Lung, and Blood Institute, National Institutes of Health FX This work was supported by the Intramural Research Program of Clinical Center Pharmacy Department and the National Heart, Lung, and Blood Institute, National Institutes of Health. There was no commercial sponsorship. NR 43 TC 2 Z9 2 U1 5 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD FEB 15 PY 2016 VL 310 IS 4 BP 1354 EP 1364 DI 10.1152/ajplung.00081.2015 PG 11 WC Physiology; Respiratory System SC Physiology; Respiratory System GA DD7DU UT WOS:000370084700006 ER PT J AU Filson, CP Shelton, JB Tan, HJ Kwan, L Skolarus, TA Saigal, CS Litwin, MS AF Filson, Christopher P. Shelton, Jeremy B. Tan, Hung-Jui Kwan, Lorna Skolarus, Ted A. Saigal, Christopher S. Litwin, Mark S. TI Expectant management of veterans with early-stage prostate cancer SO CANCER LA English DT Article DE active surveillance; expectant management; prostate cancer; veterans' health; watchful waiting ID POPULATION-BASED COHORT; LOW-RISK; RADICAL PROSTATECTOMY; ACTIVE SURVEILLANCE; TRENDS; MEN; RECOMMENDATIONS; PREFERENCES; COMORBIDITY; SURVIVAL AB BACKGROUNDFor certain men with low-risk prostate cancer, aggressive treatment results in marginal survival benefits while exposing them to urinary and sexual side effects. Nevertheless, expectant management has been underused. In the current study, the authors evaluated the association between various factors and expectant management use among veterans diagnosed with prostate cancer. METHODSThe authors identified men diagnosed with prostate cancer in 2008. The outcome of interest was use of expectant management, based on documentation captured through an in-depth chart review. Multivariable regression models were fit to examine associations between use of expectant management and patient demographics, cancer severity, and facility characteristics. The authors assessed variation across 21 tertiary care regions and 52 facilities by generating predicted probabilities for receipt of expectant management. RESULTSExpectant management was more common among patients aged 75 years (40% vs 27% for those aged<55 years; odds ratio, 2.57) and those with low-risk tumors (49% vs 20% for patients with high-risk tumors; odds ratio, 5.35). There was no association noted between patient comorbidity and receipt of expectant management (P=.90). There were also no associations found between facility factors and use of expectant management (all P>.05). Among ideal candidates for expectant management, receipt of expectant management varied considerably across individual facilities (0%-85%; P<.001). CONCLUSIONSPatient age and tumor risk were found to be more strongly associated with use of expectant management than patient comorbidity. Although use of expectant management appears broadly appropriate, there was variation in expectant management noted between hospitals that was apparently not attributable to facility factors. Research determining the basis of this variation, with a focus on providers, will be critical to help optimize prostate cancer treatment for veterans. (c) 2015 American Cancer Society. C1 [Filson, Christopher P.] Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd NE,Bldg B,1st Fl,Ste 1400, Atlanta, GA 30322 USA. [Filson, Christopher P.; Shelton, Jeremy B.; Tan, Hung-Jui; Kwan, Lorna; Saigal, Christopher S.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Filson, Christopher P.] Vet Affairs Atlanta Healthcare Syst, Decatur, GA USA. [Shelton, Jeremy B.; Skolarus, Ted A.; Saigal, Christopher S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shelton, Jeremy B.; Saigal, Christopher S.] Vet Affairs Ann Arbor Healthcare Syst, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA. [Skolarus, Ted A.] Univ Michigan, Dept Urol, Dow Div Hlth Serv Res, Ann Arbor, MI 48109 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Filson, CP (reprint author), Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd NE,Bldg B,1st Fl,Ste 1400, Atlanta, GA 30322 USA. EM cfilson@emory.edu FU American Cancer Society [PF-14-161-01-CPHPS]; Urology Care Foundation Research Scholars Program FX Christopher P. Filson was supported in part by postdoctoral fellowships from the American Cancer Society (PF-14-161-01-CPHPS) and the Urology Care Foundation Research Scholars Program for work performed as part of the current study. NR 27 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 15 PY 2016 VL 122 IS 4 BP 626 EP 633 DI 10.1002/cncr.29785 PG 8 WC Oncology SC Oncology GA DD5YA UT WOS:000369999600018 PM 26540451 ER PT J AU Cunningham, MA Wirth, JR Scott, JL Eudaly, J Collins, EL Gilkeson, GS AF Cunningham, Melissa A. Wirth, Jena R. Scott, Jennifer L. Eudaly, Jackie Collins, Erin L. Gilkeson, Gary S. TI Early Ovariectomy Results in Reduced Numbers of CD11c+/CD11b+Spleen Cells and Impacts Disease Expression in Murine Lupus SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE systemic lupus erythematosus; mouse models; estrogen; ovariectomy; dendritic cells ID ESTROGEN-RECEPTOR-ALPHA; DENDRITIC CELLS; AUTOIMMUNE-DISEASE; B-CELLS; SEX-HORMONES; NITRIC-OXIDE; 17-BETA-ESTRADIOL; ERYTHEMATOSUS; DIFFERENTIATION; MACROPHAGES AB Ninety percent of those diagnosed with systemic lupus erythematosus are female, with peak incidence between the ages of 15 and 45, when women are most hormonally active. Despite significant research effort, the mechanisms underlying this sex bias remain unclear. We previously showed that a functional knockout of estrogen receptor alpha (ER alpha) resulted in significantly reduced renal disease and increased survival in murine lupus. Dendritic cell (DC) development, which requires both estrogen and ER alpha, is impacted, as is activation status and cytokine production. Since both estrogen and testosterone levels have immunomodulating effects, we presently studied the phenotype of NZM2410 lupus-prone mice following post- and prepubertal ovariectomy (OVX) +/- estradiol (E2) replacement to determine the impact of hormonal status on disease expression and DC development in these mice. We observed a trend toward survival benefit in addition to decreased proteinuria and improved renal histology in the early OVX, but not late OVX- or E2-repleted WT mice. Interestingly, there was also a significant difference in splenic DC subsets by flow cytometry. Spleens from NZM mice OVX'd early had a significant decrease in proinflammatory CD11c+CD11b+ DCs (vs. unmanipulated WTs, late OVX- and E2-repleted mice). These early OVX'd animals also had a significant increase in tolerogenic CD11c+CD8a+ DCs vs. WT. These data join a growing body of evidence that supports a role for hormone modulation of DCs that likely impacts the penetrance and severity of autoimmune diseases, such as lupus. C1 [Cunningham, Melissa A.; Wirth, Jena R.; Scott, Jennifer L.; Eudaly, Jackie; Collins, Erin L.; Gilkeson, Gary S.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Rheumatol & Immunol, Charleston, SC 29425 USA. RP Cunningham, MA (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Rheumatol & Immunol, Charleston, SC 29425 USA. EM cunnima@musc.edu OI Cunningham, Melissa/0000-0002-9207-1986 FU South Carolina Clinical & Translational Research (SCTR) Institute; NUI/NCRR [UR1 RR029880, UL1 RR029882]; VA Medical Research Service Merit Award [1I01BX000470-01] FX This publication was supported by The South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NUI/NCRR Grant number UR1 RR029880 and UL1 RR029882; and a VA Medical Research Service Merit Award 1I01BX000470-01. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCRR. NR 46 TC 0 Z9 0 U1 2 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD FEB 15 PY 2016 VL 7 AR 31 DI 10.3389/fimmu.2016.00031 PG 10 WC Immunology SC Immunology GA DD7RW UT WOS:000370122800001 PM 26913030 ER PT J AU Carreno, FR Frazer, A AF Carreno, Flavia R. Frazer, Alan TI The Allure of Transcutaneous Vagus Nerve Stimulation as a Novel Therapeutic Modality SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID TREATMENT-RESISTANT DEPRESSION; DELTA-FOSB IMMUNOREACTIVITY; BRAIN C1 [Carreno, Flavia R.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Carreno, Flavia R.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA. [Frazer, Alan] Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Carreno, FR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM Carrenof@uthscsa.edu NR 10 TC 0 Z9 0 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2016 VL 79 IS 4 BP 260 EP 261 DI 10.1016/j.biopsych.2015.11.016 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DA9BT UT WOS:000368102300002 PM 26796874 ER PT J AU Ritchie, C Andersen, R Eng, J Garrigues, SK Intinarelli, G Kao, H Kawahara, S Patel, K Sapiro, L Thibault, A Tunick, E Barnes, DE AF Ritchie, Christine Andersen, Robin Eng, Jessica Garrigues, Sarah K. Intinarelli, Gina Kao, Helen Kawahara, Suzanne Patel, Kanan Sapiro, Lisa Thibault, Anne Tunick, Erika Barnes, Deborah E. TI Implementation of an Interdisciplinary, Team-Based Complex Care Support Health Care Model at an Academic Medical Center: Impact on Health Care Utilization and Quality of Life SO PLOS ONE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; OUTPATIENT GERIATRIC EVALUATION; DWELLING OLDER-ADULTS; LOW-INCOME SENIORS; MANAGEMENT; RESOURCES; MORTALITY; PEOPLE AB Introduction The Geriatric Resources for the Assessment and Care of Elders (GRACE) program has been shown to decrease acute care utilization and increase patient self-rated health in lowincome seniors at community-based health centers. Aims To describe adaptation of the GRACE model to include adults of all ages (named Care Support) and to evaluate the process and impact of Care Support implementation at an urban academic medical center. Setting 152 high-risk patients (>= 5 ED visits or >= 2 hospitalizations in the past 12 months) enrolled from four medical clinics from 4/29/2013 to 5/31/2014. Program Description Patients received a comprehensive in-home assessment by a nurse practitioner/social worker (NP/SW) team, who then met with a larger interdisciplinary team to develop an individualized care plan. In consultation with the primary care team, standardized care protocols were activated to address relevant key issues as needed. Program Evaluation A process evaluation based on the Consolidated Framework for Implementation Research identified key adaptations of the original model, which included streamlining of standardized protocols, augmenting mental health interventions and performing some assessments in the clinic. A summative evaluation found a significant decline in the median number of ED visits (5.5 to 0, p = 0.015) and hospitalizations (5.5 to 0, p<0.001) 6 months before enrollment in Care Support compared to 6 months after enrollment. In addition, the percent of patients reporting better self-rated health increased from 31% at enrollment to 64% at 9 months (p = 0.002). Semi-structured interviews with Care Support team members identified patients with multiple, complex conditions; little community support; and mild anxiety as those who appeared to benefit the most from the program. Discussion It was feasible to implement GRACE/Care Support at an academic medical center by making adaptations based on local needs. Care Support patients experienced significant reductions in acute care utilization and significant improvements in self-rated health. C1 [Ritchie, Christine; Eng, Jessica; Garrigues, Sarah K.; Kawahara, Suzanne; Patel, Kanan; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Ritchie, Christine; Garrigues, Sarah K.; Kawahara, Suzanne; Patel, Kanan; Barnes, Deborah E.] Univ Calif San Francisco, Div Geriatr, Tideswell UCSF, San Francisco, CA 94143 USA. [Andersen, Robin; Intinarelli, Gina; Kao, Helen; Sapiro, Lisa; Thibault, Anne; Tunick, Erika] Univ Calif San Francisco, UCSF Hlth, San Francisco, CA 94143 USA. [Eng, Jessica] San Francisco VA Med Ctr, Geriatr Palliat & Extended Care Serv, San Francisco, CA USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Res Serv, San Francisco, CA USA. RP Ritchie, C; Barnes, DE (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA USA.; Ritchie, C; Barnes, DE (reprint author), Univ Calif San Francisco, Div Geriatr, Tideswell UCSF, San Francisco, CA 94143 USA.; Barnes, DE (reprint author), San Francisco VA Med Ctr, Res Serv, San Francisco, CA USA. EM Christine.ritchie@ucsf.edu; Deborah.barnes@ucsf.edu FU S.D. Bechtel, Jr. Foundation; SCAN Foundation FX Evaluation of Care Support was supported by a grant to TideswellTM at UCSF from the S.D. Bechtel, Jr. Foundation. The SCAN Foundation provided support for the training and implementation assistance provided by the Indiana University Geriatrics GRACE Training and Resource Center to the UCSF Care Support program. The SCAN Foundation - advancing a coordinated and easily navigated system of high-quality services for older adults that preserve dignity and independence. For more information, please visit www.TheSCANFoundation.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 1 Z9 1 U1 8 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 12 PY 2016 VL 11 IS 2 AR e0148096 DI 10.1371/journal.pone.0148096 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6SI UT WOS:000370054100017 PM 26871704 ER PT J AU Connolly, KR Thase, ME AF Connolly, K. Ryan Thase, Michael E. TI Vortioxetine: a New Treatment for Major Depressive Disorder SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs); Vortioxetine; antidepressants; major depressive disorder (MDD); multimodal serotonin modulator ID PLACEBO-CONTROLLED TRIAL; 5 MG VORTIOXETINE; DOUBLE-BLIND; LU AA21004; MULTIMODAL ANTIDEPRESSANT; 5-HT DEPLETION; OPEN-LABEL; EFFICACY; ADULTS; SAFETY AB Introduction: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). Areas Covered: This article will review the basic clinical pharmacology of vortioxetine, summarize the major clinical trials that were performed prior to approval by the US Food and Drug Administration (FDA), discuss relevant post-marketing studies of this drug, and offer expert commentary on the significance of this new agent in clinical practice. Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov. Other referenced studies were identified via a MEDLINE database literature search in August 2015 using the key search terms, vortioxetine and Lu AA21004, combined with additional terms that included pharmacological profile, pharmacokinetics, drug interactions, adverse effects, side effects, safety, major depression, and major depressive disorder. We identified relevant systematic reviews, meta-analyses, randomized trials and preclinical studies of importance. Expert Opinion: Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants. The most common side effects are nausea, vomiting and constipation. Results of several studies indicate that vortioxetine may have therapeutic effects on cognition (e.g., memory and executive functioning) that exceed that of standard antidepressants. Disadvantages include cost and the current paucity of long-term efficacy data from large clinical trials. The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option. C1 [Connolly, K. Ryan; Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Connolly, K. Ryan; Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Thase, ME (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.; Thase, ME (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu FU Agency for Healthcare Research and Quality; Alkermes; AssureRx; Avanir; Forest Pharmaceuticals; Janssen; National Institute of Mental Health; Otsuka Pharmaceuticals FX M E Thase has been an advisory/consultant for Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb Company, Cerecor, Inc., Eli Lilly & Co., Forest Laboratories, Gerson Lehrman Group, Fabre-Kramer Pharmaceuticals, Inc., GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Inc., Merck and Co. Inc. (formerly Schering Plough and Organon), Moksha8, Naurex, Inc., Neuronetics, Inc., Novartis, Ortho-McNeil Pharmaceuticals (Johnson & Johnson; Janssen), Otsuka, Pamlab, L.L.C. (Nestle) Pfizer (formerly Wyeth Ayerst Pharmaceuticals), Shire US Inc., Sunovion Pharmaceuticals, Inc., Trius Therapeutical, Inc. and Takeda. He has received grant support from Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, National Institute of Mental Health and Otsuka Pharmaceuticals. M E Thase has equity holdings in MedAvante, Inc. and receives royalties from American Psychiatric Foundation, Guilford Publications, Herald House and W.W. Norton & Company, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 50 TC 3 Z9 3 U1 8 U2 21 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD FEB 11 PY 2016 VL 17 IS 3 BP 421 EP 431 DI 10.1517/14656566.2016.1133588 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DE0DD UT WOS:000370294100001 PM 26679430 ER PT J AU Erchegyi, J Wang, LX Gulyas, J Samant, M Perrin, MH Lewis, K Miller, C Vaughan, J Donaldson, C Fischer, W Low, W Yakabi, S Karasawa, H Tache, Y Rivier, C Rivier, J AF Erchegyi, Judit Wang, Lixin Gulyas, Jozsef Samant, Manoj Perrin, Marilyn H. Lewis, Kathy Miller, Charleen Vaughan, Joan Donaldson, Cynthia Fischer, Wolfgang Low, William Yakabi, Seiichi Karasawa, Hiroshi Tache, Yvette Rivier, Catherine Rivier, Jean TI Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins) SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID HORMONE-RECEPTOR ANTAGONIST; STRESS-RELATED ALTERATIONS; COLONIC MOTOR FUNCTION; COMPETITIVE ANTAGONISTS; SEQUENCE-ANALYSIS; RHESUS-MONKEY; RATS; SECRETION; INJECTION; SAUVAGINE AB CRF mediates numerous stress-related endocrine, autonomic, metabolic, and behavioral responses. We present the synthesis and chemical and biological properties of astressin B analogues {cydo(30-33)[D-Phe(12),Nle(21,38),C(alpha)MeLeu(27,40),Glu(30),Lys(33)]-acetyl-h/r-CRF(9-41)}. Out of 37 novel peptides, 17 (2, 4, 6-8, 10, 11, 16, 17, 27, 29, 30, 32-36) and 16 (3, 5, 9, 12-15, 18, 19, 22-26, 28, 31) had k(i) to CRF receptors in the high picomolar and low nanomole ranges, respectively. Peptides 1, 2, and 11 inhibited h/rCRF and urocortin 1-induced cAMP release from AtT20 and A7r5 cells. When Astressin C 2 was administered to adrenalectomized rats at 1.0 mg subcutaneously, it inhibited ACTH release for >7 d. Additional rat data based on the inhibitory effect of (2) on h/rCRF-induced stimulation of colonic secretory motor activity and urocortin 2-induced delayed gastric emptying also indicate a safe and long-lasting antagonistic effect. The overall properties of selected analogues may fulfill the criteria expected from clinical candidates. C1 [Erchegyi, Judit; Gulyas, Jozsef; Samant, Manoj; Perrin, Marilyn H.; Lewis, Kathy; Miller, Charleen; Vaughan, Joan; Donaldson, Cynthia; Fischer, Wolfgang; Low, William; Rivier, Catherine; Rivier, Jean] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Ctr, Div Digest Dis, Los Angeles, CA 90073 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Rivier, J (reprint author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM jrivier@salk.edu FU NIH [P01 DK026741-34, R01 DK057238]; VA Career Scientist Award; NIH (Animal Core) [DK041301] FX We thank D. Kirby for the synthesis of 11, Y. Haas for technical assistance, and D. Doan for manuscript preparation. J.R. is the Dr. Frederik Paulsen Chair in Neurosciences. This work was supported by NIH Grants P01 DK026741-34 (J.R, J.E., M.H.P., J.G., M.S., K.L., C.M., J.V., W.F., W.L.), DK041301 (Animal Core, Y.T., L.W.), R01 DK057238 (Y.T.), and VA Career Scientist Award (Y.T.). NR 38 TC 0 Z9 0 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD FEB 11 PY 2016 VL 59 IS 3 BP 854 EP 866 DI 10.1021/acs.jmedchem.5b00926 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DD8YL UT WOS:000370212700005 PM 26789203 ER PT J AU Yueh, AE Payne, SN Leystra, AA Van De Hey, DR Foley, TM Pasch, CA Clipson, L Matkowskyj, KA Deming, DA AF Yueh, Alexander E. Payne, Susan N. Leystra, Alyssa A. Van De Hey, Dana R. Foley, Tyler M. Pasch, Cheri A. Clipson, Linda Matkowskyj, Kristina A. Deming, Dustin A. TI Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K SO PLOS ONE LA English DT Article ID COLORECTAL-CANCER; GENETIC ALTERATIONS; PIK3CA MUTATION; PATHWAY; INHIBITION AB The phosphoinositide 3-kinase (PI3K) signaling pathway is critical for multiple important cellular functions, and is one of the most commonly altered pathways in human cancers. We previously developed a mouse model in which colon cancers were initiated by a dominant active PI3K p110-p85 fusion protein. In that model, well-differentiated mucinous adenocarcinomas developed within the colon and initiated through a non-canonical mechanism that is not dependent on WNT signaling. To assess the potential relevance of PI3K mutations in human cancers, we sought to determine if one of the common mutations in the human disease could also initiate similar colon cancers. Mice were generated expressing the Pik3-ca(H1047R) mutation, the analog of one of three human hotspot mutations in this gene. Mice expressing a constitutively active PI3K, as a result of this mutation, develop invasive adenocarcinomas strikingly similar to invasive adenocarcinomas found in human colon cancers. These tumors form without a polypoid intermediary and also lack nuclear CTNNB1 (beta-catenin), indicating a non-canonical mechanism of tumor initiation mediated by the PI3K pathway. These cancers are sensitive to dual PI3K/mTOR inhibition indicating dependence on the PI3K pathway. The tumor tissue remaining after treatment demonstrated reduction in cellular proliferation and inhibition of PI3K signaling. C1 [Yueh, Alexander E.; Van De Hey, Dana R.; Foley, Tyler M.; Deming, Dustin A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Sch Med & Publ Hlth, Madison, WI USA. [Payne, Susan N.; Pasch, Cheri A.; Matkowskyj, Kristina A.; Deming, Dustin A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Leystra, Alyssa A.; Clipson, Linda] Univ Wisconsin, Dept Oncol, Madison, WI USA. [Matkowskyj, Kristina A.] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth Madison, Madison, WI USA. [Matkowskyj, Kristina A.; Deming, Dustin A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Deming, DA (reprint author), Univ Wisconsin, Dept Med, Div Hematol & Oncol, Sch Med & Publ Hlth, Madison, WI USA.; Deming, DA (reprint author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.; Deming, DA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM ddeming@medicine.wisc.edu FU National Institutes of Health [P30 CA014520]; UW Carbone Cancer Center; UW Department of Medicine; UW School of Medicine and Public Health; UW Graduate School through the Wisconsin Alumni Research Foundation; Funk Out Cancer; UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group FX This project was supported by the National Institutes of Health (http://www.nih.gov/) P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); start-up funds (D.A.D) from the UW Carbone Cancer Center, UW Department of Medicine, UW School of Medicine and Public Health, and the UW Graduate School through the Wisconsin Alumni Research Foundation; Funk Out Cancer (http://www.funkoutcancer.com/) and UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 10 PY 2016 VL 11 IS 2 AR e0148730 DI 10.1371/journal.pone.0148730 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6PR UT WOS:000370046600102 PM 26863299 ER PT J AU Lee, JS Giesler, DL Gellad, WF Fine, MJ AF Lee, Jonathan S. Giesler, Daniel L. Gellad, Walid F. Fine, Michael J. TI Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID BETA-LACTAM MONOTHERAPY; QUALITY-OF-CARE; ELDERLY-PATIENTS; OUTCOMES; MORTALITY; METAANALYSIS; PATIENT; LACTAM/MACROLIDE; AZITHROMYCIN; ASSOCIATION AB IMPORTANCE Antibiotic therapy is the cornerstone of medical management for community-acquired pneumonia. OBJECTIVE To assess the associations between 3 key aspects of antibiotic therapy (optimal time to antibiotic initiation, initial antibiotic selection, and criteria for the transition from intravenous to oral therapy) and short-term mortality in adults hospitalized with community-acquired pneumonia. EVIDENCE REVIEW Bibliographic databases of MEDLINE, EMBASE, and the Cochrane Collaboration were searched for studies of adults hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1995, until November 5, 2015. FINDINGS Twenty studies (17 observational and 3 randomized trials) met eligibility criteria. Among 8 observational studies identified, the 4 largest (study populations of 2878 to 1 170 022) found that antibiotic initiation within 4 to 8 hours of hospital arrival was associated with relative reductions of 5% to 43% in mortality; the 4 smallest studies (study populations of 451 to 2076) found no associations between the timing of antibiotic initiation and mortality. One cluster randomized trial (n = 1737) demonstrated noninferiority of beta-lactam monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566), with an absolute adjusted difference of 2.5%(90% CI, -0.6% to 5.2%) in 90-day mortality favoring beta-lactam monotherapy. A second randomized trial (n = 580) failed to demonstrate noninferiority of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an absolute difference of 7.6%(1-sided 90% CI upper limit, 13.0%) in attainment of clinical stability on hospital day 7 favoring beta-lactam plus macrolide combination therapy. Six of 8 observational studies (study populations of 1188 to 24 780) found that beta-lactam plus macrolide combination therapy was associated with relative reductions of 26% to 68% in short-term mortality and all 3 observational studies (study populations of 2068 to 24 780) reported that fluoroquinolone monotherapy was associated with relative reductions of 30% to 43% in mortality compared with beta-lactam monotherapy. One randomized trial (n = 302) reported significantly reduced hospital length of stay (absolute difference, 1.9 days; 95% CI, 0.6 to 3.2 days), but no differences in treatment failure when objective clinical criteria were used to decide when to transition patients from intravenous to oral therapy. CONCLUSIONS AND RELEVANCE In adults hospitalized with community-acquired pneumonia, antibiotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoroquinolone monotherapy initiated within 4 to 8 hours of hospital arrival was associated with lower adjusted short-term mortality, supported predominantly by low-quality observational studies. One randomized trial supports the use of objective clinical criteria to guide the transition from intravenous to oral antibiotic therapy. C1 [Lee, Jonathan S.; Giesler, Daniel L.; Gellad, Walid F.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Lee, Jonathan S.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Gellad, Walid F.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA. EM michael.fine@va.gov NR 44 TC 14 Z9 15 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 9 PY 2016 VL 315 IS 6 BP 593 EP 602 DI 10.1001/jama.2016.0115 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DD0UJ UT WOS:000369635200018 PM 26864413 ER PT J AU Wong, SY Tan, MGK Banks, WA Wong, WSF Wong, PTH Lai, MKP AF Wong, Siew Ying Tan, Michelle G. K. Banks, William A. Wong, W. S. Fred Wong, Peter T. -H. Lai, Mitchell K. P. TI Andrographolide attenuates LPS-stimulated up-regulation of C-C and C-X-C motif chemokines in rodent cortex and primary astrocytes SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Andrographolide; Cytokines; Chemokines; Astrocyte; Neuroinflammation ID NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; RECEPTOR MODULATORS DECREASE; CEREBRAL-ISCHEMIA; BACTERIAL-MENINGITIS; CEREBROSPINAL-FLUID; SPINAL-CORD; TNF-ALPHA; IN-VITRO; MULTIPLE-SCLEROSIS AB Background: Andrographolide is the major bioactive compound isolated from Andrographis paniculata, a native South Asian herb used medicinally for its anti-inflammatory properties. In this study, we aimed to assess andrographolide's potential utility as an anti-neuroinflammatory therapeutic. Methods: The effects of andrographolide on lipopolysaccharide (LPS)-induced chemokine up-regulation both in mouse cortex and in cultured primary astrocytes were measured, including cytokine profiling, gene expression, and, in cultured astrocytes, activation of putative signaling regulators. Results: Orally administered andrographolide significantly attenuated mouse cortical chemokine levels from the C-C and C-X-C subfamilies. Similarly, andrographolide abrogated a range of LPS-induced chemokines as well as tumor necrosis factor (TNF)-alpha in astrocytes. In astrocytes, the inhibitory actions of andrographolide on chemokine and TNF-alpha up-regulation appeared to be mediated by nuclear factor-kappa B (NF-kappa B) or c-Jun N-terminal kinase (JNK) activation. Conclusions: These results suggest that andrographolide may be useful as a therapeutic for neuroinflammatory diseases, especially those characterized by chemokine dysregulation. C1 [Wong, Siew Ying; Tan, Michelle G. K.; Wong, W. S. Fred; Wong, Peter T. -H.; Lai, Mitchell K. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore. [Tan, Michelle G. K.] Singapore Gen Hosp, Dept Clin Res, Singapore, Singapore. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Wong, W. S. Fred] Natl Univ Singapore, Immunol Program, Inst Life Sci, Singapore 117548, Singapore. RP Lai, MKP (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore. EM mitchell.lai@dementia-research.org OI Lai, Mitchell K.P./0000-0001-7685-1424; Wong, Siew Ying/0000-0002-3152-9930 FU Yong Loo Lin School of Medicine, National University of Singapore [W184-000-223-133]; Singapore National Medical Research Council [NMRC/CBRG/0027/2012] FX This study was supported by the Yong Loo Lin School of Medicine, National University of Singapore (grant W184-000-223-133) to MKPL and the Singapore National Medical Research Council (NMRC/CBRG/0027/2012) to WSFW. We thank Y Zhu for the technical assistance. NR 72 TC 3 Z9 3 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD FEB 9 PY 2016 VL 13 AR 34 DI 10.1186/s12974-016-0498-6 PG 11 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DD5HN UT WOS:000369954000002 PM 26860080 ER PT J AU Peralta, CA McClure, LA Scherzer, R Odden, MC White, CL Shlipak, M Benavente, O Pergola, P AF Peralta, Carmen A. McClure, Leslie A. Scherzer, Rebecca Odden, Michelle C. White, Carole L. Shlipak, Michael Benavente, Oscar Pergola, Pablo TI Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial SO CIRCULATION LA English DT Article DE cerebrovascular disorders; hypertension; kidney; stroke ID GLOMERULAR-FILTRATION-RATE; CONVERTING ENZYME-INHIBITOR; TYPE-2 DIABETES-MELLITUS; STAGE RENAL-DISEASE; CLINICAL-TRIALS; GFR DECLINE; END-POINT; HYPERTENSION; PROGRESSION; OUTCOMES AB Background The effect of intensive blood pressure (BP) lowering on kidney function among individuals with established cerebrovascular disease and preserved estimated glomerular filtration rate (eGFR) is not established. Methods and Results- Among 2610 participants randomized to a lower (< 130 mm Hg) versus higher ( 130- 149 mm Hg) systolic BP target with repeated measures of serum creatinine, we evaluated differences by study arm in annualized eGFR decline and rapid decline ( eGFR decline > 30%) using linear mixed models and logistic regression, respectively. We assessed associations of both treatment and kidney function decline with stroke, major vascular events, and the composite of stroke, death, major vascular events, or myocardial infarction using multivariable Cox regression, separately and jointly including a test for interaction. Analyses were conducted by treatment arm. Mean age was 63 +/- 11 years; 949 participants ( 36%) were diabetic; and mean eGFR was 80 +/- 19 mL center dot min- 1 center dot 1.73 m- 2. At 9 months, achieved systolic BP was 137 +/- 15 versus 127 +/- 14 mm Hg in the higher versus lower BP group, and differences were maintained throughout follow- up ( mean, 3.2 years). Compared with the higher target, the lower BP target had a - 0.50- mL center dot min- 1 center dot 1.73 m- 2 per year ( 95% confidence interval [ CI], - 0.79 to - 0.21) faster eGFR decline. Differences were most pronounced during the first year (- 2.1 mL center dot min- 1 center dot 1.73 m- 2; 95% CI, - 0.97 to - 3.2), whereas rates of eGFR decline did not differ after year 1 (- 0.095; 95% CI, - 0.47 to 0.23). A total of 313 patients ( 24%) in the lower BP group had rapid kidney function decline compared with 247 ( 19%) in the higher BP group ( odds ratio, 1.4; 95% CI, 1.1- 1.6). Differences in rapid decline by treatment arm were apparent in the first year ( odds ratio, 1.4; 95% CI, 1.1- 1.8) but were not significant after year 1 ( odds ratio, 1.0; 95% CI, 0.73- 1.4). Rapid decline was associated with higher risk for stroke, major vascular events, and composite after full adjustment among individuals randomized to the higher BP target ( stroke hazard ratio, 1.93; 95% CI, 1.15- 3.21) but not the lower BP arm ( stroke hazard ratio, 0.93; 95% CI, 0.50- 1.75; all P for interaction < 0.06). Conclusions In patients with prior lacunar stroke and relatively preserved kidney function, intensive BP lowering was associated with a greater likelihood of rapid kidney function decline. Differences were observed primarily during the first year of antihypertensive treatment. Rapid kidney function decline was not associated with increased risk for clinical events among those undergoing intensive BP lowering. C1 [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94121 USA. [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [McClure, Leslie A.] Univ Alabama Birmingham, Birmingham, AL USA. [Odden, Michelle C.] Oregon State Univ, Corvallis, OR 97331 USA. [White, Carole L.; Pergola, Pablo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Benavente, Oscar] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Peralta, CA (reprint author), Univ Calif San Francisco, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU Robert Wood Johnson Foundation Harold Amos Grant; [1R01AG046206-01A1]; [5R03DK095877-03] FX Dr Peralta was funded by grant 1R01AG046206-01A1, 5R03DK095877-03, and the Robert Wood Johnson Foundation Harold Amos Grant. NR 38 TC 9 Z9 9 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 9 PY 2016 VL 133 IS 6 BP 584 EP 591 DI 10.1161/CIRCULATIONAHA.115.019657 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DC8XV UT WOS:000369504400007 PM 26762524 ER PT J AU Abbott, RD Ross, GW Petrovitch, H Masaki, KH Launer, LJ Nelson, JS White, LR Tanner, CM AF Abbott, Robert D. Ross, G. Webster Petrovitch, Helen Masaki, Kamal H. Launer, Lenore J. Nelson, James S. White, Lon R. Tanner, Caroline M. TI Midlife milk consumption and substantia nigra neuron density at death SO NEUROLOGY LA English DT Article ID IDIOPATHIC PARKINSONS-DISEASE; CORONARY-HEART-DISEASE; ORGANOCHLORINE PESTICIDES; DAIRY-PRODUCTS; FUTURE RISK; LIFE-STYLE; MEN; CALIFORNIA; STROKE; HAWAII AB Objective:To examine the relationship between midlife milk intake and Parkinson disease (PD) incidence through associations with substantia nigra (SN) neuron density and organochlorine pesticide exposure in decedent brains from the Honolulu-Asia Aging Study.Methods:Milk intake data were collected from 1965 to 1968 in 449 men aged 45-68 years with postmortem examinations from 1992 to 2004. Neuron density (count/mm(2)) was measured in quadrants from a transverse section of the SN. Additional measures included brain residues of heptachlor epoxide, an organochlorine pesticide found at excessively high levels in the milk supply in Hawaii in the early 1980s.Results:Neuron density was lowest in nonsmoking decedents who consumed high amounts of milk (>16 oz/d). After removing cases of PD and dementia with Lewy bodies, adjusted neuron density in all but the dorsomedial quadrant was 41.5% lower for milk intake >16 oz/d vs intake that was less (95% confidence interval 22.7%-55.7%, p < 0.001). Among those who drank the most milk, residues of heptachlor epoxide were found in 9 of 10 brains as compared to 63.4% (26/41) for those who consumed no milk (p = 0.017). For those who were ever smokers, an association between milk intake and neuron density was absent.Conclusions:Milk intake is associated with SN neuron loss in decedent brains unaffected by PD. Whether contamination of milk with organochlorine pesticides has a role in SN neurodegeneration warrants further study. C1 [Abbott, Robert D.] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan. [Abbott, Robert D.; Ross, G. Webster; Petrovitch, Helen; Nelson, James S.; White, Lon R.] Pacific Hlth Res & Educ Inst, Honolulu, HI USA. [Ross, G. Webster] Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [Abbott, Robert D.; Ross, G. Webster; Petrovitch, Helen; Masaki, Kamal H.] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, John A Hartford Fdn Ctr Excellence Geriatr, Honolulu, HI 96822 USA. [Ross, G. Webster; Petrovitch, Helen; White, Lon R.] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Masaki, Kamal H.] Kuakini Med Ctr, Honolulu, HI USA. [Launer, Lenore J.] NIA, Bethesda, MD 20892 USA. [Tanner, Caroline M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Abbott, RD (reprint author), Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan.; Abbott, RD (reprint author), Pacific Hlth Res & Educ Inst, Honolulu, HI USA.; Abbott, RD (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, John A Hartford Fdn Ctr Excellence Geriatr, Honolulu, HI 96822 USA. EM rda3e@virginia.edu FU National Institute on Aging [N01-AG-4-2149, 1 UO1 AG19349, 5 R01 AG017155]; National Heart, Lung, and Blood Institute [N01-HC-05102]; National Institute of Neurological Disorders and Stroke [5 R01 NS041265]; United States Department of the Army [DAMD17-98-1-8621]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs; Kuakini Medical Center; National Institute on Aging FX Supported by a contract (N01-AG-4-2149) and grants (1 UO1 AG19349 and 5 R01 AG017155) from the National Institute on Aging, by a contract (N01-HC-05102) from the National Heart, Lung, and Blood Institute, by a grant (5 R01 NS041265) from the National Institute of Neurological Disorders and Stroke, by a grant from the United States Department of the Army (DAMD17-98-1-8621), by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, by the Kuakini Medical Center, and in part by the Intramural Research Program of the National Institute on Aging. The information contained in this article does not necessarily reflect the position or the policy of the US Government, and no official endorsement should be inferred. NR 39 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 9 PY 2016 VL 86 IS 6 BP 512 EP 519 DI 10.1212/WNL.0000000000002254 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC9KT UT WOS:000369541200005 PM 26658906 ER PT J AU Vistamehr, A Kautz, SA Bowden, MG Neptune, RR AF Vistamehr, Arian Kautz, Steven A. Bowden, Mark G. Neptune, Richard R. TI Correlations between measures of dynamic balance in individuals with post-stroke hemiparesis SO JOURNAL OF BIOMECHANICS LA English DT Article DE Berg balance scale; Dynamic gait index; Margin of stability; Angular momentum; Biomechanics ID PLANE ANGULAR-MOMENTUM; HUMAN WALKING; STROKE REHABILITATION; LATERAL BALANCE; SUPPORT LIMB; OLDER-ADULTS; GAIT INDEX; STABILITY; FALLS; MARGINS AB Mediolateral balance control during walking is a challenging task in post-stroke hemiparetic individuals. To detect and treat dynamic balance disorders, it is important to assess balance using reliable methods. The Berg Balance Scale (BBS), Dynamic Gait Index (DGI), margin-of-stability (MoS), and peak-to-peak range of angular-momentum (H) are some of the most commonly used measures to assess dynamic balance and fall risk in clinical and laboratory settings. However, it is not clear if these measures lead to similar conclusions. Thus, the purpose of this study was to assess dynamic balance in post-stroke hemiparetic individuals using BBS, DGI, MoS and the range of H and determine if these measure are correlated. BBS and DGI were collected from 19 individuals post-stroke. Additionally, kinematic and kinetic data were collected while the same individuals walked at their self-selected speed. MoS and the range of H were calculated in the mediolateral direction for each participant. Correlation analyses revealed moderate associations between all measures. Overall, a higher range of angular-momentum was associated with a higher MoS, wider step width and lower BBS and DGI scores, indicating poor balance control. Further, only the MoS from the paretic foot placement, but not the nonparetic foot, correlated with the other balance measures. Although moderate correlations existed between all the balance measures, these findings do not necessarily advocate the use of a single measure as each test may assess different constructs of dynamic balance. These findings have important implications for the use and interpretation of dynamic balance assessments. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Vistamehr, Arian] Brooks Rehabil Hosp, Motion Anal Ctr, Jacksonville, FL USA. [Kautz, Steven A.; Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu FU American Heart Association SouthWest Affiliate pre-doctoral fellowship [12PRE12030414]; Rehabilitation Research and Development Service of the Department of Veteran's Affairs [N0787-W]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20-GM109040] FX The authors would like to acknowledge Ms. Leah Carter for her valuable contributions to this study. This work was supported by an American Heart Association SouthWest Affiliate pre-doctoral fellowship (12PRE12030414), the Rehabilitation Research and Development Service of the Department of Veteran's Affairs (N0787-W) and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant number P20-GM109040. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the AHA, the VA or the NIH. NR 37 TC 2 Z9 3 U1 7 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD FEB 8 PY 2016 VL 49 IS 3 BP 396 EP 400 DI 10.1016/j.jbiomech.2015.12.047 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DF7PA UT WOS:000371548700012 PM 26795124 ER PT J AU Kristianto, J Litscher, SJ Johnson, MG Patel, F Patel, M Fisher, J Zastrow, RK Radcliff, AB Blank, RD AF Kristianto, Jasmin Litscher, Suzanne J. Johnson, Michael G. Patel, Forum Patel, Mital Fisher, Jacqueline Zastrow, Ryley K. Radcliff, Abigail B. Blank, Robert D. TI Congenic Strains Confirm the Pleiotropic Effect of Chromosome 4 QTL on Mouse Femoral Geometry and Biomechanical Performance SO PLOS ONE LA English DT Article ID QUANTITATIVE TRAIT LOCI; BONE-MINERAL DENSITY; CORTICAL BONE; SEX-DIFFERENCES; GENETIC COMPOSITION; CANDIDATE GENES; SKELETAL SIZE; BODY-SIZE; MICE; STRENGTH AB A pleiotropic quantitative trait locus (QTL) for bone geometry and mechanical performance in mice was mapped to distal chromosome 4 via an intercross of recombinant congenic mice HcB-8 and HcB-23. To study the QTL in isolation, we have generated C3H. B10-(rs6355453-rs13478087) (C. B. 4.3) and C3H. B10-(rs6369860-D4Mit170) (C. B. 4.2) congenic strains that harbor similar to 20 Mb and similar to 3 Mb, respectively, of chromosome 4 overlapping segments from C57BL/10ScSnA (B10) within the locus on a C3H/DiSnA (C3H) background. Using 3-point bend testing and standard beam equations, we phenotyped these mice for femoral mid-diaphyseal geometry and biomechanical performance. We analyzed the results via 2-way ANOVA, using sex and genotype as factors. In the C. B. 4.3 strain, we found that homozygous B10/B10 male mice had smaller cross sectional area (CSA) and reduced total displacement than homozygous C3H/C3H mice. Sex by genotype interaction was also observed for maximum load and stiffness for C3H/C3H and B10/B10 mice, respectively. In C. B. 4.2 strain, we found that homozygous B10/B10 mice had lower total displacement, post-yield displacement (PYD), stiffness, yield load and maximum load than mice harboring C3H allele. Sex by genotype interaction was observed in B10/B10 mice for perimeter, outer minor axis (OMA) and CSA. There were no significant differences in tissue level mechanical performance, which suggest that the QTL acts primarily on circumferential bone size. These data confirm the prior QTL mapping data and support other work demonstrating the importance of chromosome 4 QTL on bone modeling and bone responses to mechanical loading. C1 [Kristianto, Jasmin; Litscher, Suzanne J.; Johnson, Michael G.; Patel, Forum; Patel, Mital; Fisher, Jacqueline; Zastrow, Ryley K.; Radcliff, Abigail B.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Blank, Robert D.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Blank, Robert D.] Milwaukee VA Med Ctr, Milwaukee, WI USA. RP Kristianto, J (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. EM jkristianto@medicine.wisc.edu OI Blank, Robert Daniel/0000-0003-2950-1944 FU Office of Research and Development, Rehabilitation Research and Development Service [I21 RX1440]; Merit Review Award from the Office of Research and Development, Biomedical and Laboratory Research and Development Service, the Department of Veterans Affairs; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health [NIH AR54753]; NIH [AR54753] FX We would like to thank Marc Drezner and Baozhi Yuan for helpful discussions. This material is based on work supported in part by award I21 RX1440, by the Office of Research and Development, Rehabilitation Research and Development Service, and a Merit Review Award from the Office of Research and Development, Biomedical and Laboratory Research and Development Service, the Department of Veterans Affairs, and performed in the Geriatrics Research, Education, and Clinical Center at the William S. Middleton Memorial Veterans Hospital. The views expressed here are those of the authors, and the contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.; Research reported in this publication was supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health under Award Number NIH AR54753. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.; Funded by NIH AR54753. www.nih.gov. (Robert Blank). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 5 PY 2016 VL 11 IS 2 AR e0148571 DI 10.1371/journal.pone.0148571 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9PR UT WOS:000369554000127 PM 26849124 ER PT J AU Zaynagetdinov, R Sherrill, TP Gleaves, LA Hunt, P Han, W McLoed, AG Saxon, JA Tanjore, H Gulleman, PM Young, LR Blackwell, TS AF Zaynagetdinov, Rinat Sherrill, Taylor P. Gleaves, Linda A. Hunt, Pierre Han, Wei McLoed, Allyson G. Saxon, Jamie A. Tanjore, Harikrishna Gulleman, Peter M. Young, Lisa R. Blackwell, Timothy S. TI Chronic NF-kappa B activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs SO ONCOTARGET LA English DT Article DE NF-kappa B; COPD; lung cancer; macrophage; tregs ID OBSTRUCTIVE PULMONARY-DISEASE; REGULATORY T-CELLS; RETINOIC ACID; BRONCHIAL BIOPSIES; MACROPHAGES; CARCINOGENESIS; EXPRESSION; BETA; TUMORIGENESIS; INFLAMMATION AB Nuclear Factor (NF)-kappa B is positioned to provide the interface between COPD and carcinogenesis through regulation of chronic inflammation in the lungs. Using a tetracycline-inducible transgenic mouse model that conditionally expresses activated I kappa B kinase beta (IKK beta) in airway epithelium (IKTA), we found that sustained NF-kappa B signaling results in chronic inflammation and emphysema by 4 months. By 11 months of transgene activation, IKTA mice develop lung adenomas. Investigation of lung inflammation in IKTA mice revealed a substantial increase in M2-polarized macrophages and CD4(+)/CD25(+)/FoxP3(+) regulatory T lymphocytes (Tregs). Depletion of alveolar macrophages in IKTA mice reduced Tregs, increased lung CD8(+) lymphocytes, and reduced tumor numbers following treatment with the carcinogen urethane. Alveolar macrophages from IKTA mice supported increased generation of inducible Foxp3(+) Tregs ex vivo through expression of TGF beta and IL-10. Targeting of TGF beta and IL-10 reduced the ability of alveolar macrophages from IKTA mice to induce Foxp3 expression on T cells. These studies indicate that sustained activation of NF-kappa B pathway links COPD and lung cancer through generation and maintenance of a pro-tumorigenic inflammatory environment consisting of alternatively activated macrophages and regulatory T cells. C1 [Zaynagetdinov, Rinat; Sherrill, Taylor P.; Gleaves, Linda A.; Hunt, Pierre; Han, Wei; Tanjore, Harikrishna; Young, Lisa R.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Med, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. [McLoed, Allyson G.; Saxon, Jamie A.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA. [Blackwell, Timothy S.] US Dept Vet Affairs, Nashville, TN 37232 USA. [Gulleman, Peter M.; Young, Lisa R.] Vanderbilt Univ, Dept Pediat, Sch Med, Div Pulm Med, Nashville, TN 37232 USA. RP Zaynagetdinov, R (reprint author), Vanderbilt Univ, Dept Med, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. EM rinat.z.zaynagetdinov@vanderbilt.edu FU Lung Cancer Initiative of North Carolina; National Institutes of Health [T32HL094296, R01 HL119503]; Department of Veterans Affairs Merit Review Award [1101BX002378]; Vanderbilt-Ingram Cancer Center Spore Grant; Free to Breathe FX This work was supported by a Grant from the Lung Cancer Initiative of North Carolina and Free to Breathe (R.Z.), by National Institutes of Health Grants T32HL094296 (R.Z.) and R01 HL119503 (L.R.Y), by the Department of Veterans Affairs Merit Review Award 1101BX002378 (T.S.B), and by a Vanderbilt-Ingram Cancer Center Spore Grant 2010 (T.S.B). NR 30 TC 2 Z9 2 U1 3 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 2 PY 2016 VL 7 IS 5 BP 5470 EP 5482 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD5HD UT WOS:000369952800028 PM 26756215 ER PT J AU Hassan, A Ahlskog, JE Matsumoto, JY Milber, JM Bower, JH Wilkinson, JR AF Hassan, Anhar Ahlskog, J. Eric Matsumoto, Joseph Y. Milber, Joshua M. Bower, James H. Wilkinson, Jayne R. TI Orthostatic tremor Clinical, electrophysiologic, and treatment findings in 184 patients SO NEUROLOGY LA English DT Article ID MYOCLONUS AB Objective:To evaluate the clinical, electrophysiologic, and treatment outcome features of orthostatic tremor (OT) in a large case series.Methods:We performed medical record review of 184 patients who met clinical and electrodiagnostic criteria for OT from 1976 to 2013 at the Mayo Clinic. Demographic, clinical, electrophysiologic, and treatment data were extracted.Results:The majority of OT cases were female (63.6%) and mean age at onset was 59.3 years (range 13-85 years). Diagnosis was delayed by a mean of 7.2 years (range 0-44 years). The average tremor frequency was 15.7 Hz (range 12.5-20 Hz), and transmitted to the arms on weight-bearing (95.5%). Patients reported a spectrum of progressive orthostatic leg symptoms, relieved by sitting or leaning. Falls were reported in 24.1%. Coexistent neurologic disorders included essential tremor (22.8%), other tremor (4.9%), and parkinsonism (8.7%). Family history of OT was noted in 4.9%. Of 46 medications trialed, 24 failed to provide any benefit. Benzodiazepines provided at least mild benefit in 55.9%, and moderate to marked benefit in 31.5%; -blockers (31.0%) and anticonvulsants (25.0%) provided mild benefit, and the remainder were largely ineffective. Medication benefit waned over time. Deep brain stimulation (DBS) was effective in 2 cases.Conclusion:OT predominantly affects female seniors, and the diagnosis should be considered with any orthostatic-induced leg symptoms, and confirmed by surface EMG. Benzodiazepines are the most efficacious treatment, followed by -blockers and anticonvulsants. DBS should be further explored for treatment. C1 [Hassan, Anhar; Ahlskog, J. Eric; Matsumoto, Joseph Y.; Bower, James H.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Milber, Joshua M.] SUNY Downstate Coll Med, Brooklyn, NY USA. [Wilkinson, Jayne R.] Univ Penn, Philadelphia, PA 19104 USA. [Wilkinson, Jayne R.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. RP Hassan, A (reprint author), Mayo Clin, Dept Neurol, Rochester, MN USA. EM hassan.anhar@mayo.edu NR 15 TC 7 Z9 8 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 2 PY 2016 VL 86 IS 5 BP 458 EP 464 DI 10.1212/WNL.0000000000002328 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DD1HZ UT WOS:000369673200010 PM 26747880 ER PT J AU Boutin, M Sun, Y Shacka, JJ Auray-Blais, C AF Boutin, Michel Sun, Ying Shacka, John J. Auray-Blais, Christiane TI Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease SO ANALYTICAL CHEMISTRY LA English DT Article ID NEURONOPATHIC GAUCHER-DISEASE; ALPHA-SYNUCLEIN; GLUCOCEREBROSIDASE; ACCUMULATION; QUANTITATION; DEFICIENCY; QUADRUPOLE; BIOMARKERS; PLASMA; MODEL AB Previous studies demonstrated that Parkinson disease (PD) is associated with a decreased activity of the glucocerebrosidase (GCase) enzyme in brain tissues. The objective of this study was to determine if GCase deficiency is associated with the accumulation of its glucosylceramide (GluCer) substrate in PD brain tissues. An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed, optimized, and validated for the multiplex analysis of GluCer isoforms (C18:0, C20:0, C22:0, C24:1, and C24:0) in brain tissue samples. These molecules were chromatographically separated from their isobaric galactosylceramide (GalCer) counterparts using normal phase chromatography. The analysis was performed by tandem mass spectrometry in the multiple reaction monitoring (MRM) acquisition mode. Limits of detection ranging from 0.4 to 1.1 nmol/g brain tissue were established for the different GluCer isoforms analyzed. For the first time, GluCer isoform levels were analyzed in temporal cortex brain tissue samples from 26 PD patients who were divided into three PD disease stages (IIa, III, and IV) according to the Unified Staging System for Lewy Body Disorders. These specimens were compared with brain tissue samples from 12 controls and 6 patients with Incidental Lewy Body Disease. No significant GluCer concentration differences were observed between the 5 sample groups. The GluCer isoform levels were also normalized with their matching GalCer isoforms. The normalized results showed a trend for GluCer levels which increased with PD severity. However, the differences observed between the groups were not significant, owing likely to the high standard deviations measured. C1 [Boutin, Michel; Auray-Blais, Christiane] Univ Sherbrooke, Div Med Genet, Dept Pediat, Ctr Rech,CHUS,Fac Med & Hlth Sci, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada. [Sun, Ying] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, R Bldg Room 1401,3333 Burnet Ave, Cincinnati, OH 45229 USA. [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol Div, 1670 Univ Blvd,VH G019H, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Auray-Blais, C (reprint author), Univ Sherbrooke, Div Med Genet, Dept Pediat, Ctr Rech,CHUS,Fac Med & Hlth Sci, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada. EM christiane.auray-blais@usherbrooke.ca FU Michael J. Fox Foundation for Parkinson's Research FX This research was funded by the Michael J. Fox Foundation for Parkinson's Research. We are grateful to Waters Corporation for their continued scientific support and partnership. We would like to thank Michael P. Nelson, Ph.D. at University of Alabama at Birmingham for his support in preparing the brain tissue samples. We would like to sincerely thank Dr. Joe T. R. Clarke for his expertise and insight and Marie-Pierre Garant for statistical analysis support. NR 25 TC 4 Z9 4 U1 5 U2 18 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD FEB 2 PY 2016 VL 88 IS 3 BP 1856 EP 1863 DI 10.1021/acs.analchem.5b04227 PG 8 WC Chemistry, Analytical SC Chemistry GA DC8LM UT WOS:000369471100053 PM 26735924 ER PT J AU Merrins, MJ Poudel, C McKenna, JP Ha, J Sherman, A Bertram, R Satin, LS AF Merrins, Matthew J. Poudel, Chetan McKenna, Joseph P. Ha, Joon Sherman, Arthur Bertram, Richard Satin, Leslie S. TI Phase Analysis of Metabolic Oscillations and Membrane Potential in Pancreatic Islet beta-Cells SO BIOPHYSICAL JOURNAL LA English DT Article ID PULSATILE INSULIN-SECRETION; PURINE NUCLEOTIDE CYCLE; GLYCOLYTIC PATHWAY; CA2+; GLUCOSE; CALCIUM; MODEL; DEHYDROGENASE; ACTIVATION; MECHANISMS AB Metabolism in islet beta-cells displays oscillations that can trigger pulses of electrical activity and insulin secretion. There has been a decades-long debate among islet biologists about whether metabolic oscillations are intrinsic or occur in response to oscillations in intracellular Ca2+ that result from bursting electrical activity. In this article, the dynamics of oscillatory metabolism were investigated using five different optical reporters. Reporter activity was measured simultaneously with membrane potential bursting to determine the phase relationships between the metabolic oscillations and electrical activity. Our experimental findings suggest that Ca2+ entry into beta-cells stimulates the rate of mitochondrial metabolism, accounting for the depletion of glycolytic intermediates during each oscillatory burst. We also performed Ca2+ clamp tests in which we clamped membrane potential with the K-ATP channel-opener diazoxide and KCl to fix Ca2+ at an elevated level. These tests confirm that metabolic oscillations do not require Ca2+ oscillations, but show that Ca2+ plays a larger role in shaping metabolic oscillations than previously suspected. A dynamical picture of the mechanisms of oscillations emerged that requires the restructuring of contemporary mathematical beta-cell models, including our own dual oscillator model. In the companion article, we modified our model to account for these new data. C1 [Merrins, Matthew J.; Poudel, Chetan] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Endocrinol Diabet & Metab, Madison, WI USA. [Merrins, Matthew J.; Poudel, Chetan] Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.; Poudel, Chetan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Dept Math, Tallahassee, FL 32306 USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. [Ha, Joon; Sherman, Arthur] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA. [Satin, Leslie S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA. [Satin, Leslie S.] Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. RP Satin, LS (reprint author), Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.; Satin, LS (reprint author), Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. EM lsatin@umich.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK46409, K01-DK101683]; NIH FX This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases, including grants R01-DK46409 to L.S.S. and K01-DK101683 to M.J.M. A.S. and J.H. were supported by the Intramural Research Program of the NIH. NR 39 TC 4 Z9 4 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD FEB 2 PY 2016 VL 110 IS 3 BP 691 EP 699 DI 10.1016/j.bpj.2015.12.029 PG 9 WC Biophysics SC Biophysics GA DC8KH UT WOS:000369467800018 PM 26840733 ER PT J AU McKenna, JP Ha, J Merrins, MJ Satin, LS Sherman, A Bertram, R AF McKenna, Joseph P. Ha, Joon Merrins, Matthew J. Satin, Leslie S. Sherman, Arthur Bertram, Richard TI Ca2+ Effects on ATP Production and Consumption Have Regulatory Roles on Oscillatory Islet Activity SO BIOPHYSICAL JOURNAL LA English DT Article ID PANCREATIC BETA-CELLS; PULSATILE INSULIN-SECRETION; METABOLIC OSCILLATIONS; GLYCOLYTIC OSCILLATIONS; ELECTRICAL-ACTIVITY; GLUCOSE-METABOLISM; CALCIUM; PHOSPHOFRUCTOKINASE; MODEL; MEMBRANE AB Pancreatic islets respond to elevated blood glucose by secreting pulses of insulin that parallel oscillations in beta-cell metabolism, intracellular Ca2+ concentration, and bursting electrical activity. The mechanisms that maintain an oscillatory response are not fully understood, yet several models have been proposed. Only some can account for experiments supporting that metabolism is intrinsically oscillatory in beta-cells. The dual oscillator model (DOM) implicates glycolysis as the source of oscillatory metabolism. In the companion article, we use recently developed biosensors to confirm that glycolysis is oscillatory and further elucidate the coordination of metabolic and electrical signals in the insulin secretory pathway. In this report, we modify the DOM by incorporating an established link between metabolism and intracellular Ca2+ to reconcile model predictions with experimental observations from the companion article. With modification, we maintain the distinguishing feature of the DOM, oscillatory glycolysis, but introduce the ability of Ca2+ influx to reshape glycolytic oscillations by promoting glycolytic efflux. We use the modified model to explain measurements from the companion article and from previously published experiments with islets. C1 [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Dept Math, Tallahassee, FL 32306 USA. [Ha, Joon; Sherman, Arthur] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Satin, Leslie S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA. [Satin, Leslie S.] Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. [Bertram, Richard] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA. [Bertram, Richard] Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. RP Bertram, R (reprint author), Florida State Univ, Dept Math, Tallahassee, FL 32306 USA.; Bertram, R (reprint author), Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.; Bertram, R (reprint author), Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. EM bertram@math.fsu.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK46409, K01-DK101683]; Intramural Research Program of the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases) FX This work was partially supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (grant No. R01-DK46409 to L.S.S. and grant No. K01-DK101683 to M.J.M.). A.S. and J.H. were supported by the Intramural Research Program of the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases). NR 46 TC 2 Z9 2 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD FEB 2 PY 2016 VL 110 IS 3 BP 733 EP 742 DI 10.1016/j.bpj.2015.11.3526 PG 10 WC Biophysics SC Biophysics GA DC8KH UT WOS:000369467800022 PM 26840737 ER PT J AU Bradley, SM O'Donnell, CI Grunwald, GK Liu, CF Hebert, PL Maddox, TM Jesse, RL Fihn, SD Rumsfeld, JS Ho, PM AF Bradley, Steven M. O'Donnell, Colin I. Grunwald, Gary K. Liu, Chuan-Fen Hebert, Paul L. Maddox, Thomas M. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. Ho, P. Michael TI Facility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short- Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program Response SO CIRCULATION LA English DT Letter C1 [Bradley, Steven M.; O'Donnell, Colin I.; Grunwald, Gary K.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA. [O'Donnell, Colin I.; Grunwald, Gary K.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.; Fihn, Stephan D.] US Dept Vet Affairs, Vet Hlth Adm, Washington, DC USA. RP Bradley, SM (reprint author), VA Eastern Colorado Hlth Care Syst, Denver, CO USA.; Bradley, SM (reprint author), Univ Colorado, Sch Med, Aurora, CO USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 2 PY 2016 VL 133 IS 5 BP E377 EP E377 DI 10.1161/CIRCULATIONAHA.115.019552 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DD1IC UT WOS:000369673500005 PM 26831442 ER PT J AU Chen-Scarabelli, C Scarabelli, TM AF Chen-Scarabelli, Carol Scarabelli, Tiziano M. TI Cyclosporine A Prior to Primary PCI in STEMI Patients The Coup de Grace to Post-Conditioning? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE cardioprotection; coronary occlusion; infarct size; mitochondrial permeability transition pores; myocardial reperfusion injury ID ELEVATION MYOCARDIAL-INFARCTION; REPERFUSION; INJURY; TRIAL; CARDIOPROTECTION C1 [Chen-Scarabelli, Carol; Scarabelli, Tiziano M.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Scarabelli, Tiziano M.] Univ Alabama Birmingham, Div Cardiovasc Dis, 1530 3rd Ave,South Tinsley Harrison Tower, Birmingham, AL 35294 USA. RP Scarabelli, TM (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 1530 3rd Ave,South Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM tscarabelli@uabmc.edu NR 14 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 2 PY 2016 VL 67 IS 4 BP 375 EP 378 DI 10.1016/j.jacc.2015.11.024 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6HO UT WOS:000368615600004 PM 26821624 ER PT J AU Carson, AP Muntner, P Selvin, E Carnethon, MR Li, XL Gross, MD Garvey, WT Lewis, CE AF Carson, April P. Muntner, Paul Selvin, Elizabeth Carnethon, Mercedes R. Li, Xuelin Gross, Myron D. Garvey, W. Timothy Lewis, Cora E. TI Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes SO BMJ OPEN DIABETES RESEARCH & CARE LA English DT Article ID HEMOGLOBIN A(1C) LEVELS; GLYCATED ALBUMIN; ALTERNATIVE MARKERS; BLOOD-GLUCOSE; RISK; 1,5-ANHYDROGLUCITOL; FRUCTOSAMINE; ADULTS; ASSOCIATION; MELLITUS AB Objective: It is well known that A1c varies by race. However, racial differences in other biomarkers of hyperglycemia are less well characterized. The objective of this study was to determine whether average levels of glycemic markers differ by race in adults with and without diagnosed diabetes, before and after accounting for postchallenge glucose. Research design and methods: This cross-sectional study included 2692 middle-aged men and women (5.5% with diagnosed diabetes; 44% African-American; and 56% white) from the Coronary Artery Risk Development in Young Adults Study (2005-2006) who had fasting glucose, 2-hour postchallenge glucose, A1c, glycated albumin, fructosamine, and 1,5-anhydroglucitol (1,5-AG) measured. Multiple linear regression was used to evaluate racial differences in mean levels of each glycemic marker stratified by the diabetes status and adjusted for sociodemographics, cardiovascular factors, and postchallenge glucose. Results: Among those with diagnosed diabetes, racial differences were not observed for any of the glycemic markers. In contrast, among those without diagnosed diabetes, African-Americans had higher mean levels than whites of A1c (beta=0.19% points; 95% CI 0.14 to 0.24), glycated albumin (beta=0.82% points; 95% CI 0.68 to 0.97), fructosamine (beta=8.68 mu mol/L; 95% CI 6.68 to 10.68), and 2-hour glucose (beta=3.50 mg/dL; 95% CI 0.10 to 6.90) after multivariable adjustment, whereas there were no statistically significant racial difference in 1,5-AG. The racial differences observed for A1c, glycated albumin, and fructosamine persisted after further adjustment for fasting and 2-hour glucose and were of similar magnitude (SD units). Conclusions: Racial differences in glycemic marker levels were evident among middle-aged adults without diagnosed diabetes even after adjustment for postchallenge glucose. Whether these racial differences in biomarkers of hyperglycemia affect the risk of complications warrants additional study. C1 [Carson, April P.; Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Selvin, Elizabeth] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Carnethon, Mercedes R.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Li, Xuelin; Lewis, Cora E.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. [Gross, Myron D.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Carson, AP (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. EM apcarson@uab.edu FU NCATS NIH HHS [UL1 TR000165, UL1 TR001417]; NHLBI NIH HHS [HHSN268201300027C, HHSN268200900041C, HHSN268201300025C, HHSN268201300026C, HHSN268201300028C, HHSN268201300029C, R01 HL053560]; NIDDK NIH HHS [F32 DK009528, K01 DK095928, K24 DK106414, P30 DK079626] NR 33 TC 3 Z9 3 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2052-4897 J9 BMJ OPEN DIAB RES CA JI BMJ Open Diab. Res. Care PD FEB PY 2016 VL 4 IS 1 AR e000213 DI 10.1136/bmjdrc-2016-000213 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA1DQ UT WOS:000386333100047 PM 27335652 ER PT J AU Berry, ABL Butler, KA Harrington, C Braxton, MO Walker, AJ Pete, N Johnson, T Oberle, MW Haselkorn, J Nichol, WP Haselkorn, M AF Berry, Andrew B. L. Butler, Keith A. Harrington, Craig Braxton, Melissa O. Walker, Amy J. Pete, Nikki Johnson, Trevor Oberle, Mark W. Haselkorn, Jodie Nichol, W. Paul Haselkorn, Mark TI Using conceptual work products of health care to design health IT SO JOURNAL OF BIOMEDICAL INFORMATICS LA English DT Article DE Model-based design; Health IT; Electronic health record; Workflow; Conceptual work products; Case management; Information architecture; User interface; Human-computer interaction ID TASK-ANALYSIS; FRAMEWORK AB This paper introduces a new, model -based design method for interactive health information technology (IT) systems. This method extends workflow models with models of conceptual work products. When the health care work being modeled is substantially cognitive, tacit, and complex in nature, graphical workflow models can become too complex to be useful to deigners. Conceptual models complement and simplify workflows by providing an explicit specification for the information product they must produce. We illustrate how conceptual work products can be modeled using standard software modeling language, which allows them to provide fundamental requirements for what the workflow must accomplish and the information that a new system should provide. Developers can use these specifications to envision how health IT could enable an effective cognitive strategy as a workflow with precise information requirements. We illustrate the new method with a study conducted in an outpatient multiple sclerosis (MS) clinic. This study shows specifically how the different phases of the method can be carried out, how the method allows for iteration across phases, and how the method generated a health IT design for case management of MS that is efficient and easy to use. (C) 2015 Elsevier Inc. All rights reserved. C1 [Berry, Andrew B. L.; Butler, Keith A.; Braxton, Melissa O.; Pete, Nikki; Johnson, Trevor; Haselkorn, Mark] Univ Washington, Dept Human Ctr Design & Engn, Coll Engn, Campus Box 352315, Seattle, WA 98195 USA. [Harrington, Craig] Univ Texas Houston, Sch Biomed Informat, 7000 Fannin St,Suite 600, Houston, TX 77030 USA. [Walker, Amy J.] Univ Washington, Sch Nursing, 1959 NE Pacific St, Seattle, WA 98195 USA. [Oberle, Mark W.] Univ Washington, Sch Publ Hlth, Box 357230, Seattle, WA 98195 USA. [Haselkorn, Jodie; Nichol, W. Paul] Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Butler, KA (reprint author), Univ Washington, Dept Human Ctr Design & Engn, Coll Engn, Campus Box 352315, Seattle, WA 98195 USA. EM ablberry@uw.edu; Keith.A.Butler@gmail.com; craig.j.harrington@uth.tmc.edu; braxtm@uw.edu; walkeraj@uw.edu; peten@uw.edu; trevorj@uw.edu; moberle@uw.edu; Jodie.Haselkorn@va.gov; Paul.Nichol@va.gov; markh@uw.edu FU Agency for Healthcare Research and Quality [R01HS021233]; VA Puget Sound Health Care System, Seattle, Washington FX This project was supported by Grant Number R01HS021233 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. We gratefully acknowledge participation by the VHA MS COE West and VHA Office of Informatics and Analytics. The research with human subjects was conducted in accordance with UW IRB 40065, VA IRB MIRB0553, and UT-Houston IRB HSC-SBMI-14-0136. We would like to thank Dr. Lucas McCarthy for his analysis of data feasibility, Dr. Chris Esposito for programming P-CMS, Christina Chung for assistance with data collection and analysis, Yi-Chen Sung for assistance designing prototypes and figures, and Tongfang Sun for assistance with manuscript preparation. NR 36 TC 1 Z9 1 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-0464 EI 1532-0480 J9 J BIOMED INFORM JI J. Biomed. Inform. PD FEB PY 2016 VL 59 BP 15 EP 30 DI 10.1016/j.jbi.2015.10.014 PG 16 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA DX9HJ UT WOS:000384703900002 PM 26528606 ER PT J AU Wecht, JM Weir, JP Radulovic, M Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Radulovic, Miroslav Bauman, William A. TI Effects of midodrine and L-NAME on systemic and cerebral hemodynamics during cognitive activation in spinal cord injury and intact controls SO PHYSIOLOGICAL REPORTS LA English DT Article DE Blood pressure; cerebral blood flow; cognition; L-NAME; Midodrine; NOS inhibition; spinal cord injury; tetraplegia ID BLOOD-PRESSURE ABNORMALITIES; OXIDE SYNTHASE INHIBITION; ORTHOSTATIC HYPOTENSION; HEART-RATE; SERIAL 7S; FLOW; TETRAPLEGIA; PERFORMANCE; HYDROCHLORIDE; RESPONSES AB We previously showed that increases in mean arterial pressure (MAP) following administration of midodrine hydrochloride (MH) and nitro-L-arginine methyl ester (L-NAME) resulted in increased mean cerebral blood flow velocity (MFV) during head-up tilt in hypotensive individuals with spinal cord injury (SCI) and question if this same association was evident during cognitive activation. Herein, we report MAP and MFV during two serial subtraction tasks (SSt) given before (predrug) and after (postdrug) administration of MH; (10 mg), L-NAME (1 mg/kg) or no drug (ND) in 15 subjects with SCI compared to nine able-bodied (AB) controls. Three-way factorial analysis of variance (ANOVA) models were used to determine significant main and interaction effects for group (SCI, AB), visit (MH, L-NAME, ND), and time (predrug, postdrug) for MAP and MFV during the two SSt. The three-way interaction was significant for MAP (F = 4.262; P = 0.020); both MH (30 +/- 26 mmHg; P < 0.05) and L-NAME (27 +/- 22 mmHg; P < 0.01) significantly increased MAP in the SCI group, but not in the AB group. There was a significant visit by time interaction for MFV suggesting an increase from predrug to postdrug following L-NAME (6 +/- 8 cm/sec; P < 0.05) and MH (4 +/- 7 cm/sec; P < 0.05), regardless of study group, with little change following ND (3 +/- 3 cm/sec). The relationship between change in MAP and MFV was significant in the SCI group following administration of MH (r(2) = 0.38; P < 0.05) and L-NAME (r(2) = 0.32; P < 0.05). These antihypotensive agents, at the doses tested, raised MAP, which was associated with an increase MFV during cognitive activation in hypotensive subjects with SCI. C1 [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VAMC, VA RR&D Natl Ctr Med Consequences Spinal Cord Inj, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VAMC, Med Serv, Bronx, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VAMC, VA RR&D Natl Ctr Med Consequences Spinal Cord Inj, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov NR 30 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2051-817X J9 PHYSIOL REP JI PHYSIOL. REP. PD FEB PY 2016 VL 4 IS 3 AR e12683 DI 10.14814/phy2.12683 PG 9 WC Physiology SC Physiology GA DR9SI UT WOS:000380236000002 ER PT J AU Nguyen, KL Tian, X Alam, S Mehari, A Leung, SW Seamon, C Allen, D Minniti, CP Sachdev, V Arai, AE Kato, GJ AF Kim-Lien Nguyen Tian, Xin Alam, Shoaib Mehari, Alem Leung, Steve W. Seamon, Catherine Allen, Darlene Minniti, Caterina P. Sachdev, Vandana Arai, Andrew E. Kato, Gregory J. TI Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease SO HAEMATOLOGICA LA English DT Letter DE pulmonary hypertension; magnetic resonance imaging; right ventricle; cardiomyopathy; sickle cell disease ID RIGHT HEART CATHETERIZATION; PULMONARY-HYPERTENSION; MORTALITY; ANEMIA; ADULTS C1 [Alam, Shoaib; Sachdev, Vandana] Lung & Blood Inst, Cardiovasc & Pulm Branch, Bethesda, MD USA. [Mehari, Alem; Seamon, Catherine; Allen, Darlene; Minniti, Caterina P.; Kato, Gregory J.] Lung & Blood Inst, Sickle Cell Vasc Dis Sect, Hematol Branch, Bethesda, MD USA. [Tian, Xin] NHLBI, Off Biostat Res, Bethesda, MD USA. [Kim-Lien Nguyen; Mehari, Alem; Leung, Steve W.; Arai, Andrew E.] Howard Univ, Coll Med, Washington, DC USA. [Kim-Lien Nguyen] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA USA. [Kim-Lien Nguyen] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Kato, Gregory J.] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA. [Kato, Gregory J.] Univ Pittsburgh, Adult Sickle Cell Ctr Excellence, Pittsburgh, PA USA. [Minniti, Caterina P.] Montefiore Med Ctr, Sickle Cell Ctr, Div Hematol Oncol, New York, NY USA. [Leung, Steve W.] Univ Kentucky, Div Cardiovasc Med, Lexington, KY USA. RP Kato, GJ (reprint author), Lung & Blood Inst, Sickle Cell Vasc Dis Sect, Hematol Branch, Bethesda, MD USA.; Kato, GJ (reprint author), Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA.; Kato, GJ (reprint author), Univ Pittsburgh, Adult Sickle Cell Ctr Excellence, Pittsburgh, PA USA. EM katogj@upmc.edu RI Kato, Gregory/I-7615-2014; Leung, Steve/E-5624-2011 OI Kato, Gregory/0000-0003-4465-3217; Leung, Steve/0000-0003-2832-2258; Nguyen, Kim-Lien/0000-0002-8854-2976 FU NHLBI NIH HHS [ZIA HL004607, ZIA HL006011, ZIA HL006012, ZIA HL006015, ZIA HL006137, ZID HL006140, ZIE HL006139]; PHS HHS [1ZIAHL004607, 1ZIAHL006012, 1ZIAHL006015, 1ZIAHL006137, 1ZIDHL006140, 1ZIEHL006139, 1ZIAHL006011] NR 15 TC 2 Z9 2 U1 1 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD FEB PY 2016 VL 101 IS 2 BP E40 EP E43 DI 10.3324/haematol.2015.125229 PG 4 WC Hematology SC Hematology GA DQ4EI UT WOS:000379156300001 PM 26589907 ER PT J AU Erickson, ZD Mena, SJ Pierre, JM Blum, LH Martin, E Hellemann, GS Aragaki, DR Firestone, L Lee, C Lee, P Kunkel, CF Ames, D AF Erickson, Zachary D. Mena, Shirley J. Pierre, Joseph M. Blum, Lisa H. Martin, Eda Hellemann, Gerhard S. Aragaki, Dixie R. Firestone, Lisa Lee, Catherine Lee, Paul Kunkel, Charles F. Ames, Donna TI Behavioral Interventions for Antipsychotic Medication-Associated Obesity: A Randomized, Controlled Clinical Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID LIFE-STYLE INTERVENTION; WEIGHT-GAIN; MENTAL-ILLNESS; PROGRAM; SCHIZOPHRENIA; PSYCHOTHERAPY; MAINTENANCE; PREDICTORS; REDUCTION; METFORMIN AB Objective: To demonstrate the effectiveness of a Diabetes Prevention Program-inspired 12-month behavioral intervention for patients with severe mental illness (SMI) and medication-associated obesity. Method: This randomized, controlled, parallel, superiority study screened 225 volunteers from November 2005 to August 2008 at the VA Greater Los Angeles Healthcare System. 122 outpatients with DSM-IV-diagnosed SMI taking antipsychotic medications who had >= 7% weight gain or body mass index (BMI) > 25 were randomized by computer-generated number to Lifestyle Balance treatment intervention (n = 60) or usual care control (n = 62) groups. Clinical raters were masked to randomization. Treatment intervention included weekly classes and individual counseling for 8 weeks, food and exercise diaries, rewards, caregiver consultations, and monthly booster classes and counseling for 1 year. Controls received self-help materials and visited at equivalent intervals without formal classes or counseling. Outcomes were changes in anthropometric measurements, psychiatric symptoms, health knowledge, and glucose, hemoglobin A1c, and lipid levels. Results: Our intention-to-treat analysis found significant differences in predicted trajectory of mean weight change between the groups over 12 months (P < .01), with treatment participants expected to lose an average 4.6 kg, while control participants would gain an average 0.6 kg. BMI and body fat percentage followed the same pattern. Both groups demonstrated statistically significant improvements in health knowledge quiz scores over time (P = .006), without significant difference between groups. Conclusions: Treatment was more effective than usual care control in treating medication-associated obesity, independent of SMI diagnosis, antipsychotic medication, and knowledge gained, suggesting that behavioral interventions are effective in SMI patients. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Erickson, Zachary D.; Mena, Shirley J.; Blum, Lisa H.; Martin, Eda] VA Greater Los Angeles Healthcare Syst, Res Dept, Los Angeles, CA USA. [Pierre, Joseph M.; Ames, Donna] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Aragaki, Dixie R.; Firestone, Lisa; Lee, Catherine; Lee, Paul; Kunkel, Charles F.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. [Pierre, Joseph M.; Aragaki, Dixie R.; Firestone, Lisa; Lee, Catherine; Lee, Paul; Kunkel, Charles F.; Ames, Donna] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Hellemann, Gerhard S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. RP Ames, D (reprint author), 11301 Wilshire Blvd,B151H, Los Angeles, CA 90073 USA. EM donna.ames@va.gov FU Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development; Veterans Affairs Merit Review Rehabilitation Research and Development Service (Washington, DC) [D3925-R] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development. Funded by Veterans Affairs Merit Review Rehabilitation Research and Development Service (Washington, DC; project number D3925-R). NR 28 TC 0 Z9 0 U1 8 U2 11 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2016 VL 77 IS 2 BP E183 EP E189 DI 10.4088/JCP.14m09552 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MJ UT WOS:000379249200009 PM 26930534 ER PT J AU Cooper, SA Desjardins, PJ Turk, DC Dworkin, RH Katz, NP Kehlet, H Ballantyne, JC Burke, LB Carragee, E Cowan, P Croll, S Dionne, RA Farrar, JT Gilron, I Gordon, DB Iyengar, S Jay, GW Kalso, EA Kerns, RD McDermott, MP Raja, SN Rappaport, BA Rauschkolb, C Royal, MA Segerdahl, M Stauffer, JW Todd, KH Vanhove, GF Wallace, MS West, C White, RE Wu, C AF Cooper, Stephen A. Desjardins, Paul J. Turk, Dennis C. Dworkin, Robert H. Katz, Nathaniel P. Kehlet, Henrik Ballantyne, Jane C. Burke, Laurie B. Carragee, Eugene Cowan, Penney Croll, Scott Dionne, Raymond A. Farrar, John T. Gilron, Ian Gordon, Debra B. Iyengar, Smriti Jay, Gary W. Kalso, Eija A. Kerns, Robert D. McDermott, Michael P. Raja, Srinivasa N. Rappaport, Bob A. Rauschkolb, Christine Royal, Mike A. Segerdahl, Marta Stauffer, Joseph W. Todd, Knox H. Vanhove, Geertrui F. Wallace, Mark S. West, Christine White, Richard E. Wu, Christopher TI Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations SO PAIN LA English DT Review DE Randomized clinical trials; Acute pain; Research design; Assay sensitivity; Proof-of-concept trials; Clinical trial methods ID POSTOPERATIVE DENTAL PAIN; INDIVIDUAL PATIENT METAANALYSIS; PLACEBO-CONTROLLED TRIALS; ACTIVE-CONTROL TRIALS; MOVEMENT-EVOKED PAIN; DOUBLE-BLIND; RATING-SCALES; PARECOXIB SODIUM; MISSING DATA; EFFICACY AB This article summarizes the results of a meeting convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) on key considerations and best practices governing the design of acute pain clinical trials. We discuss the role of early phase clinical trials, including pharmacokinetic-pharmacodynamic (PK-PD) trials, and the value of including both placebo and active standards of comparison in acute pain trials. This article focuses on single-dose and short-duration trials with emphasis on the perioperative and study design factors that influence assay sensitivity. Recommendations are presented on assessment measures, study designs, and operational factors. Although most of the methodological advances have come from studies of postoperative pain after dental impaction, bunionectomy, and other surgeries, the design considerations discussed are applicable to many other acute pain studies conducted in different settings. C1 [Cooper, Stephen A.] Stephen A Cooper LLC, Palm Beach Gardens, FL USA. [Desjardins, Paul J.] Tufts Univ, Desjardins Associates LLC, Boston, MA 02111 USA. [Desjardins, Paul J.] Tufts Univ, Dept Oral & Maxillofacial Surg, Boston, MA 02111 USA. [Turk, Dennis C.; Ballantyne, Jane C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Anesthesiol, Rochester, NY USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Neurol, Rochester, NY USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA. [Katz, Nathaniel P.] Analges Solut, Needham, MA USA. [Kehlet, Henrik] Rigshosp, Sect Surg Pathophysiol, Copenhagen, Denmark. [Burke, Laurie B.] Univ Maryland, Dept Hlth Serv Res, Baltimore, MD 21201 USA. [Burke, Laurie B.] LORA Grp LLC, Royal Oak, MD USA. [Carragee, Eugene] Stanford Univ, Dept Orthoped Surg, Palo Alto, CA 94304 USA. [Cowan, Penney] Amer Chron Pain Assoc, Rocklin, CA USA. [Croll, Scott] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Dionne, Raymond A.] E Carolina Univ, Dept Pharmacol, Greenville, NC USA. [Dionne, Raymond A.] E Carolina Univ, Dept Toxicol, Greenville, NC USA. [Dionne, Raymond A.] E Carolina Univ, Dept Foundat Sci, Greenville, NC USA. [Farrar, John T.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gilron, Ian] Queens Univ, Dept Anesthesiol, Kingston, ON, Canada. [Gordon, Debra B.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA USA. [Iyengar, Smriti] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Jay, Gary W.] Advise Clin, Raleigh, NC USA. [Kalso, Eija A.] Univ Helsinki, Dept Anaesthesia Intens Care & Pain Med, Helsinki, Finland. [Kalso, Eija A.] Helsinki Univ Hosp, Helsinki, Finland. [Kerns, Robert D.] US Dept Vet Affairs, New Haven, CT USA. [Raja, Srinivasa N.; Wu, Christopher] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA. [Rappaport, Bob A.] Analges Concepts LLC, Arlington, VA USA. [Rauschkolb, Christine] Johnson & Johnson Pharmaceut Res & Dev, Titusville, NY USA. [Royal, Mike A.] Sorrento Therapeut, San Diego, CA USA. [Segerdahl, Marta] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden. [Stauffer, Joseph W.] Johns Hopkins Univ, Baltimore, MD USA. [Stauffer, Joseph W.] Cara Therapeut, Shelton, CT USA. [Todd, Knox H.] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA. [Vanhove, Geertrui F.] NeurogesX, San Carlos, CA USA. [Wallace, Mark S.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA. [West, Christine] Pfizer Inc, Groton, CT 06340 USA. [White, Richard E.] Endo Pharmaceut, Chadds Ford, PA USA. RP Cooper, SA (reprint author), 40 Durand Rd, Maplewood, NJ 07040 USA. EM paul.j.desjardins@gmail.com FU Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); FDA; US Department of Veteran Affairs; US National Institutes of Health FX Preparation of the background literature reviews and draft manuscripts was supported by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); public-private partnership with the US Food and Drug Administration (FDA) ACTTION has received research contracts, grants, and other revenue from the FDA, multiple pharmaceutical and device companies, and other sources. No official endorsement by the FDA, US Department of Veteran Affairs, US National Institutes of Health, or the pharmaceutical and medical devices companies that have provided unrestricted grants to support the activities of IMMPACT and ACTTION should be inferred. NR 74 TC 3 Z9 3 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD FEB PY 2016 VL 157 IS 2 BP 288 EP 301 DI 10.1097/j.pain.0000000000000375 PG 14 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DP1NV UT WOS:000378257600004 PM 26683233 ER PT J AU Hwang, YC Fujimoto, WY Hayashi, T Kahn, SE Leonetti, DL Boyko, EJ AF Hwang, You-Cheol Fujimoto, Wilfred Y. Hayashi, Tomoshige Kahn, Steven E. Leonetti, Donna L. Boyko, Edward J. TI Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; METABOLIC RISK-FACTORS; JAPANESE-AMERICAN MEN; INCIDENT HYPERTENSION; INSULIN SENSITIVITY; FAT DISTRIBUTION; OBESE ADULTS; BODY-FAT; PLASMA; PREVALENCE AB Context: Atherogenic dyslipidemia is frequently observed in persons with a greater amount of visceral adipose tissue (VAT). However, it is still uncertain whether VAT is independently associated with the future development of atherogenic dyslipidemia. Objectives: The aim of this study was to determine whether baseline and changes in VAT and subcutaneous adipose tissue (SAT) are associated with future development of atherogenic dyslipidemia independent of baseline lipid levels and standard anthropometric indices. Design and Setting: Community-based prospective cohort study with 5 years of follow-up. Participants: A total of 452 Japanese Americans (240 men, 212 women), aged 34-75 years were assessed at baseline and after 5 years of follow-up. Main Outcome Measures: Abdominal fat areas were measured by computed tomography. Atherogenic dyslipidemia was defined as one or more abnormalities in high-density lipoprotein (HDL) cholesterol, triglycerides, or non-HDL cholesterol levels. Results: Baseline VAT and change in VAT over 5 years were independently associated with log-transformed HDL cholesterol, log-transformed triglyceride, and non-HDL cholesterol after 5 years (standardized beta = -0.126, 0.277, and 0.066 for baseline VAT, respectively, and -0.095, 0.223, and 0.090 for change in VAT, respectively). However, baseline and change in SAT were not associated with any future atherogenic lipid level. In multivariate logistic regression analysis, incremental change in VAT (odds ratio [95% confidence interval], 1.73 [1.20-2.48]; P = .003), triglycerides (4.01 [1.72-9.33]; P < .001), HDL cholesterol (0.32 [0.18-0.58]; P < .001), and non-HDL cholesterol (7.58 [4.43-12.95]; P < .001) were significantly associated with the future development of atherogenic dyslipidemia independent of age, sex, diastolic blood pressure, homeostasis model assessment insulin resistance, body mass index (BMI), change in BMI, SAT, and baseline atherogenic lipid levels. Conclusion: Baseline and change in VAT were independent predictors for future development of atherogenic dyslipidemia. However, BMI, waist circumference, and SAT were not associated with future development of atherogenic dyslipidemia. C1 [Hwang, You-Cheol; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Hwang, You-Cheol] Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp Gangdong, Div Endocrinol & Metab,Dept Med, Seoul 134727, South Korea. [Fujimoto, Wilfred Y.; Kahn, Steven E.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98105 USA. [Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 3-3-138, Osaka, Japan. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98108 USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), VA Puget Sound, S-123-PCC,1660 South Columbian Way, Seattle, WA 98108 USA. EM eboyko@uw.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU King County Japanese American community FX We dedicate this manuscript to the memory of Marguerite J. McNeely who for many years played an important role as investigator in the Japanese American Community Diabetes Study. Her critical contributions will be missed. We are grateful to the King County Japanese American community for support and cooperation. NR 35 TC 4 Z9 4 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2016 VL 101 IS 2 BP 678 EP 685 DI 10.1210/jc.2015-3246 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP6XI UT WOS:000378642700038 PM 26636177 ER PT J AU Duca, LM Maahs, DM Schauer, IE Bergman, BC Nadeau, KJ Bjornstad, P Rewers, M Snell-Bergeon, JK AF Duca, Lindsey M. Maahs, David M. Schauer, Irene E. Bergman, Bryan C. Nadeau, Kristen J. Bjornstad, Petter Rewers, Marian Snell-Bergeon, Janet K. TI Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CORONARY-ARTERY CALCIFICATION; CARDIOVASCULAR-DISEASE; PITTSBURGH EPIDEMIOLOGY; GLUCOSE CLAMP; RESISTANCE; HYPERTENSION; COMPLICATION; NEPHROPATHY; ADOLESCENTS; OBESITY AB Context: People with type 1 diabetes (T1D) have markedly reduced insulin sensitivity (IS) compared to their nondiabetic counterparts, and reduced IS is linked to higher cardiovascular risk. Objective: This study aimed to develop and validate an improved method for estimating IS in people with T1D. Design: Prospective cohort. Setting: Adults (36 with T1D, 41 nondiabetic) were recruited from the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study for measurement of IS by hyperinsulinemic-euglycemic clamp to develop a clinically useful IS prediction equation (eIS) for T1D and nondiabetic individuals. These equations were then compared with previously published equations from the SEARCH and Pittsburgh Epidemiology of Diabetes Complications studies for the ability to predict measured IS in test sets of adults and adolescents from independent clamp studies. Intervention: None. Main Outcome Measure: Comparison of clamp-measured IS to estimated IS. Results: The best-fit prediction model (eIS) differed by diabetes status and included waist circumference, triglycerides, adiponectin, and diastolic blood pressure in all CACTI adults and insulin dose in adults with T1D (adjusted R-2 = 0.64) or fasting glucose and hemoglobin A1c (HbA1c) in nondiabetic adults (adjusted R-2 = 0.63). The eIS highly correlated with clamp-measured IS in all of the non-CACTI comparison populations (r = 0.83, P = .0002 in T1D adults; r = 0.71, P = .01 in nondiabetic adults; r = 0.44, P = .008 in T1D adolescents; r = 0.44, P = .006 in nondiabetic adolescents). Conclusions: eIS performed better than previous equations for estimating IS in individuals with and without T1D. These equations could simplify point-of-care assessment of IS to identify patients who could benefit from targeted intervention. C1 [Duca, Lindsey M.; Maahs, David M.; Bjornstad, Petter; Rewers, Marian; Snell-Bergeon, Janet K.] Univ Colorado, Sch Med, Barbara Davis Ctr Diabet, Aurora, CO 80045 USA. [Duca, Lindsey M.; Maahs, David M.; Snell-Bergeon, Janet K.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Schauer, Irene E.; Bergman, Bryan C.] Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Sch Med, Aurora, CO 80045 USA. [Nadeau, Kristen J.] Univ Colorado, Sch Med, Div Pediat Endocrinol, Dept Pediat, Aurora, CO 80045 USA. [Schauer, Irene E.] Denver VA Med Ctr, Denver, CO 80220 USA. RP Duca, LM (reprint author), Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Sch Med, Box A-140,1775 Aurora Court, Aurora, CO 80045 USA. EM Lindsey.Duca@ucdenver.edu OI Bergman, Bryan/0000-0002-9561-1052; Bjornstad, Petter/0000-0002-5160-2947 FU National Institutes of Health (NIH) [M01 RR000051]; Colorado Clinical and Translational Sciences Institute (CCTSI) [UL1 TR000154]; NIH National Heart, Lung and Blood Institute [R01 HL61753, R01 HL079611, R01 HL11309]; American Diabetes Association [1-10-JF-50, 7-13-CD-10, 7-11-CD-08]; Juvenile Diabetes Research Foundation [11-2010-343, 17-2013-313]; NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) [K12 5K12HD057022-04]; National Center for Research Resources [K23 RR020038-01]; NIH [R56 DK088971]; Office of Research in Women's Health BIRCWH K12 Program; Diabetes Endocrinology Research Center Clinical Investigation Core Grant [P30 DK57516] FX The study was performed at the Barbara Davis Center for Childhood Diabetes in Denver, Colorado, and at the Clinical Translational Research Centers (CTRC) at the University of Colorado and Children's Hospital Colorado and was supported by the National Institutes of Health (NIH) Grant M01 RR000051 and Colorado Clinical and Translational Sciences Institute (CCTSI) Grant UL1 TR000154. Support was provided by the NIH National Heart, Lung and Blood Institute Grants R01 HL61753, R01 HL079611, and R01 HL11309; the American Diabetes Association Junior Faculty Award 1-10-JF-50 and 7-13-CD-10 (to J.K.S.-B.), American Diabetes Association Grant 7-11-CD-08, the Juvenile Diabetes Research Foundation Grant 11-2010-343 and 17-2013-313, NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Grant K12 5K12HD057022-04, the National Center for Research Resources Grant K23 RR020038-01, NIH Grant R56 DK088971 (to K.J.N.), Office of Research in Women's Health BIRCWH K12 Program (to I.E.S.), and Diabetes Endocrinology Research Center Clinical Investigation Core Grant P30 DK57516. NR 28 TC 1 Z9 1 U1 1 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2016 VL 101 IS 2 BP 686 EP 695 DI 10.1210/jc.2015-3272 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP6XI UT WOS:000378642700039 PM 26672636 ER PT J AU Abe, J Alop-Mabuti, A Burger, P Button, J Ellsberry, M Hitzeman, J Morgenstern, D Nunies, K Strother, M Darling-Munson, J Chan, YL Cassady, R Vasconcellos, SMK Iseman, MD Chan, ED Honda, JR AF Abe, Jonathan Alop-Mabuti, Aleena Burger, Peyton Button, Jackson Ellsberry, Madeline Hitzeman, Jaycinth Morgenstern, David Nunies, Kasey Strother, Mara Darling-Munson, Jared Chan, Yvonne L. Cassady, Robert Vasconcellos, Sarah Maile K. Iseman, Michael D. Chan, Edward D. Honda, Jennifer R. TI Comparing the temporal colonization and microbial diversity of showerhead biofilms in Hawai'i and Colorado SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE microbial biofilms; environmental health; water quality; citizen science; microbiology education ID MYCOBACTERIAL LUNG-DISEASE; WATER DISTRIBUTION-SYSTEMS; NONTUBERCULOUS MYCOBACTERIA; PULMONARY-DISEASE; HOUSEHOLD; INFECTION; AVIUM; INTRACELLULARE; EPIDEMIOLOGY; PATHOGENS AB The household is a potential source of opportunistic pathogens to humans, a particularly critical issue for immunodeficient individuals. An important human-microbe interface is the biofilm that develops on showerhead surfaces. Once microbe-laden biofilms become aerosolized, they can potentially be inhaled into the lungs. Understanding how quickly a new showerhead becomes colonized would provide useful information to minimize exposure to potentially pathogenic environmental microbes. High school scientists sampled the inner surfaces of pre-existing and newly fitted showerheads monthly over a nine-month period and applied standard microbiologic culture techniques to qualitatively assess microbial growth. Water chemistry was also monitored using commercial test strips. Sampling was performed in households on Oahu, Hawai'i and Denver, Colorado, representing warm/humid and cold/arid environments, respectively. Pre-existing showerheads in Hawai'i showed more diverse microbial growth and significantly greater microbial numbers than a comparable showerhead from Colorado. New, chrome-plated or plastic showerheads in Hawai'i showed diverse and abundant growth one month after installment compared to new showerheads from Colorado. The pH, total chlorine and water hardness levels varied significantly between the Hawai'i and Colorado samples. Enthusiastic student and teacher participation allowed us to answer long-standing questions regarding the temporal colonization of microbial biofilms on pre-existing and new showerhead surfaces. C1 [Abe, Jonathan; Chan, Yvonne L.] Iolani Sch, Honolulu, HI 96826 USA. [Alop-Mabuti, Aleena; Button, Jackson; Hitzeman, Jaycinth; Nunies, Kasey; Vasconcellos, Sarah Maile K.] Isl Pacific Acad, Kapolei, HI 96707 USA. [Burger, Peyton; Ellsberry, Madeline; Morgenstern, David; Strother, Mara; Cassady, Robert] Standley Lake High Sch, Denver, CO 80021 USA. [Darling-Munson, Jared; Iseman, Michael D.; Chan, Edward D.; Honda, Jennifer R.] Natl Jewish Hlth, 1400 Jackson St,Neustadt Bldg,Room D509, Denver, CO 80206 USA. [Chan, Edward D.; Honda, Jennifer R.] Univ Colorado, Dept Med, Pulm & Crit Care Med Div, Anschutz Med Campus, Aurora, CO 80045 USA. [Chan, Edward D.; Honda, Jennifer R.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus,RC2,Box C272, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu FU Randall/Maciver Trust; University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Medicine Division; Shoot for the Cure Foundation FX Dr Jennifer R. Honda is supported by the Randall/Maciver Trust, The University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Medicine Division, and The Shoot for the Cure Foundation. NR 29 TC 1 Z9 1 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0378-1097 EI 1574-6968 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD FEB PY 2016 VL 363 IS 4 AR fnw005 DI 10.1093/femsle/fnw005 PG 8 WC Microbiology SC Microbiology GA DO7MI UT WOS:000377966300010 ER PT J AU Radomski, TR Good, CB Thorpe, CT Zhao, XH Marcum, ZA Glassman, PA Lowe, J Mor, MK Fine, MJ Gellad, WF AF Radomski, Thomas R. Good, Chester B. Thorpe, Carolyn T. Zhao, Xinhua Marcum, Zachary A. Glassman, Peter A. Lowe, John Mor, Maria K. Fine, Michael J. Gellad, Walid F. TI Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY LA English DT Article ID MEDICAL-CENTER; NATIONAL FORMULARY; THERAPY; PHARMACY; COST; LOVASTATIN; BREAKING; PROGRAM; IMPACT; SWITCH AB BACKGROUND: All Department of Veterans Affairs Medical Centers (VAMCs) operate under a single national drug formulary, yet substantial variation in prescribing and spending exists across facilities. Local management of the national formulary may differ across VAMCs and may be one cause of this variation. OBJECTIVE: To characterize variation in the management of nonformulary medication requests and pharmacy and therapeutics (P&T) committee member perceptions of the formulary environment at VAMCs nationwide. METHODS: We performed an online survey of the chief of pharmacy and an additional staff pharmacist and physician on the P&T committee at all VAMCs. Respondents were asked questions regarding criteria for use for nonformulary medications, specific procedures for ordering nonformulary medications in general and specific lipid-lowering and diabetes agents, the appeals. process, and the formulary environment at their VAMCs. We compared responses across facilities and between chiefs of pharmacy, pharmacists, and physicians. RESULTS: A total of 212 chief pharmacists (n=80), staff pharmacists (n=78), and physicians (n=54) responded, for an overall response rate of 49%. In total, 107/143 (75%) different VAMCs were represented. The majority of VAMCs reported adhering to national criteria for use, with 38 (36%) being very adherent and 69 (65%) being mostly adherent. There was substantial variation between VAMCs regarding how nonformulary drugs were ordered, evaluated, and appealed. The nonformulary lipid-lowering drugs ezetimibe, rosuvastatin, and atorvastatin were viewable to providers in the order entry screen at 67 (63%), 67 (63%), and 64 (60%) VAMCs, respectively. The nonformulary diabetes medication pioglitazone was only viewable at 58 (55%) VAMCs. In the remaining VAMCs, providers could not order these nonformulary drugs through the normal order-entry process. For questions about the formulary environment, physician respondent perceptions differed from those of staff pharmacists and chief pharmacists. Compared with pharmacy chiefs and staff pharmacists, physicians were less likely to agree that providers at their VAMC prescribed too many nonformulary medications (47% and 44% vs. 12%, P<0.001), more likely to agree that providers must jump through too many hoops to prescribe nonformulary medication (5% and 3% vs. 25%, P<0.001), and more likely to agree that providers make an effort to convert new patients from non-formulary to formulary lipid-lowering (65% and 73% vs. 94%, P<0.02) and diabetic medications (49% and 50% vs. 88%, P<0.001). CONCLUSIONS: Although the Department of Veterans Affairs (VA) operates under a single national formulary, we found significant differences among VAMCs regarding their management of nonformulary medication requests. We also found differences among formulary leaders regarding their perception of the environment in which their VAMC's formulary is managed. These findings have important implications not just for VA, but for any organization that develops, implements, and manages drug formularies across multiple facilities. Copyright (C) 2016, Academy of Managed Care Pharmacy. All rights reserved. C1 [Gellad, Walid F.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Univ Dr 151c, Pittsburgh, PA 15240 USA. [Radomski, Thomas R.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,Clin Instructor, Pittsburgh, PA USA. [Radomski, Thomas R.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity REs & Promotion, Clin Res Fellow, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Hines, IL USA. [Good, Chester B.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Core Investigator, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, VA Ctr Medication Safety, Med Advisory Panel, Hines, IL USA. [Thorpe, Carolyn T.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Core Investigator, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 718 Salk Hall, Pittsburgh, PA USA. [Zhao, Xinhua] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Statistic, Pittsburgh, PA USA. [Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Med, Dept Geriatr Med, Pittsburgh, PA USA. [Glassman, Peter A.] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Med,Staff Phys, Clin Med,VA Greater Los Angles Hlthcare Syst, Los Angeles, CA USA. [Glassman, Peter A.] US Dept Vet Affairs, VA Ctr Med Safety Pharm Benefits Management Serv, Hines, IL USA. [Lowe, John] US Dept Vet Affairs, Pharm Benefits Management Serv, Pharm Compliance & Efficiency, Hines, IL USA. [Mor, Maria K.] VA Pittsburgh Hlthcare Syst, Biostat & Informat Core, Ctr Hlth Equtiy Res & Promotion, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. RP Gellad, WF (reprint author), VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. EM walid.gellad@va.gov FU Health Resources and Services Administration T32 Training Grant; VA HSR&D Career Development Award FX Radomski is funded by a Health Resources and Services Administration T32 Training Grant. Gellad is funded by a VA HSR&D Career Development Award. The authors have no other conflicts of interest to disclose. NR 26 TC 2 Z9 2 U1 0 U2 0 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 2376-0540 EI 2376-1032 J9 J MANAG CARE SPEC PH JI J. Manag. Care Spec. Pharm. PD FEB PY 2016 VL 22 IS 2 BP 114 EP U113 PG 9 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DN1BU UT WOS:000376802100003 PM 27015250 ER PT J AU Liu, XR Liu, J Zhao, SF Zhang, HY Cai, W Cai, MF Ji, XM Leak, RK Gao, YQ Chen, J Hu, XM AF Liu, Xiangrong Liu, Jia Zhao, Shangfeng Zhang, Haiyue Cai, Wei Cai, Mengfei Ji, Xunming Leak, Rehana K. Gao, Yanqin Chen, Jun Hu, Xiaoming TI Interleukin-4 Is Essential for Microglia/Macrophage M2 Polarization and Long-Term Recovery After Cerebral Ischemia SO STROKE LA English DT Article DE flow cytometry; interleukin-4; macrophages; neurological function; stroke ID BRAIN-INJURY; CNS REMYELINATION; SEX-DIFFERENCES; WHITE-MATTER; MICROGLIA; IL-4; STROKE; MICE; MACROPHAGES; DYNAMICS AB Background and Purpose-Interleukin-4 (IL-4) is a unique cytokine that may contribute to brain repair by regulating microglia/macrophage functions. Thus, we examined the effect of IL-4 on long-term recovery and microglia/macrophage polarization in 2 well-established stroke models. Methods-Transient middle cerebral artery occlusion or permanent distal middle cerebral artery occlusion was induced in wild-type and IL-4 knockout C57/BL6 mice. In a separate cohort of wild-type animals, IL-4 (60 ng/d for 7 days) or vehicle was infused into the cerebroventricle after transient middle cerebral artery occlusion. Behavioral outcomes were assessed by the Rotarod, corner, foot fault, and Morris water maze tests. Neuronal tissue loss was verified by 2 independent neuron markers. Markers of classically activated (M1) and alternatively activated (M2) microglia were assessed by real-time polymerase chain reaction, immunofluorescence, and flow cytometry. Results-Loss of IL-4 exacerbated sensorimotor deficits and impaired cognitive functions <= 21 days post injury. In contrast to the delayed deterioration of neurological functions, IL-4 deficiency increased neuronal tissue loss only in the acute phase (5 days) after stroke and had no impact on neuronal tissue loss 14 or 21 days post injury. Loss of IL-4 promoted expression of M1 microglia/macrophage markers and impaired expression of M2 markers at 5 and 14 days post injury. Administration of IL-4 into the ischemic brain also enhanced long-term functional recovery. Conclusions-The cytokine IL-4 improves long-term neurological outcomes after stroke, perhaps through M2 phenotype induction in microglia/macrophages. These results are the first to suggest that immunomodulation with IL-4 is a promising approach to promote long-term functional recovery after stroke. C1 [Liu, Xiangrong; Zhao, Shangfeng; Zhang, Haiyue; Cai, Wei; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Liu, Xiangrong; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing, Peoples R China. [Liu, Jia; Cai, Mengfei; Gao, Yanqin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Chen, Jun; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hu, XM (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM hux2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU National Institutes of Health [NS092618, NS095671, NS089534]; American Heart Association [13SDG14570025]; Chinese Natural Science Foundation [81471209, 81171149, 81371306, 81228008]; Veteran's Affairs research career scientist award FX This work was supported by the National Institutes of Health grants NS092618 (to Dr Hu), NS095671 and NS089534 (to Dr Chen), grant 13SDG14570025 from the American Heart Association (to Dr Hu), the Chinese Natural Science Foundation grants 81471209 (to Dr Liu), 81171149, 81371306 (to Dr Gao), and 81228008 (to Dr Chen). Dr Chen is also supported by a Veteran's Affairs research career scientist award. NR 30 TC 8 Z9 9 U1 10 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2016 VL 47 IS 2 BP 498 EP + DI 10.1161/STROKEAHA.115.012079 PG 11 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA DN4MD UT WOS:000377040200042 PM 26732561 ER PT J AU Wang, T Ren, Z Ding, Y Fang, Z Sun, Z MacDonald, ML Sweet, RA Wang, JR Chen, W AF Wang, Ting Ren, Zhao Ding, Ying Fang, Zhou Sun, Zhe MacDonald, Matthew L. Sweet, Robert A. Wang, Jieru Chen, Wei TI FastGGM: An Efficient Algorithm for the Inference of Gaussian Graphical Model in Biological Networks SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID EXPRESSION DATA; ASTHMA; LASSO; DISCOVERY; SELECTION AB Biological networks provide additional information for the analysis of human diseases, beyond the traditional analysis that focuses on single variables. Gaussian graphical model (GGM), a probability model that characterizes the conditional dependence structure of a set of random variables by a graph, has wide applications in the analysis of biological networks, such as inferring interaction or comparing differential networks. However, existing approaches are either not statistically rigorous or are inefficient for high-dimensional data that include tens of thousands of variables for making inference. In this study, we propose an efficient algorithm to implement the estimation of GGM and obtain p-value and confidence interval for each edge in the graph, based on a recent proposal by Ren et al., 2015. Through simulation studies, we demonstrate that the algorithm is faster by several orders of magnitude than the current implemented algorithm for Ren et al. without losing any accuracy. Then, we apply our algorithm to two real data sets: transcriptomic data from a study of childhood asthma and proteomic data from a study of Alzheimer's disease. We estimate the global gene or protein interaction networks for the disease and healthy samples. The resulting networks reveal interesting interactions and the differential networks between cases and controls show functional relevance to the diseases. In conclusion, we provide a computationally fast algorithm to implement a statistically sound procedure for constructing Gaussian graphical model and making inference with high-dimensional biological data. The algorithm has been implemented in an R package named "FastGGM". C1 [Wang, Ting; Wang, Jieru; Chen, Wei] Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh UPMC, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA. [Ren, Zhao] Univ Pittsburgh, Dept Stat, Pittsburgh, PA USA. [Ding, Ying; Fang, Zhou; Sun, Zhe; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [MacDonald, Matthew L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. RP Chen, W (reprint author), Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh UPMC, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA.; Chen, W (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.; Chen, W (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. EM wei.chen@chp.edu OI Ding, Ying/0000-0003-1352-1000 FU VAPHS [BX000542]; UPMC Competitive Medical Research Fund; [MH16804]; [AG05133]; [AG027224]; [HG007358]; [P30CA047904] FX This work is supported by grants MH16804 (MLM), AG05133 (RAS), AG027224 (RAS), VAPHS grant BX000542 (RAS), UPMC Competitive Medical Research Fund (YD) and HG007358 (WC). The Biomedical Mass Spectrometry Center and UPCI Cancer Proteomics Facility are supported in part by award P30CA047904. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 2 Z9 2 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD FEB PY 2016 VL 12 IS 2 AR e1004755 DI 10.1371/journal.pcbi.1004755 PG 16 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA DM8AL UT WOS:000376582900026 PM 26872036 ER PT J AU Padula, CB Weitlauf, JC Rosen, AC Reiber, G Cochrane, BB Naughton, MJ Li, WJ Rissling, M Yaffe, K Hunt, JR Stefanick, ML Goldstein, MK Espeland, MA AF Padula, Claudia B. Weitlauf, Julie C. Rosen, Allyson C. Reiber, Gayle Cochrane, Barbara B. Naughton, Michelle J. Li, Wenjun Rissling, Michelle Yaffe, Kristine Hunt, Julie R. Stefanick, Marcia L. Goldstein, Mary K. Espeland, Mark A. TI Longitudinal Cognitive Trajectories of Women Veterans from the Women's Health Initiative Memory Study SO GERONTOLOGIST LA English DT Article DE Women; Veterans; Cognition; Cognitive decline; Risk factors ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; RISK-FACTORS; CARDIOVASCULAR-DISEASE; HORMONE-THERAPY; IMPAIRMENT; DEMENTIA; DECLINE; DYSLIPIDEMIA AB Purpose of the Study: A comparison of longitudinal global cognitive functioning in women Veteran and non-Veteran participants in the Women's Health Initiative (WHI). Design and Methods: We studied 7,330 women aged 65-79 at baseline who participated in the WHI Hormone Therapy Trial and its ancillary Memory Study (WHIMS). Global cognitive functioning (Modified Mini-Mental State Examination [3MSE]) in Veterans (n = 279) and non-Veterans (n = 7,051) was compared at baseline and annually for 8 years using generalized linear modeling methods. Results: Compared with non-Veterans, Veteran women were older, more likely to be Caucasian, unmarried, and had higher rates of educational and occupational attainment. Results of unadjusted baseline analyses suggest 3MSE scores were similar between groups. Longitudinal analyses, adjusted for age, education, ethnicity, and WHI trial assignment revealed differences in the rate of cognitive decline between groups over time, such that scores decreased more in Veterans relative to non-Veterans. This relative difference was more pronounced among Veterans who were older, had higher educational/occupational attainment and greater baseline prevalence of cardiovascular risk factors (e.g., smoking) and cardiovascular disease (e.g., angina, stroke). Implications: Veteran status was associated with higher prevalence of protective factors that may have helped initially preserve cognitive functioning. However, findings ultimately revealed more pronounced cognitive decline among Veteran relative to non-Veteran participants, likely suggesting the presence of risks that may impact neuropathology and the effects of which were initially masked by Veterans' greater cognitive reserve. C1 [Padula, Claudia B.; Weitlauf, Julie C.; Rosen, Allyson C.] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, 3801 Miranda Ave, Palo Alto, CA 94304 USA. [Padula, Claudia B.; Weitlauf, Julie C.; Rosen, Allyson C.] Stanford Univ, Dept Psychiat & Behav Sci, 3801 Miranda Ave, Palo Alto, CA 94304 USA. [Weitlauf, Julie C.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Cochrane, Barbara B.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Naughton, Michelle J.] Ohio State Univ, Coll Med, Div Populat Sci, Columbus, OH 43210 USA. [Li, Wenjun] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Li, Wenjun] Univ Massachusetts, Sch Med, Dept Prevent & Behav Med, Worcester, MA USA. [Rissling, Michelle] Mid Atlantic MIRECC, Durham VA Med Ctr, Durham, NC USA. [Yaffe, Kristine] Sierra Pacif MIRECC, San Francisco VA Med Ctr, UCSF Dept Psychiat Neurol & Epidemiol & Biostat, San Francisco, CA USA. [Hunt, Julie R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Stanford Ctr Prevent Res, Dept Med, Stanford, CA 94305 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA. [Goldstein, Mary K.] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, GRECC,Dept Med,Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USA. [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, One Med Ctr Blvd, Winston Salem, NC USA. RP Padula, CB (reprint author), VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Padula, CB (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM padula@stanford.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health; U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health; and the U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. NR 46 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 IS 1 SI SI BP 115 EP 125 DI 10.1093/geront/gnv663 PG 11 WC Gerontology SC Geriatrics & Gerontology GA DJ5AW UT WOS:000374220200013 PM 26615021 ER PT J AU Karel, MJ Teri, L McConnell, E Visnic, S Karlin, BE AF Karel, Michele J. Teri, Linda McConnell, Eleanor Visnic, Stephanie Karlin, Bradley E. TI Effectiveness of Expanded Implementation of STAR-VA for Managing Dementia-Related Behaviors Among Veterans SO GERONTOLOGIST LA English DT Article DE Interdisciplinary training; Dementia; Challenging behaviors; Veterans; Nursing homes ID LONG-TERM-CARE; NEUROPSYCHIATRIC SYMPTOMS; HEALTH; MANAGEMENT; TOOLKIT; ANXIETY; HOMES AB Purpose of the Study: Nonpharmacological, psychosocial approaches are first-line treatments for managing behavioral symptoms in dementia, but they can be challenging to implement in long-term care settings. The Veterans Health Administration implemented STAR-VA, an interdisciplinary behavioral approach for managing challenging dementia-related behaviors in its Community Living Center (CLCs, nursing home care) settings. This study describes how the program was implemented and provides an evaluation of Veteran clinical outcomes and staff feedback on the intervention. Design and Methods: One mental health professional and registered nurse team from 17 CLCs completed STAR-VA training, which entailed an experiential workshop followed by 6 months of expert consultation as they worked with their teams to implement STAR-VA with Veterans identified to have challenging dementia-related behaviors. The frequency and severity of target behaviors and symptoms of depression, anxiety, and agitation were evaluated at baseline and at intervention completion. Staff provided feedback regarding STAR-VA feasibility and impact. Results: Seventy-one Veterans completed the intervention. Behaviors clustered into 6 types: care refusal or resistance, agitation, aggression, vocalization, wandering, and other. Frequency and severity of target behaviors and symptoms of depression, anxiety, and agitation all significantly decreased, with overall effect sizes of 1 or greater. Staff rated both benefits for Veterans and program feasibility favorably. Implications: This evaluation supports the feasibility and effectiveness of STAR-VA, an interdisciplinary, behavioral intervention for managing challenging behaviors among residents with dementia in CLCs. C1 [Karel, Michele J.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA. [Teri, Linda] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [McConnell, Eleanor] Durham VA Geriatr Res Educ & Clin Ctr, Durham, NC USA. [McConnell, Eleanor] Duke Univ, Sch Med, Durham, NC USA. [Visnic, Stephanie] Vet Affairs Ann Arbor Healthcare Syst, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA. [Karlin, Bradley E.] Educ Dev Ctr Inc, New York, NY USA. [Karlin, Bradley E.] Northeastern Univ, Bouve Coll Hlth Sci, Sch Nursing, Boston, MA 02115 USA. RP Karel, MJ (reprint author), VA Cent Off, Mental Hlth Serv 10P4M, 1575 1 St NW, Washington, DC 20420 USA. EM Michele.Karel@va.gov FU Mental Health Services, U. S. Department of Veterans Affairs (VA) Central Office FX This project was supported by Mental Health Services, U. S. Department of Veterans Affairs (VA) Central Office. NR 36 TC 4 Z9 4 U1 3 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 IS 1 SI SI BP 126 EP 134 DI 10.1093/geront/gnv068 PG 9 WC Gerontology SC Geriatrics & Gerontology GA DJ5AW UT WOS:000374220200014 PM 26185155 ER PT J AU Kopacz, MS Rasmussen, KA Searle, RF Wozniak, BM Titus, CE AF Kopacz, Marek S. Rasmussen, Kathy A. Searle, Robert F. Wozniak, Barbara M. Titus, Caitlin E. TI Veterans, guilt, and suicide risk: An opportunity to collaborate with chaplains? SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Editorial Material ID PASTORAL CARE SERVICES; MOOD DISORDERS; DEPRESSION; FORGIVENESS; PERSONNEL; IDEATION; THERAPY; COMBAT; SHAME C1 [Kopacz, Marek S.; Rasmussen, Kathy A.; Titus, Caitlin E.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Rasmussen, Kathy A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Searle, Robert F.] US Dept Vet Affairs, Canandaigua VA Med Ctr, Canandaigua, NY USA. [Wozniak, Barbara M.] Jagiellonian Univ, Coll Med, Dept Med Sociol, Epidemiol & Prevent Med, Krakow, Poland. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 40 TC 1 Z9 1 U1 1 U2 1 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD FEB PY 2016 VL 83 IS 2 BP 101 EP 105 DI 10.3949/ccjm.83a.15070 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DK3TR UT WOS:000374840800006 PM 26871385 ER PT J AU Patel, AM Lee, JXW Pham, AQ Yusin, JS AF Patel, Anil M. Lee, Joyce X. W. Pham, Andrew Q. Yusin, Joseph S. TI Self-Injectable Epinephrine Adherence Survey Amongst Veterans SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Patel, Anil M.; Lee, Joyce X. W.; Pham, Andrew Q.; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 602 BP AB184 EP AB184 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403048 ER PT J AU Pham, AQ Lee, JXW Lin, C Liang, E Yusin, JS AF Pham, Andrew Q. Lee, Joyce Xiang Wu Lin, Connie Liang, Emily Yusin, Joseph S. TI Characterization of Patients with Low Ige Levels SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Pham, Andrew Q.; Lee, Joyce Xiang Wu; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Lin, Connie; Liang, Emily] Cedars Sinai Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 573 BP AB174 EP AB174 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403019 ER PT J AU Philipp, AT Jones, AH Zeitz, H Yusin, JS AF Philipp, Ami Thakor Jones, Alesia Hawkins Zeitz, Howard Yusin, Joseph S. TI Adolescent Asthmatics' Use of the Internet and Other Management Strategies SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Philipp, Ami Thakor; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Jones, Alesia Hawkins] Univ Illinois, Coll Med, Rockford, IL 61107 USA. [Zeitz, Howard] Univ Illinois, Coll Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 322 BP AB99 EP AB99 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005402013 ER PT J AU Kirkwood, CM MacDonald, ML Schempf, TA Vatsavayi, AV Ikonomovic, MD Koppel, JL Ding, Y Sun, M Kofler, JK Lopez, OL Yates, NA Sweet, RA AF Kirkwood, Caitlin M. MacDonald, Matthew L. Schempf, Tadhg A. Vatsavayi, Anil V. Ikonomovic, Milos D. Koppel, Jeremy L. Ding, Ying Sun, Mai Kofler, Julia K. Lopez, Oscar L. Yates, Nathan A. Sweet, Robert A. TI Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; Frontotemporal lobar degeneration; Human postmortem brain tissue; Visinin-like 1 protein (Vilip-1) ID CEREBROSPINAL-FLUID; COGNITIVE DECLINE; TANGLE FORMATION; BRAIN-INJURY; LEWY BODIES; BIOMARKER; DEMENTIA; CONSORTIUM; PATHOLOGY; VILIP-1 AB Recent studies have implicated the neuronal calcium-sensing protein visinin-like 1 protein (Vilip-1) as a peripheral biomarker in Alzheimer disease (AD), but little is known about expression of Vilip-1 in the brains of patients with AD. We used targeted and quantitative mass spectrometry to measure Vilip-1 peptide levels in the entorhinal cortex (ERC) and the superior frontal gyrus (SF) from cases with early to moderate stage AD, frontotemporal lobar degeneration (FTLD), and cognitively and neuropathologically normal elderly controls. We found that Vilip-1 levels were significantly lower in the ERC, but not in SF, of AD subjects compared to normal controls. In FTLD cases, Vilip-1 levels in the SF were significantly lower than in normal controls. These findings suggest a unique role for cerebrospinal fluid Vilip-1 as a biomarker of ERC neuron loss in AD. C1 [Kirkwood, Caitlin M.; MacDonald, Matthew L.; Schempf, Tadhg A.; Sweet, Robert A.] Univ Pittsburgh, Sch Hlth Sci, Translat Neurosci Program, Pittsburgh, PA USA. [Kirkwood, Caitlin M.; MacDonald, Matthew L.; Schempf, Tadhg A.; Ikonomovic, Milos D.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Sch Hlth Sci, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Sch Hlth Sci, Pittsburgh, PA 15260 USA. [Kofler, Julia K.] Univ Pittsburgh, Dept Pathol, Sch Hlth Sci, Pittsburgh, PA USA. [MacDonald, Matthew L.; Ding, Ying; Sun, Mai; Yates, Nathan A.] Univ Pittsburgh, Biomed Mass Spectrometry Ctr, Sch Hlth Sci, Pittsburgh, PA USA. [Kirkwood, Caitlin M.; Yates, Nathan A.] Univ Pittsburgh, Dept Cell Biol, Sch Hlth Sci, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Vatsavayi, Anil V.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Koppel, Jeremy L.] Litwin Zucker Res Ctr Study Alzheimers Dis, Manhasset, NY USA. [Koppel, Jeremy L.] Feinstein Inst Med Res, Manhasset, NY USA. [Koppel, Jeremy L.] North Shore LIJ Hlth Syst, Zucker Hillside Hosp, Glen Oaks, NY USA. RP Sweet, RA (reprint author), 3811 OHara St,BST W1645, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Ding, Ying/0000-0003-1352-1000 FU VAPHS [BX000542]; [MH16804]; [AG05133]; [AG014449]; [AG027224]; [P30CA047904] FX This work was supported by grants MH16804 (MLM), AG05133 (OLL), AG014449 (MDI), AG027224 (RAS), and VAPHS grant BX000542 (RAS). The Biomedical Mass Spectrometry Center and UPCI Cancer Proteomics Facility are supported in part by award P30CA047904. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 41 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD FEB PY 2016 VL 75 IS 2 BP 175 EP 182 DI 10.1093/jnen/nlv018 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DK9DN UT WOS:000375230800008 PM 26769253 ER PT J AU Burgio, KL Williams, BR Dionne-Odom, JN Redden, DT Noh, H Goode, PS Kvale, E Bakitas, M Bailey, FA AF Burgio, Kathryn L. Williams, Beverly R. Dionne-Odom, J. Nicholas Redden, David T. Noh, Hyunjin Goode, Patricia S. Kvale, Elizabeth Bakitas, Marie Bailey, F. Amos TI Racial Differences in Processes of Care at End of Life in VA Medical Centers: Planned Secondary Analysis of Data from the BEACON Trial SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID SMALL-SAMPLE ADJUSTMENTS; NURSING-HOME RESIDENTS; IN-HOSPITAL DEATH; ADVANCE DIRECTIVES; ETHNIC DISPARITIES; HEALTH EQUITY; OLDER-ADULTS; VETERANS; SYSTEM; CANCER AB Background: Racial differences exist for a number of health conditions, services, and outcomes, including end-of-life (EOL) care. Objective: The aim of the study was to examine differences in processes of care in the last 7 days of life between African American and white inpatients. Methods: Secondary analysis was conducted of data collected in the Best Practices for End-of-Life Care for Our Nation's Veterans (BEACON) trial (conducted 2005-2011). Subjects were 4891 inpatient decedents in six Veterans Administration Medical Centers. Data were abstracted from decedents' medical records. Multi-variable analyses were conducted to examine the relationship between race and each of 18 EOL processes of care controlling for patient characteristics, study site, year of death, and whether the observation was pre- or post-intervention. Results: The sample consisted of 1690 African American patients (34.6%) and 3201 white patients (65.4%). African Americans were less likely to have: do not resuscitate (DNR) orders (odds ratio [ OR]: 0.67; p = 0.004), advance directives (OR: 0.71; p = 0.023), active opioid orders (OR: 0.64, p = 0.0008), opioid medications administered (OR: 0.61, p = 0.004), benzodiazepine orders (OR: 0.68, p < 0.0001), benzodiazepines administered (OR: 0.61, p < 0.0001), antipsychotics administered (OR: 0.73, p = 0.004), and steroids administered (OR: 0.76, p = 0.020). Racial differences were not found for other processes of care, including palliative care consultation, pastoral care, antipsychotic and steroid orders, and location of death. Conclusions: Racial differences exist in some but not all aspects of EOL care. Further study is needed to understand the extent to which racial differences reflect different patient needs and preferences and whether interventions are needed to reduce disparities in patient/family education or access to quality EOL care. C1 [Burgio, Kathryn L.; Williams, Beverly R.; Redden, David T.; Goode, Patricia S.; Kvale, Elizabeth; Bakitas, Marie; Bailey, F. Amos] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA. [Burgio, Kathryn L.; Williams, Beverly R.; Redden, David T.; Goode, Patricia S.; Kvale, Elizabeth; Bakitas, Marie; Bailey, F. Amos] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Atlanta, GA USA. [Burgio, Kathryn L.; Williams, Beverly R.; Goode, Patricia S.; Kvale, Elizabeth; Bailey, F. Amos] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Dionne-Odom, J. Nicholas; Bakitas, Marie] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Redden, David T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Noh, Hyunjin] Univ Alabama, Tuscaloosa, AL USA. [Bailey, F. Amos] Univ Colorado, Dept Med, Denver, CO USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, 11G 700 South 19th St, Birmingham, AL 35233 USA. EM kburgio@uabmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service ("Intervention to Improve Care at Life's End in VA Medical Centers'') [IIR 03-126]; University of Alabama at Birmingham Cancer Prevention and Control Training Program [5R25CA047888]; National Palliative Care Research Center Career Development Award FX This research was supported by a Merit Review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IIR 03-126, "Intervention to Improve Care at Life's End in VA Medical Centers''; PI: K.L. Burgio, Co-PI: F.A. Bailey). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Kathryn Burgio, PhD, is director of the Deep South Resource Center for Minority Aging Research (RCMAR; P30AG031054). J. Nicholas Dionne-Odom, PhD, is a post-doctoral fellow supported by the University of Alabama at Birmingham Cancer Prevention and Control Training Program (5R25CA047888) and by a National Palliative Care Research Center Career Development Award. Hyunjin Noh, PhD, is a scholar with the Deep South Resource Center for Minority Aging Research (RCMAR; P30AG031054). NR 56 TC 2 Z9 2 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2016 VL 19 IS 2 SI SI BP 157 EP 163 DI 10.1089/jpm.2015.0311 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DK9SA UT WOS:000375270400009 PM 26840851 ER PT J AU Huang, CHS Crowther, M Allen, RS DeCoster, J Kim, G Azuero, C Ang, XY Kvale, E AF Huang, Chao-Hui Sylvia Crowther, Martha Allen, Rebecca S. DeCoster, Jamie Kim, Giyeon Azuero, Casey Ang, Xinying Kvale, Elizabeth TI A Pilot Feasibility Intervention to Increase Advance Care Planning among African Americans in the Deep South SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; HEALTH LITERACY; DECISION-MAKING; PALLIATIVE CARE; END; DISPARITIES; COMMUNITY; BARRIERS; PREFERENCES AB Background: Despite growing efforts to facilitate advance care planning (ACP) to decrease health disparities in palliative care, low completion rates of advance directives (AD) have been consistently found among African Americans. Objective: The objective was to examine the feasibility of a multicomponent ACP intervention program that integrates motivational interviewing, evidence-based ACP facilitation program (Respecting Choices (R)), and health-literacy adjusted AD. This pilot study aims to address the unique barriers to ACP engagement among African Americans in the Deep South. Methods: The design was a mixed-method randomized controlled trial design. Analysis of covariance (ANCOVA) and thematic content analysis (TCA) were conducted to identify barriers and facilitators for ACP engagement and to assess feasibility, knowledge, and intention to complete an AD. Thirty community-dwelling African Americans (mean age M=55.43, SD = 6.71, range = 47-73) were recruited from the Deep South and randomly assigned to receive intervention (n = 15) or educational material (n = 15) at a local university medical center. Results: All participants (n = 30) reported high satisfaction (M= 4.81, SD = 0.44, max score = 5) and increased intent to complete an AD at postintervention. A significant increase in knowledge on AD from baseline to postintervention was observed in the intervention group-t(14)=-3.06, p = 0.01, d = 1.67); no significant change was found for control. Lack of information, mistrust of doctors, and avoidance of discussing death were primary barriers to ACP discussions. Facilitators include ACP education, decreased mistrust, and proactive initiation of ongoing ACP discussions. Conclusions: Feasibility data revealed successful implementation of a brief intervention to increase ACP engagement and willingness to complete an AD among southern African Americans. C1 [Huang, Chao-Hui Sylvia; Azuero, Casey; Kvale, Elizabeth] Univ Alabama Birmingham, Dept Med, Ctr Palliat & Support Care, CH-19 Suite 219 933 19th St South, Birmingham, AL 35205 USA. [Huang, Chao-Hui Sylvia; Crowther, Martha; Allen, Rebecca S.; Kim, Giyeon; Azuero, Casey] Univ Alabama, Alabama Inst Aging, Tuscaloosa, AL USA. [Crowther, Martha; Allen, Rebecca S.; Kim, Giyeon; Azuero, Casey; Ang, Xinying] Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA. [DeCoster, Jamie] Univ Virginia, Ctr Adv Study Teaching & Learning, Charlottesville, VA USA. [Ang, Xinying] East Virginia Med Sch, Dept Psychiat & Behav Sci, Nortolk, VA USA. [Azuero, Casey; Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huang, CHS (reprint author), Univ Alabama Birmingham, Dept Med, Ctr Palliat & Support Care, CH-19 Suite 219 933 19th St South, Birmingham, AL 35205 USA. EM chhuang@uabmc.edu OI Allen, Rebecca Sue/0000-0002-2563-4996 NR 40 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2016 VL 19 IS 2 SI SI BP 164 EP 173 DI 10.1089/jpm.2015.0334 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DK9SA UT WOS:000375270400010 PM 26840852 ER PT J AU Bastian, LA Gray, KE DeRycke, E Mirza, S Gierisch, JM Haskell, SG Magruder, KM Wakelee, HA Wang, AG Ho, GYF LaCroix, AZ AF Bastian, Lori A. Gray, Kristen E. DeRycke, Eric Mirza, Shireen Gierisch, Jennifer M. Haskell, Sally G. Magruder, Kathryn M. Wakelee, Heather A. Wang, Ange Ho, Gloria Y. F. LaCroix, Andrea Z. TI Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Lung cancer; Smoking; Tobacco; Women Veterans ID NEVER-SMOKERS; CIGARETTE-SMOKING; RISK-FACTORS; US MILITARY; TOBACCO USE; MORTALITY; PREVALENCE; PROMOTION; BEHAVIORS; TRENDS AB Introduction: Women Veterans may have higher rates of both active and passive tobacco exposure than their civilian counterparts, thereby increasing their risk for lung cancer. Purpose of the Study: To compare differences in active and passive smoking exposure and lung cancer incidence among women Veterans and non-Veterans using prospective data from the Women's Health Initiative (WHI). Design and Methods: We used data from the WHI, which collected longitudinal demographic, clinical, and laboratory data on 161,808 postmenopausal women. We employed linear and multinomial regression and generalized linear models to compare active and passive smoking exposure between Veterans and non-Veterans and Cox proportional hazards models to estimate differences in lung cancer incidence rates. Results: After adjustment, Veterans had 2.54 additional pack years of smoking compared with non-Veterans (95% confidence interval [CI] 1.68, 3.40). Veterans also had a 1% increase in risk of any passive smoking exposure (95% CI 1.00, 1.02) and a 9% increase in risk of any workplace exposure (95% CI 1.07, 1.11) compared with non-Veterans. After adjustment for age and smoking exposures, Veterans did not have a higher risk of lung cancer compared with non-Veterans (relative risk = 1.06 95% CI 0.86, 1.30). Implications: Women Veterans had higher rates of tobacco use and exposure to passive smoking, which were associated with a higher risk for lung cancer compared with non-Veterans. Clinicians who care for Veterans need to be aware that older women Veterans have more exposures to risk factors for lung cancer. C1 [Bastian, Lori A.; DeRycke, Eric; Mirza, Shireen] VA Connecticut, 555 Willard Ave, Newington, CT 06111 USA. [Bastian, Lori A.] Univ Connecticut, Div Gen Internal Med, Farmington, CT USA. [Gray, Kristen E.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Gray, Kristen E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Mirza, Shireen] Univ Connecticut, Dept Med, Newington, CT USA. [Gierisch, Jennifer M.] Durham VA Med Ctr, Durham, NC USA. [Gierisch, Jennifer M.] Duke Univ, Dept Med, Durham, NC USA. [Haskell, Sally G.] Womens Hlth Serv, VA Off Patient Care, Washington, DC USA. [Haskell, Sally G.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Haskell, Sally G.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Magruder, Kathryn M.] VA Med Ctr, Charleston, SC USA. [Wakelee, Heather A.] Stanford Univ, Dept Med, Oncol, Stanford, CA 94305 USA. [Wang, Ange] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Ho, Gloria Y. F.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA. RP Bastian, LA (reprint author), VA Connecticut, 555 Willard Ave, Newington, CT 06111 USA. EM lori.bastian@va.gov FU National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C]; U.S. Department of Veterans Affairs; Health Service Research Development [CRE 12-008]; VA Health Services Research and Development (HSRD) [TPP 61-029]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The Women's Health Initiative programs are funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services through contracts, HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C. Dr. Bastian was supported by the U.S. Department of Veterans Affairs; Health Service Research & Development CRE 12-008. Dr. Gray was supported by VA Health Services Research and Development (HSR&D) Postdoctoral Fellowship (TPP 61-029). This research was also supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 36 TC 1 Z9 1 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S102 EP S111 DI 10.1093/geront/gnv664 PG 10 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500011 PM 26768384 ER PT J AU Bastian, LA Hayes, PM Haskell, SG Atkins, D Reiber, GE LaCroix, AZ Yano, EM AF Bastian, Lori A. Hayes, Patricia M. Haskell, Sally G. Atkins, David Reiber, Gayle E. LaCroix, Andrea Z. Yano, Elizabeth M. TI Improving Our Understanding of Health Issues in Older Women Veterans SO GERONTOLOGIST LA English DT Editorial Material ID CARE C1 [Bastian, Lori A.; Haskell, Sally G.] Vet Affairs VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. [Hayes, Patricia M.; Haskell, Sally G.] Vet Hlth Adm, Womens Hlth Serv, Washington, DC USA. [Haskell, Sally G.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Atkins, David] Hlth Serv Res & Dev Serv, Dept Vet Affairs, Washington, DC USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA. [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Bastian, LA (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave Mail Code 151, West Haven, CT 06516 USA. EM lori.bastian@va.gov FU National Heart, Lung and Blood Institute, National Institute of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs Health Services Research and Development VA HSRD FOP [FOP 14-439, SDR 10-012]; VA Women's Health Services; VA HSR&D VA Senior Research Career Scientist Awards [RCS 98-353, RCS 05-195] FX The WHI program is funded by the National Heart, Lung and Blood Institute, National Institute of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.; This work was also supported by the Department of Veterans Affairs Health Services Research and Development VA HSR&D FOP 14-439 and SDR 10-012, and the VA Women's Health Services. Dr. Reiber's and Yano's efforts were supported by VA HSR&D VA Senior Research Career Scientist Awards (Reiber Project RCS 98-353 and Yano Project RCS 05-195). NR 19 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S10 EP S13 DI 10.1093/geront/gnv672 PG 4 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500003 PM 26768383 ER PT J AU Gray, KE Katon, JG Rillamas-Sun, E Bastian, LA Nelson, KM LaCroix, AZ Reiber, GE AF Gray, Kristen E. Katon, Jodie G. Rillamas-Sun, Eileen Bastian, Lori A. Nelson, Karin M. LaCroix, Andrea Z. Reiber, Gayle E. TI Association Between Chronic Conditions and Physical Function Among Veteran and Non-Veteran Women With Diabetes SO GERONTOLOGIST LA English DT Article DE Physical function; Diabetes; Veterans; Women's issues; Chronic illness ID POSTTRAUMATIC-STRESS-DISORDER; LOWER-EXTREMITY DISABILITY; CENTERED MEDICAL HOME; QUALITY-OF-LIFE; OLDER WOMEN; MILITARY SERVICE; UNITED-STATES; HEALTH SURVEY; SELF-REPORTS; MELLITUS AB Purpose of the Study: To compare the number of chronic conditions among a list of 12 and their association with physical function among postmenopausal non-Veteran and Veteran women with diabetes. Design and Methods: Among women with diabetes from the Women's Health Initiative, we compared the average number of chronic conditions between non-Veterans and Veterans and the association between total number of chronic conditions on subsequent RAND-36 physical function. To examine associations between each condition and subsequent physical function, we compared women with diabetes plus one chronic condition to women with diabetes alone using linear regression in separate models for each condition and for non-Veterans and Veterans. Results: Both non-Veterans (N = 23,542) and Veterans (N = 618) with diabetes had a median of 3 chronic conditions. Decreases in physical function for each additional condition were larger among Veterans than non-Veterans (-6.3 vs. -4.1 points). Decreases in physical function among women with diabetes plus one chronic condition were greater than that reported for diabetes alone for all combinations and were more pronounced among Veterans (non-Veterans: -11.1 to -24.2, Veterans: -16.6 to -40.4 points). Hip fracture, peripheral artery disease, cerebrovascular disease, and coronary disease in combination with diabetes were associated with the greatest decreases in physical function. Implications: Chronic conditions were common among postmenopausal women with diabetes and were associated with large declines in physical function, particularly among Veterans. Interventions to prevent and reduce the impact of these conditions and facilitate coordination of care among women with diabetes may help them maintain physical function. C1 [Gray, Kristen E.; Katon, Jodie G.; Rillamas-Sun, Eileen; Nelson, Karin M.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Gray, Kristen E.; Katon, Jodie G.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Katon, Jodie G.] Womens Hlth Serv, VA Off Patient Care, Washington, DC USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Bastian, Lori A.] VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Div Gen Internal Med, Farmington, CT USA. [Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, San Diego, CA 92103 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP Gray, KE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM kristen.gray2@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201 100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; U.S. Department of Veterans Affairs Health Services Research & Development Program [TPP 61-029]; U.S. Department of Veterans Affairs Office of Patient Care, Women's Health Services; VA Puget Sound Center of Innovation for Veteran-Centered and Value-Driven Care; Department of Veterans Affairs Health Services Research and Development VA HSRD [FOP 14-439]; VA Office of Women's Health; VA HSR&D Senior Research Career Scientist Award [RCS 98-353] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services (grant numbers HHSN268201100046C, HHSN268201100001C, HHSN268201 100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C).; WHI Investigators-Program Office: Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller (National Heart, Lung, and Blood Institute, Bethesda, MD). Clinical Coordinating Center: Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg (Fred Hutchinson Cancer Research Center, Seattle, WA). Investigators and Academic Centers: JoAnn E. Manson (Brigham and Women's Hospital, Harvard Medical School, Boston, MA); Barbara V. Howard (MedStar Health Research Institute/Howard University, Washington, DC); Marcia L. Stefanick (Stanford Prevention Research Center, Stanford, CA); Rebecca Jackson (The Ohio State University, Columbus, OH); Cynthia A. Thomson (University of Arizona, Tucson/Phoenix, AZ); Jean Wactawski-Wende (University at Buffalo, Buffalo, NY); Marian Limacher (University of Florida, Gainesville/Jacksonville, FL); Robert Wallace (University of Iowa, Iowa City/Davenport, IA); Lewis Kuller (University of Pittsburgh, Pittsburgh, PA); and Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, NC). Women's Health Initiative Memory Study: Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, NC). For a list of all the investigators who have contributed to WHI science, please visit: https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20I nvestigator%20Long%20List.pdf This work was also supported by the U.S. Department of Veterans Affairs Health Services Research & Development Program (Postdoctoral Fellowship TPP 61-029 to K. E. Gray); U.S. Department of Veterans Affairs Office of Patient Care, Women's Health Services; and the VA Puget Sound Center of Innovation for Veteran-Centered and Value-Driven Care (to J. G. Katon). This work was also supported by the Department of Veterans Affairs Health Services Research and Development VA HSR&D FOP 14-439; the VA Office of Women's Health; and a VA HSR&D Senior Research Career Scientist Award (Project RCS 98-353 to G. E. Reiber). NR 75 TC 0 Z9 0 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S112 EP S125 DI 10.1093/geront/gnv675 PG 14 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500012 PM 26768385 ER PT J AU LaCroix, AZ Rillamas-Sun, E Woods, NF Weitlauf, J Zaslavsky, O Shih, R LaMonte, MJ Bird, C Yano, EM LeBoff, M Washington, D Reiber, G AF LaCroix, Andrea Z. Rillamas-Sun, Eileen Woods, Nancy F. Weitlauf, Julie Zaslavsky, Oleg Shih, Regina LaMonte, Michael J. Bird, Chloe Yano, Elizabeth M. LeBoff, Meryl Washington, Donna Reiber, Gayle TI Aging Well Among Women Veterans Compared With Non-Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Healthy aging; disability; Quality of life; Women Veterans ID QUALITY-OF-LIFE; CARE UTILIZATION; SOCIAL SUPPORT; OLDER WOMEN; RESILIENCE; OUTCOMES; THERAPY; STRESS; SCALE; USERS AB Purpose of the Study: To examine whether Veteran status influences (a) women's survival to age 80 years without disease and disability and (b) indicators of successful, effective, and optimal aging at ages 80 years and older. Design and Methods: The Women's Health Initiative (WHI) enrolled 161,808 postmenopausal women aged 50-79 years from 1993 to 1998. We compared successful aging indicators collected in 2011-2012 via mailed questionnaire among 33,565 women (921 Veterans) who reached the age of 80 years and older, according to Veteran status. A second analysis focused on women with intact mobility at baseline who could have reached age 80 years by December 2013. Multinominal logistic models examined Veteran status in relation to survival to age 80 years without major disease or mobility disability versus having prevalent or incident disease, having mobility disability, or dying prior to age 80 years. Results: Women Veterans aged 80 years and older reported significantly lower perceived health, physical function, life satisfaction, social support, quality of life, and purpose in life scale scores compared with non-Veterans. The largest difference was in physical function scores (53.0 for Veterans vs 59.5 for non-Veterans; p < .001). Women Veterans were significantly more likely to die prior to age 80 years than non-Veteran WHI participants (multivariate adjusted odds ratio = 1.20; 95% confidence interval, 1.04-1.38). In both Veteran and non-Veteran women, healthy survival was associated with not smoking, higher physical activity, healthy body weight, and fewer depressive symptoms. C1 [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, San Diego, CA 92103 USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Woods, Nancy F.] Univ Washington, Seattle WHI Clin Ctr, Biobehav Nursing, Seattle, WA 98195 USA. [Weitlauf, Julie] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA USA. [Weitlauf, Julie] Ctr Innovat Implementat, La Jolla, CA USA. [Weitlauf, Julie] Stanford Univ, Dept Psychiat & Behav Sci, Stanford Canc Inst, Palo Alto, CA 94304 USA. [Zaslavsky, Oleg] Univ Haifa, Fac Hlth Sci & Social Welf, IL-31999 Haifa, Israel. [Shih, Regina] RAND Corp, Arlington, VA USA. [LaMonte, Michael J.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Bird, Chloe] RAND Corp, Santa Monica, CA USA. [Yano, Elizabeth M.; Washington, Donna] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [LeBoff, Meryl] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens,Dept Med, Boston, MA USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP LaCroix, AZ (reprint author), Univ Calif San Diego, Div Epidemiol, Dept Family Med & Publ Hlth, 9500 Gilman Dr 0725, La Jolla, CA 92093 USA. EM alacroix@ucsd.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (HSRD) Service [FOP14-439]; VA Office of Women's Health; VA HSR&D Senior Research Career Scientist awards [98-353, 05-195] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.; This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (HSR&D) Service FOP14-439 and the VA Office of Women's Health. Drs. Reiber and Yano were funded through VA HSR&D Senior Research Career Scientist awards (RCS # 98-353 and RCS # 05-195, respectively). NR 44 TC 1 Z9 1 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S14 EP S26 DI 10.1093/geront/gnv124 PG 13 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500004 PM 26768388 ER PT J AU Washington, DL Gray, K Hoerster, KD Katon, JG Cochrane, BB LaMonte, MJ Weitlauf, JC Groessl, E Bastian, L Vitolins, MZ Tinker, L AF Washington, Donna L. Gray, Kristen Hoerster, Katherine D. Katon, Jodie G. Cochrane, Barbara B. LaMonte, Michael J. Weitlauf, Julie C. Groessl, Erik Bastian, Lori Vitolins, Mara Z. Tinker, Lesley TI Trajectories in Physical Activity and Sedentary Time Among Women Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Women Veterans; Health behavior; Physical activity; Sedentary lifestyle; Sedentary behavior; Health trajectory; Longitudinal Study; Postmenopausal ID LONGITUDINAL DATA-ANALYSIS; OLDER-ADULTS; CARDIOVASCULAR-DISEASE; POPULATION HEALTH; UNITED-STATES; PREVALENCE; BEHAVIOR; PREVENTION; QUESTIONNAIRE; MORTALITY AB Purpose of the Study: Trajectories of physical activity (PA) and sedentary time (ST) after military separation are likely important determinants of women's health outcomes later in life, because low PA and high ST are known contributors to premature mortality risk. Our objective was to compare longitudinal trajectories of recreational PA and ST between Veteran and non-Veteran postmenopausal women from the Women's Health Initiative (WHI). Design and Methods: Women Veteran (n = 3,719) and non-Veteran (n = 141,800) WHI participants were included. Self-reported participation in recreational PA, converted to metabolic equivalent (MET)-hours/week, was prospectively assessed over 8 years. Self-reported ST, defined as hours/day sitting or lying down, was collected at baseline and at Years 3 and 6. Generalized estimating equations were used to compare trajectories of PA and ST between Veterans and non-Veterans, adjusted for demographics and lifestyle behaviors. Results: Veterans had higher baseline PA than non-Veterans (13.2 vs 12.5 MET-hours/week, p = .03). PA declined for both groups, with a steeper decline among Veterans (change/visit year -0.19 vs -0.02 MET-hours/week; interaction p < .001). At baseline, Veterans and non-Veterans had similar levels of ST (107.2 vs 105.9 hours/week, p = 0.42). Over time, ST remained stable among Veterans but declined slightly among non-Veterans (change/visit year -0.19 vs -0.49 hours/week; interaction p = .01). C1 [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA. [Gray, Kristen; Hoerster, Katherine D.; Katon, Jodie G.] VA Puget Sound Hlth Care Syst Hlth Serv Res & Dev, Seattle, WA USA. [Gray, Kristen; Katon, Jodie G.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Katon, Jodie G.] VA Off Patient Care, Womens Hlth Serv, Seattle, WA USA. [Cochrane, Barbara B.; Tinker, Lesley] Univ Washington, Sch Nursing, Seattle, WA USA. [Cochrane, Barbara B.; Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [LaMonte, Michael J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Weitlauf, Julie C.] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA USA. [Weitlauf, Julie C.] Ctr Innovat Implementat, Seattle, WA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Groessl, Erik] VA San Diego Hlth Serv Res & Dev Unit, San Diego, CA USA. [Groessl, Erik] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Bastian, Lori] VA Connecticut Healthcare Syst, New Haven, CT USA. [Vitolins, Mara Z.] Wake Forest Univ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.r This research was also supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 49 TC 0 Z9 0 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S27 EP S39 DI 10.1093/geront/gnv676 PG 13 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500005 PM 26768390 ER PT J AU Washington, DL Bird, CE LaMonte, MJ Goldstein, KM Rillamas-Sun, E Stefanick, ML Woods, NF Bastian, LA Gass, M Weitlauf, JC AF Washington, Donna L. Bird, Chloe E. LaMonte, Michael J. Goldstein, Karen M. Rillamas-Sun, Eileen Stefanick, Marcia L. Woods, Nancy F. Bastian, Lori A. Gass, Margery Weitlauf, Julie C. TI Military Generation and Its Relationship to Mortality in Women Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Women Veterans; Mortality; Cohort effect; Longitudinal study ID UNITED-STATES; WAR; SERVICE; CANCER; RISK; LIFE AB Purpose of the Study: Women's military roles, exposures, and associated health outcomes have changed over time. However, mortality risk-within military generations or compared with non-Veteran women-has not been assessed. Using data from the Women's Health Initiative (WHI), we examined all-cause and cause-specific mortality by Veteran status and military generation among older women. Design and Methods: WHI participants (3,719 Veterans; 141,802 non-Veterans), followed for a mean of 15.2 years, were categorized into pre-Vietnam or Vietnam/after generations based on their birth cohort. We used cox proportional hazards models to examine the association between Veteran status and mortality by generation. Results: After adjusting for sociodemographic characteristics and WHI study arm, all-cause mortality hazard rate ratios (HRs) for Veterans relative to non-Veterans were 1.16 (95% CI: 1.09-1.23) for pre-Vietnam and 1.16 (95% CI: 0.99-1.36) for Vietnam/after generations. With additional adjustment for health behaviors and risk factors, this excess mortality rate persisted for pre-Vietnam but attenuated for Vietnam/after generations. After further adjustment for medical morbidities, across both generations, Veterans and non-Veterans had similar all-cause mortality rates. Relative to non-Veterans, adjusting for sociodemographics and WHI study arm, pre-Vietnam generation Veterans had higher cancer, cardiovascular, and trauma-related morality rates; Vietnam/after generation Veterans had the highest trauma-related mortality rates (HR = 2.93, 1.64-5.23). Implications: Veterans' higher all-cause mortality rates were limited to the pre-Vietnam generation, consistent with diminution of the healthy soldier effect over the life course. Mechanisms underlying Vietnam/after generation Veteran trauma-related mortality should be elucidated. Efforts to modify salient health risk behaviors specific to each military generation are needed. C1 [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, VA Hlth Serv Res & Dev HSR&D, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Bird, Chloe E.] RAND Corp, Pardee Rand Grad Sch, Santa Monica, CA USA. [LaMonte, Michael J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Goldstein, Karen M.] Durham VA Hlth Care Syst, Durham, NC USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Seatle, WA USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Stanford Ctr Hlth Res Women & Sex Differences Med, Stanford, CA 94305 USA. [Woods, Nancy F.] Univ Washington, Sch Nursing, Div Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Bastian, Lori A.] VA Connecticut, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, West Haven, CT USA. [Gass, Margery] North Amer Menopause Soc, Mayfield Hts, OH USA. [Weitlauf, Julie C.] Sierra Pacific MIRECC, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Weitlauf, Julie C.] Ctr Innovat Implementat, San Diego, CA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The research reported here was supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 40 TC 0 Z9 0 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S126 EP S137 DI 10.1093/geront/gnv669 PG 12 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500013 PM 26768386 ER PT J AU Weitlauf, JC Washington, DL Stefanick, ML AF Weitlauf, Julie C. Washington, Donna L. Stefanick, Marcia L. TI Who Are the Women Veterans in the Women's Health Initiative? SO GERONTOLOGIST LA English DT Editorial Material ID MILITARY SERVICE; MORTALITY; CANCER C1 [Weitlauf, Julie C.] Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA 94304 USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Ctr Implementat Innovat Ci2i, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford Prevent Res Ctr Stanford, Stanford, CA 94305 USA. RP Weitlauf, JC (reprint author), Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA 94304 USA.; Weitlauf, JC (reprint author), Stanford Univ, Sch Med, Ctr Implementat Innovat Ci2i, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. EM wjulie1@stanford.edu FU Women's Mental Health and Aging Core of the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC); VA Office of Women's Health and VA Health Services Research and Development [VA HSRD FOP 14-439] FX This editorial was supported, in part, by the Women's Mental Health and Aging Core of the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC) and the VA Office of Women's Health and VA Health Services Research and Development (VA HSR&D FOP 14-439). NR 22 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S6 EP S9 DI 10.1093/geront/gnv674 PG 4 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500002 PM 26768392 ER PT J AU Ramage, AE Litz, BT Resick, PA Woolsey, MD Dondanville, KA Young-McCaughan, S Borah, AM Borah, EV Peterson, AL Fox, PT AF Ramage, Amy E. Litz, Brett T. Resick, Patricia A. Woolsey, Mary D. Dondanville, Katherine A. Young-McCaughan, Stacey Borah, Adam M. Borah, Elisa V. Peterson, Alan L. Fox, Peter T. CA STRONG STAR Consortium TI Regional cerebral glucose metabolism differentiates danger- and non-danger-based traumas in post-traumatic stress disorder SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE post-traumatic stress disorder; FDG PET; glucose metabolism; fear ID FUNCTIONAL CONNECTIVITY; BRAIN NETWORKS; PSYCHOMETRIC PROPERTIES; CINGULATE CORTEX; AMYGDALA VOLUME; WAR VETERANS; METAANALYSIS; PTSD; RELIABILITY; ANXIETY AB Post-traumatic stress disorder (PTSD) is presumably the result of life threats and conditioned fear. However, the neurobiology of fear fails to explain the impact of traumas that do not entail threats. Neuronal function, assessed as glucose metabolism with 18fluoro-deoxyglucose positron emission tomography, was contrasted in active duty, treatment-seeking US Army Soldiers with PTSD endorsing either danger-(n = 19) or non-danger-based (n = 26) traumas, and was compared with soldiers without PTSD (Combat Controls, n = 26) and Civilian Controls (n = 24). Prior meta-analyses of regions associated with fear or trauma script imagery in PTSD were used to compare glucose metabolism across groups. Danger-based traumas were associated with higher metabolism in the right amygdala than the control groups, while non-danger-based traumas associated with heightened precuneus metabolism relative to the danger group. In the danger group, PTSD severity was associated with higher metabolismin precuneus and dorsal anterior cingulate and lower metabolismin left amygdala (R-2 = 0.61). In the non-danger group, PTSD symptom severity was associated with higher precuneus metabolismand lower right amygdala metabolism( R-2 = 0.64). These findings suggest a biological basis to consider subtyping PTSD according to the nature of the traumatic context. C1 [Ramage, Amy E.; Dondanville, Katherine A.; Young-McCaughan, Stacey; Borah, Elisa V.; Peterson, Alan L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Ramage, Amy E.; Woolsey, Mary D.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 7703 Floyd Curl Dr,MSC 6240, San Antonio, TX 78229 USA. [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Washington, DC USA. [Litz, Brett T.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA. [Resick, Patricia A.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC USA. [Borah, Adam M.] Carl R Darnall Army Med Ctr, Ft Hood, TX USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pok Fu Lam, Hong Kong, Peoples R China. RP Ramage, AE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 7703 Floyd Curl Dr,MSC 6240, San Antonio, TX 78229 USA. EM ramagea@uthscsa.edu FU Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-109, W81XWH-08-02-0112, W81XWH-08-02-0114, W81XWH-08-02-0116]; U.S. Department of Defense, Defense Health Program; U.S. Department of Veterans Affairs, Office of Research & Development through the Psychological Health and Traumatic Brain Injury Research Program (PH/TBI RP), Consortium to Alleviate PTSD (CAP) [W81XWH-13-2-0065] FX The data collection for this study was conducted with support to the STRONG STAR Multidisciplinary PTSD Research Consortium from the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-02-109 (Alan Peterson), W81XWH-08-02-0112 (Peter Fox), W81XWH-08-02-0114 (Brett Litz), and W81XWH-08-02-0116 (Patricia Resick). The analysis and interpretation of data for this study was supported by the U.S. Department of Defense, Defense Health Program and the U.S. Department of Veterans Affairs, Office of Research & Development through the Psychological Health and Traumatic Brain Injury Research Program (PH/TBI RP), Consortium to Alleviate PTSD (CAP) award W81XWH-13-2-0065. NR 58 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD FEB PY 2016 VL 11 IS 2 BP 234 EP 242 DI 10.1093/scan/nsv102 PG 9 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA DJ5DL UT WOS:000374226900005 PM 26373348 ER PT J AU Day, MA Ehde, DM Ward, LC Hartoonian, N Alschuler, KN Turner, AP Kraft, GH Jensen, MP AF Day, Melissa A. Ehde, Dawn M. Ward, L. Charles Hartoonian, Narineh Alschuler, Kevin N. Turner, Aaron P. Kraft, George H. Jensen, Mark P. TI An Empirical Investigation of a Biopsychosocial Model of Pain in Multiple Sclerosis SO CLINICAL JOURNAL OF PAIN LA English DT Article DE multiple sclerosis; biopsychosocial model; structural equation model; pain ID QUALITY-OF-LIFE; LARGE COMMUNITY SAMPLE; MAJOR DEPRESSION; MEDIATING ROLE; PRIMARY-CARE; FATIGUE; PREVALENCE; SEVERITY; OUTCOMES; IMPACT AB Objectives: Pain is a significant problem for many individuals with multiple sclerosis (MS). Pain is often associated with other MS symptoms (eg, physical, sensorimotor, cognitive declines), and both pain and MS symptoms are hypothesized to contribute to psychosocial problems (eg, depression), other symptoms (eg, fatigue, sleep disturbance), and functional impairments (eg, pain interference). On the basis of a biopsychosocial model, we sought to: (1) examine the associations between pain, MS symptoms, depression, psychosocial, and functional variables and (2) identify possible risk and protective factors associated with pain in MS. Materials and Methods: A cross-sectional survey was completed by 424 individuals with MS. Pain, MS symptoms, demographics, MS diagnostic factors, and psychosocial and functional variables were assessed. Data were analyzed by structural equation models. Results: Participants were predominantly white (92%), middle-aged (mean=50.7 y), and female (80%). Results indicated that pain severity and depression accounted for > 50% of the variance in pain interference. Although pain contributed minimally to fatigue and sleep quality, depression and MS symptoms predicted 49% of the variance in fatigue, and depression was largely responsible for the 40% of predicted variance in sleep quality. Identified risk factors for pain were low educational attainment and lack of a committed/marital relationship, even while controlling for diagnostic and other key demographic variables. Discussion: Results highlight the importance of targeting interventions toward improving coping skills and social support within the context of pain and MS. Research is needed to determine whether effectively targeting depression in MS results in improvements of other critical psychosocial and physical functioning domains. C1 [Day, Melissa A.] Univ Queensland, Sch Psychol, 1100 Nudgee Rd, Brisbane, Qld 4014, Australia. [Ehde, Dawn M.; Hartoonian, Narineh; Alschuler, Kevin N.; Turner, Aaron P.; Kraft, George H.; Jensen, Mark P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hartoonian, Narineh; Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ward, L. Charles] VA Med Ctr, Psychol Serv, Tuscaloosa, AL USA. [Hartoonian, Narineh; Turner, Aaron P.] VA MS Ctr Excellence, Seattle, WA USA. RP Day, MA (reprint author), Univ Queensland, Sch Psychol, 1100 Nudgee Rd, Brisbane, Qld 4014, Australia. EM Melissa.Day@acu.edu.au FU Department of Education, NIDRR, Washington, DC [H133B080025]; National Institutes of Health, Bethesda, Maryland [5U01AR052171-03]; National Multiple Sclerosis Society, New York City, NY [MB 0026, MB 0008] FX Supported by grants from the Department of Education, NIDRR grant number H133B080025, Washington, DC; National Institutes of Health, Grant 5U01AR052171-03, Bethesda, Maryland; and the National Multiple Sclerosis Society, Grants MB 0026 and MB 0008, New York City, NY. The authors declare no conflict of interest. NR 42 TC 1 Z9 2 U1 5 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0749-8047 EI 1536-5409 J9 CLIN J PAIN JI Clin. J. Pain PD FEB PY 2016 VL 32 IS 2 BP 155 EP 163 DI 10.1097/AJP.0000000000000240 PG 9 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA DI9MW UT WOS:000373828000009 PM 26741742 ER PT J AU Robbins, J Humpal, NS Banaszynski, K Hind, J Rogus-Pulia, N AF Robbins, JoAnne Humpal, Naomi S. Banaszynski, Kelsey Hind, Jacqueline Rogus-Pulia, Nicole TI Age-Related Differences in Pressures Generated During Isometric Presses and Swallows by Healthy Adults SO DYSPHAGIA LA English DT Article DE Swallowing; Dysphagia; Tongue strength; Aging; Deglutition; Deglutition disorders ID TONGUE STRENGTH; OLDER-ADULTS; RISK-FACTOR; DYSPHAGIA; PREVALENCE; SARCOPENIA; MUSCLES; IMPACT AB The aim of this prospective observational study was to determine the associations among age, maximum lingual isometric pressures, and maximum swallow pressures in specific regions of the tongue. Individuals 21 years and older who reported normal swallowing were enrolled. Seventy-one healthy adults were stratified by age into young (21-40 years), middle (41-60), and old (61-82) groups. Maximum pressures were measured for each individual during isometric tongue press tasks as well as saliva, 5, and 10 mL thin liquid bolus swallows at 5 sensors located on the hard palate: front, middle, left, right, and back. Lower maximum lingual pressures for all tasks were associated with increased age (p < 0.04). Saliva pressures exhibited a different pressure pattern than bolus swallows with pressures higher than bolus swallows on middle (p < 0.03) and back (p < 0.05) tongue sensors but not in the front. Diminished swallow pressure reserve (maximum isometric pressure-maximum swallow pressure) also was found with increased age (p < 0.03). Isometric pressures were greater than swallow pressures in young and middle age groups at both the front (p < 0.04) and back (p < 0.03) sensors, but only significantly greater at the front sensor for the oldest group (p < 0.04). Older healthy adults have lower lingual isometric pressures and lower swallow pressures than younger healthy adults. Elders have a decreased swallow pressure reserve to draw upon during occasions of physiological stress. While the exact mechanisms for age-related decline in lingual pressures remain unclear, they are likely due, at least in part, to sarcopenia. Saliva, 5, and 10 mL thin boluses also exhibit different age-related declines in pressure at specific sensors, indicating they may elicit different muscle activation patterns. C1 [Robbins, JoAnne; Rogus-Pulia, Nicole] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison GRECC, 2500 Overlook Terrace,Room D4220, Madison, WI 53705 USA. [Robbins, JoAnne; Rogus-Pulia, Nicole] Univ Wisconsin, Dept Med, SMPH, Madison, WI 53706 USA. [Humpal, Naomi S.] Univ Wisconsin, Coll Engn, Dept Biomed Engn, Madison, WI 53706 USA. [Banaszynski, Kelsey] WhiteWave Foods, 1900 Cherry St, Louisville, CO USA. [Hind, Jacqueline] Swallow Solut LLC, 401 Charmany Dr, Madison, WI 53719 USA. RP Rogus-Pulia, N (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison GRECC, 2500 Overlook Terrace,Room D4220, Madison, WI 53705 USA.; Rogus-Pulia, N (reprint author), Univ Wisconsin, Dept Med, SMPH, Madison, WI 53706 USA. EM npulia@wisc.edu NR 26 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD FEB PY 2016 VL 31 IS 1 BP 90 EP 96 DI 10.1007/s00455-015-9662-x PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DI8IP UT WOS:000373745000010 PM 26525059 ER PT J AU Maier, MM Ross, DB Chartier, M Belperio, PS Backus, LI AF Maier, Marissa M. Ross, David B. Chartier, Maggie Belperio, Pamela S. Backus, Lisa I. TI Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID GENOTYPE 1 INFECTION; UNITED-STATES; PLUS RIBAVIRIN; AFFAIRS CARE; PREVALENCE; SOFOSBUVIR; LEDIPASVIR AB Objectives. We measured the quality of HCV care using a cascade of HCV care model. Methods. We estimated the number of patients diagnosed with chronic HCV, linked to HCV care, treated with HCV antivirals, and having achieved a sustained virologic response (SVR) in the electronic medical record data from the Veterans Health Administration's Corporate Data Warehouse and the HCV Clinical Case Registry in 2013. Results. Of the estimated 233 898 patients with chronic HCV, 77% (181 168) were diagnosed, 69% (160 794) were linked to HCV care, 17% (39 388) were treated with HCV antivirals, and 7% (15 983) had achieved SVR. Conclusions. This Cascade of HCV Care provides a clinically relevant model to measure the quality of HCV care within a health care system and to compare HCV care across health systems. C1 [Maier, Marissa M.] Vet Hlth Adm, VA Portland Hlth Care Syst, Portland, OR USA. [Maier, Marissa M.; Ross, David B.; Chartier, Maggie] VHA, Off Publ Hlth, HIV Hepatitis & Publ Hlth Pathogens Programs, Washington, DC USA. [Ross, David B.] VA Washington DC Hlth Care Syst, Washington, DC USA. [Chartier, Maggie] VHA, VA San Francisco Hlth Care Syst, San Francisco, CA USA. [Belperio, Pamela S.] VHA, VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. [Belperio, Pamela S.; Backus, Lisa I.] VHA, Off Publ Hlth Populat Hlth, Washington, DC USA. [Backus, Lisa I.] VHA, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Maier, MM (reprint author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mail Code P3ID, Portland, OR 97239 USA. EM Marissa.Maier@va.gov NR 18 TC 2 Z9 2 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2016 VL 106 IS 2 BP 353 EP 358 DI 10.2105/AJPH.2015.302927 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DI3VY UT WOS:000373429000043 PM 26562129 ER PT J AU Hagiwara, Y Healy, J Ghannam, S Lee, S Sanchez-Reilly, S AF Hagiwara, Yuya Healy, Jennifer Ghannam, Sammar Lee, Shuko Sanchez-Reilly, Sandra TI Development and Validation of a Family Meeting OSCE Assessment Tool (FMOSCEAT) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hagiwara, Yuya] Avera Med Grp Palliat Med, San Antonio, TX USA. [Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ghannam, Sammar] Univ Texas San Antonio, San Antonio, TX USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA TH331A BP 332 EP 333 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900084 ER PT J AU Mireles, C Healy, J Lee, S Sanchez-Reilly, S Kapp, B AF Mireles, Christina Healy, Jennifer Lee, Shuko Sanchez-Reilly, Sandra Kapp, Bethany TI Nurses Have the Magic Touch: Determining the Effect of Embedding a Palliative Care Nurse Within the MICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Mireles, Christina; Healy, Jennifer; Sanchez-Reilly, Sandra; Kapp, Bethany] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA FR420A BP 354 EP 355 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900127 ER PT J AU Amdur, S Seetharama, A Lee, S Ross, J Sanchez-Reilly, S AF Amdur, Shira Seetharama, Aparna Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Good Mourning, YouTube! Grieving and Bereaving on the World's Most Popular Video Sharing Website SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Amdur, Shira; Seetharama, Aparna; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Seetharama, Aparna; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA FR461D BP 373 EP 374 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900162 ER PT J AU Petrillo, L McMahan, R Sudore, R AF Petrillo, Laura McMahan, Ryan Sudore, Rebecca TI What Is a Serious Medical Decision? Patients' And Surrogates' Perceptions of Serious Decisions and What Is Important in Making Them SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Petrillo, Laura] San Francisco Dept Vet Affairs, San Francisco, CA USA. [Petrillo, Laura; McMahan, Ryan; Sudore, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sudore, Rebecca] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S766 BP 443 EP 444 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900289 ER PT J AU Veeder, H Stowers, K Linden, J Lee, S Sanchez-Reilly, S AF Veeder, Heather Stowers, Katie Linden, James Lee, Shuko Sanchez-Reilly, Sandra TI Protecting Our Vulnerable Population: Screening for Mistreatment in Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Veeder, Heather; Stowers, Katie; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Linden, James] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S776 BP 449 EP 450 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900299 ER PT J AU Williams, S Lee, S Healy, J Sanchez-Reilly, S AF Williams, Sherry Lee, Shuko Healy, Jennifer Sanchez-Reilly, Sandra TI How Come They Don't Come? Identifying Reasons of No-Shows Among a Palliative Care Outpatient Clinic SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Williams, Sherry; Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Williams, Sherry; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S775 BP 449 EP 449 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900298 ER PT J AU Kapp, B Mireles, C Sanchez-Reilly, S Healy, J Lee, S AF Kapp, Bethany Mireles, Christina Sanchez-Reilly, Sandra Healy, Jennifer Lee, Shuko TI Benefits of Palliative Care in the MICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Kapp, Bethany; Mireles, Christina; Sanchez-Reilly, Sandra; Healy, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S781 BP 452 EP 453 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900304 ER PT J AU May, L Sanchez-Reilly, S Frausto, E Lee, S Garcia, J AF May, Linda Sanchez-Reilly, Sandra Frausto, Edggar Lee, Shuko Garcia, Jessica TI Yes, I Can Live with Less Pain: A Pain Educational Intervention Improving Patient-Centered Care and Attitudes Among Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [May, Linda; Sanchez-Reilly, Sandra; Frausto, Edggar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Garcia, Jessica] Symptom Management Consultants, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S784 BP 454 EP 454 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900307 ER PT J AU Klein, D Dinardo, D Hwa, S Superson, J Chang, V Olson, E AF Klein, David Dinardo, Daniel Hwa, Stephanie Superson, Jennifer Chang, Victor Olson, Ellen TI Comparison of Symptoms in Patients with Lung Cancer and Hepatocellular Cancer Referred for Palliative Care at a VA Medical Center SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Klein, David] Hosp New York, Queens, NY USA. [Dinardo, Daniel] St Johns Episcopal Hosp, Merrick, NY USA. [Hwa, Stephanie] James J Peters VA Med Ctr, New York, NY USA. [Superson, Jennifer] James J Peters VA Med Ctr, Brooklyn, NY USA. [Chang, Victor] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Olson, Ellen] James J Peters Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S791 BP 458 EP 458 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900314 ER PT J AU Monskaya, M Pruskowski, J Garcia, Y Chang, V Olson, E AF Monskaya, Milena Pruskowski, Jennifer Garcia, Yleana Chang, Victor Olson, Ellen TI Dosing of Analgesics for Patients with Liver Cancer or Lung Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Monskaya, Milena] JJPMC, Brooklyn, NY USA. [Pruskowski, Jennifer] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Garcia, Yleana] Kaweah Delta Hlth Care Dist, Visalia, CA USA. [Chang, Victor] Vet Adm New Jersey Hlth Care Syst, E Orange, NJ USA. [Olson, Ellen] James J Peters Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S792 BP 458 EP 459 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900315 ER PT J AU Apelo, SIA Neuman, JC Baar, EL Syed, FA Cummings, NE Brar, HK Pumper, CP Kimple, ME Lamming, DW AF Apelo, Sebastian I. Arriola Neuman, Joshua C. Baar, Emma L. Syed, Faizan A. Cummings, Nicole E. Brar, Harpreet K. Pumper, Cassidy P. Kimple, Michelle E. Lamming, Dudley W. TI Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system SO AGING CELL LA English DT Article DE aging; mechanistic target of rapamycin; mice; rapamycin ID MAMMALIAN LIFE-SPAN; INSULIN-RESISTANCE; T-CELLS; MICE; MTORC2; EXPRESSION; RICTOR; RESPONSES; QUALITY; TISSUE AB Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA-approved drug rapamycin has been shown to promote lifespan and delay age-related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucose intolerance and immunosuppression, which may preclude the long-term prophylactic use of rapamycin as a therapy for age-related diseases. While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin. We hypothesized that different rapamycin dosing schedules or the use of FDA-approved rapamycin analogs with different pharmacokinetics might expand the therapeutic window of rapamycin by more specifically targeting mTORC1. Here, we identified an intermittent rapamycin dosing schedule with minimal effects on glucose tolerance, and we find that this schedule has a reduced impact on pyruvate tolerance, fasting glucose and insulin levels, beta cell function, and the immune system compared to daily rapamycin treatment. Further, we find that the FDA-approved rapamycin analogs everolimus and temsirolimus efficiently inhibit mTORC1 while having a reduced impact on glucose and pyruvate tolerance. Our results suggest that many of the negative side effects of rapamycin treatment can be mitigated through intermittent dosing or the use of rapamycin analogs. C1 [Apelo, Sebastian I. Arriola; Baar, Emma L.; Syed, Faizan A.; Cummings, Nicole E.; Brar, Harpreet K.; Pumper, Cassidy P.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI USA. [Apelo, Sebastian I. Arriola; Neuman, Joshua C.; Baar, Emma L.; Syed, Faizan A.; Cummings, Nicole E.; Brar, Harpreet K.; Pumper, Cassidy P.; Kimple, Michelle E.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. [Neuman, Joshua C.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI USA. [Cummings, Nicole E.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI USA. [Lamming, Dudley W.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 FU National Institute of Health/National Institute on Aging [AG041765]; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Diabetes Association [1-14-BS-115]; NIH/NIDDK [R01 DK102598]; University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]; UW Institute on Aging [NIA T32 AG000213] FX The Lamming lab is supported by a K99/R00 Pathway to Independence Award to D.W.L. from the National Institute of Health/National Institute on Aging (AG041765), as well as startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. This work was also supported by grants from the American Diabetes Association (1-14-BS-115) and the NIH/NIDDK (R01 DK102598) to M.E.K. D.W.L. is a member of the UW-Carbone Cancer Center (UWCCC), and use of the UWCCC Flow Cytometry Laboratory, a Shared Service of the UWCCC, was supported in part by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520. J.C.N. is supported in part by a training grant from the UW Institute on Aging (NIA T32 AG000213). This work was supported using facilities and resources at the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 42 TC 6 Z9 6 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 28 EP 38 DI 10.1111/acel.12405 PG 11 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000004 ER PT J AU Martin, SA DeMuth, TM Miller, KN Pugh, TD Polewski, MA Colman, RJ Eliceiri, KW Beasley, TM Johnson, SC Anderson, RM AF Martin, Stephen A. DeMuth, Tyler M. Miller, Karl N. Pugh, Thomas D. Polewski, Michael A. Colman, Ricki J. Eliceiri, Kevin W. Beasley, Timothy Mark Johnson, Sterling C. Anderson, Rozalyn M. TI Regional metabolic heterogeneity of the hippocampus is nonuniformly impacted by age and caloric restriction SO AGING CELL LA English DT Article DE aging; metabolism; caloric restriction; hippocampus; mitochondria; neuroprotection ID GLYCOGEN-SYNTHASE KINASE-3; RHESUS-MONKEYS; ALZHEIMERS-DISEASE; OXIDATIVE-METABOLISM; ENERGY-METABOLISM; CELLS; FLUORESCENCE; NADH; PGC-1-ALPHA; BRAIN AB The hippocampus is critical for cognition and memory formation and is vulnerable to age-related atrophy and loss of function. These phenotypes are attenuated by caloric restriction (CR), a dietary intervention that delays aging. Here, we show significant regional effects in hippocampal energy metabolism that are responsive to age and CR, implicating metabolic pathways in neuronal protection. In situ mitochondrial cytochrome c oxidase activity was region specific and lower in aged mice, and the impact of age was region specific. Multiphoton laser scanning microscopy revealed region- and age-specific differences in nicotinamide adenine dinucleotide (NAD)-derived metabolic cofactors. Age-related changes in metabolic parameters were temporally separated, with early and late events in the metabolic response to age. There was a significant regional impact of age to lower levels of PGC-1 alpha, a master mitochondrial regulator. Rather than reversing the impact of age, CR induced a distinct metabolic state with decreased cytochrome c oxidase activity and increased levels of NAD(P) H. Levels of hippocampal PGC-1 alpha were lower with CR, as were levels of GSK3 beta, a key regulator of PGC-1 alpha turnover and activity. Regional distribution and colocalization of PGC-1 alpha and GSK3 beta in mouse hippocampus was similar in monkeys. Furthermore, the impact of CR to lower levels of both PGC-1 alpha and GSK3 beta was also conserved. The studies presented here establish the hippocampus as a highly varied metabolic environment, reveal cell-type and regional specificity in the metabolic response to age and delayed aging by CR, and suggest that PGC-1 alpha and GSK3 beta play a role in implementing the neuroprotective program induced by CR. C1 [Martin, Stephen A.; DeMuth, Tyler M.; Miller, Karl N.; Pugh, Thomas D.; Polewski, Michael A.; Johnson, Sterling C.; Anderson, Rozalyn M.] SMPH, Dept Med, Div Geriatr, Madison, WI 53705 USA. [Colman, Ricki J.] Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Eliceiri, Kevin W.] Univ Wisconsin, Lab Opt & Computat Instrumentat, Madison, WI 53706 USA. [Beasley, Timothy Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Beasley, Timothy Mark] Birmingham Atlanta Vet Adm Hosp, GRECC, Birmingham, AL 35294 USA. [Johnson, Sterling C.; Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. RP Anderson, RM (reprint author), William S Middleton VA Hosp, GRECC D5214,2500 Overlook Terrace, Madison, WI 53705 USA. EM rmanderson@medicine.wisc.edu FU NIH/NIA R01 [AG037000, AG043125]; ADRC [AG033514]; UW Institute on Aging [AG000213]; UW Department of Nutritional Sciences [DK007665] FX This work was supported by NIH/NIA R01 grants AG037000, AG043125, and ADRC grant AG033514. SAM and KNM are supported by T32 fellowships from the UW Institute on Aging AG000213 and the UW Department of Nutritional Sciences DK007665, respectively. The study was conducted with the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 47 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 100 EP 110 DI 10.1111/acel.12418 PG 11 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000011 PM 26521867 ER PT J AU Baar, EL Carbajal, KA Ong, IM Lamming, DW AF Baar, Emma L. Carbajal, Kathryn A. Ong, Irene M. Lamming, Dudley W. TI Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice SO AGING CELL LA English DT Article DE aging; mice; mTOR; mTORC1; mTORC2; rapamycin; sexual dimorphism ID LIFE-SPAN; CALORIC RESTRICTION; DIETARY RESTRICTION; S6 KINASE; RAPAMYCIN; LONGEVITY; EXPRESSION; RESVERATROL; SENSITIVITY; INHIBITION AB Inhibition of the mTOR (mechanistic Target Of Rapamycin) signaling pathway robustly extends the lifespan of model organisms including mice. The precise molecular mechanisms and physiological effects that underlie the beneficial effects of rapamycin are an exciting area of research. Surprisingly, while some data suggest that mTOR signaling normally increases with age in mice, the effect of age on mTOR signaling has never been comprehensively assessed. Here, we determine the age-associated changes in mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2) signaling in the liver, muscle, adipose, and heart of C57BL/6J. Nia mice, the lifespan of which can be extended by rapamycin treatment. We find that the effect of age on several different readouts of mTORC1 and mTORC2 activity varies by tissue and sex in C57BL/6J. Nia mice. Intriguingly, we observed increased mTORC1 activity in the liver and heart tissue of young female mice compared to male mice of the same age. Tissue and substrate-specific results were observed in the livers of HET3 and DBA/2 mouse strains, and in liver, muscle and adipose tissue of F344 rats. Our results demonstrate that aging does not result in increased mTOR signaling in most tissues and suggest that rapamycin does not promote lifespan by reversing or blunting such an effect. C1 [Baar, Emma L.; Carbajal, Kathryn A.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Baar, Emma L.; Carbajal, Kathryn A.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. [Ong, Irene M.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Ong, Irene M.; Lamming, Dudley W.] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu FU National Institute of Health/NIA [AG041765]; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; Research Supplement to Promote Diversity in Health-Related Research [AG041765-04S1]; University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]; Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX The Lamming lab is supported by a K99/R00 Pathway to Independence Award to DWL from the National Institute of Health/NIA (AG041765), as well as startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. KAC was supported in part by a Research Supplement to Promote Diversity in Health-Related Research (AG041765-04S1). IO is supported by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520 and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 45 TC 11 Z9 11 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 155 EP 166 DI 10.1111/acel.12425 PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000017 PM 26695882 ER PT J AU Chidi, AP Rogal, S Bryce, CL Fine, MJ Good, CB Myaskovsky, L Rustgi, VK Tsung, A Smith, KJ AF Chidi, Alexis P. Rogal, Shari Bryce, Cindy L. Fine, Michael J. Good, Chester B. Myaskovsky, Larissa Rustgi, Vinod K. Tsung, Allan Smith, Kenneth J. TI Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C SO HEPATOLOGY LA English DT Article ID GENOTYPE 1 INFECTION; UNITED-STATES VETERANS; ALL-CAUSE MORTALITY; VIRUS-INFECTION; CHRONIC HCV; COMPENSATED CIRRHOSIS; LIVER-TRANSPLANTATION; PEGYLATED INTERFERON; VIROLOGICAL RESPONSE; SOFOSBUVIR AB Recently approved, interferon-free medication regimens for treating hepatitis C are highly effective, but extremely costly. We aimed to identify cost-effective strategies for managing treatment-naive U.S. veterans with new hepatitis C medication regimens. We developed a Markov model with 1-year cycle length for a cohort of 60-year-old veterans with untreated genotype 1 hepatitis C seeking treatment in a typical year. We compared using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvir to treat: (1) any patient seeking treatment; (2) only patients with advanced fibrosis or cirrhosis; or (3) patients with advanced disease first and healthier patients 1 year later. The previous standard of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for comparison. Patients could develop progressive fibrosis, cirrhosis, or hepatocellular carcinoma, undergo transplantation, or die. Complications were less likely after sustained virological response. We calculated the incremental cost per quality-adjusted life year (QALY) and varied model inputs in one-way and probabilistic sensitivity analyses. We used the Veterans Health Administration perspective with a lifetime time horizon and 3% annual discounting. Treating any patient with ombitasvir-based therapy was the preferred strategy ($ 35,560; 14.0 QALYs). All other strategies were dominated (greater costs/QALY gained than more effective strategies). Varying treatment efficacy, price, and/or duration changed the preferred strategy. In probabilistic sensitivity analysis, treating any patient with ombitasvir-based therapy was cost-effective in 70% of iterations at a $ 50,000/QALY threshold and 65% of iterations at a $ 100,000/QALY threshold. Conclusion: Managing any treatment-naive genotype 1 hepatitis C patient with ombitasvir-based therapy is the most economically efficient strategy, although price and efficacy can impact cost-effectiveness. It is economically unfavorable to restrict treatment to patients with advanced disease or use a staged treatment strategy. C1 [Chidi, Alexis P.; Rogal, Shari; Bryce, Cindy L.; Fine, Michael J.; Good, Chester B.; Myaskovsky, Larissa; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, 3471 Fifth Ave,Suite 300, Pittsburgh, PA 15213 USA. [Chidi, Alexis P.; Rogal, Shari; Fine, Michael J.; Good, Chester B.; Myaskovsky, Larissa; Smith, Kenneth J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Chidi, Alexis P.; Tsung, Allan] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Bryce, Cindy L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Good, Chester B.] US Dept Vet Affairs, VA Ctr Medicat Safety, Hines, IL USA. [Rustgi, Vinod K.] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. RP Chidi, AP (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 3471 Fifth Ave,Suite 300, Pittsburgh, PA 15213 USA. EM apc10@pitt.edu OI Bryce, Cindy/0000-0001-6356-6675 FU National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR000145] FX AC was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR000145. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the VA Healthcare Systems. NR 56 TC 7 Z9 7 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD FEB PY 2016 VL 63 IS 2 BP 428 EP 436 DI 10.1002/hep.28327/suppinfo PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DI1ZZ UT WOS:000373296800001 PM 26524695 ER PT J AU Bachhuber, MA Maughan, BC Mitra, N Feingold, J Starrels, JL AF Bachhuber, Marcus A. Maughan, Brandon C. Mitra, Nandita Feingold, Jordyn Starrels, Joanna L. TI Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas SO INTERNATIONAL JOURNAL OF DRUG POLICY LA English DT Article DE Benzodiazepines; Prescription drug misuse; Health policy; Public policy; Public health ID PHARMACOLOGICAL-TREATMENT; OPIOID ANALGESICS; ABUSE; DISORDERS; ANXIETY; ASSOCIATION; GUIDELINES; IMPACT AB Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95% CI:-0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95% CI: 0.2-1.5]; p = 0.011), but not in year two (0.3 [95% CI: 2.1-2.81; p = 0.78) or year three or later (2.1 [95% CI: 0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety. Published by Elsevier B.V. C1 [Bachhuber, Marcus A.; Maughan, Brandon C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bachhuber, Marcus A.; Maughan, Brandon C.; Mitra, Nandita] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.; Maughan, Brandon C.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Feingold, Jordyn] Univ Penn, Philadelphia, PA 19104 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. RP Bachhuber, MA (reprint author), 1303-A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM marcus.bachhuber@gmail.com; bmaughan@gmail.com; nanditam@mail.med.upenn.edu; jordyn.feingold@gmail.com; jostarre@montefiore.org OI Bachhuber, Marcus/0000-0002-5610-8382 FU National Institute on Drug Abuse [K23DA027719]; Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania FX This study was supported by funding from the National Institute on Drug Abuse (K23DA027719) and a Matt Slap Pilot Research Award from the Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania. The funding bodies had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 32 TC 3 Z9 3 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0955-3959 EI 1873-4758 J9 INT J DRUG POLICY JI Int. J. Drug Policy PD FEB PY 2016 VL 28 BP 120 EP 123 DI 10.1016/j.drugpo.2015.08.005 PG 4 WC Substance Abuse SC Substance Abuse GA DH3LJ UT WOS:000372688200015 PM 26345658 ER PT J AU Kasckow, J Youk, A Anderson, SJ Dew, MA Butters, MA Marron, MM Begley, AE Szanto, K Dombrovski, AY Mulsant, BH Lenze, EJ Reynolds, CF AF Kasckow, John Youk, Ada Anderson, Stewart J. Dew, Mary Amanda Butters, Meryl A. Marron, Megan M. Begley, Amy E. Szanto, Katalin Dombrovski, Alexander Y. Mulsant, Benoit H. Lenze, Eric J. Reynolds, Charles F., III TI Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Suicide; Trajectory; Antidepressant; Depression; Late life ID NEUROPSYCHOLOGICAL STATUS; PSYCHIATRIC OUTPATIENTS; REPEATABLE BATTERY; SAS PROCEDURE; RISK-FACTORS; ATTEMPTERS; SCALE; BEHAVIOR AB Suicide is a public health concern in older adults. Recent cross sectional studies suggest that impairments in executive functioning, memory and attention are associated with suicidal ideation in older adults. It is unknown whether these neuropsychological features predict persistent suicidal ideation. We analyzed data from 468 individuals >= age 60 with major depression who received venlafaxine XR monotherapy for up to 16 weeks. We used latent class growth modeling to classify groups of individuals based on trajectories of suicidal ideation. We also examined whether cognitive dysfunction predicted suicidal ideation while controlling for time-dependent variables including depression severity, and age and education. The optimal model using a zero inflated Poisson link classified individuals into four groups, each with a distinct temporal trajectory of suicidal ideation: those with 'minimal suicidal ideation' across time points; those with 'low suicidal ideation'; those with 'rapidly decreasing suicidal ideation'; and those with 'high and persistent suicidal ideation'. Participants in the 'high and persistent suicidal ideation' group had worse scores relative to those in the "rapidly decreasing suicidal ideation" group on the Color-Word 'inhibition/switching' subtest from the Delis-Kaplan Executive Function Scale, worse attention index scores on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and worse total RBANS index scores. These findings suggest that individuals with poorer ability to switch between inhibitory and non-inhibitory responses as well as worse attention and worse overall cognitive status are more likely to have persistently higher levels of suicidal ideation. Clinicaltrial.gov number: NCF00892047. Published by Elsevier Ltd. C1 [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, Behav Hlth, Pittsburgh, PA 15240 USA. [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA 15240 USA. [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, CHERP, Pittsburgh, PA 15240 USA. [Kasckow, John; Dew, Mary Amanda; Butters, Meryl A.; Begley, Amy E.; Szanto, Katalin; Dombrovski, Alexander Y.; Mulsant, Benoit H.; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Kasckow, John; Youk, Ada; Anderson, Stewart J.; Dew, Mary Amanda] Univ Pittsburgh, Grad Sch Publ Hlth, Biostat, Pittsburgh, PA 15213 USA. [Dew, Mary Amanda; Marron, Megan M.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol, Pittsburgh, PA 15213 USA. [Mulsant, Benoit H.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Mulsant, Benoit H.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lenze, Eric J.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Kasckow, J (reprint author), Univ DR C, VA Pittsburgh Hlth Care Syst, Behav Hlth, Pittsburgh, PA 15240 USA. EM kasckowjw@upmc.edu OI Youk, Ada/0000-0001-6912-9759 FU NIH [R01-MH083660, P30 MH090333]; UPMC Endowment in Geriatric Psychiatry; Taylor Family Institute for Innovative Psychiatric Research; National Center for Advancing Translational Sciences; Campbell Family Mental Health Research Institute FX Supported by NIH grant R01-MH083660, P30 MH090333, the UPMC Endowment in Geriatric Psychiatry, Taylor Family Institute for Innovative Psychiatric Research, National Center for Advancing Translational Sciences and the Campbell Family Mental Health Research Institute. NR 40 TC 1 Z9 1 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2016 VL 73 BP 96 EP 101 DI 10.1016/j.jpsychires.2015.11.004 PG 6 WC Psychiatry SC Psychiatry GA DI1JD UT WOS:000373251500012 PM 26708830 ER PT J AU Sacks, GD Lawson, EH Dawes, AJ Weiss, RE Russell, MM Brook, RH Zingmond, DS Ko, CY AF Sacks, Greg D. Lawson, Elise H. Dawes, Aaron J. Weiss, Robert E. Russell, Marcia M. Brook, Robert H. Zingmond, David S. Ko, Clifford Y. TI Variation in Hospital Use of Postacute Care After Surgery and the Association With Care Quality SO MEDICAL CARE LA English DT Article DE hospital quality; variation in care; care coordination; surgery; post-acute care ID POST-ACUTE CARE; GEOGRAPHIC-VARIATION; SURGICAL QUALITY; HEALTH-CARE; IMPROVEMENT PROGRAM; AMERICAN-COLLEGE; MEDICARE; DISCHARGE; REHABILITATION; PREFERENCES AB Background: Little is known about hospital use of postacute care after surgery and whether it is related to measures of surgical quality. Research Design: We used data merged between a national surgery registry, Medicare inpatient claims, the Area Resource File, and the American Hospital Association Annual Survey (2005-2008). Using bivariate and multivariate analyses, we calculated hospital-level, risk-adjusted rates of postacute care use for both inpatient facilities (IF) and home health care (HHC), and examined the association of these rates with hospital quality measures, including mortality, complications, readmissions, and length of stay. Results: Of 112,620 patients treated at 217 hospitals, 18.6% were discharged to an IF, and 19.9% were discharged with HHC. Even after adjusting for differences in patient and hospital characteristics, hospitals varied widely in their use of both IF (mean, 20.3%; range, 2.7%-39.7%) and HHC (mean, 22.3%; range, 3.1%-57.8%). A hospital's risk-adjusted postoperative mortality rate or complication rate was not significantly associated with its use of postacute care, but higher 30-day readmission rates were associated with higher use of IF (24.1% vs. 21.2%, P=0.03). Hospitals with longer average length of stay used IF less frequently (19.4% vs. 24.4%, P < 0.01). Conclusions: Hospitals vary widely in their use of postacute care. Although hospital use of postacute care was not associated with risk-adjusted complication or mortality rates, hospitals with high readmission rates and shorter lengths of stay used inpatient postacute care more frequently. To reduce variations in care, better criteria are needed to identify which patients benefit most from these services. C1 [Sacks, Greg D.; Lawson, Elise H.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Weiss, Robert E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. [Brook, Robert H.; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 NR 34 TC 1 Z9 1 U1 5 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2016 VL 54 IS 2 BP 172 EP 179 DI 10.1097/MLR.0000000000000463 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XI UT WOS:000372935000010 PM 26595222 ER PT J AU Sada, Y Hou, J Richardson, P El-Serag, H Davila, J AF Sada, Yvonne Hou, Jason Richardson, Peter El-Serag, Hashem Davila, Jessica TI Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing SO MEDICAL CARE LA English DT Article DE hepatocellular cancer; natural language processing; pathology; radiology ID UNITED-STATES; CARCINOMA; VETERANS; SYSTEM AB Background:Accurate identification of hepatocellular cancer (HCC) cases from automated data is needed for efficient and valid quality improvement initiatives and research. We validated HCC International Classification of Diseases, 9th Revision (ICD-9) codes, and evaluated whether natural language processing by the Automated Retrieval Console (ARC) for document classification improves HCC identification.Methods:We identified a cohort of patients with ICD-9 codes for HCC during 2005-2010 from Veterans Affairs administrative data. Pathology and radiology reports were reviewed to confirm HCC. The positive predictive value (PPV), sensitivity, and specificity of ICD-9 codes were calculated. A split validation study of pathology and radiology reports was performed to develop and validate ARC algorithms. Reports were manually classified as diagnostic of HCC or not. ARC generated document classification algorithms using the Clinical Text Analysis and Knowledge Extraction System. ARC performance was compared with manual classification. PPV, sensitivity, and specificity of ARC were calculated.Results:A total of 1138 patients with HCC were identified by ICD-9 codes. On the basis of manual review, 773 had HCC. The HCC ICD-9 code algorithm had a PPV of 0.67, sensitivity of 0.95, and specificity of 0.93. For a random subset of 619 patients, we identified 471 pathology reports for 323 patients and 943 radiology reports for 557 patients. The pathology ARC algorithm had PPV of 0.96, sensitivity of 0.96, and specificity of 0.97. The radiology ARC algorithm had PPV of 0.75, sensitivity of 0.94, and specificity of 0.68.Conclusions:A combined approach of ICD-9 codes and natural language processing of pathology and radiology reports improves HCC case identification in automated data. C1 [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Baylor Coll Med, Houston, TX 77030 USA. [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Baylor Coll Med, Hlth Serv Res & Dev Sect, Houston, TX 77030 USA. [Sada, Yvonne] Baylor Coll Med, Dept Oncol, Houston, TX 77030 USA. [Hou, Jason; El-Serag, Hashem] Baylor Coll Med, Dept Gastroenterol, Houston, TX 77030 USA. RP Sada, Y (reprint author), Michael E DeBakey Vet Adm Med Ctr, HSR&D Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM yhlam@bcm.edu FU National Cancer Institute [R01 CA160738]; Michael E. DeBakey Veterans Affairs Medical Center; Dan Duncan Cancer Center, Houston, TX FX Supported in part by the National Cancer Institute (R01 CA160738, PI: J.D.), the facilities and resources of the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020), Michael E. DeBakey Veterans Affairs Medical Center, and the Dan Duncan Cancer Center, Houston, TX. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veteran Affairs. NR 14 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2016 VL 54 IS 2 BP E9 EP E14 DI 10.1097/MLR.0b013e3182a30373 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XJ UT WOS:000372935100001 PM 23929403 ER PT J AU Fouts, DE Matthias, MA Adhikarla, H Adler, B Amorim-Santos, L Berg, DE Bulach, D Buschiazzo, A Chang, YF Galloway, RL Haake, DA Haft, DH Hartskeerl, R Ko, AI Levett, PN Matsunaga, J Mechaly, AE Monk, JM Nascimento, ALT Nelson, KE Palsson, B Peacock, SJ Picardeau, M Ricaldi, JN Thaipandungpanit, J Wunder, EA Yang, XF Zhang, JJ Vinetz, JM AF Fouts, Derrick E. Matthias, Michael A. Adhikarla, Haritha Adler, Ben Amorim-Santos, Luciane Berg, Douglas E. Bulach, Dieter Buschiazzo, Alejandro Chang, Yung-Fu Galloway, Renee L. Haake, David A. Haft, Daniel H. Hartskeerl, Rudy Ko, Albert I. Levett, Paul N. Matsunaga, James Mechaly, Ariel E. Monk, Jonathan M. Nascimento, Ana L. T. Nelson, Karen E. Palsson, Bernhard Peacock, Sharon J. Picardeau, Mathieu Ricaldi, Jessica N. Thaipandungpanit, Janjira Wunder, Elsio A., Jr. Yang, X. Frank Zhang, Jun-Jie Vinetz, Joseph M. TI What Makes a Bacterial Species Pathogenic?: Comparative Genomic Analysis of the Genus Leptospira SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID COMPLEMENT REGULATOR C4BP; FAINEI SEROVAR HURSTBRIDGE; VIRULENCE-ASSOCIATED GENES; OUTER-MEMBRANE PROTEINS; LPS BIOSYNTHETIC LOCI; DNA-DNA HYBRIDIZATION; SIGNAL PEPTIDASE-II; L-GLUTAMATE OXIDASE; ESCHERICHIA-COLI; BORRELIA-BURGDORFERI AB Leptospirosis, caused by spirochetes of the genus Leptospira, is a globally widespread, neglected and emerging zoonotic disease. While whole genome analysis of individual pathogenic, intermediately pathogenic and saprophytic Leptospira species has been reported, comprehensive cross-species genomic comparison of all known species of infectious and non-infectious Leptospira, with the goal of identifying genes related to pathogenesis and mammalian host adaptation, remains a key gap in the field. Infectious Leptospira, comprised of pathogenic and intermediately pathogenic Leptospira, evolutionarily diverged from non-infectious, saprophytic Leptospira, as demonstrated by the following computational biology analyses: 1) the definitive taxonomy and evolutionary relatedness among all known Leptospira species; 2) genomically-predicted metabolic reconstructions that indicate novel adaptation of infectious Leptospira to mammals, including sialic acid biosynthesis, pathogen-specific porphyrin metabolism and the first-time demonstration of cobalamin (B12) autotrophy as a bacterial virulence factor; 3) CRISPR/Cas systems demonstrated only to be present in pathogenic Leptospira, suggesting a potential mechanism for this clade's refractoriness to gene targeting; 4) finding Leptospira pathogen-specific specialized protein secretion systems; 5) novel virulence-related genes/gene families such as the Virulence Modifying (VM) (PF07598 paralogs) proteins and pathogen-specific adhesins; 6) discovery of novel, pathogen-specific protein modification and secretion mechanisms including unique lipoprotein signal peptide motifs, Sec-independent twin arginine protein secretion motifs, and the absence of certain canonical signal recognition particle proteins from all Leptospira; and 7) and demonstration of infectious Leptospira-specific signal-responsive gene expression, motility and chemotaxis systems. By identifying large scale changes in infectious (pathogenic and intermediately pathogenic) vs. non-infectious Leptospira, this work provides new insights into the evolution of a genus of bacterial pathogens. This work will be a comprehensive roadmap for understanding leptospirosis pathogenesis. More generally, it provides new insights into mechanisms by which bacterial pathogens adapt to mammalian hosts. C1 [Fouts, Derrick E.; Haft, Daniel H.; Nelson, Karen E.] J Craig Venter Inst, Rockville, MD USA. [Matthias, Michael A.; Berg, Douglas E.; Vinetz, Joseph M.] Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA. [Adhikarla, Haritha; Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Adler, Ben] Monash Univ, Dept Microbiol, Australian Res Council, Ctr Excellence Struct & Funct Microbial Gen, Clayton, Vic 3168, Australia. [Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Fundacao Oswaldo Cruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil. [Bulach, Dieter] Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic, Australia. [Buschiazzo, Alejandro; Mechaly, Ariel E.] Inst Pasteur, Lab Mol & Struct Microbiol, Montevideo, Uruguay. [Buschiazzo, Alejandro] Inst Pasteur, Dept Struct Biol & Chem, Paris, France. [Chang, Yung-Fu] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA. [Galloway, Renee L.] Ctr Dis Control & Prevent, BSPB, DHCPP, NCEZID,OID,CDC,DHHS, Atlanta, GA USA. [Haake, David A.; Matsunaga, James] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hartskeerl, Rudy] Royal Trop Inst KIT, WHO FAO OIE, Amsterdam, Netherlands. [Hartskeerl, Rudy] Royal Trop Inst KIT, Natl Collaborating Ctr Reference & Res Leptospiro, KIT Biomed Res, Amsterdam, Netherlands. [Levett, Paul N.] Govt Saskatchewan, Dis Control Lab Regina, Saskatoon, SK, Canada. [Monk, Jonathan M.; Palsson, Bernhard] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA. [Nascimento, Ana L. T.] Inst Butantan, Ctr Biotecnol, Sao Paulo, SP, Brazil. [Nascimento, Ana L. T.] Univ Sao Paulo, Programa Interunidades Biotecnol, Inst Ciencias Biomed, Sao Paulo, SP, Brazil. [Peacock, Sharon J.] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England. [Picardeau, Mathieu] Inst Pasteur, Biol Spirochetes Unit, Natl Reference Ctr, Paris, France. [Picardeau, Mathieu] WHO Collaborating Ctr Leptospirosis, Paris, France. [Ricaldi, Jessica N.; Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru. [Thaipandungpanit, Janjira] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. [Yang, X. Frank; Zhang, Jun-Jie] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. [Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. RP Fouts, DE (reprint author), J Craig Venter Inst, Rockville, MD USA.; Fouts, DE; Vinetz, JM (reprint author), Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. EM dfouts@jcvi.org; jvinetz@ucsd.edu RI Ko, Albert/P-2343-2015; Wunder, Elsio/C-2733-2013; zhang, junjie/P-2376-2015 OI Ko, Albert/0000-0001-9023-2339; zhang, junjie/0000-0002-5108-2072; Nascimento, Ana Lucia /0000-0003-4851-0870; Mechaly, Ariel/0000-0002-5305-7495 FU federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C]; U.S. Public Health Service [U19AI115658, R01AI108276, D43TW007120, K24AI068903, R21AI115273, R01AI052473, R25TW009338, U01AI088752, R01TW009504, R01AI121207]; ANII (Uruguay) [FSA_1_2013_1_12557, ALI_1_2014_1_4982] FX This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract Number HHSN272200900007C. This work was also supported in part by the following U.S. Public Health Service grants: U19AI115658 (JMV), R01AI108276 (JMV), D43TW007120 (JMV), K24AI068903 (JMV), R21AI115273 (MAM), R01AI052473 (AIK), U01AI088752 (AIK), R25TW009338 (AIK), R01TW009504 (AIK), and R01AI121207 (AIK). In addition, support to the A. Buschiazzo team was provided in part by grants FSA_1_2013_1_12557 and ALI_1_2014_1_4982 from ANII (Uruguay). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 214 TC 13 Z9 13 U1 8 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004403 DI 10.1371/journal.pntd.0004403 PG 57 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300024 PM 26890609 ER PT J AU Aghagolzadeh, M Truccolo, W AF Aghagolzadeh, Mehdi Truccolo, Wilson TI Inference and Decoding of Motor Cortex Low-Dimensional Dynamics via Latent State-Space Models SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Brain-machine interfaces (BMI); collective dynamics; neural encoding; point processes ID NEURAL POPULATION-DYNAMICS; GRASP; REACH; VARIABILITY AB Motor cortex neuronal ensemble spiking activity exhibits strong low-dimensional collective dynamics (i.e., coordinated modes of activity) during behavior. Here, we demonstrate that these low-dimensional dynamics, revealed by unsupervised latent state-space models, can provide as accurate or better reconstruction of movement kinematics as direct decoding from the entire recorded ensemble. Ensembles of single neurons were recorded with triple microelectrode arrays (MEAs) implanted in ventral and dorsal premotor (PMv, PMd) and primary motor (M1) cortices while nonhuman primates performed 3-D reach-to-grasp actions. Low-dimensional dynamics were estimated via various types of latent state-space models including, for example, Poisson linear dynamic system (PLDS) models. Decoding from low-dimensional dynamics was implemented via point process and Kalman filters coupled in series. We also examined decoding based on a predictive subsampling of the recorded population. In this case, a supervised greedy procedure selected neuronal subsets that optimized decoding performance. When comparing decoding based on predictive subsampling and latent state-space models, the size of the neuronal subset was set to the same number of latent state dimensions. Overall, our findings suggest that information about naturalistic reach kinematics present in the recorded population is preserved in the inferred low-dimensional motor cortex dynamics. Furthermore, decoding based on unsupervised PLDS models may also outperform previous approaches based on direct decoding from the recorded population or on predictive subsampling. C1 [Aghagolzadeh, Mehdi; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02912 USA. RP Aghagolzadeh, M; Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.; Truccolo, W (reprint author), Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.; Truccolo, W (reprint author), US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02912 USA. EM Mehdi_Aghagolzadeh@Brown.edu; Wilson_Truccolo@Brown.edu FU National Institute of Neurological Disorders and Stroke (NINDS) [NS057389, R01 NS25074]; Defense Advanced Research Projects Agency [DARPA REPAIR N66001-10-C-2010]; Pablo J. Salame'88 Goldman Sachs endowed Assistant Professorship in Computational Neuroscience FX This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS), K01 Career Award NS057389 and R01 NS25074, by the Defense Advanced Research Projects Agency (DARPA REPAIR N66001-10-C-2010), and by the Pablo J. Salame'88 Goldman Sachs endowed Assistant Professorship in Computational Neuroscience. NR 28 TC 4 Z9 4 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD FEB PY 2016 VL 24 IS 2 BP 272 EP 282 DI 10.1109/TNSRE.2015.2470527 PG 11 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA DG4FP UT WOS:000372027300008 PM 26336135 ER PT J AU Schoenfeld, AJ Grady, D AF Schoenfeld, Adam Jacob Grady, Deborah TI Adverse Effects Associated With Proton Pump Inhibitors SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID METAANALYSIS; IMPACT; RISK C1 [Schoenfeld, Adam Jacob; Grady, Deborah] Univ Calif San Francisco, 3333 Calif St,Ste 265,POB 0936, San Francisco, CA 94118 USA. [Grady, Deborah] San Francisco VA Med Ctr, Med, San Francisco, CA USA. RP Schoenfeld, AJ (reprint author), Univ Calif San Francisco, 3333 Calif St,Ste 265,POB 0936, San Francisco, CA 94118 USA. EM Adam.Schoenfeld@ucsf.edu NR 12 TC 13 Z9 14 U1 4 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 172 EP 174 DI 10.1001/jamainternmed.2015.7927 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600007 PM 26751904 ER PT J AU Wong, SPY Vig, EK Taylor, JS Burrows, NR Liu, CF Williams, DE Hebert, PL O'Hare, AM AF Wong, Susan P. Y. Vig, Elizabeth K. Taylor, Janelle S. Burrows, Nilka R. Liu, Chuan-Fen Williams, Desmond E. Hebert, Paul L. O'Hare, Ann M. TI Timing of Initiation of Maintenance Dialysis A Qualitative Analysis of the Electronic Medical Records of a National Cohort of Patients From the Department of Veterans Affairs SO JAMA INTERNAL MEDICINE LA English DT Article ID DECISION-MAKING; HEALTH-CARE; KIDNEY-DISEASE; SURVIVAL; COMORBIDITY; MORTALITY; HARMFUL; TRENDS; START; AGE AB IMPORTANCE There is often considerable uncertainty about the optimal time to initiate maintenance dialysis in individual patients and little medical evidence to guide this decision. OBJECTIVE To gain a better understanding of the factors influencing the timing of initiation of dialysis in clinical practice. DESIGN, SETTING, AND PARTICIPANTS A qualitative analysis was conducted using the electronic medical records from the Department of Veterans Affairs (VA) of a national random sample of 1691 patients for whom the decision to initiate maintenance dialysis occurred in the VA between January 1, 2000, and December 31, 2009. Data analysis took place from June 1 to November 30, 2014. MAIN OUTCOMES AND MEASURES Central themes related to the timing of initiation of dialysis as documented in patients' electronic medical records. RESULTS Of the 1691 patients, 1264 (74.7%) initiated dialysis as inpatients and 1228 (72.6%) initiated dialysis with a hemodialysis catheter. Cohort members met with a nephrologist during an outpatient clinic visit a median of 3 times (interquartile range, 0-6) in the year prior to initiation of dialysis. The mean (SD) estimated glomerular filtration rate at the time of initiation for cohort members was 10.4 (5.7) mL/min/1.73m(2). The timing of initiation of dialysis reflected the complex interplay of at least 3 interrelated and dynamic processes. The first was physician practices, which ranged from practices intended to prepare patients for dialysis to those intended to forestall the need for dialysis by managing the signs and symptoms of uremia with medical interventions. The second process was sources of momentum. Initiation of dialysis was often precipitated by clinical events involving acute illness or medical procedures. In these settings, the imperative to treat often seemed to override patient choice. The third process was patient-physician dynamics. Interactions between patients and physicians were sometimes adversarial, and physician recommendations to initiate dialysis sometimes seemed to conflict with patient priorities. CONCLUSIONS AND RELEVANCE The initiation of maintenance dialysis reflects the care practices of individual physicians, sources of momentum for initiation of dialysis, interactions between patients and physicians, and the complex interplay of these dynamic processes over time. Our findings suggest opportunities to improve communication between patients and physicians and to better align these processes with patients' values, goals, and preferences. C1 [Wong, Susan P. Y.; Vig, Elizabeth K.; O'Hare, Ann M.] Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. [Vig, Elizabeth K.; O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. [Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Burrows, Nilka R.] Ctr Dis Control & Prevent, Chron Kidney Dis Initiat, Div Diabet Translat, Atlanta, GA USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Innovat, Washington, DC USA. [Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Williams, Desmond E.] Ctr Dis Control & Prevent, Liberia Country Off, Div Global Hlth Protect, Atlanta, GA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU United States Department of Veterans Affairs [VA IIR 09-094]; VA Puget Sound Healthcare System [IAA 15FED1505101-0001]; Centers for Disease Control and Prevention [IAA 15FED1505101-0001]; Clinical Scientist in Nephrology Fellowship from the American Kidney Fund; Department of Veterans Affairs Health Services Research and Development Service; National Institutes of Health FX This study was supported by grant VA IIR 09-094 from the United States Department of Veterans Affairs and by Interagency Agreement IAA 15FED1505101-0001 between the VA Puget Sound Healthcare System and the Centers for Disease Control and Prevention. Dr Wong is supported by the Clinical Scientist in Nephrology Fellowship from the American Kidney Fund. Drs O'Hare, Hebert, and Liu reported having received research funding from the Department of Veterans Affairs Health Services Research and Development Service. Dr O'Hare also reported having received research funding from the National Institutes of Health and an honorarium from the American Society of Nephrology. NR 36 TC 9 Z9 9 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 228 EP 235 DI 10.1001/jamainternmed.2015.7412 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600017 PM 26809745 ER PT J AU Good, CB McConnell, M Downs, JR AF Good, Chester B. McConnell, Mark Downs, John R. TI Finding the Balance of Less Is More SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Good, Chester B.] Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Med, Pittsburgh, PA USA. [McConnell, Mark] Oscar G Johnson Vet Affairs Med Clin, Primary Care, Iron Mt, MI USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Med, San Antonio, TX 78229 USA. RP Good, CB (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Med, Univ Dr C, Pittsburgh, PA 15240 USA. EM chester.good@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 282 EP 283 DI 10.1001/jamainternmed.2015.8089 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600045 PM 26830244 ER PT J AU Harris, JP Struzyna, LA Murphy, PL Adewole, DO Kuo, E Cullen, DK AF Harris, J. P. Struzyna, L. A. Murphy, P. L. Adewole, D. O. Kuo, E. Cullen, D. K. TI Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain SO JOURNAL OF NEURAL ENGINEERING LA English DT Article DE neurotransplantation; transplantation; bioengineering; cell replacement; axonal tracts; tissue engineering; biomaterials ID LONG-TERM SURVIVAL; STEM-CELL TRANSPLANTATION; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; IN-VITRO; CARBOXYMETHYL CELLULOSE; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; CHONDROITINASE ABC; NEURITE OUTGROWTH AB Objective. Connectome disruption is a hallmark of many neurological diseases and trauma with no current strategies to restore lost long-distance axonal pathways in the brain. We are creating transplantable micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of embedded neurons and long axonal tracts to integrate with the nervous system to physically reconstitute lost axonal pathways. Approach. We advanced micro-tissue engineering techniques to generate micro-TENNs consisting of discrete populations of mature primary cerebral cortical neurons spanned by long axonal fascicles encased in miniature hydrogel micro-columns. Further, we improved the biomaterial encasement scheme by adding a thin layer of low viscosity carboxymethylcellulose (CMC) to enable needle-less insertion and rapid softening for mechanical similarity with brain tissue. Main results. The engineered architecture of cortical micro-TENNs facilitated robust neuronal viability and axonal cytoarchitecture to at least 22 days in vitro. Micro-TENNs displayed discrete neuronal populations spanned by long axonal fasciculation throughout the core, thus mimicking the general systems-level anatomy of gray matter-white matter in the brain. Additionally, micro-columns with thin CMC-coating upon mild dehydration were able to withstand a force of 893 +/- 457 mN before buckling, whereas a solid agarose cylinder of similar dimensions was predicted to withstand less than 150 mu N of force. This thin CMC coating increased the stiffness by three orders of magnitude, enabling needle-less insertion into brain while significantly reducing the footprint of previous needle-based delivery methods to minimize insertion trauma. Significance. Our novel micro-TENNs are the first strategy designed for minimally invasive implantation to facilitate nervous system repair by simultaneously providing neuronal replacement and physical reconstruction of long-distance axon pathways in the brain. The micro-TENN approach may offer the ability to treat several disorders that disrupt the connectome, including Parkinson's disease, traumatic brain injury, stroke, and brain tumor excision. C1 [Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA. [Harris, J. P.; Struzyna, L. A.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Struzyna, L. A.; Adewole, D. O.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Cullen, DK (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM dkacy@mail.med.upenn.edu FU Penn Medicine Neuroscience Center; National Science Foundation [DGE-1321851]; National Institutes of Health [T32-NS043126, T32-GM007517]; Department of Veterans Affairs (RRD Merit Review) [B1097-I]; US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207 004] FX Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126 & T32-GM007517), Department of Veterans Affairs (RR&D Merit Review #B1097-I), and the US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207 004). The authors would like to thank Rob Mauck and Mike Hast in the Penn Center for Musculoskeletal Disorders Core for help in mechanical testing. Additional thanks go to Vincent Wu, Norma Alexis Brown, Alan He, Camila Robles-Oteiza, and Parker Schabel for technical contributions. NR 83 TC 2 Z9 3 U1 5 U2 24 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 EI 1741-2552 J9 J NEURAL ENG JI J. Neural Eng. PD FEB PY 2016 VL 13 IS 1 AR 016019 DI 10.1088/1741-2560/13/1/016019 PG 19 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA DF7XD UT WOS:000371570200020 PM 26760138 ER PT J AU Ly, M Adluru, N Destiche, DJ Lu, SY Oh, JM Hoscheidt, SM Alexander, AL Okonkwo, OC Rowley, HA Sager, MA Johnson, SC Bendlin, BB AF Ly, Martina Adluru, Nagesh Destiche, Daniel J. Lu, Sharon Y. Oh, Jennifer M. Hoscheidt, Siobhan M. Alexander, Andrew L. Okonkwo, Ozioma C. Rowley, Howard A. Sager, Mark A. Johnson, Sterling C. Bendlin, Barbara B. TI Fornix Microstructure and Memory Performance Is Associated with Altered Neural Connectivity during Episodic Recognition SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Aging; Task-related functional connectivity; fMRI; gPPI; Fractional anisotropy; Episodic recognition ID WHITE-MATTER MICROSTRUCTURE; AGE-RELATED DIFFERENCES; ALZHEIMERS-DISEASE; FUNCTIONAL CONNECTIVITY; ENTORHINAL CORTEX; WORKING-MEMORY; OLDER-ADULTS; PREFRONTAL CORTEX; COGNITIVE DECLINE; BRAIN ACTIVITY AB Objectives: The purpose of this study was to assess whether age-related differences in white matter microstructure are associated with altered task-related connectivity during episodic recognition. Methods: Using functional magnetic resonance imaging and diffusion tensor imaging from 282 cognitively healthy middle-to-late aged adults enrolled in the Wisconsin Registry for Alzheimer's Prevention, we investigated whether fractional anisotropy (FA) within white matter regions known to decline with age was associated with task-related connectivity within the recognition network. Results: There was a positive relationship between fornix FA and memory performance, both of which negatively correlated with age. Psychophysiological interaction analyses revealed that higher fornix FA was associated with increased task-related connectivity amongst the hippocampus, caudate, precuneus, middle occipital gyrus, and middle frontal gyrus. In addition, better task performance was associated with increased task-related connectivity between the posterior cingulate gyrus, middle frontal gyrus, cuneus, and hippocampus. Conclusions: The findings indicate that age has a negative effect on white matter microstructure, which in turn has a negative impact on memory performance. However, fornix microstructure did not significantly mediate the effect of age on performance. Of interest, dynamic functional connectivity was associated with better memory performance. The results of the psychophysiological interaction analysis further revealed that alterations in fornix microstructure explain-at least in part-connectivity among cortical regions in the recognition memory network. Our results may further elucidate the relationship between structural connectivity, neural function, and cognition. C1 [Ly, Martina; Oh, Jennifer M.; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Ly, Martina; Oh, Jennifer M.; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Rowley, Howard A.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Ly, Martina; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Ly, Martina] Univ Wisconsin, Neurosci Training Program, Madison, WI 53792 USA. [Ly, Martina; Adluru, Nagesh; Destiche, Daniel J.; Lu, Sharon Y.; Alexander, Andrew L.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA.; Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU National Institutes of Health [R01 AG037639, R01 AG027161, ADRC P50 AG033514, R01 AG021155, T32 GM007507, T32 AG000213]; Veterans Administration Merit Review Grant [I01CX000165]; Waisman Center Core Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [P30 HD003352-45] FX This work was supported by the National Institutes of Health (B.B.B., R01 AG037639), (S.C.J., R01 AG027161), (ADRC P50 AG033514), (S.C.J., R01 AG021155), (T32 GM007507), (T32 AG000213); Veterans Administration Merit Review Grant (S.C.J., I01CX000165); and the Waisman Center Core Grant (P30 HD003352-45) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The project was also facilitated by the facilities and resources at the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI. The authors gratefully acknowledge Nancy Davenport, Amy Hawley, Sandra Harding, Caitlin Cleary, Jay Fruehling, Chuck Illingworth, and the support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where imaging data were collected. Above all, we thank our dedicated volunteers for their participation in this research. Ly, Adluru, Destiche, Lu, Oh, Hoscheidt, Okonkwo, Sager, Johnson, and Bendlin report no conflicts of interest. Rowley has provided consultation to and/or received honoraria from GE Healthcare, Bracco, Lundbeck, HL Gore, and Eli Lilly. Alexander is part owner and Chief Operating Officer of inSERT, Inc. NR 89 TC 0 Z9 0 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD FEB PY 2016 VL 22 IS 2 SI SI BP 191 EP 204 DI 10.1017/S1355617715001216 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA DF8TE UT WOS:000371631200007 PM 26888616 ER PT J AU Hugos, CL Chen, YY Chen, ZQ Turner, A Haselkorn, JK Chiara, T McCoy, SC Bever, C Bourdette, D AF Hugos, Cinda L. Chen, Yiyi Chen, Zunqiu Turner, Aaron Haselkorn, Jodie K. Chiara, Toni McCoy, Sean C. Bever, Christopher Bourdette, Dennis TI A multicenter randomized controlled trial in people with multiple sclerosis comparing the effects of two group programs on fatigue and self-efficacy SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT ACTRIMS Forum CY FEB 18-20, 2016 CL New Orleans, LA SP ACTRIMS C1 [Hugos, Cinda L.; Bourdette, Dennis] VA Portland Hlth Care Syst, Portland, OR USA. [Chen, Yiyi; Chen, Zunqiu] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chen, Zunqiu; Turner, Aaron; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Chiara, Toni; McCoy, Sean C.] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Bever, Christopher] VA Maryland Hlth Care Syst, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD FEB PY 2016 VL 22 SU 1 MA P065 BP 33 EP 34 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF9CE UT WOS:000371657100077 ER PT J AU Durazzo, TC Mattsson, N Weiner, MW AF Durazzo, Timothy C. Mattsson, Niklas Weiner, Michael W. CA Alzheimer's Dis Neuroimaging TI Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; PROCESSING-SPEED; RISK-FACTORS; IMPAIRMENT; DEMENTIA; BIOMARKERS; BETA AB Introduction: Chronic cigarette smoking is associated with increased risk for Alzheimer's disease (AD). The goal of this study was to determine if smoking history moderated the associations of age and APOE genotype (the most robust risk factors for AD) on brain amyloid deposition, glucose metabolism, and neurocognition in cognitively-normal elders. Methods: Participants (n = 264) were grouped according to their APOE epsilon 4 carrier status (epsilon 4 carrier: APOE4+; non-epsilon 4 carrier: APOE4-) and smoking status (smokers: at least 1 year of smoking during lifetime; never-smokers: no history of smoking). Approximately 89% of the smoking sample was former-smokers. We specifically tested for interactions of smoking status with APOE epsilon 4 carrier status and age on measures of cortical amyloid deposition, glucose metabolism, and neurocognition. Results: (1) smoking status interacted with APOE epsilon 4 carrier status, where smoker APOE4+ showed lower glucose metabolism and poorer auditory-verbal learning and memory than never-smoking APOE4-, never-smoking APOE4+, and smoking APOE4-; (2) smoking status interacted with age on measures of semantic fluency, processing speed/set-shifting and global neurocognition; smokers, irrespective of APOE epsilon 4 carrier status, demonstrated poorer performance with increasing age than never-smokers; and (3) smoking APOE4+ and never-smoking APOE4+ showed greater cortical amyloid deposition than never-smoking APOE4-and smoking APOE4-. Conclusions: The findings indicate consideration of smoking history is essential to both better understand the factors associated with neurobiological and neurocognitive abnormalities in elders, and the risk for development of AD-related neuropathology. C1 [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Mattsson, Niklas] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu OI Preda, Adrian /0000-0003-3373-2438 FU National Institutes of Health [NIH DA24136]; National Institute on Aging [U01 AG024904]; National Institute of Biomedical Imaging and Bioengineering; NIH [P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435]; Dana Foundation FX The study sponsors had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. This work was supported by the National Institutes of Health (NIH DA24136 to TCD) and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. All data collection and sharing for this project was supported by ADNI. ADNI is funded by the National Institute on Aging (U01 AG024904 to MWW), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co, Medpace, Inc, Merck and Co, Inc, Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc, and Wyeth, as well as nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University Southern California. This research was also supported by NIH grants P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, and The Dana Foundation. The above funding agencies had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript. Original data used in preparation of this article were obtained from the ADNI database (www.loni.usc.edu/ADNI). As such, the investigators within ADNI contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Authorship _List.pdf. NR 51 TC 4 Z9 4 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2016 VL 18 IS 2 BP 204 EP 211 DI 10.1093/ntr/ntv075 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DE0FV UT WOS:000370301200013 PM 25847292 ER PT J AU Belalcazar, LM Papandonatos, GD Erar, B Peter, I Alkofide, H Balasubramanyam, A Brautbar, A Kahn, SE Knowler, WC Ballantyne, CM McCaffery, JM Huggins, GS AF Belalcazar, L. Maria Papandonatos, George D. Erar, Bahar Peter, Inga Alkofide, Hadeel Balasubramanyam, Ashok Brautbar, Ariel Kahn, Steven E. Knowler, William C. Ballantyne, Christie M. McCaffery, Jeanne M. Huggins, Gordon S. CA Look AHEAD Study TI Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE lifestyle; GCKR; behavioral intervention; triglycerides; C-reactive protein; obesity; diabetes mellitus ID C-REACTIVE PROTEIN; FASTING PLASMA-GLUCOSE; TYPE-2 DIABETES RISK; CARDIOVASCULAR-DISEASE; TRIGLYCERIDE LEVELS; REDUCING LIPIDS; INDIVIDUALS; HOMEOSTASIS; ASSOCIATION; PREVALENCE AB Background- Glucokinase regulatory protein (GCKR) inhibitors offer a novel treatment approach for glucose control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern. GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP. Methods and Results- We investigated whether a 1-year intensive lifestyle intervention (ILI) for weight loss would avert the unfavorable cardiometabolic effects associated with GCKR Leu446Pro when compared with a diabetes mellitus support and education arm in overweight/obese individuals with type 2 diabetes mellitus with triglyceride (n=3214) and CRP (n=1411) data participating in a randomized lifestyle intervention study for weight loss, Action for Health in Diabetes Mellitus (Look AHEAD). Once demographics, medication use and baseline adiposity, and fitness were accounted for, ILI did not modify the baseline association of GCKR-Leu446Pro with elevated triglycerides (beta +/- SE=0.067 +/- 0.013, P=1.5x10(-7) and beta +/- SE=0.052 +/- 0.015, P=5x10(-4)) or with elevated CRP (beta +/- SE=0.136 +/- 0.034, P=5.1x10(-5)and beta +/- SE=0.903 +/- 0.038, P=0.015) in the overall sample and Non-Hispanic Whites, respectively. The lack of a protective effect from ILI at 1 year when compared with diabetes mellitus support and education (ILI versus diabetes mellitus support and education interaction for triglyceride and CRP change, respectively: P=0.64 and 0.37 in the overall sample; P=0.27 and 0.05 in Non-Hispanic Whites) persisted after additional adjustment for changes in adiposity and fitness. Conclusions- Moderate improvements in adiposity and fitness with ILI did not mitigate the adverse cardiometabolic effects of GCKR inhibition in overweight/obese individuals with diabetes mellitus. C1 [Belalcazar, L. Maria; Ballantyne, Christie M.] Univ Texas Med Branch, Dept Internal Med, Div Endocrinol & Metab, Galveston, TX 77555 USA. [Papandonatos, George D.; Erar, Bahar] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA. [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Alkofide, Hadeel] Tufts Univ, Sackler Sch Biomed Res, Clin Translat Sci Program, Boston, MA 02111 USA. [Balasubramanyam, Ashok] Baylor Coll Med, Div Endocrinol Diabet & Metab, Diabet Res Ctr, Translat Metab Unit, Houston, TX 77030 USA. [Brautbar, Ariel] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix, AZ USA. [Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. [McCaffery, Jeanne M.] Miriam Hosp, Dept Psychiat & Human Behav, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA. [McCaffery, Jeanne M.] Brown Med Sch, Providence, RI USA. [Huggins, Gordon S.] Tufts Med Ctr, Ctr Translat Genom, Mol Cardiol Res Inst, Boston, MA 02111 USA. [Huggins, Gordon S.] Tufts Univ, Boston, MA 02111 USA. RP Huggins, GS (reprint author), Tufts Med Ctr, MCRI Ctr Translat Genom, Boston, MA 02111 USA.; Huggins, GS (reprint author), Tufts Univ, Sch Med, Boston, MA 02111 USA. EM ghuggins@tuftsmedicalcenter.org OI Papandonatos, George/0000-0001-6770-932X; Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services from the National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; National Institutes of Health (NIH) Office of Research on Women's Health; Centers for Disease Control and Prevention; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056 44]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346]; [DK090043-02]; [X01 HG006659]; [HL09051401] FX This study was funded by DK090043-02 and X01 HG006659 (Drs Papandonatos, McCaffery, Huggins) and HL09051401 (Drs Belalcazar and Ballantyne). Look AHEAD was supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; National Institutes of Health (NIH) Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the IHS or other funding sources. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056 44) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). The following organizations have committed to make major contributions to Look AHEAD: Federal Express; Health Management Resources; Johnson & Johnson, LifeScan Inc; Optifast-Novartis Nutrition; Roche Pharmaceuticals; Ross Product Division of Abbott Laboratories; Slim-Fast Foods Company; and Unilever. NR 32 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2016 VL 9 IS 1 BP 71 EP 78 DI 10.1161/CIRCGENETICS.115.001192 PG 8 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA DF0FI UT WOS:000371014100010 PM 26578543 ER PT J AU Bansal, N Simmons, KD Epstein, AJ Morris, JB Kelz, RR AF Bansal, Neha Simmons, Kristina D. Epstein, Andrew J. Morris, Jon B. Kelz, Rachel R. TI Using Patient Outcomes to Evaluate General Surgery Residency Program Performance SO JAMA SURGERY LA English DT Article ID QUALITY-OF-CARE; TRAINING-PROGRAMS; COST-EFFECTIVENESS; MORTALITY-RATES; FAILURE; RESCUE; STAY AB IMPORTANCE To evaluate and financially reward general surgery residency programs based on performance, performance must first be defined and measureable. OBJECTIVE To assess general surgery residency program performance using the objective clinical outcomes of patients operated on by program graduates. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted of discharge records from 349 New York and Florida hospitals between January 1, 2008, and December 31, 2011. The records comprised 230 769 patients undergoing 1 of 24 general surgical procedures performed by 454 surgeons from 73 general surgery residency programs. Analysis was conducted from June 4, 2014, to June 16, 2015. MAIN OUTCOMES AND MEASURES In-hospital death; development of 1 or more postoperative complications before discharge; prolonged length of stay, defined as length of stay greater than the 75th percentile when compared with patients undergoing the same procedure type at the same hospital; and failure to rescue, defined as in-hospital death after the development of 1 or more postoperative complications. RESULTS Patients operated on by surgeons trained in residency programs that were ranked in the top tertile were significantly less likely to experience an adverse event than were patients operated on by surgeons trained in residency programs that were ranked in the bottom tertile. Adjusted adverse event rates for patients operated on by surgeons trained in programs that were ranked in the top tertile and those who were operated on by surgeons trained in programs that were ranked in the bottom tertile were, respectively, 0.483% vs 0.476% for death, 9.68% vs 10.79% for complications, 16.76% vs 17.60% for prolonged length of stay, and 2.68% vs 2.98% for failure to rescue (all P < .001). The differences remained significant in procedure-specific subset analyses. The rankings were significantly correlated among some but not all outcome measures. The magnitude of the effect of the residency program on the outcomes achieved by the graduates decreased with increasing years of practice. Within the analyses of surgeons within 20, 10, and 5 years of practice, the relative difference in adjusted adverse event rates across the individual models between the top and bottom tertiles ranged from 1.5% to 12.3%(20 years), 9.1% to 33.8% (10 years), and 8.0% to 44.4%(5 years). CONCLUSIONS AND RELEVANCE Objective data were successfully used to rank the clinical outcomes achieved by graduates of general surgery residency programs. Program rankings differed by the outcome measured. The magnitude of differences across programs was small. Careful consideration must be used when identifying potential targets for payment-for-performance initiatives in graduate medical education. C1 [Bansal, Neha; Epstein, Andrew J.; Morris, Jon B.; Kelz, Rachel R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bansal, Neha; Simmons, Kristina D.; Morris, Jon B.; Kelz, Rachel R.] Univ Penn Hlth Syst, Dept Surg, Ctr Surg & Hlth Econ, 3400 Spruce St,4 Silverstein Bldg, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Kelz, Rachel R.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Kelz, RR (reprint author), Univ Penn Hlth Syst, Dept Surg, Ctr Surg & Hlth Econ, 3400 Spruce St,4 Silverstein Bldg, Philadelphia, PA 19104 USA. EM rachel.kelz@uphs.upenn.edu NR 33 TC 2 Z9 2 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2016 VL 151 IS 2 BP 111 EP 119 DI 10.1001/jamasurg.2015.3637 PG 9 WC Surgery SC Surgery GA DF4LH UT WOS:000371319200003 PM 26510131 ER PT J AU Sobel, M Tang, GL AF Sobel, Michael Tang, Gale L. TI Inflammation, Endoleaks, and Aortic Remodeling-The Chicken or the Egg SO JAMA SURGERY LA English DT Editorial Material C1 VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Sobel, M (reprint author), Univ Washington, Div Vasc Surg, Dept Surg, VA Puget Sound Hlth Care Syst, 1660 Columbian Way S, Seattle, WA 98108 USA. EM sobelm@uw.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2016 VL 151 IS 2 BP 154 EP 154 DI 10.1001/jamasurg.2015.3246 PG 1 WC Surgery SC Surgery GA DF4LH UT WOS:000371319200012 PM 26502236 ER PT J AU Zaman, T Boyd, JW AF Zaman, Tauheed Boyd, J. Wesley TI The Authors Reply to Cannabis Use Disorders and ADHD SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter C1 [Zaman, Tauheed] UCSF, San Francisco VA Med Ctr, Addict & Recovery Treatment Serv, San Francisco, CA USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Ctr Bioeth, Cambridge, MA 02138 USA. RP Boyd, JW (reprint author), Cambridge Hlth Alliance, 26 Cent St, Somerville, MA 02143 USA. EM jwboyd@cha.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD FEB PY 2016 VL 10 IS 1 BP 70 EP 71 DI 10.1097/ADM.0000000000000185 PG 2 WC Substance Abuse SC Substance Abuse GA DE0CS UT WOS:000370293000013 ER PT J AU Shen, Q Huang, SL Duong, TQ AF Shen, Qiang Huang, Shiliang Duong, Timothy Q. TI T-2*-weighted fMRI time-to-peak of oxygen challenge in ischemic stroke SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE Functional MRI; focal ischemia; perfusion-weighted MRI; diffusion-weighted MRI; BOLD contrast ID PERFUSION MRI; POSTISCHEMIC HYPERPERFUSION; QUANTITATIVE PERFUSION; FUNCTIONAL MRI; TISSUE FATE; DIFFUSION; PENUMBRA; REPERFUSION; RAT; STIMULATION AB T-2*-weighted MRI of transient oxygen challenge (OC) showed exaggerated OC percent changes in the ischemic tissue at risk compared to normal tissue. One ambiguity is that regions with high vascular density also showed exaggerated OC percent changes. This study explored time-to-peak (TTP) of the OC percent changes to improve the utility of T-2*-weighted OC MRI. Experiments were performed longitudinally at 30 min, 150 min and 24 h after transient (60-min) stroke in rats. Ischemic core, normal, and mismatch tissue were classified pixel-by-pixel based on apparent diffusion coefficient and cerebral blood flow. Major findings were: (i) Delayed OC TTP was localized to and corresponded well with the perfusion-diffusion mismatch. (ii) By contrast, the exaggerated OC percent changes were less localized, with changes not only in the at-risk tissue but also in some areas of the contralesional hemisphere with venous vessel origins. (iii) The OC time-course of the mismatch tissue was biphasic, with a faster initial increase followed by a slower increase. (iv) At-risk tissue with delayed TTP and exaggerated OC was normal after reperfusion and the at-risk tissue was mostly (83 +/- 18%) rescued by reperfusion as indicated by normal 24-h T-2. OC TTP offers unique information toward better characterization of at-risk tissue in ischemic stroke. C1 [Shen, Qiang; Huang, Shiliang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Shen, Q; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM shenq3@uthscsa.edu; duongt@uthscsa.edu FU NIH [R01-NS45879]; American Heart Association [EIA 0940104N, SDG 0830293N, 12BGIA9300047] FX This work was supported by the NIH (grant no. R01-NS45879) and the American Heart Association (grant nos. EIA 0940104N, SDG 0830293N and 12BGIA9300047). NR 24 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2016 VL 36 IS 2 BP 283 EP 291 DI 10.1177/0271678X15606461 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA DF4EG UT WOS:000371299800004 PM 26661164 ER PT J AU Gellad, WF AF Gellad, Walid F. TI The Veterans Choice Act and Dual Health System Use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID CARE C1 [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. EM walid.gellad@va.gov FU HSRD VA [I01 HX001765] NR 3 TC 3 Z9 3 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2016 VL 31 IS 2 BP 153 EP 154 DI 10.1007/s11606-015-3492-2 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DF2GQ UT WOS:000371161000008 PM 26289922 ER PT J AU Beben, T Ix, JH Shlipak, MG Sarnak, MJ Fried, LF Hoofnagle, AN Chonchol, M Kestenbaum, BR de Boer, IH Rifkin, DE AF Beben, Tomasz Ix, Joachim H. Shlipak, Michael G. Sarnak, Mark J. Fried, Linda F. Hoofnagle, Andrew N. Chonchol, Michel Kestenbaum, Bryan R. de Boer, Ian H. Rifkin, Dena E. TI Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE fibroblast growth factor 23; frailty; mortality ID LOW VITAMIN-D; OLDER-ADULTS; PARATHYROID-HORMONE; 25-HYDROXYVITAMIN D; MUSCLE STRENGTH; CYSTATIN-C; DISEASE; MEN; INFLAMMATION; ASSOCIATION AB ObjectivesTo evaluate whether fibroblast growth factor 23 (FGF-23) is related to frailty and to characterize the nature of their joint association with mortality. DesignCross-sectional analysis for frailty and longitudinal cohort analysis for mortality. SettingCardiovascular Health Study. ParticipantsCommunity-dwelling individuals (N= 2,977; mean age 77.94.7, 40% male, 83% white). MeasurementsThe predictor was serum FGF-23 concentration (C-terminal enzyme-linked immunosorbent assay), and the outcomes were frailty status (determined according to frailty phenotype criteria of weight loss, weakness, exhaustion, slowness, and low physical activity) and mortality. Multinomial logistic regression was used to assess the cross-sectional association between FGF-23 and frailty and prefrailty, adjusting for demographic characteristics, cardiovascular disease and risk factors, and kidney markers. Proportional hazards Cox proportional hazards regression was used to assess the association between FGF-23, frailty, and all-cause mortality. ResultsMean estimated glomerular filtration rate (eGFR) was 64 +/- 17mL/min per 1.73m(2). Median FGF-23 was 70.3RU/mL (interquartile range 53.4-99.2); 52% were prefrail, and 13% were frail. After multivariate adjustment, each doubling in FGF-23 concentration was associated with 38% (95% confidence interval (CI)=17-62%) higher odds of frailty than of nonfrailty and 16% (95% CI=3-30%) higher odds of prefrailty. FGF-23 (hazard ratio (HR)=1.16, 95% CI=1.10-1.23) and frailty (HR=1.82, 95% CI=1.57-2.12) were independently associated with mortality, but neither association was meaningfully attenuated when adjusted for the other. ConclusionIn a large cohort of older adults, higher FGF-23 was independently associated with prevalent frailty and prefrailty. FGF-23 and frailty were independent and additive risk factors for mortality. FGF-23 may be a marker for functional outcomes. C1 [Beben, Tomasz; Ix, Joachim H.; Rifkin, Dena E.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Beben, Tomasz; Ix, Joachim H.; Rifkin, Dena E.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.] Veteran Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Nephrol Sect, Pittsburgh, PA USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA. [Kestenbaum, Bryan R.; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Kestenbaum, Bryan R.; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Dept Med, Seattle, WA 98195 USA. RP Beben, T (reprint author), 9500 Gilman Dr 9111H, La Jolla, CA 92093 USA. EM tbeben@ucsd.edu FU National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, HHSN268200800007C, N01HC 55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295]; National Institute on Aging [R01AG 023629]; American Heart Association [14EIA18560026]; National Institutes of Health [T32 HL007261, RO1 HL096851, R01 HL096851, K23 DK091521, R01 HL073208, R01 AG027002, R01 DK087726] FX The CHS was supported by Contracts HHSN268201200036C, HHSN268200800007C, N01HC 55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and Grant U01HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG 023629 from the National Institute on Aging. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NHLBI, or CHS. Dr. Beben was supported by Grant T32 HL007261, Dr. Ix by Grant RO1 HL096851, Dr. Ix by Grant R01 HL096851 and an American Heart Association Established Investigator Award 14EIA18560026, Dr. Rifkin by Grant K23 DK091521, Dr. Shlipak by Grant R01 HL073208, Dr. Sarnak by Grant R01 AG027002, and Dr. De Boer by Grant R01 DK087726 all from the National Institutes of Health, except where otherwise noted. NR 33 TC 0 Z9 0 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 270 EP 276 DI 10.1111/jgs.13951 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000003 PM 26889836 ER PT J AU Wang, SY Aldridge, MD Gross, CP Canavan, M Cherlin, E Johnson-Hurzeler, R Bradley, E AF Wang, Shi-Yi Aldridge, Melissa D. Gross, Cary P. Canavan, Maureen Cherlin, Emily Johnson-Hurzeler, Rosemary Bradley, Elizabeth TI Transitions Between Healthcare Settings of Hospice Enrollees at the End of Life SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospice; transitions in care; end-of-life care ID MARKET-STRUCTURE; HEART-FAILURE; NURSING-HOME; CANCER; POPULATION; INDICATORS; FACILITIES; INPATIENT; VARIABLES; PATTERNS AB ObjectivesTo characterize the number and types of care transitions in the last 6months of life of individuals who used hospice and to examine factors associated with having multiple transitions in care. DesignRetrospective cohort study. SettingOne hundred percent fee-for-service Medicare decedent claims data. ParticipantsMedicare beneficiaries aged 66 and older who died between July 1, 2011, and December 31, 2011, and were enrolled in hospice at some time during the last 6months of life. MeasurementsHierarchical generalized linear modeling was used to identify individual, hospice, and regional factors associated with transitions. The sequence of transitions across healthcare settings was described. Healthcare transitions after hospice enrollment included from and to the hospital, skilled nursing facility, home health agency program, hospice, or home without receiving any service in these four healthcare settings. ResultsOf 311,090 hospice decedents, 31,675 (10.2%) had at least one transition after hospice enrollment, and this varied substantially across the United States; 6.6% of all decedents had more than one transition in care after hospice enrollment (range 2-19 transitions). Of hospice users with transitions, 53.4% were admitted to hospitals, 17.7% were admitted to skilled nursing facilities, 9.6% used home health agencies, and 25.8% had transitions to home without receiving the services from the healthcare settings examined. In adjusted analyses, decedents who were younger, nonwhite, enrolled in a for-profit or small hospice program, or had less access to hospital-based palliative care had significantly higher odds of having at least one transition. ConclusionA notable proportion of hospice users experience at least one transition in care in the last 6months of life, suggesting that further research on the effect of transitions on users and families is warranted. C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St New, New Haven, CT 06520 USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Univ, Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res Ctr, New Haven, CT 06520 USA. [Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Aldridge, Melissa D.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA. [Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA. [Johnson-Hurzeler, Rosemary] John D Thompson Hosp Inst Educ Training & Res In, Branford, CT USA. RP Wang, SY (reprint author), Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St New, New Haven, CT 06520 USA. EM shiyi.wang@yale.edu FU Medtronic, Inc.; Johnson Johnson, Inc.; 21st Century Oncology; National Cancer Institute [1R01CA116398-01A2]; National Institute of Nursing Research [1R01NR013499-01A1] FX Dr. Gross receives support from Medtronic, Inc., Johnson & Johnson, Inc., and 21st Century Oncology. These sources of support were not used for any portion of the current manuscript. None of the other coauthors have conflicts to report.; This study was supported by Grant 1R01CA116398-01A2 from the National Cancer Institute (Drs. Aldridge and Bradley), the John D. Thompson Foundation (Dr. Bradley), and Grant 1R01NR013499-01A1 from the National Institute of Nursing Research (Dr. Aldridge). NR 41 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 314 EP 322 DI 10.1111/jgs.13939 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000009 PM 26889841 ER PT J AU Naples, JG Hanlon, JT Schmader, KE Semla, TP AF Naples, Jennifer G. Hanlon, Joseph T. Schmader, Kenneth E. Semla, Todd P. TI Recent Literature on Medication Errors and Adverse Drug Events in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medication errors; adverse drug events; literature ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; ADVANCED DEMENTIA; CLINICAL-TRIAL; CARE; PEOPLE; INTERVENTION; FALLS; POLYPHARMACY; PHARMACIST AB Medication errors and adverse drug events are common in older adults, but locating literature addressing these issues is often challenging. The objective of this article is to summarize recent studies addressing medication errors and adverse drug events in a single location to improve accessibility for individuals working with older adults. A comprehensive literature search for studies published in 2014 was conducted, and 51 potential articles were identified. After critical review, 17 studies were selected for inclusion based on innovation; rigorous observational or experimental study designs; and use of reliable, valid measures. Four articles characterizing potentially inappropriate prescribing and interventions to optimize medication regimens were annotated and critiqued in detail. The authors hope that health policy-makers and clinicians find this information helpful in improving the quality of care for older adults. C1 [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Sch Med, Div Geriatr,Dept Med, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Semla, Todd P.] Pharm Benefits Management Serv, Dept Vet Affairs, Hines, IL USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Semla, TP (reprint author), Pharm Benefits Management 10P4P, Hines, IL 60141 USA. EM t-semla@northwestern.edu FU National Institute of Aging (NIA) [T32-AG021885]; NIA [P30AG024827, K07AG033174, R01AG037451, P30AG028716]; Donoghue Foundation; Agency for Healthcare Research and Quality [R18 HS023779]; Veterans Affairs Health Services Research and Development Service Merit Awards [IIR 12-379, IIR 14-297] FX Dr. Naples's fellowship is supported by National Institute of Aging (NIA) Grant T32-AG021885. Dr. Hanlon is supported by NIA Grants P30AG024827, K07AG033174, and R01AG037451; a grant from the Donoghue Foundation; grant R18 HS023779 from the Agency for Healthcare Research and Quality, and Veterans Affairs Health Services Research and Development Service Merit Awards IIR 12-379 and IIR 14-297. Dr. Schmader is supported by NIA Grant P30AG028716. NR 35 TC 1 Z9 1 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 401 EP 408 DI 10.1111/jgs.13922 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000022 PM 26804210 ER PT J AU Rogus-Pulia, N Rusche, N Hind, JA Zielinski, J Gangnon, R Safdar, N Robbins, J AF Rogus-Pulia, Nicole Rusche, Nicole Hind, Jacqueline A. Zielinski, Jill Gangnon, Ronald Safdar, Nasia Robbins, JoAnne TI Effects of Device-Facilitated Isometric Progressive Resistance Oropharyngeal Therapy on Swallowing and Health-Related Outcomes in Older Adults with Dysphagia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dysphagia; oropharyngeal; lingual; strengthening; pneumonia ID PENETRATION-ASPIRATION SCALE; LINGUAL EXERCISE; STROKE PATIENTS; PNEUMONIA; PERFORMANCE; STRENGTH; PEOPLE; COST AB Swallowing disorders (dysphagia) are associated with malnutrition, aspiration pneumonia, and mortality in older adults. Strengthening interventions have shown promising results, but the effectiveness of treating dysphagia in older adults remains to be established. The Swallow STRengthening OropharyNGeal (Swallow STRONG) Program is a multidisciplinary program that employs a specific approach to oropharyngeal strengtheningdevice-facilitated (D-F) isometric progressive resistance oropharyngeal (I-PRO) therapywith the goal of reducing health-related sequelae in veterans with dysphagia. Participants completed 8 weeks of D-F I-PRO therapy while receiving nutritional counseling and respiratory status monitoring. Assessments were completed at baseline, 4, and 8 weeks. At each visit, videofluoroscopic swallowing studies were performed. Dietary and swallowing-related quality of life questionnaires were administered. Long-term monitoring for 6-17 months after enrollment allowed for comparison of pneumonia incidence and hospitalizations to the 6-17 months before the program. Veterans with dysphagia confirmed with videofluoroscopy (N = 56; 55 male, 1 female; mean age 70) were enrolled. Lingual pressures increased at anterior (effect estimate = 92.5, P < .001) and posterior locations (effect estimate = 85.4, P < .001) over 8 weeks. Statistically significant improvements occurred on eight of 11 subscales of the Quality of Life in Swallowing Disorders (SWAL-QOL) Questionnaire (effect estimates = 6.5-19.5, P < .04) and in self-reported sense of effort (effect estimate = -18.1, P = .001). Higher Functional Oral Intake Scale scores (effect estimate = 0.4, P = .02) indicated that participants were able to eat less-restrictive diets. There was a 67% reduction in pneumonia diagnoses, although the difference was not statistically significant. The number of hospital admissions decreased significantly (effect estimate = 0.96; P = .009) from before to after enrollment. Findings suggest that the Swallow STRONG multidisciplinary oropharyngeal strengthening program may be an effective treatment for older adults with dysphagia. C1 [Rogus-Pulia, Nicole] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Div Gastroenterol, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Div Hepatol, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Speech Swallowing & Dining Enhancement Program, Madison, WI USA. [Rusche, Nicole] Swallow STRengthening OropharyNGeal Program, Madison, WI USA. [Hind, Jacqueline A.] Swallow Solut LLC, Clin Affairs, Madison, WI USA. [Zielinski, Jill] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Div Infect Dis, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Dept Med, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Safdar, Nasia; Robbins, JoAnne] Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Rogus-Pulia, N (reprint author), 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA. EM npulia@wisc.edu FU Geriatrics and Extended Care division of the VA through a T21 Non-Institutional Long Term Care grant FX Funding was provided by the Geriatrics and Extended Care division of the VA through a T21 Non-Institutional Long Term Care grant. The authors would like to acknowledge Sue McCartney, MS, RD, for providing nutritional support and counseling and Kevin Bjork, MS, NP, for monitoring participants' respiratory health. NR 20 TC 1 Z9 1 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 417 EP 424 DI 10.1111/jgs.13933 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000024 PM 26804715 ER PT J AU Forman, DE AF Forman, Daniel E. TI Cardiac Rehabilitation: The Mandate Grows SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID AMERICAN-HEART-ASSOCIATION; PREVENTION; EXERCISE; DELIVERY C1 [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Med, Pittsburgh, PA USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu NR 20 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2016 VL 91 IS 2 BP 125 EP 128 DI 10.1016/j.mayocp.2015.12.009 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DF3MN UT WOS:000371248500004 PM 26847999 ER PT J AU Thakore, NP Samantaray, S Park, S Nozaki, K Smith, JA Cox, A Krause, J Banik, NL AF Thakore, Nakul P. Samantaray, Supriti Park, Sookyoung Nozaki, Kenkichi Smith, Joshua A. Cox, April Krause, James Banik, Naren L. TI Molecular Changes in Sub-lesional Muscle Following Acute Phase of Spinal Cord Injury SO NEUROCHEMICAL RESEARCH LA English DT Article DE Spinal cord injury; Muscle atrophy; Protein degradation; Protein synthesis; Inflammation; E3-ubiquitin ligases ID CROSS-SECTIONAL AREA; SKELETAL-MUSCLE; PROTEIN-METABOLISM; MESSENGER-RNA; RAT SOLEUS; EXPRESSION; CALPAIN; ATROPHY; STIMULATION; HUMANS AB To clarify the molecular changes of sublesional muscle in the acute phase of spinal cord injury (SCI), a moderately severe injury (40 g cm) was induced in the spinal cord (T10 vertebral level) of adult male Sprague-Dawley rats (injury) and compared with sham (laminectomy only). Rats were sacrificed at 48 h (acute) post injury, and gastrocnemius muscles were excised. Morphological examination revealed no significant changes in the muscle fiber diameter between the sham and injury rats. Western blot analyses performed on the visibly red, central portion of the gastrocnemius muscle showed significantly higher expression of muscle specific E3 ubiquitin ligases (muscle ring finger-1 and muscle atrophy f-box) and significantly lower expression of phosphorylated Akt-1/2/3 in the injury group compared to the sham group. Cyclooxygenase 2, tumor necrosis factor alpha (TNF-alpha), and caspase-1, also had a significantly higher expression in the injury group; although, the mRNA levels of TNF-alpha and IL-6 did not show any significant difference between the sham and injury groups. These results suggest activation of protein degradation, deactivation of protein synthesis, and development of inflammatory reaction occurring in the sublesional muscles in the acute phase of SCI before overt muscle atrophy is seen. C1 [Thakore, Nakul P.; Samantaray, Supriti; Park, Sookyoung; Nozaki, Kenkichi; Smith, Joshua A.; Cox, April; Banik, Naren L.] Med Univ S Carolina, Dept Neurosurg & Neurol, 96 Jonathan Lucas St,309 CSB,MSC 606, Charleston, SC 29425 USA. [Park, Sookyoung] Kyungnam Univ, Dept Phys Therapy, Chang Won, South Korea. [Krause, James] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Nozaki, Kenkichi] Univ Alabama Birmingham, Dept Neurol, Div Neuromuscular Dis, UAB Stn, Birmingham, AL 35294 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurosurg & Neurol, 96 Jonathan Lucas St,309 CSB,MSC 606, Charleston, SC 29425 USA.; Banik, NL (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM baniknl@musc.edu FU National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS-NIH) [NS031622]; Ralph H. Johnson Veterans Administration Medical Center [1IOBX001262, 1IOBX002349-01]; State of South Carolina Spinal Cord Injury Research Foundation [SCIRF 2012-001]; National Institutes of Health from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455] FX We would like to acknowledge Ms. Margaret Romonov for her assistance in the muscle biopsy slicing and H&E staining and Dr. Varduhi H. Knaryan for valuable discourse. The funding for this project was provided in part by R01 Grants from National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS-NIH; NS031622), Ralph H. Johnson Veterans Administration Medical Center (1IOBX001262 and 1IOBX002349-01) and the State of South Carolina Spinal Cord Injury Research Foundation (SCIRF 2012-001). This work was conducted in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. NR 44 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-3190 EI 1573-6903 J9 NEUROCHEM RES JI Neurochem. Res. PD FEB PY 2016 VL 41 IS 1-2 SI SI BP 44 EP 52 DI 10.1007/s11064-015-1696-9 PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DF5SO UT WOS:000371412800006 PM 26290268 ER PT J AU Tackett, MJ Nash, L Stucky, KJ Nierenberg, B AF Tackett, M. Jan Nash, Laurie Stucky, Kirk Jeffrey Nierenberg, Barry TI Supervision in Rehabilitation Psychology: Application of Beatrice Wright's Value-Laden Beliefs and Principles SO REHABILITATION PSYCHOLOGY LA English DT Article DE supervision; rehabilitation; mentoring; clinical training; residency training ID COMPETENCE AB Clinical supervision is of critical importance for training subsequent generations of psychologists. Specialty training in rehabilitation psychology requires exposure to specific knowledge, skills, and attitudes related to disability and specialized supervision and mentorship. In the literature to date, minimal guidance exists regarding supervision training and methods specifically for rehabilitation psychologists. This article aims to provoke discussion regarding supervision practice and dissemination of the values fundamental to our specialty. The foundational wisdom of Dr. Beatrice Wright (1983) is applied for the purposes of this endeavor. Examples of clinical supervision scenarios are presented as teaching vignettes to demonstrate ways in which supervisors and mentors can incorporate this content, promote discussion, and apply it to real-world practice. Impact and Implications This article describes the importance of specialty clinical supervision in rehabilitation psychology. In addition, a model is advanced for providing supervision and values clarification based on foundational rehabilitation psychology literature. This article suggests ongoing dissemination of core rehabilitation psychology values through supervision and mentoring relationships, as well as processes for improving supervision practice in the specialty. C1 [Tackett, M. Jan] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. [Tackett, M. Jan] Univ Washington, Seattle, WA 98195 USA. [Nash, Laurie] Shepherd Ctr, Atlanta, GA USA. [Stucky, Kirk Jeffrey] Hurley Med Ctr, Flint, MI USA. [Nierenberg, Barry] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA. RP Tackett, MJ (reprint author), Univ Washington, Seattle Div, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM meredith.tackett@va.gov NR 16 TC 2 Z9 2 U1 0 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2016 VL 61 IS 1 BP 74 EP 81 DI 10.1037/rep0000070 PG 8 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA DF4EZ UT WOS:000371302000008 PM 26881309 ER PT J AU Liu, Y Mallampalli, RK AF Liu, Yuan Mallampalli, Rama K. TI Small molecule therapeutics targeting F-box proteins in cancer SO SEMINARS IN CANCER BIOLOGY LA English DT Review DE Ubiquitin; E3 ligase; F-box protein; Small molecule inhibitor; Cancer ID SCF UBIQUITIN-LIGASE; NF-KAPPA-B; CELL-CYCLE ARREST; PHOSPHORYLATION-DEPENDENT UBIQUITINATION; ANAPHASE PROMOTING COMPLEX/CYCLOSOME; TUMOR-SUPPRESSOR; BETA-TRCP; C-MYC; MEDIATED DEGRADATION; SKP2 PROTEIN AB The ubiquitin proteasome system (UPS) plays vital roles in maintaining protein equilibrium mainly through proteolytic degradation of targeted substrates. The archetypical SCF ubiquitin E3 ligase complex contains a substrate recognition subunit F-box protein that recruits substrates to the catalytic ligase core for its polyubiquitylation and subsequent proteasomal degradation. Several well-characterized F-box proteins have been demonstrated that are tightly linked to neoplasia. There is mounting information characterizing F-box protein-substrate interactions with the rationale to develop unique therapeutics for cancer treatment. Here we review that how F-box proteins function in cancer and summarize potential small molecule inhibitors for cancer therapy. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Liu, Yuan; Mallampalli, Rama K.] Univ Pittsburgh, Ctr Excellence, Acute Lung Injury, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US National Institutes of Health [HL096376, P01 HL114453]; United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; United States Department of Veterans Affairs FX The authors apologize for the omission of many colleagues' work owing to space constraints. Work in the Mallampalli laboratory is partly supported by the US National Institutes of Health R01 Grant HL096376 and P01 HL114453 (to R.K.M.), and is partly supported by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by a Merit Review award from the United States Department of Veterans Affairs (to R.K.M.). NR 177 TC 3 Z9 3 U1 1 U2 5 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1044-579X J9 SEMIN CANCER BIOL JI Semin. Cancer Biol. PD FEB PY 2016 VL 36 BP 105 EP 119 DI 10.1016/j.semcancer.2015.09.014 PG 15 WC Oncology SC Oncology GA DF7QY UT WOS:000371553900011 PM 26427329 ER PT J AU Zaman, T Boyd, JW AF Zaman, Tauheed Boyd, J. Wesley TI The Authors Reply to Cannabis Use Disorders and ADHD SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter C1 [Zaman, Tauheed] UCSF, San Francisco VA Med Ctr, Addict & Recovery Treatment Serv, San Francisco, CA USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Ctr Bioeth, Cambridge, MA 02138 USA. RP Boyd, JW (reprint author), Cambridge Hlth Alliance, 26 Cent St, Somerville, MA 02143 USA. EM jwboyd@cha.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD FEB PY 2016 VL 10 IS 1 BP 70 EP 71 DI 10.1097/ADM.0000000000000185 PG 2 WC Substance Abuse SC Substance Abuse GA DE0CV UT WOS:000370293300002 ER PT J AU McCutchan, PK Liu, X LeardMann, CA Smith, TC Boyko, EJ Gore, KL Freed, MC Engel, CC AF McCutchan, Phoebe K. Liu, Xian LeardMann, Cynthia A. Smith, Tyler C. Boyko, Edward J. Gore, Kristie L. Freed, Michael C. Engel, Charles C. TI Deployment, combat, and risk of multiple physical symptoms in the US military: a prospective cohort study SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Signs and symptoms; Military medicine; Military personnel; Veterans health; Cohort studies ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CLINICAL-TRIAL; PERSIAN-GULF-WAR; SOMATIC SYMPTOMS; MILLENNIUM COHORT; PRIMARY-CARE; CHRONIC PAIN; IRAQ WAR; SERVICE MEMBERS; HEALTH OUTCOMES AB Purpose: Multiple physical symptoms (MPS) have historically been observed after deployment to a combat zone and are often disabling in nature. This study examined longitudinal trends in MPS status and its relationship to deployment in U.S. military service members. Methods: Using longitudinal data from panel 1 participants in the Millennium Cohort Study (n = 76,924), MPS status was assessed at three time points (2001-2008) using the 15 -item Patient Health Questionnaire. Probability of reporting MPS was analyzed using mixed-effects multinomial logit regression, with time and deployment experience as main explanatory variables. Results: After adjustment for demographic, military, and health characteristics, service members who deployed with combat were significantly more likely to report MPS at each time point compared with those not deployed (odds ratio [OR] and 95% confidence interval [CI] for wave 1 =1.49 [1.47-1.52], wave 2 = 1.73 [1.69-1.78], wave 3 = 2.08 [2.03-2.12]), and those who deployed without combat (OR and CI for wave 1 = 2.66 [2.59-2.74], wave 2 = 1.81 [1.75-1.87]; wave 3 = 1.68 [1.63-1.74]). Conclusions: Longitudinal trends indicate that the probability of reporting MPS has increased consistently over time only for those deployed, regardless of combat experience. (C) 2016 Elsevier Inc. All rights reserved. C1 [McCutchan, Phoebe K.; Liu, Xian; Freed, Michael C.] Def Ctr Excellence Psychol Hlth, Deployment Hlth Clin Ctr, Silver Spring, MD USA. [McCutchan, Phoebe K.; Liu, Xian; Freed, Michael C.] Def Ctr Traumat Brain Injury, Deployment Hlth Clin Ctr, Silver Spring, MD USA. [McCutchan, Phoebe K.; Liu, Xian; LeardMann, Cynthia A.] Henry M Jackson Fdn Adv Mil Med Inc, Bethesda, MD USA. [Liu, Xian; Freed, Michael C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA. [LeardMann, Cynthia A.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA USA. [Smith, Tyler C.] Natl Univ, Sch Hlth & Human Serv, Dept Community Hlth, San Diego, CA USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Gore, Kristie L.; Engel, Charles C.] RAND Corp, Behav & Policy Sci, Arlington, VA USA. [McCutchan, Phoebe K.] Amer Univ, Dept Psychol, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. [Freed, Michael C.] NIMH, Div Serv & Intervent Res, Serv Res & Clin Epidemiol Branch, 6001 Execut Blvd, Bethesda, MD 20892 USA. [Engel, Charles C.] RAND Corp, Behav & Policy Sci, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA. RP McCutchan, PK (reprint author), Amer Univ, Dept Psychol, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. EM phoebe.mccutchan@gmail.com OI Boyko, Edward/0000-0002-3695-192X FU Management Information Division, U.S. Defense Manpower Data Center (Seaside, CA); Military Operational Medicine Research Program; U.S. Army Medical Research and Materiel Command (Fort Detrick, MD); Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland - Department of Defense [60002]; Deployment Health Clinical Center; VA Puget Sound Health Care System FX In addition to the authors, the Millennium Cohort Study team includes Richard Armenta, PhD, Lauren Bauer, MPH, Madeline Cross, James Davies, CPT Carrie Donoho, PhD, CDR Dennis Faix, MD, Lt Col Susan Farrish, MD, Toni Geronimo, Kathleen Gunn, William Lee, Hector Lemus, PhD, Gordon Lynch, Denise Lovec-Jenkins, David Luxton PhD, Danielle Mitchell, Kristin Motylinski, Anna Nagel, MPH, Chiping Nieh, PhD, Chris O'Malley, MPH, Serguey Parkhomovsky, Anet Petrosyan, Christopher Phillips, MD, MPH, Teresa Powell, MPH, Ben Porter, PhD, Rudy Rull, PhD, Kari Sausedo, MA, Beverly Sheppard, Steven Speigle, Evelyn Sun, MPH, Valerie Stander, PhD, Laura Tobin, MPH, Daniel Trone, PhD, Jennifer Walstrom, from the Deployment Health Research Department, Naval Health Research Center, San Diego, CA. We thank Hector Lemus, PhD (Naval Health Research Center, San Diego, CA) for his contribution in providing statistical support and consultation for this study. In addition, we thank Michelle LeWark from the Naval Health Research Center (San Diego, CA) for her technical review and editing of this article. We appreciate the support from the Management Information Division, U.S. Defense Manpower Data Center (Seaside, CA); Military Operational Medicine Research Program and U.S. Army Medical Research and Materiel Command (Fort Detrick, MD).; The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland (supported by the Department of Defense, under work unit no. 60002). The Deployment Health Clinical Center provided funding for P.K.M., X.L., K.L.G, and M.C.F.'s efforts in this project. VA Puget Sound Health Care System provided support for E.J.B's participation in this research. The funding organizations had no role in the design and conduct of the study; collection, analysis, or preparation of data; or preparation, review, or approval of the article. NR 58 TC 1 Z9 1 U1 5 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD FEB PY 2016 VL 26 IS 2 BP 122 EP 128 DI 10.1016/j.annepidem.2015.12.001 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE8MG UT WOS:000370889500006 PM 26781443 ER PT J AU Villatte, JL Vilardaga, R Villatte, M Vilardaga, JCP Atkins, DC Hayes, SC AF Villatte, Jennifer L. Vilardaga, Roger Villatte, Matthieu Vilardaga, Jennifer C. Plumb Atkins, David C. Hayes, Steven C. TI Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Acceptance and commitment therapy; Component analysis; Modular design; Single case experimental design; Acceptance; Values; Mindfulness; Therapy process ID RANDOMIZED EFFECTIVENESS TRIAL; PSYCHOTHERAPY PROCESS; ANXIETY DISORDERS; TREATMENT DESIGNS; MENTAL-ILLNESS; METAANALYSIS; COMPONENT; INTERVENTIONS; MINDFULNESS; ATTITUDES AB A modular, transdiagnostic approach to treatment design and implementation may increase the public health impact of evidence-based psychosocial interventions. Such an approach relies on algorithms for selecting and implementing treatment components intended to have a specific therapeutic effect, yet there is little evidence for how components function independent of their treatment packages when employed in clinical service settings. This study aimed to demonstrate the specificity of treatment effects for two components of Acceptance and Commitment Therapy (ACT), a promising candidate for modularization. A randomized, nonconcurrent, multiple-baseline across participants design was used to examine component effects on treatment processes and outcomes in 15 adults seeking mental health treatment. The ACT OPEN module targeted acceptance and cognitive defusion; the ACT ENGAGED module targeted values-based activation and persistence. According to Tau-U analyses, both modules produced significant improvements in psychiatric symptoms, quality of life, and targeted therapeutic processes. ACT ENGAGED demonstrated greater improvements in quality of life and values-based activation. ACT OPEN showed greater improvements in symptom severity, acceptance, and defusion. Both modules improved awareness and non-reactivity, which were mutually targeted, though using distinct intervention procedures. Both interventions demonstrated high treatment acceptability, completion, and patient satisfaction. Treatment effects were maintained at 3-month follow up. ACT components should be considered for inclusion in a modular approach to implementing evidence-based psychosocial interventions for adults. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Villatte, Jennifer L.; Vilardaga, Roger; Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. [Villatte, Matthieu] Evidence Based Practice Inst, Seattle, WA USA. [Vilardaga, Jennifer C. Plumb] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Hayes, Steven C.] Univ Nevada, Dept Psychol, Reno, NV 89557 USA. RP Villatte, JL (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. EM villatte@uw.edu; vilardag@uw.edu; matt@ebpi.org; jennifer.plumbvilardaga@va.gov; datkins@uw.edu; hayes@unr.edu OI Atkins, David/0000-0002-5781-9880; Hayes, Steven/0000-0003-4399-6859 FU National Institute of Mental Health [F31MH096341]; [T32MH096341] FX First author J.L.V. was assisted in the preparation of this manuscript by grant number F31MH096341 from the National Institute of Mental Health. First author J.L.V. and second author R.V. were assisted in preparation of this manuscript by grant number T32MH096341. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health, who had no involvement in the design or execution of the study. NR 59 TC 3 Z9 3 U1 6 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD FEB PY 2016 VL 77 BP 52 EP 61 DI 10.1016/j.brat.2015.12.001 PG 10 WC Psychology, Clinical SC Psychology GA DE8PR UT WOS:000370899200007 PM 26716932 ER PT J AU Singh, J Ramachandaran, R AF Singh, Jasvinder A. Ramachandaran, Rekha TI Does rural residence impact total ankle arthroplasty utilization and outcomes? SO CLINICAL RHEUMATOLOGY LA English DT Article DE Outcomes; Residence; Rural; Total ankle arthroplasty; Urban; Utilization ID INPATIENT SAMPLE NIS; OPEN APPENDECTOMY; REPLACEMENT; POPULATION; DATABASE AB The objective of this study was to compare total ankle arthroplasty (TAA) utilization and outcomes by patient residence. We used the Nationwide Inpatient Sample (NIS) from 2003 to 2011 to compare utilization and outcomes (post-arthroplasty discharge disposition, length of hospitalization, and mortality) by rural vs. urban residence. Ten thousand eight hundred thirty-three patients in urban and 3,324 patients in rural area underwent TAA. Compared to rural residents, urban residents had: lower mean age, 62.4 vs. 61.8 years (p < 0.0001); higher percent of women, 49 vs. 56 % (p = 0.0008); and lower proportion of Whites, 93 vs. 86 % (p = 0.0005). There were rural-urban disparities in TAA utilization in 2003 (0.32 vs. 0.39/100,000; p = 0.021), but not in 2011 (1.19 vs. 1.17/100,00; p = 0.80). TAA outcomes did not differ by rural vs. urban residence: (1) 11.3 % rural vs. 14.2 % urban residents were discharged to an inpatient facility (p = 0.098); (2) length of hospital stay above the median stay, was 44.8 vs. 42.2 % (p = 0.30); and (3) mortality was 0.2 vs. 0.1 %, respectively (p = 0.81). Multivariable-adjusted logistic regression models did not show any significant differences in discharge to home, length of stay, or mortality, by residence. Our study demonstrated an absence of any evidence of rural-urban differences in TAA outcomes. The rural-urban differences in TAA utilization noted in 2003 were no longer significant in 2011. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit SMART C, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandaran, Rekha] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, J (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, J (reprint author), Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit SMART C, Birmingham, AL USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631] FX JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891; National Institute of Aging (NIA) U01 AG018947; National Cancer Institute (NCI) U10 CA149950; and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD FEB PY 2016 VL 35 IS 2 BP 381 EP 386 DI 10.1007/s10067-015-2908-z PG 6 WC Rheumatology SC Rheumatology GA DE7MN UT WOS:000370821300014 PM 25771850 ER PT J AU Annapureddy, N Elsallabi, O Baker, J Sreih, AG AF Annapureddy, Narender Elsallabi, Osama Baker, Joshua Sreih, Antoine G. TI Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3 SO CLINICAL RHEUMATOLOGY LA English DT Article DE ANCA-associated Vasculitis; Disease activity measures; Patient-Reported Outcomes; RAPID3; Validation of measures ID QUALITY-OF-LIFE; HEALTH-ASSESSMENT QUESTIONNAIRE; PRIMARY SYSTEMIC VASCULITIS; GRANULOMATOSIS; WEGENERS; DISEASE; MDHAQ AB The objective of this study was to determine health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) as measured by the "routine assessment of patient index data 3" (RAPID3) and whether RAPID3 is correlated with disease activity as determined by the Birmingham Vasculitis Activity Score (BVAS). Data from patients at an academic institution vasculitis clinic seen between Jan 2010 and Jan 2012 were collected using chart review. BVAS and RAPID3 scores were calculated at each patient visit. RAPID3 was compared between patients in remission (BVAS = 0) and patients with active disease (BVAS > =1) at all visits for four consecutive visits, when data available, at least 3 months apart during the period mentioned. Robust generalized estimating equations (GEE) in linear regression models evaluated associations between the RAPID3 and BVAS over all available observations, adjusting for intra-subject correlations. Thirty-four patients were included in the study, 26 had granulomatosis with polyangiitis (GPA), five microscopic polyangiitis (MPA), and three eosinophilic granulomatosis with polyangiitis (EGPA). Patients at first visit had impaired HRQoL as measured by RAPID3 [6.8 (3.1-12.6)]. The median RAPID3 scores were higher in patients with active disease as compared to patients in remission (7.0 vs. 3.0, p = 0.115; 8.8 vs. 1.0, p = 0.011; 6.1 vs. 2.0, p = 0.032; and 11.7 vs. 2.0, p = 0.128 for visits 1, 2, 3, and 4, respectively). In longitudinal GEE models incorporating all observations there was a strong association between the RAPID3 (per 1 unit) and BVAS (per 1 unit) [beta 0.21 (0.10, 0.32) p < 0.001]. RAPID3 can be used to measure HRQoL in patients with AAV. RAPID3 correlated significantly with BVAS. RAPID3 can discriminate between disease states in AAV. This instrument may help document patient experience and add to clinical decisions. C1 [Annapureddy, Narender] Vanderbilt Univ, Div Rheumatol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Elsallabi, Osama] Creighton Univ, Dept Med, Omaha, NE 68178 USA. [Baker, Joshua] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Baker, Joshua; Sreih, Antoine G.] Univ Penn, Div Rheumatol, 3400 Spruce St,1407 Penn Tower, Philadelphia, PA 19104 USA. [Baker, Joshua] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Annapureddy, Narender; Sreih, Antoine G.] Rush Univ, Div Rheumatol, Chicago, IL 60612 USA. RP Sreih, AG (reprint author), Univ Penn, Div Rheumatol, 3400 Spruce St,1407 Penn Tower, Philadelphia, PA 19104 USA.; Sreih, AG (reprint author), Rush Univ, Div Rheumatol, Chicago, IL 60612 USA. EM antoine.sreih@uphs.upenn.edu OI Annapureddy, Narender/0000-0002-4012-3406 NR 18 TC 2 Z9 2 U1 3 U2 3 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD FEB PY 2016 VL 35 IS 2 BP 395 EP 400 DI 10.1007/s10067-015-2921-2 PG 6 WC Rheumatology SC Rheumatology GA DE7MN UT WOS:000370821300016 PM 25822996 ER PT J AU Buttner, MM Bormann, JE Weingart, K Andrews, T Ferguson, M Afari, N AF Buttner, Melissa M. Bormann, Jill E. Weingart, Kimberly Andrews, Taylor Ferguson, Marjorie Afari, Niloofar TI Multi-site evaluation of a complementary, spiritually-based intervention for Veterans: The Mantram Repetition Program SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE LA English DT Article DE Complementary therapies; Dissemination; Mindfulness; Program evaluation; Relaxation techniques; Veterans ID WELL-BEING SCALE; POSTTRAUMATIC-STRESS-DISORDER; ALTERNATIVE MEDICINE USE; FUNCTIONAL ASSESSMENT; TRIAL; PTSD; CARE AB Background: Mental and physical symptoms affect Veterans' quality of life. Despite available conventional treatments, an increasing number of Veterans are seeking complementary approaches to symptom management. Research on the Mantram Repetition Program (MRP), a spiritually-based intervention, has shown significant improvements in psychological distress and spiritual well-being in randomized trials. However, these findings have not been replicated in real-world settings. Methods: In this naturalistic study, we analyzed outcomes from 273 Veterans who participated in MRP at six sites and explored outcomes based on facilitator training methods. Measures included satisfaction and symptoms of anxiety, depression, and somatization using the Brief Symptom Inventory-18; Functional Assessment of Chronic Illness Therapy-Spiritual Well-being questionnaire; and the Mindfulness Attention Awareness Scale. Results: There were significant improvements in all outcomes ( p's <.001) regardless of how facilitators were trained. Patient satisfaction was high. Conclusion: The MRP was disseminated successfully yielding improvements in psychological distress, spiritual well-being, and mindfulness. Published by Elsevier Ltd. C1 [Buttner, Melissa M.; Bormann, Jill E.; Afari, Niloofar] VA San Diego Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Buttner, Melissa M.; Bormann, Jill E.; Weingart, Kimberly; Andrews, Taylor; Afari, Niloofar] VA San Diego Healthcare Syst, San Diego, CA USA. [Buttner, Melissa M.; Afari, Niloofar] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Buttner, Melissa M.; Ferguson, Marjorie] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bormann, Jill E.] Univ San Diego, Hahn Sch Nursing & Hlth Sci, San Diego, CA 92110 USA. RP Bormann, JE (reprint author), San Diego Healthcare Syst, 3350 La Jolla Village Dr 111n-1, San Diego, CA 92161 USA. EM Jill.Bormann@va.gov FU Department of Veterans Affairs; VA San Diego Healthcare System; Center of Excellence for Stress and Mental Health (CESAMH) FX This material is based upon work supported by the Department of Veterans Affairs, VA San Diego Healthcare System, and the Center of Excellence for Stress and Mental Health (CESAMH). We thank Ms. Jan Wong and Ms. Suzanne Milligan from VA Employee Education Services (EES) for their assistance in implementing the 2-Day Facilitator Trainings. We especially thank all of the clinicians who brought the Mantram Repetition Program to their facilities and especially all the Veterans who participated in this project. None of the authors have any conflicts of interest to declare. The views expressed in this paper are those of the authors only and do not reflect the official policy or position of the institutions with which the authors are affiliated, nor the Department of Veteran's Affairs, or the United States Government. NR 28 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1744-3881 EI 1873-6947 J9 COMPLEMENT THER CLIN JI Complement. Ther. Clin. Pract. PD FEB PY 2016 VL 22 BP 74 EP 79 DI 10.1016/j.ctcp.2015.12.008 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DE7YW UT WOS:000370854000015 PM 26850810 ER PT J AU Kopacz, MS Connery, AL Bishop, TM Bryan, CJ Drescher, KD Currier, JM Pigeon, WR AF Kopacz, Marek S. Connery, April L. Bishop, Todd M. Bryan, Craig J. Drescher, Kent D. Currier, Joseph M. Pigeon, Wilfred R. TI Moral injury: A new challenge for complementary and alternative medicine SO COMPLEMENTARY THERAPIES IN MEDICINE LA English DT Article DE Moral injury; Pastoral care; Mindfulness; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH; SUICIDAL IDEATION; PSYCHOMETRIC EVALUATION; INTEGRATIVE MEDICINE; MINDFULNESS PROGRAM; MILITARY PERSONNEL; SERVICE MEMBERS; PASTORAL CARE AB Moral injury represents an emerging clinical construct recognized as a source of morbidity in current and former military personnel. Finding effective ways to support those affected by moral injury remains a challenge for both biomedical and complementary and alternative medicine. This paper introduces the concept of moral injury and suggests two complementary and alternative medicine, pastoral care and mindfulness, which may prove useful in supporting military personnel thought to be dealing with moral injury. Research strategies for developing an evidence-base for applying these, and other, complementary and alternative medicine modalities to moral injury are discussed. Published by Elsevier Ltd C1 [Kopacz, Marek S.; Bishop, Todd M.; Pigeon, Wilfred R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Connery, April L.] US Dept Vet Affairs, Canandaigua VA Med Ctr, Canandaigua, NY USA. [Bishop, Todd M.; Pigeon, Wilfred R.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA. [Drescher, Kent D.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA. [Currier, Joseph M.] Univ S Alabama, Dept Psychol, CCP, Mobile, AL 36688 USA. RP Kopacz, MS (reprint author), Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov OI Bishop, Todd/0000-0001-8551-2117; Bryan, Craig/0000-0002-9714-0733 FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention; VA's VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, NY FX Dr. Bishop is supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention. This work was funded, in part, by the VA's VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, NY. The views expressed are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or the U.S. Government. The authors gratefully acknowledge the contribution of Jeffrey Millegan, MD, MPH, FAPA, and Constance M. Cass, MPA, to the development of this paper. NR 79 TC 2 Z9 2 U1 2 U2 9 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0965-2299 EI 1873-6963 J9 COMPLEMENT THER MED JI Complement. Ther. Med. PD FEB PY 2016 VL 24 BP 29 EP 33 DI 10.1016/j.ctim.2015.11.003 PG 5 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DE8NY UT WOS:000370894100006 PM 26860798 ER PT J AU Chiang, SR Levin, HS Wilde, E Haneef, Z AF Chiang, Sharon Levin, Harvey S. Wilde, Elisabeth Haneef, Zulfi TI White matter structural connectivity changes correlate with epilepsy duration in temporal lobe epilepsy SO EPILEPSY RESEARCH LA English DT Article DE Temporal lobe epilepsy; Diffusion tensor imaging; Progression; Mean diffusivity; Fractional anisotropy ID DIFFUSION-TENSOR MRI; HIPPOCAMPAL SCLEROSIS; QUANTITATIVE MRI; AUTOMATED SEGMENTATION; ABNORMALITIES; NETWORKS; BRAIN; FEATURES; VOLUMES; CORTEX AB Purpose: Temporal lobe epilepsy (TLE) is thought to be a network disease and structural changes using diffusion tensor imaging (DTI) have been shown. However, lateralized differences in the structural integrity of TLE, as well as changes in structural integrity with longer disease duration, have not been well defined. Methods: We examined the fractional anisotropy (FA) and mean diffusivity (MD) in the hippocampus, as well as its primary (cingulum and fornix) and remote (uncinate and external capsule) connections in both right and left TLE. Changes in diffusion measures over the disease course were examined by correlating FA and MD in the various structures with epilepsy duration. The potential for each measure of anisotropy and diffusivity as a marker of TLE laterality was investigated using random forest (RF) analysis. Results: MD was increased in the bilateral hippocampus, cingulum, fornix and the right external capsule in both left and right TLE compared to controls. In addition, left TLE exhibited an increased MD in the ipsilateral uncinate fasciculus and bilateral external capsules. A decrease in FA was seen in the left cingulum in left TLE. RF analysis demonstrated that MD of the right hippocampus and FA of the left external capsule were important predictors of TLE laterality. An association of increased MD with epilepsy duration was seen in the left hippocampus in left TLE. Conclusion: Evidence of disrupted white matter architecture in the hippocampus and its primary and remote connections were demonstrated in TLE. While changes in the hippocampus and cingulum were more prominent in right TLE, remote changes were more prominent in left TLE. MD of the right hippocampus and FA of the left external capsule were found to be the strongest structural predictors of TLE laterality. Changes associated with duration of epilepsy indicated that changes in structural integrity may be progressive over the disease course. This study illustrates the potential of structural diffusion tensor imaging in elucidating pathophysiology, enhancing diagnosis and assisting prognostication. (C) 2015 Elsevier B.V. All rights reserved. C1 [Chiang, Sharon] Rice Univ, Dept Stat, Houston, TX 77251 USA. [Levin, Harvey S.; Wilde, Elisabeth] Baylor Coll Med, Dept Phys Med, Houston, TX 77030 USA. [Haneef, Zulfi] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Haneef, Zulfi] Michael E DeBakey VA Med Ctr, Neurol Care Line, Houston, TX USA. [Levin, Harvey S.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA. RP Chiang, SR (reprint author), Rice Univ, Dept Stat, Houston, TX 77251 USA. EM sc4712@rice.edu; hlevin@bcm.edu; ewilde@bcm.edu; zulfi.haneef@bcm.edu FU National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences [2T15LM007093-21]; National Institutes of Health [5T32CA096520-07]; Moody Foundation; Epilepsy Foundation of America; Baylor College of Medicine Computational and Integrative Biomedical Research Center Seed Grant Awards FX Sharon Chiang's contributions to this article include study concept or design, statistical analysis, drafting/revising the manuscript for content, and analysis/interpretation of data. Harvey S. Levin's contributions to this article include revising the manuscript for content. Elisabeth Wilde's contributions to this article include revising the manuscript for content. Zulfi Haneef's contributions to this article include study concept or design, drafting/revising the manuscript for content, analysis/interpretation of data, study supervision, and obtaining funding. The authors acknowledge Raja Muthupillai, Claudio Arenas, Cynthia Calija, Sikawat Thanaviratananich, and Christina Thomas for help with methodology, recruitment, and data collection. Funding for the design and conduct of this study; for the collection, management, analysis, and interpretation of the data; and for the preparation, review, and approval of the manuscript was provided by the Epilepsy Foundation of America. Support for this publication was provided by the National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences (Grant #2T15LM007093-21) (SC); the National Institutes of Health (Grant #5T32CA096520-07) (SC); the Moody Foundation (HSL); Epilepsy Foundation of America (Research Grants Program) (ZH); and the Baylor College of Medicine Computational and Integrative Biomedical Research Center Seed Grant Awards (ZH). NR 58 TC 5 Z9 6 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2016 VL 120 BP 37 EP 46 DI 10.1016/j.eplepsyres.2015.12.002 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DE9ZQ UT WOS:000370998800007 PM 26709881 ER PT J AU Torolira, D Suchomelova, L Wasterlain, CG Niquet, J AF Torolira, Daniel Suchomelova, Lucie Wasterlain, Claude G. Niquet, Jerome TI Widespread neuronal injury in a model of cholinergic status epilepticus in postnatal day 7 rat pups SO EPILEPSY RESEARCH LA English DT Article DE Immature brain; Seizures; Fluoro-Jade B; Active caspase-3; Neonate; Hippocampus ID RECURRENT NEONATAL SEIZURES; EARLY-LIFE SEIZURES; LONG-TERM CONSEQUENCES; NERVE AGENT EXPOSURE; MEDIODORSAL NUCLEUS; EXCITATORY ACTIONS; BRAIN-DEVELOPMENT; 12-DAY-OLD RATS; IMMATURE RATS; HIPPOCAMPUS AB Objective: Status Epilepticus (SE) is common in neonates and infants, and is associated with neuronal injury and adverse developmental outcomes. However, the role of SE in this injury is uncertain. Until now, we have lacked an animal model in which seizures result in neuronal injury in rodent models at ages below postnatal day 12 (P12) unless seizures are combined with inflammatory stressors. Methods: We induced SE with high-dose lithium and pilocarpine in P7 rats, which are developmentally close to human neonates. Several EEG measures and O-2 saturation were recorded during the 6 h following initiation of SE. We assessed neuronal injury at 6 and 24 h post-SE onset using Fluoro-Jade B staining (FJB) and caspase-3a immunoreactivity (IR). Results: EEGs showed continuous polyspikes activity for 54.3 +/- 6.7 min, while O-2 saturation showed no significant hypoxemia. By 24 h after SE onset, significant neuronal injury was observed in CA1/subiculum, CA3, dentate gyrus, thalamus, neocortex, amygdala, piriform cortex, lateral entorhinal cortex, hypothalamus, caudate putamen, globus pallidus, ventral pallidum, and nucleus accumbens. At 24 h post-SE, caspase-3a IR was significantly increased in CA1/subiculum, thalamus, and neocortex compared to sham, and caspase-3a IR neurons had fragmented nuclei, suggesting that SE triggered an irreversible form of cell injury. Significance: In conclusion, we have developed a model of cholinergic SE in P7 rat pups, which combines high survival (69.9% survival at 24 h) and widespread brain injury. These studies suggest that the immature brain is vulnerable to severe forms of SE. Published by Elsevier B.V. C1 [Torolira, Daniel; Suchomelova, Lucie; Wasterlain, Claude G.; Niquet, Jerome] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA 90073 USA. [Wasterlain, Claude G.; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU Merit Review Award from the United States (U.S.) Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) [I01 BX000273-07]; NINDS [UO1 NS074926] FX This work was supported in part by Merit Review Award # I01 BX000273-07 from the United States (U.S.) Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) and NINDS (grant UO1 NS074926; CW). NR 42 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2016 VL 120 BP 47 EP 54 DI 10.1016/j.eplepsyres.2015.11.005 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DE9ZQ UT WOS:000370998800008 PM 26709882 ER PT J AU Chen, S Whitson, H Quinones, A Thielke, S AF Chen, Sunny Whitson, Heather Quinones, Ana Thielke, Stephen TI Comparative health and self-rated health are equivalently associated with health indicators among older adults SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Letter ID MORTALITY; ASSESSMENTS C1 [Chen, Sunny; Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. [Whitson, Heather] Duke Univ, Med Ctr, Dept Med Geriatr & Ophthalmol, DUMC Box 3003, Durham, NC 27710 USA. [Whitson, Heather] Duke Univ, Med Ctr, Aging Ctr, DUMC Box 3003, Durham, NC 27710 USA. [Whitson, Heather] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 508 Fulton St,3rd Floor GRECC, Durham, NC 27705 USA. [Quinones, Ana] Oregon Hlth & Sci Univ, Sch Publ Hlth, 3181 SW Sam Jackson Pk Rd,Mail Code CB669, Portland, OR 97239 USA. [Quinones, Ana] Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code CB669, Portland, OR 97239 USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific St,Box 356560, Seattle, WA 98195 USA. RP Thielke, S (reprint author), Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA.; Thielke, S (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific St,Box 356560, Seattle, WA 98195 USA. EM sthielke@u.washington.edu OI Quinones, Ana/0000-0001-6554-7734 FU NHLBI NIH HHS [R25 HL105430, R25HL105430]; NIA NIH HHS [K23-AG-032867, K23 AG032867, P30 AG028716, P30-AG-028716, R01 AG043438]; NIMH NIH HHS [K23 MH093591] NR 8 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD FEB PY 2016 VL 70 BP 279 EP 280 DI 10.1016/j.jclinepi.2015.08.022 PG 2 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DE5NE UT WOS:000370676900041 PM 26386324 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Ambulatory blood pressure monitoring to diagnose hypertension-an idea whose time has come SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Editorial Material C1 [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Med, Reno, NV 89557 USA. [Bloch, Michael J.] Renown Inst Heart & Vasc Hlth, Vasc Care, Reno, NV USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, Dept Internal Med, Vasc Care,Renown Heart & Vasc Inst, Reno, NV 89557 USA. EM Michael@bluesprucemed.com NR 7 TC 4 Z9 4 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD FEB PY 2016 VL 10 IS 2 BP 89 EP 91 DI 10.1016/j.jash.2015.10.010 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE8MB UT WOS:000370889000001 PM 26654344 ER PT J AU Ibrahim-Verbaas, CA Bressler, J Debette, S Schuur, M Smith, AV Bis, JC Davies, G Trompet, S Smith, JA Wolf, C Chibnik, LB Liu, Y Vitart, V Kirin, M Petrovic, K Polasek, O Zgaga, L Fawns-Ritchie, C Hoffmann, P Karjalainen, J Lahti, J Llewellyn, DJ Schmidt, CO Mather, KA Chouraki, V Sun, Q Resnick, SM Rose, LM Oldmeadow, C Stewart, M Smith, BH Gudnason, V Yang, Q Mirza, SS Jukema, JW Dejager, PL Harris, TB Liewald, DC Amin, N Coker, LH Stegle, O Lopez, OL Schmidt, R Teumer, A Ford, I Karbalai, N Becker, JT Jonsdottir, MK Au, R Fehrmann, RSN Herms, S Nalls, M Zhao, W Turner, ST Yaffe, K Lohman, K van Swieten, JC Kardia, SLR Knopman, DS Meeks, WM Heiss, G Holliday, EG Schofield, PW Tanaka, T Stott, DJ Wang, J Ridker, P Gow, AJ Pattie, A Starr, JM Hocking, LJ Armstrong, NJ McLachlan, S Shulman, JM Pilling, LC Eiriksdottir, G Scott, RJ Kochan, NA Palotie, A Hsieh, YC Eriksson, JG Penman, A Gottesman, RF Oostra, BA Yu, L DeStefano, AL Beiser, A Garcia, M Rotter, JI Nothen, MM Hofman, A Slagboom, PE Westendorp, RGJ Buckley, BM Wolf, PA Uitterlinden, AG Psaty, BM Grabe, HJ Bandinelli, S Chasman, DI Grodstein, F Roikkonen, K Lambert, JC Porteous, DJ Price, JF Sachdev, PS Ferrucci, L Attia, JR Rudan, I Hayward, C Wright, AF Wilson, JF Cichon, S Franke, L Schmidt, H Ding, J de Craen, AJM Fornage, M Bennett, DA Deary, IJ Ikram, MA Launer, LJ Fitzpatrick, AL Seshadri, S van Duijn, CM Mosley, TH AF Ibrahim-Verbaas, C. A. Bressler, J. Debette, S. Schuur, M. Smith, A. V. Bis, J. C. Davies, G. Trompet, S. Smith, J. A. Wolf, C. Chibnik, L. B. Liu, Y. Vitart, V. Kirin, M. Petrovic, K. Polasek, O. Zgaga, L. Fawns-Ritchie, C. Hoffmann, P. Karjalainen, J. Lahti, J. Llewellyn, D. J. Schmidt, C. O. Mather, K. A. Chouraki, V. Sun, Q. Resnick, S. M. Rose, L. M. Oldmeadow, C. Stewart, M. Smith, B. H. Gudnason, V. Yang, Q. Mirza, S. S. Jukema, J. W. Dejager, P. L. Harris, T. B. Liewald, D. C. Amin, N. Coker, L. H. Stegle, O. Lopez, O. L. Schmidt, R. Teumer, A. Ford, I. Karbalai, N. Becker, J. T. Jonsdottir, M. K. Au, R. Fehrmann, R. S. N. Herms, S. Nalls, M. Zhao, W. Turner, S. T. Yaffe, K. Lohman, K. van Swieten, J. C. Kardia, S. L. R. Knopman, D. S. Meeks, W. M. Heiss, G. Holliday, E. G. Schofield, P. W. Tanaka, T. Stott, D. J. Wang, J. Ridker, P. Gow, A. J. Pattie, A. Starr, J. M. Hocking, L. J. Armstrong, N. J. McLachlan, S. Shulman, J. M. Pilling, L. C. Eiriksdottir, G. Scott, R. J. Kochan, N. A. Palotie, A. Hsieh, Y-C Eriksson, J. G. Penman, A. Gottesman, R. F. Oostra, B. A. Yu, L. DeStefano, A. L. Beiser, A. Garcia, M. Rotter, J. I. Noethen, M. M. Hofman, A. Slagboom, P. E. Westendorp, R. G. J. Buckley, B. M. Wolf, P. A. Uitterlinden, A. G. Psaty, B. M. Grabe, H. J. Bandinelli, S. Chasman, D. I. Grodstein, F. Roikkonen, K. Lambert, J-C Porteous, D. J. Price, J. F. Sachdev, P. S. Ferrucci, L. Attia, J. R. Rudan, I. Hayward, C. Wright, A. F. Wilson, J. F. Cichon, S. Franke, L. Schmidt, H. Ding, J. de Craen, A. J. M. Fornage, M. Bennett, D. A. Deary, I. J. Ikram, M. A. Launer, L. J. Fitzpatrick, A. L. Seshadri, S. van Duijn, C. M. Mosley, T. H. CA Generation Scotland TI GWAS for executive function and processing speed suggests involvement of the CADM2 gene SO MOLECULAR PSYCHIATRY LA English DT Article ID ONSET ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; COGNITIVE FUNCTION; LINKAGE ANALYSIS; COMMON VARIANTS; LOCI; INTELLIGENCE; EXPRESSION; DISORDER; SCHIZOPHRENIA AB To identify common variants contributing to normal variation in two specific domains of cognitive functioning, we conducted a genome-wide association study (GWAS) of executive functioning and information processing speed in non-demented older adults from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium. Neuropsychological testing was available for 5429-32 070 subjects of European ancestry aged 45 years or older, free of dementia and clinical stroke at the time of cognitive testing from 20 cohorts in the discovery phase. We analyzed performance on the Trail Making Test parts A and B, the Letter Digit Substitution Test (LDST), the Digit Symbol Substitution Task (DSST), semantic and phonemic fluency tests, and the Stroop Color and Word Test. Replication was sought in 1311-21860 subjects from 20 independent cohorts. A significant association was observed in the discovery cohorts for the single-nucleotide polymorphism (SNP) rs17518584 (discovery P-value = 3.12 x 10(-8)) and in the joint discovery and replication meta-analysis (P-value = 3.28 x 10(-9) after adjustment for age, gender and education) in an intron of the gene cell adhesion molecule 2 (CADM2) for performance on the LDST/DSST. Rs17518584 is located about 170 kb upstream of the transcription start site of the major transcript for the CADM2 gene, but is within an intron of a variant transcript that includes an alternative first exon. The variant is associated with expression of CADM2 in the cingulate cortex (P-value= 4x10(-4)). The protein encoded by CADM2 is involved in glutamate signaling (P-value = 7.22 x 10(-15)), gamma-aminobutyric acid (GABA) transport (P-value = 1.36 x 10(-11)) and neuron cell-cell adhesion (P-value = 1.48 x 10(-13)). Our findings suggest that genetic variation in the CADM2 gene is associated with individual differences in information processing speed. C1 [Ibrahim-Verbaas, C. A.; Schuur, M.; Amin, N.; Oostra, B. A.; van Duijn, C. M.] Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Rotterdam, Netherlands. [Ibrahim-Verbaas, C. A.; Schuur, M.; van Swieten, J. C.; Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands. [Bressler, J.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Human Genet Ctr, Houston, TX 77030 USA. [Debette, S.; Au, R.; DeStefano, A. L.; Beiser, A.; Wolf, P. A.; Seshadri, S.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Debette, S.] Univ Bordeaux, Epidemiol & Biostat, U897, INSERM, Bordeaux, France. [Debette, S.] Bordeaux Univ Hosp, Dept Neurol, Bordeaux, France. [Smith, A. V.; Gudnason, V.; Eiriksdottir, G.] Iceland Heart Assoc, Kopavogur, Iceland. [Smith, A. V.; Gudnason, V.] Univ Iceland, Fac Med, Reykjavik, Iceland. [Bis, J. C.; Psaty, B. M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Davies, G.; Fawns-Ritchie, C.; Liewald, D. C.; Gow, A. J.; Pattie, A.; Starr, J. M.; Deary, I. J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland. [Trompet, S.; Jukema, J. W.] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands. [Trompet, S.; de Craen, A. J. M.] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands. [Smith, J. A.; Zhao, W.; Kardia, S. L. R.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Wolf, C.; Karbalai, N.] Max Planck Inst Psychiat, RG Stat Genet, Munich, Germany. [Chibnik, L. B.; Dejager, P. L.] Brigham & Womens Hosp, Div Neurol, Program Translat Neuropsychiat Gen, Boston, MA 02115 USA. [Liu, Y.; Lohman, K.] Wake Forest Sch Med, Dept Epidemiol, Winston Salem, NC USA. [Petrovic, K.; Schmidt, R.; Schmidt, H.] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland. [Kirin, M.; Stewart, M.; McLachlan, S.; Price, J. F.; Rudan, I.; Wilson, J. F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. [Petrovic, K.; Schmidt, R.; Schmidt, H.] Med Univ & Gen Hosp Graz, Dept Neurol, Graz, Austria. [Polasek, O.] Univ Split, Dept Publ Hlth, Split, Croatia. [Zgaga, L.] Trintiy Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland. [Hoffmann, P.; Cichon, S.] Res Ctr Juelich, Inst Neurosci & Med INM1, Julich, Germany. [Hoffmann, P.; Herms, S.; Cichon, S.] Univ Basel, Dept Biomed, Div Med Genet, Basel, Switzerland. [Hoffmann, P.; Herms, S.; Noethen, M. M.; Cichon, S.] Univ Bonn, Inst Human Genet, Life & Brain Res Ctr, Dept Genom, Bonn, Germany. [Karjalainen, J.; Fehrmann, R. S. N.; Franke, L.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands. [Lahti, J.; Roikkonen, K.] Univ Helsinki, Inst Behav Sci, Helsinki, Finland. [Lahti, J.; Eriksson, J. G.] Folkhalsan Res Ctr, Helsinki, Finland. [Llewellyn, D. J.] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England. [Schmidt, C. O.] Univ Med Greifswald, Inst Community Med, Greifswald, Germany. [Mather, K. A.; Armstrong, N. J.; Kochan, N. A.; Sachdev, P. S.] Univ New S Wales, UNSW Med, Sch Psychiat, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. [Chouraki, V.; Lambert, J-C] Univ Lille Nord France, Inst Pasteur Lille, U1167, INSERM, Lille, France. [Sun, Q.; Grodstein, F.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Sun, Q.; Grodstein, F.] Harvard Univ, Sch Med, Boston, MA USA. [Resnick, S. M.] NIA, Lab Behav Neurosci, NIH, Baltimore, MD 21224 USA. [Rose, L. M.; Ridker, P.; Chasman, D. I.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Oldmeadow, C.; Holliday, E. G.; Scott, R. J.; Attia, J. R.] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2300, Australia. [Oldmeadow, C.; Holliday, E. G.; Scott, R. J.; Attia, J. R.] Univ Newcastle, Fac Hlth, Newcastle, NSW 2300, Australia. [Smith, B. H.] Univ Dundee, Med Res Inst, Dundee, Scotland. [Yang, Q.; Au, R.; DeStefano, A. L.; Beiser, A.; Wolf, P. A.; Seshadri, S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Yang, Q.; Wang, J.; DeStefano, A. L.; Beiser, A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Mirza, S. S.; Hofman, A.; Uitterlinden, A. G.; Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Mirza, S. S.; Hofman, A.; Uitterlinden, A. G.; Ikram, M. A.; van Duijn, C. M.] Netherlands Consortium Hlth Ageing, Leiden, Netherlands. [Harris, T. B.; Garcia, M.; Launer, L. J.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Liewald, D. C.; Gow, A. J.; Deary, I. J.] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland. [Coker, L. H.] Wake Forest Sch Med, Div Publ Hlth Sci & Neurol, Winston Salem, NC USA. [Stegle, O.] Max Planck Inst Intelligent Syst, Max Planck Inst Dev Biol, Tubingen, Germany. [Lopez, O. L.; Becker, J. T.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Teumer, A.] Univ Med Greifswald, Interfaculty Inst Genet & Funct Genom, Greifswald, Germany. [Ford, I.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland. [Becker, J. T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Becker, J. T.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Jonsdottir, M. K.] Landspitali Hosp, Reykjavik, Iceland. [Nalls, M.] NIA, Lab Neurogenet, Bethesda, MD 20892 USA. [Turner, S. T.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA. [Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knopman, D. S.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Meeks, W. M.] Univ Mississippi, Med Ctr, Dept Med, Div Geriatr, Jackson, MS 39216 USA. [Heiss, G.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Schofield, P. W.] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Tanaka, T.; Ferrucci, L.] NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA. [Stott, D. J.] Univ Glasgow, Dept Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. [Starr, J. M.] Alzheimer Scotland Res Ctr, Edinburgh, Midlothian, Scotland. [Hocking, L. J.] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland. [Armstrong, N. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia. [Armstrong, N. J.] Univ New S Wales, Sch Math & Stat, Sydney, NSW, Australia. [Armstrong, N. J.] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia. [Shulman, J. M.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Shulman, J. M.] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Dept Mol & Human Genet, Houston, TX 77030 USA. [Pilling, L. C.] Univ Exeter, Sch Med, Epidemiol & Publ Hlth Grp, Exeter, Devon, England. [Kochan, N. A.; Sachdev, P. S.] Prince Wales Hosp, Neuropsychiat Inst, Sydney, NSW, Australia. [Palotie, A.] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England. [Palotie, A.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland. [Palotie, A.] Univ Helsinki, Dept Med Genet, Helsinki, Finland. [Palotie, A.] Univ Cent Hosp, Helsinki, Finland. [Hsieh, Y-C] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan. [Eriksson, J. G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland. [Eriksson, J. G.] Natl Inst Hlth & Welf, Helsinki, Finland. [Eriksson, J. G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland. [Eriksson, J. G.] Vasa Cent Hosp, Vaasa, Finland. [Penman, A.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA. [Gottesman, R. F.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Yu, L.; Bennett, D. A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Rotter, J. I.] Cedars Sinai Med Ctr, Med Genet Inst, Los Angeles, CA 90048 USA. [Rotter, J. I.] Harbor UCLA Med Ctr, Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Rotter, J. I.] Harbor UCLA Med Ctr, Dept Pediat, Div Genet Outcomes, Torrance, CA 90509 USA. [Noethen, M. M.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany. [Slagboom, P. E.] Leiden Univ, Med Ctr, Dept Mol Epidemiol, Leiden, Netherlands. [Westendorp, R. G. J.] Leiden Acad Vital & Ageing, Leiden, Netherlands. [Buckley, B. M.] Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland. [Uitterlinden, A. G.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Psaty, B. M.; Fitzpatrick, A. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, B. M.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Grabe, H. J.] HELIOS Hosp Stralsund, Univ Med Greifswald, Dept Psychiat & Psychotherapy, Stralsund, Germany. [Ibrahim-Verbaas, C. A.; Bressler, J.; Debette, S.; Schuur, M.; Smith, A. V.; Bis, J. C.; Davies, G.; Bandinelli, S.] Azienda Sanitaria Firenze, Geriatr Unit, Florence, Italy. [Porteous, D. J.] Univ Edinburgh, Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland. [Ding, J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA. [Fornage, M.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA. [Fornage, M.] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands. [Mosley, T. H.] Univ Mississippi, Med Ctr, Dept Med & Neurol, Jackson, MS 39216 USA. RP Mosley, TH (reprint author), Univ Mississippi, Med Ctr, Dept Med Geriatr, 2500 North State St, Jackson, MS 39216 USA. EM tmosley@umc.edu RI ; Lambert, jean-charles/A-9553-2014; Franke, Lude/P-7036-2016; Karjalainen, Juha/P-8624-2016; Slagboom, P. Eline/R-4790-2016; Fehrmann, Rudolf/E-2551-2011; Polasek, Ozren/B-6002-2011; Gudnason, Vilmundur/K-6885-2015 OI van Swieten, John /0000-0001-6278-6844; Lahti, Jari/0000-0002-4310-5297; Sachdev, Perminder/0000-0002-9595-3220; Smith, Blair/0000-0002-5362-9430; Beiser, Alexa/0000-0001-8551-7778; Smith, Jennifer/0000-0002-3575-5468; Raikkonen, Katri/0000-0003-3124-3470; Gow, Alan/0000-0002-3320-4531; Nothen, Markus/0000-0002-8770-2464; Smith, Albert Vernon/0000-0003-1942-5845; Lambert, jean-charles/0000-0003-0829-7817; Franke, Lude/0000-0002-5159-8802; Slagboom, P. Eline/0000-0002-2875-4723; Fehrmann, Rudolf/0000-0002-7516-315X; Polasek, Ozren/0000-0002-5765-1862; Stegle, Oliver/0000-0002-8818-7193; Zgaga, Lina/0000-0003-4089-9703; Hocking, Lynne J/0000-0002-2414-2826; Gudnason, Vilmundur/0000-0001-5696-0084 FU National Foundation for Alzheimer's disease and related disorders; Institut Pasteur de Lille; Centre National de Genotypage; Inserm; FRC (fondation pour la recherche sur le cerveau); Rotary; LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease); MEDIALZ Project - ERDF (European Regional Development Fund) [11001003]; Conseil Regional Nord Pas de Calais; Fondation pour la Recherche Medicale; Caisse Nationale Maladie des Travailleurs Salaries; Direction Generale de la Sante; MGEN; Institut de la Longevite; Agence Francaise de Securite Sanitaire des Produits de Sante; Aquitaine and Bourgogne Regional Councils; Fondation de France; joint French Ministry of Research/INSERM 'Cohortes et collections de donnees biologiques' program; Eisai; Wellcome Trust; British Heart Foundation; Chief Scientist Office of the Scottish Executive; NIA [N01-AG-12100]; National Heart, Lung and Blood Institute Contracts [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL70825, R01HL087641, R01HL59367, R01HL086694]; National Human Genome Research Institute [U01HG004402]; NIH Roadmap for Medical Research; Austrian Science Fond (FWF) [P20545-P05, P13180]; Intramural Research Program of the NIH, National Institute on Aging; NHLBI [HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC850863, U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393]; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) [R01AG023629, R01AG15928, R01AG20098, R01AG027058]; National Center for Advancing Translational Sciences; CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; Medical Research Council (UK); European Commission Framework 6 project EUROSPAN [LSHG-CT-2006-018947]; Republic of Croatia Ministry of Science, Education and Sports [108-1080315-0302]; Netherlands Organization for Scientific Research (NWO); Internationale Stichting Alzheimer Onderzoek (ISAO); Hersenstichting Nederland (HSN); Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI); Russian Foundation for Basic Research (RFBR); National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278, U01 HL096917, R01 HL093029]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; National Institute of Neurological Disorders and Stroke [NS17950]; National Institute of Aging [U01 AG049505, AG033193, AG008122, AG16495]; Agence National de la Recherche; Leducq Foundation; National Heart, Lung and Blood Institute [HL054464, HL054457, HL054481, HL071917, HL87660, HL043851, HL080467]; National Institute of Neurological Disorders and Stroke of the National Institutes of Health [NS041558]; Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6]; Scottish Funding Council [HR03006]; Academy of Finland; Finnish Diabetes Research Society; Folkhalsan Research Foundation; Novo Nordisk Foundation; Finska Lakaresallskapet; Signe and Ane Gyllenberg Foundation; University of Helsinki; Ministry of Education; Ahokas Foundation; Emil Aaltonen Foundation; Juho Vainio Foundation; Wellcome Trust [WT089062]; University of Newcastle's Strategic Initiative Fund; Vincent Fairfax Family Foundation; Hunter Medical Research Institute; Italian Ministry of Health [ICS 110.1RS97.71]; US National Institute on Aging [N01[AG]916413, N01[AG]821336, 263 MD 9164 13, 263 MD 821336]; Intramural Research Program, National Institute on Aging, National Institutes of Health; BBSRC; Royal Society; Chief Scientist Office of the Scottish Government; Research Into Ageing; UK Biotechnology and Biological Sciences Research Council (BBSRC); Engineering and Physical Sciences Research Council (EPSRC); Economic and Social Research Council (ESRC); MRC; NHMRC [401184]; Australian National Health & Medical Research Council [350833, 568969]; Capacity Building Grant [568940]; NHMRC Project [525453]; National Institutes of Health [CA87969, CA49449, HL34594, U01HG004399, DK058845, CA65725, CA67262, CA50385, 5UO1CA098233, EY09611, EY015473, HG004728, HL35464, CA55075, CA134958, DK070756]; MRC Human Genetics Unit; Arthritis Research UK; European Union [LSHG-CT-2006-018947]; Bristol-Myers Squibb; Netherlands Heart Foundation [2001 D 032]; European commission [223004]; Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging) [050-060-810]; Netherlands Organisation of Scientific Research NWO Investments [175.010.2005.011, 911-03-012]; Research Institute for Diseases in the Elderly [014-93-015]; Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project [050-060-810]; Erasmus Medical Center; Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission 49 (DG XII); Municipality of Rotterdam; ZonMW Veni Grant [916.13.054]; NIA Grants [P30AG10161, R01AG15819, R01AG17917, R01AG30146, K08AG34290, K25AG41906]; Federal Ministry of Education and Research [01ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs; Social Ministry of the Federal State of Mecklenburg-West Pomerania; National Cancer Institute [CA047988]; Donald W Reynolds Foundation; Fondation Leducq; Amgen FX CS: The work was made possible by the generous participation of the control subjects and their families. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille, the Centre National de Genotypage, Inserm, FRC (fondation pour la recherche sur le cerveau) and Rotary. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease). JCL was funded by the MEDIALZ Project (Grant 11001003) financed by ERDF (European Regional Development Fund) and Conseil Regional Nord Pas de Calais. The Three-City Study was performed as part of a collaboration between the Institut National de la Sante et de la Recherche Medicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, MGEN, Institut de la Longevite, Agence Francaise de Securite Sanitaire des Produits de Sante, the Aquitaine and Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM 'Cohortes et collections de donnees biologiques' program. Lille Genopole received an unconditional grant from Eisai.; AAA: We thank the cohort participants and team members who contributed to this study. Phenotype collection and DNA extraction were supported by the Wellcome Trust, the British Heart Foundation and the Chief Scientist Office of the Scottish Executive. The AAA Trial was performed and the database is maintained by members of the University of Edinburgh Molecular Epidemiology Research Group in the Centre for Population Health Sciences. We also thank staff at the Wellcome Trust Clinical Research Facility in Edinburgh where some of the research clinics and genotyping were undertaken.; AGES: Aging Gene-Environment Susceptibility-Reykjavik Study: The research has been funded by NIA Contract N01-AG-12100 with contributions from NEI, NIDCD and NHLBI, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association) and the Althingi (the Icelandic Parliament).; ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung and Blood Institute Contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute Contract U01HG004402; and National Institutes of Health Contract HHSN268200625226C. We thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.; ASPS: We thank Ing. Johann Semmler and Irmgard Polzl for creating the DNA bank and for supervising the quality management of the biobanking and DNA analyses. The ASPS is funded by the Austrian Science Fond (FWF) Grant Number P20545-P05 and P13180.; BLSA: Baltimore Longitudinal Study of Aging (BLSA): The Baltimore Longitudinal Study of Aging is supported by the Intramural Research Program of the NIH, National Institute on Aging.; Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG15928, R01AG20098, and R01AG027058 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHSNHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; CROATIA-Korcula: The CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to IR (108-1080315-0302). We would like to acknowledge the invaluable contributions of the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum Munchen, Neuherberg, Germany.; CROATIA-Vis: The CROATIA-Vis study was funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and Sports research grants to IR (108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland.; ERF: This study was financially supported by the Netherlands Organization for Scientific Research (NWO), the Internationale Stichting Alzheimer Onderzoek (ISAO), the Hersenstichting Nederland (HSN) and the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) and by the Russian Foundation for Basic Research (RFBR). We thank the participants from the Genetic Research in Isolated Populations, Erasmus Rucphen Family, who made this work possible. Also, we thank Petra Veraart for collecting all genealogical data.; FHS: This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278) and Grants (U01 HL096917 and R01 HL093029). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This study was also supported by grants from the National Institute of Neurological Disorders and Stroke (NS17950) and the National Institute of Aging (U01 AG049505, AG033193, AG008122, AG16495). The content is solely the responsibility of the authors and does not necessarily represent the official views of NINDS, NHLBI, NIA, NIH or AHA. Dr. Debette is a recipient of a Chaire d'Excellence grant from the Agence National de la Recherche and a grant from the Leducq Foundation.; GENOA: Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) was provided by the National Heart, Lung and Blood Institute (HL054464, HL054457, HL054481, HL071917 and HL87660) and the National Institute of Neurological Disorders and Stroke (NS041558) of the National Institutes of Health. Genotyping was performed at the Mayo Clinic (S.T.T., Mariza de Andrade, Julie Cunningham) and was made possible by the University of Texas Health Sciences Center (Eric Boerwinkle, Megan L Grove-Gaona). We would also like to thank the families that participated in the GENOA study.; GS: We are grateful to the GS Executive Committee Professors Blair H. Smith, David J. Porteous, Sandosh Padmanabhan and Dr. Lynne J. Hocking, and all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006].; HBCS: We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland, the Finnish Diabetes Research Society, Folkhalsan Research Foundation, Novo Nordisk Foundation, Finska Lakaresallskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation and Wellcome Trust (Grant Number WT089062).; Health ABC: This research was supported by NIA Contracts N01AG62101, N01AG62103 and N01AG62106. The genome-wide association study was funded by NIA Grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, Contract Number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging.; Hunter: The authors would like to thank the men and women participating in the HCS as well as all the staff, investigators and collaborators who have supported or been involved in the project to date. The cohort was made possible with support from the University of Newcastle's Strategic Initiative Fund, the Vincent Fairfax Family Foundation and the Hunter Medical Research Institute.; InCHIANTI: The Invechhiare in Chianti (InCHIANTI) Study was supported as a targeted project (ICS 110.1RS97.71) by the Italian Ministry of Health, by the US National Institute on Aging (Contracts N01[AG]916413, N01[AG]821336, 263 MD 9164 13, and 263 MD 821336), and, in part, by the Intramural Research Program, National Institute on Aging, National Institutes of Health.; LBC1921/LBC1936: We thank the cohort participants and team members who contributed to these studies. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the BBSRC, The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Research Into Ageing (continues as part of Age UK The Disconnected Mind project). Genotyping of the cohorts was funded by the UK Biotechnology and Biological Sciences Research Council (BBSRC). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and MRC is gratefully acknowledged.; MAS: We would like to acknowledge and thank the Sydney MAS participants and the Research Team for their contributions and assistance. We would like to specifically acknowledge the support and contributions of Professor Henry Brodaty (Chief Investigator), Dr Simone Reppermund (Study Co-ordinator), Professor Peter Schofield, Dr Arezoo Assareh and Dr John Kwok to this work. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by NHMRC Grant 401184. DNA sample preparation was undertaken in the laboratory of Professor Peter Schofield and Dr John Kwok, Neuroscience Research Australia, with the assistance of Dr Arezoo Assareh. Genotyping was performed by the Ramaciotti Centre, University of New South Wales. Sydney MAS is supported by the Australian National Health & Medical Research Council Program Grants 350833 and 568969. Karen Mather is supported by the Capacity Building Grant 568940. Nicola Armstrong is supported by the NHMRC Project Grant 525453.; Hippocampal eQTL: The hippocampal gene expression study was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia, under the auspices of the National Genome Research Network plus (NGFNplus)).; NHS: This study was supported by research Grants CA87969, CA49449, HL34594, U01HG004399, DK058845, CA65725, CA67262, CA50385, 5UO1CA098233, EY09611, EY015473, HG004728, HL35464, CA55075, CA134958 and DK070756 from the National Institutes of Health. The genotyping was partly supported by an unrestricted grant from Merck Research Laboratories. Dr Sun is supported by career development award K99HL098459 from the National Heart, Lung and Blood Institute. Supported in part by NIH.; ORCADES: ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (Contract No. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of Lorraine Anderson and the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.; PROSPER: The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr JW Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (Grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (Grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging Grant 050-060-810).; RS: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission 49 (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. Dr Ikram was supported by a ZonMW Veni Grant: 916.13.054.; RUSH: Supported in part by NIA Grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, K08AG34290 and K25AG41906.; SHIP: SHIP is part of the Community Medicine Research net of the University Medicine of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. The SHIP authors are grateful to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum Munchen) for the genotyping of the SHIP-TREND cohort.; WGHS: The WGHS is supported by HL043851 and HL080467 from the National Heart, Lung and Blood Institute and CA047988 from the National Cancer Institute, the Donald W Reynolds Foundation and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. NR 59 TC 4 Z9 5 U1 6 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2016 VL 21 IS 2 BP 189 EP 197 DI 10.1038/mp.2015.37 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA DE7LI UT WOS:000370817800005 PM 25869804 ER PT J AU Lu, AT Hannon, E Levine, ME Hao, K Crimmins, EM Lunnon, K Kozlenkov, A Mill, J Dracheva, S Horvath, S AF Lu, Ake T. Hannon, Eilis Levine, Morgan E. Hao, Ke Crimmins, Eileen M. Lunnon, Katie Kozlenkov, Alexey Mill, Jonathan Dracheva, Stella Horvath, Steve TI Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; DNA METHYLATION AGE; HUMAN LONGEVITY; HUMAN BRAIN; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; LIFE-SPAN; HUMAN TISSUES; CELL-TYPES; CLOCK AB DNA methylation (DNAm) levels lend themselves for defining an epigenetic biomarker of aging known as the 'epigenetic clock'. Our genome-wide association study (GWAS) of cerebellar epigenetic age acceleration identifies five significant (P<5.0 x 10(-8)) SNPs in two loci: 2p22.1 (inside gene DHX57) and 16p13.3 near gene MLST8 (a subunit of mTOR complex 1 and 2). We find that the SNP in 16p13.3 has a cis-acting effect on the expression levels of MLST8 (P = 6.9 x 10(-18)) in most brain regions. In cerebellar samples, the SNP in 2p22.1 has a cis-effect on DHX57 (P = 4.4 x 10(-5)). Gene sets found by our GWAS analysis of cerebellar age acceleration exhibit significant overlap with those of Alzheimer's disease (P = 4.4 x 10(-15)), age-related macular degeneration (P = 6.4 x 10(-6)), and Parkinson's disease (P = 2.6 x 10(-4)). Overall, our results demonstrate the utility of a new paradigm for understanding aging and age-related diseases: it will be fruitful to use epigenetic tissue age as endophenotype in GWAS. C1 [Lu, Ake T.; Levine, Morgan E.; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Hannon, Eilis; Lunnon, Katie; Mill, Jonathan] Univ Exeter, Sch Med, Exeter EX2 5DW, Devon, England. [Hao, Ke] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Genet & Genom Sci, New York, NY 10029 USA. [Crimmins, Eileen M.] Univ So Calif, Davis Sch Gerontol, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Mill, Jonathan] Kings Coll London, Inst Psychiat, London SE5 8AF, England. [Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA. RP Horvath, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.; Horvath, S (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA. EM shorvath@mednet.ucla.edu RI ; Mill, Jonathan/B-3276-2010 OI Hannon, Eilis/0000-0001-6840-072X; Mill, Jonathan/0000-0003-1115-3224; Lunnon, Katie/0000-0001-7570-6065 FU National Institutes of Health [NIA/NIH 5R01AG042511-02] FX The study was supported by the National Institutes of Health (NIA/NIH 5R01AG042511-02). NR 56 TC 5 Z9 5 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD FEB PY 2016 VL 7 AR 10561 DI 10.1038/ncomms10561 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF0FM UT WOS:000371014500003 PM 26830004 ER PT J AU Griffis, HM Band, RA Ruther, M Harhay, M Asch, DA Hershey, JC Hill, S Nadkarni, L Kilaru, A Branas, CC Shofer, F Nichol, G Becker, LB Merchant, RM AF Griffis, Heather M. Band, Roger A. Ruther, Matthew Harhay, Michael Asch, David A. Hershey, John C. Hill, Shawndra Nadkarni, Lindsay Kilaru, Austin Branas, Charles C. Shofer, Frances Nichol, Graham Becker, Lance B. Merchant, Raina M. TI Employment and residential characteristics in relation to automated external defibrillator locations SO AMERICAN HEART JOURNAL LA English DT Article ID HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; UNITED-STATES; SURVIVAL; NEIGHBORHOOD; RESOURCES; PLACEMENT; CPR AB Background Survival from out-of-hospital cardiac arrest (OHCA) is generally poor and varies by geography. Variability in automated external defibrillator (AED) locations may be a contributing factor. To inform optimal placement of AEDs, we investigated AED access in a major US city relative to demographic and employment characteristics. Methods and Results This was a retrospective analysis of a Philadelphia AED registry (2,559 total AEDs). The 2010 US Census and the Local Employment Dynamics database by ZIP code was used. Automated external defibrillator access was calculated as the weighted areal percentage of each ZIP code covered by a 400-m radius around each AED. Of 47 ZIP codes, only 9% (4) were high-AED-service areas. In 26% (12) of ZIP codes, less than 35% of the area was covered by AED service areas. Higher-AED-access ZIP codes were more likely to have a moderately populated residential area (P = .032), higher median household income (P = .006), and higher paying jobs (P =. 008). Conclusions The locations of AEDs vary across specific ZIP codes; select residential and employment characteristics explain some variation. Further work on evaluating OHCA locations, AED use and availability, and OHCA outcomes could inform AED placement policies. Optimizing the placement of AEDs through this work may help to increase survival. C1 [Griffis, Heather M.; Band, Roger A.; Nadkarni, Lindsay; Kilaru, Austin; Branas, Charles C.; Shofer, Frances; Becker, Lance B.; Merchant, Raina M.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA. [Ruther, Matthew] Univ Colorado, Dept Geog, Boulder, CO 80309 USA. [Harhay, Michael; Branas, Charles C.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Ctr Innovat, Philadelphia, PA 19104 USA. [Asch, David A.; Hershey, John C.; Hill, Shawndra] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Nichol, Graham] Univ Washington, Harborview Ctr Prehospital Emergency Care, Dept Med, Seattle, WA 98195 USA. RP Merchant, RM (reprint author), Univ Penn, Perelman Sch Med, 423 Guardian St,1022 Blockley, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Harhay, Michael/0000-0002-0553-674X FU National Institutes of Health (NTH), K23 Grant [10714038]; Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; Medtronic Foundation Heart Rescue Project; Penn University Research Fund; McCabe Fund, American Heart Association Beginning; NIH; Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, WA; Medtronic Foundation, Minnesota; Resuscitation Outcomes Consortium (NIH) [U01 HL077863-05]; Evaluation of Video Self-Instruction in Compressions-Only CPR; Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI) [R21 HL093641-01A1]; Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI) [R01 HL089554-03]; Resychronization/Defibrillation for Advanced Heart Failure Trial (RAF) [200211UCT-110607]; Novel Methods of Measuring Health Disparities [1RC2HL101759-01]; Cascade Cardiac Resuscitation System (Medtronic Foundation); Gambro Renal Inc, Lakewood, CO; Sotera Wireless, San Diego, CA; Lifebridge Medizintechnik AG; Ampfing, Germany; American Heart Association (AHA) Executive Database Steering Committee; Lifeline EMS Task. Force; AHA Resuscitation Science Symposium Planning Committee; AHA Advanced Cardiac Life Support Subcommittee; AHA Epidemiology and Statistics Committee; Pacific Mountain Affiliate Board of Directors, AHA FX R.M.M. has received grant/research support from the National Institutes of Health (NTH), K23 Grant 10714038, and pilot funding from Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; The Medtronic Foundation Heart Rescue Project; The Penn University Research Fund; and the McCabe Fund, American Heart Association Beginning Grant in Aid. R.A.B., J.C., O.S., H.G., A.L., J.M.A., K.L., L.N., E.S., L.S., and F.S. have no disclosures. C.C.B. has received grant/research support from NIH. D.A.A. has received grant/research support from NIH and is a consultant to VAL Health. G.N. discloses the following: Resuscitation Outcomes Consortium (NIH U01 HL077863-05) 2004-2015; co-principal investigator (co-PI), Evaluation of Video Self-Instruction in Compressions-Only CPR (Asmund S. Laerdal Foundation for Acute Medicine) 2007-2010; PI, Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI R21 HL093641-01A1) 2009-2011; PI, Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI R01 HL089554-03) 2007-2012: co-investigator (Co-I), Resychronization/Defibrillation for Advanced Heart Failure Trial (RAF 200211UCT-110607) 2003-2010; Co-I, Novel Methods of Measuring Health Disparities (1RC2HL101759-01) 2009-2011; Co-I, Cascade Cardiac Resuscitation System (Medtronic Foundation) 2010-2015; PI, Research Collaborator: Gambro Renal Inc, Lakewood, CO; Sotera Wireless, San Diego, CA; Lifebridge Medizintechnik AG; Ampfing, Germany; Other Chair, American Heart Association (AHA) Executive Database Steering Committee; Chair, Mission: Lifeline EMS Task. Force; Co-Chair, AHA Resuscitation Science Symposium Planning Committee; Member, AHA Advanced Cardiac Life Support Subcommittee; Member, AHA Epidemiology and Statistics Committee; Member, Pacific Mountain Affiliate Board of Directors, AHA. He also received travel reimbursement from AHA. L.B.B. has received grant/research support from Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, WA; and Medtronic Foundation, Minnesota. He also received speaker honoraria/consultant fees from Philips Healthcare, Seattle, WA. NR 30 TC 2 Z9 2 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2016 VL 172 BP 185 EP 191 DI 10.1016/j.ahj.2015.09.022 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DD1CS UT WOS:000369659400024 PM 26856232 ER PT J AU Graff, JN Baciarello, G Armstrong, AJ Higano, CS Iversen, P Flaig, TW Forer, D Parli, T Phung, D Tombal, B Beer, TM Sternberg, CN AF Graff, J. N. Baciarello, G. Armstrong, A. J. Higano, C. S. Iversen, P. Flaig, T. W. Forer, D. Parli, T. Phung, D. Tombal, B. Beer, T. M. Sternberg, C. N. TI Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL SO ANNALS OF ONCOLOGY LA English DT Article DE metastatic castration-resistant prostate cancer; enzalutamide; PREVAIL trial; elderly patients ID QUALITY-OF-LIFE; DOCETAXEL-BASED CHEMOTHERAPY; ABIRATERONE ACETATE; ELDERLY-PATIENTS; TRIAL; PAIN; MEN; SURVIVAL; IMPACT; FALLS AB Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged >= 75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged = 75 years (elderly) and men aged <75 years was pre-specified for the coprimary end points and adverse events (AEs). Results: Among 609 elderly patients (35%) who participated in PREVAIL, median treatment duration was 16.6 and 5.0 months in the enzalutamide and placebo arms, respectively. In the elderly subgroup, OS was greater with enzalutamide than with placebo [32.4 months (95% confidence interval (CI) 27.7-not yet reached] versus 25.1 months (95% CI 22.6-28.0); hazard ratio (HR) = 0.61 (95% CI 0.47-0.79); P = 0.0001], as was rPFS [not yet reached (95% CI 12.3-not yet reached) versus 3.7 months (95% CI 3.6-5.3); HR = 0.17 (95% CI 0.12-0.24); P < 0.0001]. Irrespective of treatment assignment, incidence of AEs was similar between the two age groups, except for an overall higher incidence of falls among elderly patients than younger patients [84/609 (13.8%) versus 62/1106 (5.6%)] and among elderly patients receiving enzalutamide than those receiving placebo [61/317 (19.2%) versus 23/292 (7.9%)]. Conclusions: Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS. Enzalutamide was well tolerated in the elderly subgroup and those aged <75 years. Age and enzalutamide treatment were associated with a higher incidence of falls. C1 [Graff, J. N.; Beer, T. M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Graff, J. N.] Portland VA Med Ctr, Div Oncol, Portland, OR USA. [Baciarello, G.; Sternberg, C. N.] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy. [Armstrong, A. J.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27706 USA. [Armstrong, A. J.] Duke Univ, Med Ctr, Div Urol, Durham, NC 27706 USA. [Armstrong, A. J.] Duke Canc Inst, Durham, England. [Higano, C. S.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. [Higano, C. S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Iversen, P.] Univ Copenhagen, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen, Denmark. [Flaig, T. W.] Univ Colorado, Ctr Canc, Dept Med Oncol, Aurora, CO USA. [Forer, D.; Parli, T.] Medivat Inc, San Francisco, CA USA. [Phung, D.] Astellas Pharma Global Dev Inc, Leiden, Netherlands. [Tombal, B.] Clin Univ St Luc, Dept Urol, Brussels, Belgium. RP Graff, JN (reprint author), Oregon Hlth & Sci Univ, Knight Canc Ctr, Portland VA Med Ctr, Div Oncol, MC CH14R,3303 SW Bond Ave, Portland, OR 97239 USA. EM graffj@ohsu.edu FU Medivation, Inc.; Astellas Pharma Global Development, Inc. FX Medivation, Inc., and Astellas Pharma Global Development, Inc., funded the PREVAIL trial, provided the study drug and collaborated with the investigators on protocol design, data analysis and interpretation, and preparation of this report, including the support of medical writing and editorial services (no grant number). NR 24 TC 7 Z9 7 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2016 VL 27 IS 2 BP 286 EP 294 DI 10.1093/annonc/mdv542 PG 10 WC Oncology SC Oncology GA DD8TF UT WOS:000370199100013 PM 26578735 ER PT J AU Cohen, ME Liu, YM Ko, CY Hall, BL AF Cohen, Mark E. Liu, Yaoming Ko, Clifford Y. Hall, Bruce L. TI Improved Surgical Outcomes for ACS NSQIP Hospitals Over Time Evaluation of Hospital Cohorts With up to 8 Years of Participation SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; profiling; risk adjustment; surgical quality improvement; time trends ID SURVEILLANCE BIAS; AMERICAN-COLLEGE; SITE INFECTIONS; QUALITY; PROGRAM AB Background:The American College of Surgeons, National Surgical Quality Improvement Program (ACS NSQIP) surgical quality feedback models are recalibrated every 6 months, and each hospital is given risk-adjusted, hierarchical model, odds ratios that permit comparison to an estimated average NSQIP hospital at a particular point in time. This approach is appropriate for relative benchmarking, and for targeting quality improvement efforts, but does not permit evaluation of hospital or program-wide changes in quality over time. We report on long-term improvement in surgical outcomes associated with participation in ACS NSQIP.Study Design:ACS NSQIP data (2006-2013) were used to create prediction models for mortality, morbidity (any of several distinct adverse outcomes), and surgical site infection (SSI). For each model, for each hospital, and for year of first participation (hospital cohort), hierarchical model observed/expected (O/E) ratios were computed. The primary performance metric was the within-hospital trend in logged O/E ratios over time (slope) for mortality, morbidity, and SSI.Results:Hospital-averaged log O/E ratio slopes were generally negative, indicating improving performance over time. For all hospitals, 62%, 70%, and 65% of hospitals had negative slopes for mortality, morbidity, and any SSI, respectively. For hospitals currently in the program for at least 3 years, 69%, 79%, and 71% showed improvement in mortality, morbidity, and SSI, respectively. For these hospitals, we estimate 0.8%, 3.1%, and 2.6% annual reductions (with respect to prior year's rates) for mortality, morbidity, and SSI, respectively.Conclusions:Participation in ACS NSQIP is associated with reductions in adverse events after surgery. The magnitude of quality improvement increases with time in the program. C1 [Cohen, Mark E.; Liu, Yaoming; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. RP Cohen, ME (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL USA. EM markcohen@facs.org NR 14 TC 24 Z9 24 U1 4 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2016 VL 263 IS 2 BP 267 EP 273 DI 10.1097/SLA.0000000000001192 PG 7 WC Surgery SC Surgery GA DD8TP UT WOS:000370200100012 PM 25723845 ER PT J AU Chidi, AP Bryce, CL Myaskovsky, L Fine, MJ Geller, DA Landsittel, DP Tsung, A AF Chidi, Alexis P. Bryce, Cindy L. Myaskovsky, Larissa Fine, Michael J. Geller, David A. Landsittel, Douglas P. Tsung, Allan TI Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma A Retrospective Cohort Study SO ANNALS OF SURGERY LA English DT Article DE access to care; HCC; health care disparities; liver cancer; socioeconomic status ID STAGE BREAST-CANCER; UNITED-STATES; GEOGRAPHIC DISPARITIES; TREATMENT CHOICES; TRAVEL-TIME; CARE; ACCESS; SURVIVAL; THERAPY; OUTCOMES AB Objective:To determine whether sociodemographic and geographic factors are associated with referral for surgery and receipt of recommended surgical intervention.Background:Surgical interventions confer survival advantages compared with palliative therapies for hepatocellular carcinoma (HCC), but disparities exist in use of surgical intervention. Few have investigated referral for surgery as a potential barrier to surgical intervention, and little is known about the effects of patient geographic factors, including proximity to surgical centers.Methods:Data were abstracted from the Pennsylvania Cancer Registry for patients with a diagnosis of HCC from 2006 to 2011. Using hospital procedure volume data from the Pennsylvania Health Care Cost Containment Council, we calculated proximity to a surgical center. We used multivariable logistic regression to determine whether geographic, racial, socioeconomic, and clinical factors were associated with referral for surgery and receipt of a recommended surgical intervention.Results:Of 3576 patients with HCC, 41.0% were referred for surgery. Patients who lived closer to a surgical center were less likely to be referred for surgery (adjusted odds ratio=0.79; 95% confidence interval, 0.68-0.92). Surgical referral was less likely among older, male patients with Medicaid insurance and advanced tumor stage at diagnosis. Of those referred, 1276 (87.0%) underwent surgical intervention. Proximity to a surgical center was not associated with receipt of surgical intervention (P=0.27). Patients with distant tumor stage at diagnosis were less likely to receive recommended surgical intervention (adjusted odds ratio=0.27; 95% confidence interval, 0.15-0.50).Conclusions:Geographic and sociodemographic disparities in referral for surgery may be major barriers to surgical intervention for patients with HCC. C1 [Chidi, Alexis P.; Geller, David A.; Tsung, Allan] Univ Pittsburgh, Dept Surg, Div Hepatobiliary & Pancreat Surg, Pittsburgh, PA USA. [Chidi, Alexis P.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bryce, Cindy L.; Myaskovsky, Larissa; Fine, Michael J.; Landsittel, Douglas P.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Bryce, Cindy L.; Myaskovsky, Larissa; Fine, Michael J.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Tsung, A (reprint author), UPMC Liver Canc Ctr, Montefiore Hosp, Div Hepatobiliary & Pancreat Surg, 3459 Fifth Ave,7 South, Pittsburgh, PA 15213 USA. EM tsunga@upmc.edu OI Bryce, Cindy/0000-0001-6356-6675 FU National Institutes of Health [T35DK065521, TL1TR000145, UL1TR000005] FX Supported by the National Institutes of Health (T35DK065521, TL1TR000145, UL1TR000005). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflicts of interest. NR 31 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2016 VL 263 IS 2 BP 362 EP 368 DI 10.1097/SLA.0000000000001111 PG 7 WC Surgery SC Surgery GA DD8TP UT WOS:000370200100025 PM 25563883 ER PT J AU Soble, JR Osborn, KE Mattingly, ML Vale, FL Benbadis, SR Rodgers-Neame, NT Schoenberg, MR AF Soble, Jason R. Osborn, Katie E. Mattingly, Michelle L. Vale, Fernando L. Benbadis, Selim R. Rodgers-Neame, Nancy T. Schoenberg, Mike R. TI Utility of Green's Word Memory Test Free Recall Subtest as a Measure of Verbal Memory: Initial Evidence from a Temporal Lobe Epilepsy Clinical Sample SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Epilepsy; Assessment; Learning and memory; Lateralization ID SYMPTOM VALIDITY TEST; SURGERY CANDIDATES; NEUROPSYCHOLOGICAL ASSESSMENT; EXTERNAL INCENTIVES; AMERICAN-ACADEMY; TEST-PERFORMANCE; BRAIN-INJURY; RELIABILITY; SENSITIVITY; IMPAIRMENT AB This study investigated the Word Memory Test (WMT) Free Recall (FR) subtest as a conventional memory measure. Nineteen participants with pharmacoresistant left temporal lobe epilepsy (LTLE) and 16 with right temporal lobe epilepsy (RTLE) completed the WMT, Rey Auditory Verbal Learning Test (RAVLT), and Wechsler Memory Scale-Fourth Edition Logical Memory (LM) subtest during presurgical evaluation. LTLE participants performed significantly worse on FR subtest (p < .05, eta(2)(p) = 0.17) and RAVLT Trial 7 (p < .01, eta(2)(p) = 0.25), but not on LM subtest. Age was a significant covariate for FR (p < .01, eta(2)(p) = 0.22). Logistic regression revealed FR plus age and RAVLT age-adjusted T-scores both yielded 77.1% classification accuracy and respective diagnostic odds ratios of 11.36 and 11.84. Receiver operating characteristic curves to classify seizure laterality found that RAVLT and FR were significant (area under the curve [AUC] = 0.82 and 0.74), whereas LM was nonsignificant (AUC = 0.67). Cut scores and positive/negative predictive values were established for improved clinical classification. C1 [Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Osborn, Katie E.; Mattingly, Michelle L.; Schoenberg, Mike R.] Univ S Florida, Dept Psychiat & Behav Neurosci, Morsani Coll Med, Tampa, FL USA. [Vale, Fernando L.; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL USA. [Benbadis, Selim R.; Schoenberg, Mike R.] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL 33620 USA. [Rodgers-Neame, Nancy T.] Florida Comprehens Epilepsy & Seizure Disorders C, Tampa, FL USA. RP Schoenberg, MR (reprint author), 3515 E Fletcher Ave,MDC Box 14, Tampa, FL 33613 USA. EM mschoenb@health.usf.edu NR 54 TC 0 Z9 0 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2016 VL 31 IS 1 BP 79 EP 87 DI 10.1093/arclin/acv084 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA DD8QQ UT WOS:000370192400011 PM 26663824 ER PT J AU Torrence, ND John, SE Gavett, BE O'Bryant, SE AF Torrence, Nicole D. John, Samantha E. Gavett, Brandon E. O'Bryant, Sid E. TI An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Validity; Factor analysis; Statistical model; Cognition; Neuropsychology ID ITEM BIFACTOR ANALYSIS; CLOCK DRAWING TASK; FIT INDEXES; DEMENTIA; VALIDITY; MODELS; CRITERIA; SAMPLE; RBANS AB The original factor structure of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has received little empirical support, but at least eight alternative factor structures have been identified in the literature. The current study used confirmatory factor analysis to compare the original RBANS model with eight alternatives, which were adjusted to include a general factor. Participant data were obtained from Project FRONTIER, an epidemiological study of rural health, and comprised 341 adults (229 women, 112 men) with mean age of 61.2 years (SD = 12.1) and mean education of 12.4 years (SD = 3.3). A bifactor version of the model proposed by Duff and colleagues provided the best fit to the data (CFI = 0.98; root-mean-squared error of approximation = 0.07), but required further modification to produce appropriate factor loadings. The results support the inclusion of a general factor and provide partial replication of the Duff and colleagues RBANS model. C1 [Torrence, Nicole D.; John, Samantha E.; Gavett, Brandon E.] Univ Colorado, Dept Psychol, 1420 Austin Bluffs Pkwy, Colorado Springs, CO 80907 USA. [O'Bryant, Sid E.] Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. [O'Bryant, Sid E.] Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA. [Torrence, Nicole D.] VA Puget Sound Hlth Care Syst, Amer Lake, VA USA. RP Gavett, BE (reprint author), Univ Colorado, Dept Psychol, 1420 Austin Bluffs Pkwy, Colorado Springs, CO 80907 USA. EM bgavett@uccs.edu OI O'Bryant, Sid/0000-0003-0582-5266; John, Samantha/0000-0003-1347-4865; Gavett, Brandon/0000-0003-1938-1854 FU National Institute on Aging (NIA); National Institute on Minority Health and Health Disparities(NIMHD) of the National Institutes of Health [R01AG039389, P30AG12300, L60MD001849]; Hogg Foundation for Mental Health [JRG-040, JRG-149]; Environmental Protection Agency [RD834794]; National Academy of Neuropsychology; Texas Tech University Health Sciences Center F. Marie Hall Institute for Rural & Community Health; Garrison Institute on Aging FX Research reported in this publication was supported by the National Institute on Aging (NIA) and National Institute on Minority Health and Health Disparities(NIMHD) of the National Institutes of Health under Award Numbers R01AG039389, P30AG12300, and L60MD001849. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was also funded in part by grants from the Hogg Foundation for Mental Health (JRG-040 & JRG-149), the Environmental Protection Agency (RD834794), and the National Academy of Neuropsychology. Project FRONTIER is supported by Texas Tech University Health Sciences Center F. Marie Hall Institute for Rural & Community Health and the Garrison Institute on Aging. The researchers would also like to thank the Project FRONTIER participants and research staff. NR 35 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2016 VL 31 IS 1 BP 88 EP 96 DI 10.1093/arclin/acv057 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA DD8QQ UT WOS:000370192400012 PM 26429558 ER PT J AU O'Brien, CM Flanagan, ME Bergman, AA Ebright, PR Frankel, RM AF O'Brien, Colleen M. Flanagan, Mindy E. Bergman, Alicia A. Ebright, Patricia R. Frankel, Richard M. TI "Anybody on this list that you're more worried about?" Qualitative analysis exploring the functions of questions during end of shift handoffs SO BMJ QUALITY & SAFETY LA English DT Article ID EMERGENCY-DEPARTMENT; HANDOVER; CARE; COMMUNICATION; DISCOURSE; DOCTORS AB Background Shift change handoffs are known to be a point of vulnerability in the quality, safety and outcomes of healthcare. Despite numerous efforts to improve handoff reliability, few interventions have produced lasting change. Although the opportunity to ask questions during patient handoff has been required by some regulatory bodies, the function of questions during handoff has been less well explored and understood. Objective To investigate questions and the functions they serve in nursing and medicine handoffs. Research design Qualitative thematic analysis based on audio recordings of nurse-to-nurse, medical resident-to-resident and surgical intern-to-intern handoffs. Subjects Twenty-seven nurse handoff dyads and 18 medical resident and surgical intern handoff dyads at one VA Medical Center. Results Our analysis revealed that the vast majority of questions were asked by the Incoming Providers. Although topics varied widely, the bulk of Incoming Provider questions requested information that would best help them understand individual patient conditions and plan accordingly. Other question types sought consensus on clinical reasoning or framing and alignment between the two professionals. Conclusions Handoffs are a type of socially constructed work. Questions emerge with some frequency in virtually all handoffs but not in a linear or predictable way. Instead, they arise in the moment, as necessary, and without preplanning. A checklist cannot model this process element because it is a static memory aid and questions occur in a relational context that is emergent. Studying the different functions of questions during end of shift handoffs provides insights into the interface between the technical context in which information is transferred and the social context in which meaning is created. C1 [O'Brien, Colleen M.; Frankel, Richard M.] Indiana Univ Sch Med, 340 W 10th St 6200, Indianapolis, IN 46202 USA. [O'Brien, Colleen M.] Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [O'Brien, Colleen M.; Flanagan, Mindy E.; Bergman, Alicia A.; Frankel, Richard M.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Bergman, Alicia A.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Ebright, Patricia R.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [Frankel, Richard M.] Mary Margaret Walther Ctr Res & Educ Palliat Care, Indianapolis, IN USA. RP O'Brien, CM (reprint author), Indiana Univ Sch Med, 340 W 10th St 6200, Indianapolis, IN 46202 USA. EM colmobri@iupui.edu FU VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana; VA Health Services Research Grant [IIR 7-241] FX The project reported here was supported by the VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana, and VA Health Services Research Grant No. IIR 7-241. NR 36 TC 2 Z9 2 U1 1 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2016 VL 25 IS 2 BP 76 EP 83 DI 10.1136/bmjqs-2014-003853 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD6GH UT WOS:000370022200004 PM 26217038 ER PT J AU Bergman, AA Flanagan, ME Ebright, PR O'Brien, CM Frankel, RM AF Bergman, Alicia A. Flanagan, Mindy E. Ebright, Patricia R. O'Brien, Colleen M. Frankel, Richard M. TI "Mr Smith's been our problem child today...": anticipatory management communication (AMC) in VA end of shift medicine and nursing handoffs SO BMJ QUALITY & SAFETY LA English DT Article ID SIGN-OUT; CARE; DISCONTINUITY; STRATEGIES AB Background Tools and procedures designed to improve end-of-shift handoffs through standardisation of processes and reliance on technology may miss contextually sensitive information about anticipated events that emerges during face-to-face handoff interactions. Such information, what we refer to as anticipatory management communication (AMC), is necessary to ensure timely and safe patient care, but has been little studied and understood. Objective To investigate AMC and the role it plays in nursing and medicine handoffs. Research design Qualitative thematic analysis based on audio recordings of nurse-to-nurse, medical resident-to-resident and surgical intern to-intern handoffs. Subjects 27 nurse handoff dyads and 18 medical resident and surgical intern handoff dyads at one VA Medical Center. Results Heads-up information was the most frequent type of AMC across all handoff dyads (N=257; 108 resident and 149 nursing). Indirect instructions AMC was used in a little over half the resident handoff dyads, but occurred in all nursing dyads (292 instances). Direct instructions AMC occurred in roughly equal proportion across all dyads but at a modest frequency (N=45; 28 resident and 17 nursing). Direct (if/then) contingency AMC occurred in resident handoffs more frequently than in nursing handoffs (N=32; 30 resident and 2 nursing). Conclusions The different frequencies for types of AMC likely reflect differences in how residents and nurses work and disparate professional cultures. But, verbal communication in both groups included important information unlikely to be captured in written handoff tools or the electronic medical record, underscoring the importance of direct communication to ensure safe handoffs. C1 [Bergman, Alicia A.] VA Greater Los Angeles, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA. [Flanagan, Mindy E.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Bergman, Alicia A.; Flanagan, Mindy E.; Frankel, Richard M.] Richard L Roudebush VA Med Ctr, HSR&D Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Ebright, Patricia R.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [O'Brien, Colleen M.] Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [Frankel, Richard M.] Indiana Univ, Dept Med, Indianapolis, IN 46204 USA. RP Bergman, AA (reprint author), VA Greater Los Angeles, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA. EM alicia.bergman@va.gov FU VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana [IIR 07-241-2] FX VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana, IIR 07-241-2. NR 26 TC 1 Z9 1 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2016 VL 25 IS 2 BP 84 EP 91 DI 10.1136/bmjqs-2014-003694 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD6GH UT WOS:000370022200005 PM 26221029 ER PT J AU Liang, PS Dominitz, JA AF Liang, Peter S. Dominitz, Jason A. TI Striving for Efficient, Patient-centered Endoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID COLORECTAL-CANCER; OUTPATIENT ENDOSCOPY; NON-ATTENDANCE; COLONOSCOPY; RATES; NONATTENDANCE; CAPACITY; DEMAND C1 [Liang, Peter S.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. RP Liang, PS (reprint author), Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. OI Liang, Peter/0000-0002-4160-421X FU NIDDK NIH HHS [NIH T32 DK007742] NR 19 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2016 VL 14 IS 2 BP 268 EP 270 DI 10.1016/j.cgh.2015.10.004 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1GY UT WOS:000370376300020 PM 26484705 ER PT J AU Cadoni, S Falt, P Leung, FW AF Cadoni, Sergio Falt, Premysl Leung, Felix W. TI Some Clarifications About Water-Aided Colonoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter ID UNSEDATED COLONOSCOPY; CECAL INTUBATION; CONTROLLED-TRIAL; INSUFFLATION; INFUSION; EXCHANGE C1 [Cadoni, Sergio] St Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. [Falt, Premysl] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. NR 8 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2016 VL 14 IS 2 BP 323 EP 323 DI 10.1016/j.cgh.2015.09.003 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1GY UT WOS:000370376300030 PM 26375611 ER PT J AU Carroll, WW O'Connell, BP Schlosser, RJ Gudis, DA Karnezis, TT Lawrence, LA Soler, ZM Mulligan, JK AF Carroll, William W. O'Connell, Brendan P. Schlosser, Rodney J. Gudis, David A. Karnezis, Tom T. Lawrence, Lauren A. Soler, Zachary M. Mulligan, Jennifer K. TI Fibroblast levels are increased in chronic rhinosinusitis with nasal polyps and are associated with worse subjective disease severity SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; endoscopic sinus surgery; SNOT-22; quality of life; sinusitis ID ALLERGIC FUNGAL RHINOSINUSITIS; SINONASAL OUTCOME TEST; QUALITY-OF-LIFE; MESENCHYMAL TRANSITION; INFLAMMATORY MEDIATORS; AIRWAY RESPONSIVENESS; COLLAGEN DEPOSITION; LUNG-DISEASE; SINUSITIS; ASTHMA AB BackgroundFibroblasts are implicated in tissue remodeling and recruitment of inflammatory cells in chronic rhinosinusitis (CRS). Populations of fibroblasts remain unquantified in CRS subtypes. The objectives of this study were to measure fibroblast populations in subtypes of CRS, and to investigate the association between fibroblasts and disease severity. MethodsPatients undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2011 to December 2014. Control subjects included patients undergoing endoscopic surgery for non-inflammatory conditions such as cerebrospinal fluid leak repair or non-hormone-secreting pituitary tumors. Patients completed 22-item Sino-Nasal Outcome Test (SNOT-22) questionnaires prior to surgery. Blood and tissue biopsies were taken during surgery. Percent of sinonasal fibroblasts was determined via flow cytometry by selecting fibroblast-specific protein (FSP)-positive and Mucin 1 (MUC1)-negative cells. ResultsA total of 69 patients were enrolled: control (n = 24), CRS without nasal polyps (CRSsNP) (n = 13), CRS with nasal polyps (CRSwNP) (n = 22), and allergic fungal rhinosinusitis (AFRS) (n = 10). Patients with CRSwNP had significantly more fibroblasts than both control (p < 0.001) and CRSsNP (p < 0.01). Patients with AFRS had the most fibroblasts when compared to control (p < 0.0001), CRSsNP (p < 0.0001), and CRSwNP (p < 0.05). Atopy and asthma were not associated with increased fibroblasts in CRSwNP (p = 0.21, p = 0.26, respectively). Increased fibroblasts correlated with subjective disease severity as measured by SNOT-22 for CRSwNP (p = 0.003) and AFRS (p = 0.048). ConclusionSinonasal fibroblasts are increased in CRSwNP and AFRS compared to control and CRSsNP. Increased fibroblasts correlated with worse quality of life in CRSwNP and AFRS. C1 [Carroll, William W.; O'Connell, Brendan P.; Schlosser, Rodney J.; Gudis, David A.; Karnezis, Tom T.; Lawrence, Lauren A.; Soler, Zachary M.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Academy of Otolaryngic Allery; Flight Attendant Medical Research Institute; Department of Veterans Affairs FX American Academy of Otolaryngic Allery (to B.P.O.); Flight Attendant Medical Research Institute (to J.K.M.); Department of Veterans Affairs (to R.J.S.). NR 61 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD FEB PY 2016 VL 6 IS 2 BP 162 EP 168 DI 10.1002/alr.21636 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DD8SR UT WOS:000370197700010 PM 26370180 ER PT J AU Lawrence, LA Baker, AB Nguyen, SA Karnezis, TT Soler, ZM Schlosser, RJ AF Lawrence, Lauren A. Baker, Andrew B. Nguyen, Shaun A. Karnezis, Tom T. Soler, Zachary M. Schlosser, Rodney J. TI Predictors of 30-day morbidity and mortality in transnasal microscopic pituitary tumor excision SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE anterior skull base; postoperative; endonasal approach to the pituitary; NSQIP; outcomes; adverse events ID ENDONASAL TRANSSPHENOIDAL SURGERY; ADENOMAS; COMPLICATIONS; READMISSION; EXPERIENCE; SERIES; STAY AB BackgroundThere is a lack of population-based, multi-institutional analyses of factors associated with morbidity and mortality following pituitary tumor excision. MethodsThe American College of Surgeons National Surgical Quality Improvement Project files were used to compile information on patients that had undergone transnasal microscopic pituitary tumor resection from 2006 to 2012. Patient demographics, comorbidities, operative characteristics, and morbidity and mortality in the 30 days following surgery were included. Multivariate logistic regression was used for categorical variables and multivariate linear regression was used for continuous variables to evaluate factors leading to adverse events. ResultsA total of 658 patients were included, of which 58 (8.81%) experienced a complication, reoperation or death in the 30 days following surgery. The most common complications were reoperation (3.37%), followed by unplanned reintubation (1.99%), urinary tract infection (1.68%), and transfusion (1.68%). Predictors of any complication, reoperation, or death include preoperative sepsis (odds ratio [OR] = 7.596) and lower preoperative serum albumin (OR = 6.667). Younger age predicted surgical complications (OR = 1.105). Predictors of medical complications include higher body mass index (OR = 1.112), chronic steroid use (OR = 6.568), preoperative sepsis (OR = 15.297), and lower preoperative serum hematocrit (OR = 1.225). Predictors of increased total length of hospital stay were older age ( = 0.146), higher body mass index ( = 0.188), chronic steroid use ( = 0.142), preoperative sepsis ( = 0.489), and lower preoperative serum albumin ( = -0.213). ConclusionAlthough adverse events following pituitary tumor excision are low, awareness of factors associated with morbidity and mortality in the early postoperative period may allow for improved patient monitoring and outcomes. C1 [Lawrence, Lauren A.; Baker, Andrew B.; Nguyen, Shaun A.; Karnezis, Tom T.; Soler, Zachary M.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Lawrence, LA (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge,MSC 550, Charleston, SC 29425 USA. EM lawre194@gmail.com OI Baker, Andrew/0000-0002-2041-5225 FU Optinose (Yardley, PA); Intersect ENT FX R.J.S. is a consultant for Olympus (Center Valley, PA) and has been provided grant support from Optinose (Yardley, PA) and Intersect ENT; none of these provided support for this investigation. Z.M.S. is also consultant for Olympus, but no support was provided for this investigation. NR 29 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD FEB PY 2016 VL 6 IS 2 BP 206 EP 213 DI 10.1002/alr.21641 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA DD8SR UT WOS:000370197700016 PM 26370600 ER PT J AU Riemer, C Doctor, M Dellavalle, RP AF Riemer, Christie Doctor, Monica Dellavalle, Robert P. TI Analysis of Online Ratings of Dermatologists SO JAMA DERMATOLOGY LA English DT Letter C1 [Riemer, Christie] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Doctor, Monica] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. RP Dellavalle, RP (reprint author), Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. NR 3 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD FEB PY 2016 VL 152 IS 2 BP 218 EP 220 DI 10.1001/jamadermatol.2015.4991 PG 4 WC Dermatology SC Dermatology GA DE4AT UT WOS:000370572300021 PM 26677133 ER PT J AU Cohen, AS Mitchell, KR Docherty, NM Horan, WP AF Cohen, Alex S. Mitchell, Kyle R. Docherty, Nancy M. Horan, William P. TI Vocal Expression in Schizophrenia: Less Than Meets the Ear SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; negative; alogia; blunted affect; computer ID PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS; ACOUSTIC ANALYSIS; MENTAL-ILLNESS; SPEECH FLUENCY; METAANALYSIS; DEPRESSION; DISORDERS; PROSODY; DEFICIT AB Abnormalities in nonverbal communication are a hallmark of schizophrenia. Results from studies using symptom rating scales suggest that these abnormalities are profound (i.e., 3-5 SDs) and occur across virtually every channel of vocal expression. Computerized acoustic analytic technologies, used to overcome practical and psychometric limitations with symptom rating scales, have found much more benign and isolated abnormalities. To better understand vocal deficits in schizophrenia and to advance acoustic analytic technologies for clinical and research applications, we examined archived speech samples from 5 separate studies, each using different speaking tasks (patient N = 309; control N = 117). We sought to: (a) use Principal Component Analysis (PCA) to identify independent vocal expression measures from a large set of variables, (b) quantify how patients with schizophrenia are abnormal with respect to these variables, (c) evaluate the impact of demographic and contextual factors (e.g., study site, speaking task), and (d) examine the relationship between clinically-rated psychiatric symptoms and vocal variables. PCA identified 7 independent markers of vocal expression. Most of these vocal variables varied considerably as a function of context and many were associated with demographic factors. After controlling for context and demographics, there were no meaningful differences in vocal expression between patients and controls. Within patients, vocal variables were associated with a range of psychiatric symptoms-though only pause length was significantly associated with clinically rated negative symptoms. The discussion centers on explaining the apparent discordance between clinical and computerized speech measures. C1 [Cohen, Alex S.; Mitchell, Kyle R.] Louisiana State Univ, Dept Psychol, 236 Audubon Hall, Baton Rouge, LA 70803 USA. [Docherty, Nancy M.] Kent State Univ, Dept Psychol, Kent, OH USA. [Horan, William P.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Cohen, AS (reprint author), Louisiana State Univ, Dept Psychol, 236 Audubon Hall, Baton Rouge, LA 70803 USA. EM acohen@lsu.edu FU National Institute of Mental Health [R03MH092622] FX This project was funded by Grant R03MH092622 from the National Institute of Mental Health to AC. We thank the patients and subjects who volunteered their time to participate in the study. We are also grateful to Matt Calamia for his statistical advice and consultation. NR 55 TC 2 Z9 2 U1 2 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2016 VL 125 IS 2 BP 299 EP 309 DI 10.1037/abn0000136 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA DD8GJ UT WOS:000370163500014 PM 26854511 ER PT J AU Aplin, AC Kohler, T Nicosia, R AF Aplin, Alfred C. Kohler, Ted Nicosia, Roberto TI Human Plaque-Aortic Ring Co-Culture: A Novel Assay for the Study of Atherosclerosis-Induced Angiogenesis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 316 BP 81A EP 81A PG 1 WC Pathology SC Pathology GA DE0GI UT WOS:000370302500317 ER PT J AU David, SN Arnold, S Goyal, R Goldstein, J Gellert, LL Clark, PE Hameed, O Giannico, GA AF David, Stephanie N. Arnold, Shanna Goyal, Rajen Goldstein, Jeffery Gellert, Lan L. Clark, Peter E. Hameed, Omar Giannico, Giovanna A. TI MAGI-2 is Associated with Biochemical Recurrence in Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA. US Dept Vet Affairs, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 892 BP 224A EP 225A PG 2 WC Pathology SC Pathology GA DE0GI UT WOS:000370302501376 ER PT J AU Flickinger, TE Saha, S Roter, D Korthuis, PT Sharp, V Cohn, J Eggly, S Moore, RD Beach, MC AF Flickinger, Tabor E. Saha, Somnath Roter, Debra Korthuis, P. Todd Sharp, Victoria Cohn, Jonathan Eggly, Susan Moore, Richard D. Beach, Mary Catherine TI Clinician empathy is associated with differences in patient-clinician communication behaviors and higher medication self-efficacy in HIV care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE HIV/AIDS; Patient-clinician communication; Empathy; Self-efficacy; Medication adherence ID PHYSICIAN EMPATHY; PROVIDER COMMUNICATION; HEALTH OUTCOMES; SATISFACTION; QUALITY; ADHERENCE; DISEASE; PARTNERSHIP; MULTICENTER; ASSESSMENTS AB Objective: We examined associations of clinicians' empathy with patient-clinician communication behaviors, patients' rating of care, and medication self-efficacy. Methods: We analyzed 435 adult patients and 45 clinicians at four outpatient HIV care sites in the United States. Negative binomial regressions investigated associations between clinician empathy and patient-clinician communication, assessed using the Roter Interaction Analysis System (RIAS). Logistic regressions investigated associations between clinician empathy and patient ratings of clinician communication, overall satisfaction, and medication self-efficacy. Results: Clinicians in the highest vs. lowest empathy tertile engaged in less explicitly emotional talk (IRR 0.79, p < 0.05), while clinicians in the middle vs. lowest engaged in more positive talk (IRR 1.31, p < 0.05), more questions (IRR 1.42, p < 0.05), and more patient activating talk (IRR 1.43, p < 0.05). Patients of higher empathy clinicians disclosed more psychosocial and biomedical information. Patients of clinicians in both the middle and highest (vs. lowest) empathy tertiles had greater odds of reporting highest medication self-efficacy (OR 1.80, 95% CI 1.16-2.80; OR 2.13, 95% CI 1.37-3.32). Conclusions: Clinician empathy may be expressed through addressing patient engagement in care, by fostering cognitive, rather than primarily emotional, processing. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Flickinger, Tabor E.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Roter, Debra; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Sharp, Victoria] St Lukes Roosevelt, New York, NY USA. [Cohn, Jonathan; Eggly, Susan] Wayne State Univ, Detroit, MI USA. RP Flickinger, TE (reprint author), Univ Virginia, Sch Med, Div Gen Geriatr Palliat & Hosp Med, POB 800901, Charlottesville, VA 22908 USA. EM TES3J@hscmail.mcc.virginia.edu OI Eggly, Susan/0000-0002-8137-6098; Flickinger, Tabor/0000-0001-8820-2536 FU Health Resources Service Administration; National Institute of Drug Abuse [K23 DA019808]; Agency for Healthcare Research and Quality [K08HS013903-05, AHRQ 290-01-0012]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019808). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. NR 51 TC 2 Z9 2 U1 3 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2016 VL 99 IS 2 BP 220 EP 226 DI 10.1016/j.pec.2015.09.001 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DE7GU UT WOS:000370804700006 PM 26395313 ER PT J AU Flickinger, TE Saha, S Roter, D Korthuis, PT Sharp, V Cohn, J Moore, RD Ingersoll, KS Beach, MC AF Flickinger, Tabor E. Saha, Somnath Roter, Debra Korthuis, P. Todd Sharp, Victoria Cohn, Jonathan Moore, Richard D. Ingersoll, Karen S. Beach, Mary Catherine TI Respecting patients is associated with more patient-centered communication behaviors in clinical encounters SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE HIV/AIDS; Patient-clinician communication; Respect ID HIV CARE; PHYSICIAN COMMUNICATION; PROVIDER COMMUNICATION; RACIAL DISPARITIES; HEALTH-CARE; SEXUAL-BEHAVIOR; WHITE PATIENTS; SUBSTANCE USE; ADHERENCE; SATISFACTION AB Objective: Attitudes towards patients may influence how clinicians interact. We investigated whether respect for patients was associated with communication behaviors during HIV care encounters. Methods: We analyzed audio-recordings of visits between 413 adult HIV-infected patients and 45 primary HIV care providers. The independent variable was clinician-reported respect for the patient and outcomes were clinician and patient communication behaviors assessed by the Roter Interaction Analysis System (RIAS). We performed negative binomial regressions for counts outcomes and linear regressions for global outcomes. Results: When clinicians had higher respect for a patient, they engaged in more rapport-building, social chitchat, and positive talk. Patients of clinicians with higher respect for them engaged in more rapport-building, social chitchat, positive talk, and gave more psychosocial information. Encounters between patients and clinicians with higher respect for them had more positive clinician emotional tone [regression coefficient 2.97 (1.92-4.59)], more positive patient emotional tone [2.71 (1.75-4.21)], less clinician verbal dominance [0.81 (0.68-0.96)] and more patient-centeredness [1.28 (1.09-1.51)]. Conclusions: Respect is associated with positive and patient-centered communication behaviors during encounters. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Flickinger, Tabor E.; Ingersoll, Karen S.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA. [Saha, Somnath] Portland VA Med Ctr, Dept Med, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Roter, Debra; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Sharp, Victoria] St Lukes Roosevelt, Dept Med, New York, NY USA. [Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. RP Flickinger, TE (reprint author), Univ Virginia, Sch Med, Div Gen Geriatr Palliat & Hosp Med, POB 800901, Charlottesville, VA 22908 USA. EM TES3J@hscmail.mcc.virginia.edu OI Flickinger, Tabor/0000-0001-8820-2536 FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08HS013903-05]; National Institute of Drug Abuse [K23 DA019808]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019808). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. Preliminary findings of this manuscript were presented at the National Meeting of the Society of General Internal Medicine, San Diego, California, April 2014, and the International Conference on Communication in Healthcare, Amsterdam, The Netherlands, October 2014. NR 42 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2016 VL 99 IS 2 BP 250 EP 255 DI 10.1016/j.pec.2015.08.020 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DE7GU UT WOS:000370804700010 PM 26320821 ER PT J AU Wen, JC Yeh, CK Sun, YY AF Wen, Jianchuan Yeh, Chih-Ko Sun, Yuyu TI Functionalized Denture Resins as Drug Delivery Biomaterials to Control Fungal Biofilms SO ACS BIOMATERIALS SCIENCE & ENGINEERING LA English DT Article DE denture; poly(2-hydroxyethyl methacrylate); drug delivery; fungal; biofilm-controlling ID IN-VITRO; POLY(2-HYDROXYETHYL METHACRYLATE); ANTIFUNGAL ACTIVITY; SILVER NANOPARTICLES; CANDIDA-ALBICANS; STOMATITIS; PLASMA; ETIOLOGY; SURFACE; DEVICE AB Colonization and biofilm-formation of Candida species on denture surfaces cause Candida-associated denture stomatitis (CADS), a recurring fungal infection that affects up to 67% of denture wearers. We grafted poly(2-hydroxyethyl methacrylate) (PHEMA) onto poly(methyl methacrylate) (PMMA)-based denture resins through plasma-initiated grafting polymerization. The effects of reaction conditions on grafting and the physical properties of the resulting resins were evaluated. The grafted resins showed significantly increased drug binding capability toward clotrimazole, one of the most widely used antifungal drugs. The mechanisms for the enhancement in drug binding were discussed. The new clotrimazole-containing resins provided sustained drug release for longer than 28 days, and the released drugs demonstrated potent, long-term biofilm-controlling effects against Candida, pointing to an attractive strategy in controlling CADS and related fungal infections. C1 [Wen, Jianchuan; Sun, Yuyu] Univ Massachusetts, Dept Chem, 1 Univ Ave, Lowell, MA 01854 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. RP Sun, YY (reprint author), Univ Massachusetts, Dept Chem, 1 Univ Ave, Lowell, MA 01854 USA. EM yuyu_sun@uml.edu FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1I01BX001103] FX This study was partly supported by NIDCR, NIH (R01 DE021084), and VA Merit Review (1I01BX001103). NR 43 TC 1 Z9 1 U1 3 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2373-9878 J9 ACS BIOMATER SCI ENG JI ACS Biomater. Sci. Eng. PD FEB PY 2016 VL 2 IS 2 BP 224 EP 230 DI 10.1021/acsbiomaterials.5b00416 PG 7 WC Materials Science, Biomaterials SC Materials Science GA DD4FA UT WOS:000369876700010 ER PT J AU Wecht, JM Weir, JP Martinez, S Eraifej, M Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Martinez, Stephanie Eraifej, Mastanna Bauman, William A. TI Orthostatic hypotension and orthostatic hypertension in American veterans SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Orthostatic hypotension; Orthostatic hypertension; American veterans; Prevalence; Prescription medications; Age ID CARDIOVASCULAR RISK-FACTOR; MALMO PREVENTIVE PROJECT; BLOOD-PRESSURE RESPONSE; ELDERLY HYPERTENSIVES; ATHEROSCLEROSIS RISK; EXTREME DIPPERS; MORTALITY; DISEASE; PREVALENCE; ADULTS AB Abnormal blood pressure (BP) response to orthostatic maneuvers may predict adverse health outcomes. Orthostatic hypotension (OH) is defined as a fall in BP of a parts per thousand yen20/10 mmHg, and orthostatic hypertension (OHTN) is defined as an increase in systolic BP (SBP) of a parts per thousand yen20 mmHg, with standing. Herein, we document the prevalence of OH and OHTN in American veterans. The influence of demographic characteristics, life habits, co-incident medical conditions, and prescription medication use on these prevalence rates and associations between abnormal orthostatic BP responses and severity of self-reported symptoms of fatigue, dizziness, trouble concentrating, and head and neck discomfort were determined. 286 veterans participated; 14 % were classified with OH, 22 % with OHTN, and 64 % with normal BP responses to standing (reference group). An increased prevalence of the diagnosis of diabetes mellitus (27 %) and hypertension (63 %) was noted, which did not differ by orthostatic BP classification. Veterans with OH were older than the reference group and were prescribed more antihypertensive medications than the reference and OHTN groups. While the prevalence of OH increased with age, the prevalence of OHTN was comparable in young (20-30 years) and old (70+ years) veterans (17 vs. 19 %, respectively). The severity of fatigue and dizziness was increased in veterans with OH and OHTN compared to the reference group. These data suggest a relatively high prevalence of OH and OHTN, which is associated with increased self-reported severity of fatigue and dizziness in American veterans, findings which may adversely impact long-term health outcomes. C1 [Wecht, Jill M.; Martinez, Stephanie; Eraifej, Mastanna; Bauman, William A.] James J Peters VA Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Wecht, JM (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; Wecht, JM (reprint author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service: Center of Excellence for the Medical Consequences of Spinal Cord Injury [B9212C] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service: Center of Excellence for the Medical Consequences of Spinal Cord Injury (Grant # B9212C). NR 51 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0959-9851 EI 1619-1560 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2016 VL 26 IS 1 BP 49 EP 58 DI 10.1007/s10286-015-0328-4 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DD5WL UT WOS:000369995300007 PM 26695397 ER PT J AU Dai, DW Singh, I Hershman, JM AF Dai, David W. Singh, Ishita Hershman, Jerome M. TI Lozenge-Induced Hypermineralcorticoid State--A Unique Case of Licorice Lozenges Resulting in Hypertension and Hypokalemia SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CORTISOL; RECEPTOR C1 [Singh, Ishita] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Singh, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Singh, I (reprint author), West Los Angeles VA Med Ctr, VA Greater Los Angeles Healthcare Syst, Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM isingh@mednet.ucla.edu NR 13 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2016 VL 18 IS 2 BP 159 EP 160 DI 10.1111/jch.12633 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DD5SQ UT WOS:000369985100013 PM 26212733 ER PT J AU Hochman, M Briggs-Malonson, M Wilkes, E Bergman, J Daskivich, LP Moin, T Brook, I Ryan, GW Brook, RH Mangione, CM AF Hochman, Michael Briggs-Malonson, Medell Wilkes, Erin Bergman, Jonathan Daskivich, Lauren Patty Moin, Tannaz Brook, Ilanit Ryan, Gery W. Brook, Robert H. Mangione, Carol M. TI Fostering a Commitment to Quality: Best Practices in Safety-net Hospitals SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Quality improvement; safety-net; community ID HEALTH REFORM; OF-CARE; 1990S AB In 2007, the Martin Luther King, Jr.-Harbor Hospital (MLK-Harbor), which served a large safety-net population in South Los Angeles, closed due to quality challenges. Shortly thereafter, an agreement was made to establish a new hospital, Martin Luther King, Jr. Community Hospital (MLKCH), to serve the unmet needs of the community. To assist the newly appointed MLKCH Board of Directors in building a culture of quality, we conducted a series of interviews with five high-performing hospital systems. In this report, we describe our findings. The hospitals we interviewed achieved a culture of quality by: 1) developing guiding principles that foster quality; 2) hiring and retaining personnel who are stewards of quality; 3) promoting efficient resource utilization; 4) developing a well-organized quality improvement infrastructure; and 5) cultivating integrated, patient-centric care. The institutions highlighted in this report provide important lessons for MLKCH and other safety-net institutions. C1 [Hochman, Michael; Bergman, Jonathan; Daskivich, Lauren Patty; Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA. [Hochman, Michael; Daskivich, Lauren Patty] US Dept Vet Affairs, Los Angeles, CA USA. [Hochman, Michael] AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA. [Briggs-Malonson, Medell] Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90095 USA. [Briggs-Malonson, Medell] Martin Luther King Jr Community Hosp, Los Angeles, CA USA. [Wilkes, Erin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wilkes, Erin; Daskivich, Lauren Patty] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Bergman, Jonathan] US Dept Vet Affairs, Vet Hlth Affairs, Los Angeles, CA USA. [Bergman, Jonathan] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. [Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Vet Hlth Affairs, Los Angeles, CA USA. [Brook, Ilanit] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA. [Ryan, Gery W.] Pardee RAND Grad Sch, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, US Dept Vet Affairs, Pardee RAND Grad Sch, Los Angeles, CA 90095 USA. [Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Hochman, M (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA.; Hochman, M (reprint author), US Dept Vet Affairs, Los Angeles, CA USA.; Hochman, M (reprint author), AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA. EM meh1979@gmail.com FU Robert Wood Johnson Foundation Clinical Scholars Program; U.S. Department of Veterans Affairs; National Research Award Program, National Institutes of Health FX We would like to thank the numerous people who helped us with this project including, but not limited to, Ken Wells, MD, MPH; Loretta Jones, MA; the original Martin Luther King, Jr. Community Hospital Board of Directors (Manuel A. Abascal, JD; Elaine Batchlor, MD, MPH; Linda Griego, BA; Paul King, MHA; Michael Madden, MA; Robert Margolis, MD and James Yoshioka, BS); those who graciously allowed us to interview them at Denver Health, Grady Health, Harlem Hospital Center, Mount Sinai Health System, and Virginia Mason Medical Center; and the Robert Wood Johnson Foundation Clinical Scholars Program, the U.S. Department of Veterans Affairs, and the National Research Award Program, National Institutes of Health, for supporting our efforts. NR 23 TC 0 Z9 0 U1 2 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2016 VL 27 IS 1 BP 293 EP 307 DI 10.1353/hpu.2016.0008 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DC9BD UT WOS:000369514400024 PM 27763471 ER PT J AU Armour, C Contractor, A Shea, T Elhai, JD Pietrzak, RH AF Armour, Cherie Contractor, Ateka Shea, Tracie Elhai, Jon D. Pietrzak, Robert H. TI Factor Structure of the PTSD Checklist for DSM-5 Relationships Among Symptom Clusters, Anger, and Impulsivity SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE PTSD; PCL-5; anger; impulsivity; DSM-5; confirmatory factor analysis ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE DEPENDENT INPATIENTS; CONFIRMATORY FACTOR-ANALYSIS; CLINIC-REFERRED YOUTH; 5 FACTOR MODEL; UNDERLYING DIMENSIONS; EARTHQUAKE SURVIVORS; MALE VETERANS; PSYCHOMETRIC PROPERTIES; EMOTION DYSREGULATION AB Scarce data are available regarding the dimensional structure of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) posttraumatic stress disorder (PTSD) symptoms and how factors relate to external constructs. We evaluated six competing models of DSM-5 PTSD symptoms, including Anhedonia, Externalizing Behaviors, and Hybrid models, using confirmatory factor analyses in a sample of 412 trauma-exposed college students. We then examined whether PTSD symptom clusters were differentially related to measures of anger and impulsivity using Wald chi-square tests. The seven-factor Hybrid model was deemed optimal compared with the alternatives. All symptom clusters were associated with anger; the strongest association was between externalizing behaviors and anger (r = 0.54). All symptom clusters, except reexperiencing and avoidance, were associated with impulsivity, with the strongest association between externalizing behaviors and impulsivity (r = 0.49). A seven-factor Hybrid model provides superior fit to DSM-5 PTSD symptom data, with the externalizing behaviors factor being most strongly related to anger and impulsivity. C1 [Armour, Cherie] Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. [Contractor, Ateka; Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH USA. [Contractor, Ateka; Shea, Tracie] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Shea, Tracie] Vet Affairs Med Ctr, Providence, RI USA. [Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. RP Armour, C (reprint author), Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. EM armour.cherie@gmail.com OI Armour, Cherie/0000-0001-7649-3874 NR 68 TC 4 Z9 4 U1 5 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD FEB PY 2016 VL 204 IS 2 BP 108 EP 115 DI 10.1097/NMD.0000000000000430 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DD5NP UT WOS:000369971100006 PM 26669984 ER PT J AU Murphey, MD Roberts, CC Bencardino, JT Appel, M Arnold, E Chang, EY Dempsey, ME Fox, MG Fries, IB Greenspan, BS Hochman, MG Jacobson, JA Mintz, DN Newman, JS Rosenberg, ZS Rubin, DA Small, KM Weissman, BN AF Murphey, Mark D. Roberts, Catherine C. Bencardino, Jenny T. Appel, Marc Arnold, Erin Chang, Eric Y. Dempsey, Molly E. Fox, Michael G. Fries, Ian Blair Greenspan, Bennett S. Hochman, Mary G. Jacobson, Jon A. Mintz, Douglas N. Newman, Joel S. Rosenberg, Zehava S. Rubin, David A. Small, Kirstin M. Weissman, Barbara N. TI ACR Appropriateness Criteria Osteonecrosis of the Hip SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness criteria; osteonecrosis; adult; child; MRI; radiograph ID CALVE-PERTHES-DISEASE; FEMORAL-HEAD OSTEONECROSIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUBCHONDRAL INSUFFICIENCY FRACTURE; CONTRAST-ENHANCED MRI; SICKLE-CELL-DISEASE; BONE-MARROW EDEMA; AVASCULAR NECROSIS; ASYMPTOMATIC OSTEONECROSIS; CORE DECOMPRESSION AB Osteonecrosis of the hip (Legg-Calve-Perthes) is a common disease, with 10,000-20,000 symptomatic cases annually in the United States. The disorder affects both adults and children and is most frequently associated with trauma and corticosteroid usage. The initial imaging evaluation of suspected hip osteonecrosis is done using radiography. MRI is the most sensitive and specific imaging modality for diagnosis of osteonecrosis of the hip. The clinical significance of hip osteonecrosis is dependent on its potential for articular collapse. The likelihood of articular collapse is significantly increased with involvement of greater than 30%-50% of the femoral head area, which is optimally evaluated by MRI, often in the sagittal plane. Contrast-enhanced MRI may be needed to detect early osteonecrosis of the hip in pediatric patients, revealing hypoperfusion. In patients with a contraindication for MRI, use of either CT or bone scintigraphy with SPECT (single-photon emission CT) are alternative radiologic methods of assessment. Imaging helps guide treatment, which may include core decompression, osteotomy, and ultimately, need for joint replacement. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. C1 [Murphey, Mark D.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA. [Bencardino, Jenny T.] NYU Radiol Associates, New York, NY USA. [Appel, Marc] Amer Acad Orthopaed Surgeons, James J Peters VA Med Ctr, Bronx, NY USA. [Arnold, Erin] Amer Coll Rheumatol, Orthopaed & Rheumatol North Shore, Skokie, IL USA. [Chang, Eric Y.] VA San Diego Healthcare Syst, San Diego, CA USA. [Dempsey, Molly E.] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA. [Fox, Michael G.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Fries, Ian Blair] Amer Acad Orthopaed Surgeons, Bone Spine & Hand Surg, Chartered, Brick, NJ USA. [Greenspan, Bennett S.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Hochman, Mary G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Jacobson, Jon A.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Mintz, Douglas N.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Newman, Joel S.] New England Baptist Hosp, Boston, MA USA. [Rosenberg, Zehava S.] Hosp Joint Dis & Med Ctr, New York, NY USA. [Rubin, David A.] Washington Univ, Sch Med, St Louis, MO USA. [Small, Kirstin M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Murphey, MD (reprint author), 1010 Wayne Ave Ste 320, Silver Spring, MD 20910 USA. EM mmurphey@acr.org OI Jacobson, Jon/0000-0002-3676-6628; Rosenberg MD, Zehava/0000-0003-1902-6350 NR 68 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2016 VL 13 IS 2 BP 147 EP 155 DI 10.1016/j.jacr.2015.10.033 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DD4FL UT WOS:000369877800014 PM 26846390 ER PT J AU Menon, MC Ross, MJ AF Menon, Madhav C. Ross, Michael J. TI Epithelial-to-mesenchymal transition of tubular epithelial cells in renal fibrosis: a new twist on an old tale SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID TISSUE GROWTH-FACTOR; KIDNEY FIBROSIS; DISEASE AB Recent publications have questioned whether epithelial-to-mesenchymal transition of tubular epithelial cells is an important contributor to renal fibrosis. Two recent publications describe an intratubular epithelial-to-mesenchymal transition-like program of epithelial cell dedifferentiation that may contribute to the recruitment or proliferation of interstitial myofibroblasts after kidney injury. C1 [Menon, Madhav C.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Ross, Michael J.] James J Peters VA Med Ctr, Bronx, NY USA. RP Ross, MJ (reprint author), Icahn Sch Med Mt Sinai, Div Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM michael.ross@mssm.edu NR 11 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2016 VL 89 IS 2 BP 263 EP 266 DI 10.1016/j.kint.2015.12.025 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA DD2TO UT WOS:000369775300004 PM 26806826 ER PT J AU Heatwole, C Bode, R Johnson, NE Dekdebrun, J Dilek, N Eichinger, K Hilbert, JE Logigian, E Luebbe, E Martens, W Mcdermott, MP Pandya, S Puwanant, A Rothrock, N Thornton, C Vickrey, BG Victorson, D Moxley, RT AF Heatwole, Chad Bode, Rita Johnson, Nicholas E. Dekdebrun, Jeanne Dilek, Nuran Eichinger, Katy Hilbert, James E. Logigian, Eric Luebbe, Elizabeth Martens, William Mcdermott, Michael P. Pandya, Shree Puwanant, Araya Rothrock, Nan Thornton, Charles Vickrey, Barbara G. Victorson, David Moxley, Richard T., III TI MYOTONIC DYSTROPHY HEALTH INDEX: CORRELATIONS WITH CLINICAL TESTS AND PATIENT FUNCTION SO MUSCLE & NERVE LA English DT Article DE muscle disease; myotonic dystrophy Type-1; patient-relevant; patient-reported outcome measure; quality of life; therapeutic trial ID QUALITY-OF-LIFE; FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; ACTIVITY RATING-SCALES; ADULT MUSCLE DISEASE; NATURAL-HISTORY; THERAPEUTIC TRIALS; DUCHENNE DYSTROPHY; ACTUALLY MEASURE; CTG REPEAT; RELIABILITY AB Introduction: The Myotonic Dystrophy Health Index (MDHI) is a disease-specific patient-reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type-1 (DM1). Methods: We conducted a cross-sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient-reported outcome measures. Results: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures. Conclusions: Patient-reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients. C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Eichinger, Katy; Hilbert, James E.; Logigian, Eric; Luebbe, Elizabeth; Martens, William; Mcdermott, Michael P.; Pandya, Shree; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA. [Bode, Rita] Psychometr Consultant, Chicago, IL USA. [Johnson, Nicholas E.] Univ Utah, Salt Lake City, UT USA. [Mcdermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Puwanant, Araya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Med Ctr, Los Angeles, CA 90095 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA. RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA. EM chad_heatwole@urmc.rochester.edu FU Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center [NINDS U54NS48843]; Muscular Dystrophy Association; Saunders Family Fund; Abrams Family Fund for Myotonic Dystrophy Research; University of Rochester CTSA award from the National Center for Research Resources [UL1 RR024160]; National Center for Advancing Translational Sciences of the National Institutes of Health FX Support for this research was provided by the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (NINDS U54NS48843), the Muscular Dystrophy Association, the Saunders Family Fund, and the Abrams Family Fund for Myotonic Dystrophy Research. The project described in this publication was also supported by the University of Rochester CTSA award number UL1 RR024160 from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional information regarding the MDHI is available at the Neuromuscular Institute of Quality-of-Life Studies and Outcome Measure Development website www.QOLINSTITUTE.com and MDHI licensing opportunities can be reviewed at: www.urmc.rochester.edu/techtransfer. NR 47 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD FEB PY 2016 VL 53 IS 2 BP 183 EP 190 DI 10.1002/mus.24725 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DD3RE UT WOS:000369839500003 PM 26044513 ER PT J AU Jemielita, TO Leonard, MB Baker, J Sayed, S Zemel, BS Shults, J Herskovitz, R Denburg, MR AF Jemielita, T. O. Leonard, M. B. Baker, J. Sayed, S. Zemel, B. S. Shults, J. Herskovitz, R. Denburg, M. R. TI Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bone mineral density; Parathyroid hormone; Vitamin D; Vitamin D-binding protein ID RANDOMIZED-CONTROLLED-TRIALS; NUTRITION EXAMINATION SURVEY; D SUPPLEMENTATION; AFRICAN-AMERICAN; WHITE WOMEN; SERUM 25-HYDROXYVITAMIN-D; FRACTURE PREVENTION; NATIONAL-HEALTH; CALCIUM; MEN AB A comparison of the association of different forms of 25-hydroxyvitamin D [25(OH)D] with parathyroid hormone (PTH) and with areal and volumetric bone mineral density (BMD) demonstrated that bioavailable and free 25(OH)D do not provide a better index of vitamin D status in terms of bone health compared to total 25(OH)D. Introduction This study aims to compare measures of vitamin D-binding protein (DBP) using a monoclonal versus polyclonal ELISA and assess correlations of total versus estimated free and bioavailable 25(OH)D with BMD and PTH concentrations. Methods DXA and peripheral quantitative CT (pQCT) scans were obtained in 304 adults (158 black, 146 white), ages 21-80 years. Free and bioavailable 25(OH)D were calculated from total 25(OH)D, DBP, and albumin concentrations. Multivariable linear regression with standardized beta coefficients was used to evaluate associations of bone measures and PTH with total, free, and bioavailable 25(OH)D. Results Measures of DBP obtained using a monoclonal versus polyclonal ELISA were not correlated (r (s) = 0.02, p = 0.76). Free and bioavailable 25(OH)D based on the polyclonal assay were lower in black versus white participants (p < 0.0001); this race difference was not evident using the monoclonal assay. Adjusted for age, sex, calcium intake, and race, all forms of 25(OH)D were negatively associated with PTH, but the absolute coefficient was greatest for total 25(OH)D (-0.34, p < 0.001) versus free/bioavailable 25(OH)D (-0.18/-0.24 depending on DBP assay, p <= 0.003). In analyses stratified on race, none of the measures of 25(OH)D were associated with BMD across DXA and pQCT sites. Conclusions The monoclonal versus polyclonal ELISA yielded highly discrepant measures of DBP, particularly among black individuals, likely related to established race differences in DBP polymorphisms. Contrary to prior studies, our findings indicate that using DBP to estimate bioavailable and free 25(OH)D does not provide a better index of vitamin D status in terms of bone health. C1 [Jemielita, T. O.; Baker, J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Leonard, M. B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Baker, J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Sayed, S.; Herskovitz, R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Zemel, B. S.; Shults, J.; Denburg, M. R.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. RP Denburg, MR (reprint author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM denburgm@email.chop.edu FU NIH [K23 DK093556, K24 DK076808, R01DK064966, T32DK060455]; Nephcure Foundation-American Society of Nephrology Research Grant; Veterans Affairs Clinical Science Research & Development Career Development Award FX This project was supported by NIH Grants K23 DK093556 (MRD), K24 DK076808 (MBL and JS), R01DK064966 (MBL), and T32DK060455 (TJ). Dr. Denburg was also funded by The Nephcure Foundation-American Society of Nephrology Research Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Baker is supported by a Veterans Affairs Clinical Science Research & Development Career Development Award. The contents of this work do not represent the views of the Department of Veterans Affairs or the United States Government. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. NR 53 TC 7 Z9 7 U1 1 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2016 VL 27 IS 2 BP 617 EP 626 DI 10.1007/s00198-015-3296-6 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD6PN UT WOS:000370046200020 PM 26359185 ER PT J AU McMains, KC AF McMains, Kevin Christopher TI Response to "A Beacon of Emotional Resilience in a Storm of Mistreatment?" SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Letter C1 [McMains, Kevin Christopher] South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA. RP McMains, KC (reprint author), South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2016 VL 154 IS 2 BP 398 EP 399 DI 10.1177/0194599815621529 PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA DD5VB UT WOS:000369991600035 PM 26833650 ER PT J AU Axon, RN Cole, L Moonan, A Foster, R Cawley, P Long, L Turley, CB AF Axon, R. Neal Cole, Laura Moonan, Aunyika Foster, Richard Cawley, Patrick Long, Laura Turley, Christine B. TI Evolution and Initial Experience of a Statewide Care Transitions Quality Improvement Collaborative: Preventing Avoidable Readmissions Together SO POPULATION HEALTH MANAGEMENT LA English DT Article ID HOSPITAL READMISSION; HEART-FAILURE; REHOSPITALIZATIONS; RISK AB Increasing scrutiny of hospital readmission rates has spurred a wide variety of quality improvement initiatives. The Preventing Avoidable Readmissions Together (PART) initiative is a statewide quality improvement learning collaborative organized by stakeholder organizations in South Carolina. This descriptive report focused on initial interventions with hospitals. Eligible participants included all acute care hospitals plus home health organizations, nursing facilities, hospices, and other health care organizations. Measures were degree of statewide participation, curricular engagement, adoption of evidence-based improvement strategies, and readmission rate changes. Fifty-nine of 64 (92%) acute care hospitals and 9 of 10 (90%) hospital systems participated in collaborative events. Curricular engagement included: webinars and coaching calls (49/59, 83%), statewide in-person meetings (35/59, 59%), regional in-person meetings (44/59, 75%), and individualized consultations (46/59, 78%). Among 34 (58%) participating hospitals completing a survey at the completion of Year 1, respondents indicated complete implementation of multidisciplinary rounding (58%), post-discharge telephone calls (58%), and teach-back (32%), and implementation in process of high-quality transition records (52%), improved discharge summaries (45%), and timely follow-up appointments (39%). A higher proportion of hospitals had significant decreases (10% relative change) in all-cause readmission rates for acute myocardial infarction (55.6% vs. 30.4%, P=0.01), heart failure (54.2% vs. 31.7%, P=0.09), and chronic obstructive pulmonary disease (41.7% vs. 33.3%, P=0.83) between 2011-2013 compared to earlier (2009-2011) trends. Focus on reducing readmissions is driving numerous, sometimes competing, quality improvement initiatives. PART successfully engaged the majority of acute care facilities in one state to harmonize and accelerate adoption of evidence-based care transitions strategies. (Population Health Management 2016;19:4-10) C1 [Axon, R. Neal] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Axon, R. Neal; Cawley, Patrick] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Cole, Laura; Moonan, Aunyika; Foster, Richard] South Carolina Hosp Assoc, Columbia, SC USA. [Long, Laura] BlueCross BlueShield South Carolina, Columbia, SC USA. [Turley, Christine B.] Hlth Sci S Carolina, Columbia, SC USA. [Turley, Christine B.] Univ S Carolina, Sch Med, Columbia, SC USA. RP Axon, RN (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.; Axon, RN (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.; Axon, RN (reprint author), 109 Bee St,Mail Code 111, Charleston, SC 29401 USA. EM axon@musc.edu NR 19 TC 1 Z9 1 U1 3 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD FEB 1 PY 2016 VL 19 IS 1 BP 4 EP 10 DI 10.1089/pop.2014.0182 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD4DO UT WOS:000369872900002 PM 26102592 ER PT J AU Yu, LL Rodriguez, RA Chen, LL Chen, LY Perry, G McHardy, SF Yeh, CK AF Yu, Lili Rodriguez, Roberto A. Chen, L. Laurie Chen, Liao Y. Perry, George McHardy, Stanton F. Yeh, Chih-Ko TI 1,3-propanediol binds deep inside the channel to inhibit water permeation through aquaporins SO PROTEIN SCIENCE LA English DT Article DE ligand-protein interaction; aquaporin inhibitor; molecular dynamics ID X-RAY-STRUCTURE; NEPHROGENIC DIABETES-INSIPIDUS; PLASMODIUM-FALCIPARUM; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; FREE-ENERGY; BRAIN; MICE; AQUAGLYCEROPORIN; TRAFFICKING AB Aquaporins and aquaglyceroporins (AQPs) are membrane channel proteins responsible for transport of water and for transport of glycerol in addition to water across the cell membrane, respectively. They are expressed throughout the human body and also in other forms of life. Inhibitors of human AQPs have been sought for therapeutic treatment for various medical conditions including hypertension, refractory edema, neurotoxic brain edema, and so forth. Conducting all-atom molecular dynamics simulations, we computed the binding affinity of acetazolamide to human AQP4 that agrees closely with in vitro experiments. Using this validated computational method, we found that 1,3-propanediol (PDO) binds deep inside the AQP4 channel to inhibit that particular aquaporin efficaciously. Furthermore, we used the same method to compute the affinities of PDO binding to four other AQPs and one aquaglyceroporin whose atomic coordinates are available from the protein data bank (PDB). For bovine AQP1, human AQP2, AQP4, AQP5, and Plasmodium falciparum PfAQP whose structures were resolved with high resolution, we obtained definitive predictions on the PDO dissociation constant. For human AQP1 whose PDB coordinates are less accurate, we estimated the dissociation constant with a rather large error bar. Taking into account the fact that PDO is generally recognized as safe by the US FDA, we predict that PDO can be an effective diuretic which directly modulates water flow through the protein channels. It should be free from the serious side effects associated with other diuretics that change the hydro-homeostasis indirectly by altering the osmotic gradients. C1 [Yu, Lili; Rodriguez, Roberto A.; Chen, Liao Y.] Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA. [Chen, L. Laurie] Univ Texas SW Med Ctr Dallas, Sch Med, Dallas, TX 75390 USA. [Perry, George] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. [McHardy, Stanton F.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA. [Yu, Lili] Yancheng Vocat Inst Hlth Sci, Dept Lab Med, Yancheng 224006, Jiangsu, Peoples R China. RP Chen, LY (reprint author), Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA. EM Liao.chen@utsa.edu RI Chen, Liao/B-8037-2009; Perry, George/A-8611-2009 OI Chen, Liao/0000-0003-1911-8634; Perry, George/0000-0002-6547-0172; Rodriguez, Roberto/0000-0002-3303-9564 FU NIH [GM 084834] FX Grant sponsor: NIH; Grant number: GM 084834. NR 62 TC 1 Z9 1 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0961-8368 EI 1469-896X J9 PROTEIN SCI JI Protein Sci. PD FEB PY 2016 VL 25 IS 2 BP 433 EP 441 DI 10.1002/pro.2832 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DD3JW UT WOS:000369819500012 PM 26481430 ER PT J AU Stewart, RW Tuerk, PW Metzger, IW Davidson, TM Young, J AF Stewart, Regan W. Tuerk, Peter W. Metzger, Isha W. Davidson, Tatiana M. Young, John TI A Decision-Tree Approach to the Assessment of Posttraumatic Stress Disorder: Engineering Empirically Rigorous and Ecologically Valid Assessment Measures SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; assessment; screening; decision-tree analysis; veterans ID ADMINISTERED PTSD SCALE; MENTAL-HEALTH; TREATMENT SEEKING; VIETNAM VETERANS; ASSESSMENT TOOLS; PRIMARY-CARE; CLINICIAN; CLASSIFICATION; SAMPLE; ADOLESCENTS AB Structured diagnostic interviews are widely considered to be the optimal method of assessing symptoms of posttraumatic stress; however, few clinicians report using structured assessments to guide clinical practice. One commonly cited impediment to these assessment approaches is the amount of time required for test administration and interpretation. Empirically keyed methods to reduce the administration time of structured assessments may be a viable solution to increase the use of standardized and reliable diagnostic tools. Thus, the present research conducted an initial feasibility study using a sample of treatment-seeking military veterans (N = 1,517) to develop a truncated assessment protocol based on the Clinician-Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS). Decision-tree analysis was utilized to identify a subset of predictor variables among the CAPS items that were most predictive of a diagnosis of PTSD. The algorithm-driven, atheoretical sequence of questions reduced the number of items administered by more than 75% and classified the validation sample at 92% accuracy. These results demonstrated the feasibility of developing a protocol to assess PTSD in a way that imposes little assessment burden while still providing a reliable categorization. C1 [Stewart, Regan W.; Tuerk, Peter W.; Metzger, Isha W.; Davidson, Tatiana M.; Young, John] Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA. [Tuerk, Peter W.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Young, John] Univ Mississippi, Dept Psychol, University, MS 38677 USA. RP Stewart, RW (reprint author), Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA. EM stewartr@musc.edu FU Career Development Award from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [CDA-2] FX Peter W. Tuerk's contribution to this article was partially supported by a Career Development Award (CDA-2) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (principal investigator: Peter W. Tuerk). NR 70 TC 1 Z9 1 U1 2 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2016 VL 13 IS 1 BP 1 EP 9 DI 10.1037/ser0000069 PG 9 WC Psychology, Clinical SC Psychology GA DD0FJ UT WOS:000369595500001 PM 26654473 ER PT J AU Keller, SM Tuerk, PW AF Keller, Stephanie M. Tuerk, Peter W. TI Evidence-Based Psychotherapy (EBP) Non-Initiation Among Veterans Offered an EBP for Posttraumatic Stress Disorder SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; treatment initiation; veterans; evidence-based psychotherapy ID PROLONGED EXPOSURE THERAPY; COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; TRAUMATIC BRAIN-INJURY; PTSD TREATMENT; AFGHANISTAN VETERANS; IRAQ; CARE; IMPLEMENTATION; ADHERENCE AB Current efforts to disseminate evidence-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD) in Veterans Affairs Medical Centers (VAMCs) have made effective treatment options more available throughout the system. Yet many veterans identified as likely to benefit from such services choose not to utilize them. The evidence base retarding factors that contribute to treatment initiation among those offered EBPs is still in its early-stages. The present study investigated clinical presentation, patient demographics, and environment of care factors as potential predictors of EBP treatment initiation among veterans offered such care,. The sample consisted of 324 Veterans (62% Operation Enduring Freedom [OEF]/Operation Iraqi Freedom [OM; 77% male; age M = 42.95 SD = 12.57 years), who attended an intake evaluation at a VAMC outpatient PTSD Clinical Team, were diagnosed with PTSD, and offered a course of EBP. Overall, 720 of veterans (11 = 232) who were offered an FOP initiated such treatment, and 28% of veterans (n = 92) did not initiate treatment. Veterans who initiated treatment were significantly older. Treatment initiation did not significantly differ by ethnicity, gender, or baseline PTSD severity. Significantly more veterans referred from mental health clinics initiated treatment than did veterans referred from primary care. This study examined treatment initiation among veterans who were offered FOP for PTSD. Rates of initiation differed across subgroups of veterans. Clinically, this suggests the need to tailor outreach efforts to younger veterans, OEF/OLF veterans, and veterans referred from primary care, and potentially including programming and education aimed at primary care referrers, to increase help-seeking. C1 [Keller, Stephanie M.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Keller, Stephanie M.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Keller, SM (reprint author), Ralph H Johnson VA Med Ctr, Menhil Hlth, 109 Bee St,116, Charleston, SC 29401 USA. EM smp28@case.edu FU CDA-2 award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [NCT01031979] FX Peter W. Tuerk's contribution to his research was supported in part by funding from a CDA-2 award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (principal investigator: Peter W. Tuerk; NCT01031979). NR 40 TC 0 Z9 0 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2016 VL 13 IS 1 BP 42 EP 48 DI 10.1037/ser0000064 PG 7 WC Psychology, Clinical SC Psychology GA DD0FJ UT WOS:000369595500005 PM 26654474 ER PT J AU Jahn, DR Bennett, ME Park, SG Gur, RE Horan, WP Kring, AM Blanchard, JJ AF Jahn, Danielle R. Bennett, Melanie E. Park, Stephanie G. Gur, Raquel E. Horan, William P. Kring, Ann M. Blanchard, Jack J. TI The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Social anhedonia; Social closeness; Belonging; Moderation; Protective factors ID PSYCHIATRIC RATING-SCALE; RISK-FACTORS; DEPRESSIVE SYMPTOMS; COMPLETED SUICIDE; DISORDERS; ANHEDONIA; LIFE; MOTIVATION; COMMUNITY; SPECTRUM AB Findings regarding the protective effect of social role functioning on suicide ideation in individuals with schizophrenia have been mixed. One reason for such inconsistencies in the literature may be that individuals with prominent negative symptoms of schizophrenia may not experience a desire for social closeness, and therefore social role functioning may not influence suicide risk in these individuals. The aim of this study was to examine the moderating effects of self-reported desire for social closeness and interviewer-rated negative symptoms on the relationship between social role functioning and suicide ideation. Our sample consisted of 162 individuals who had been diagnosed with schizophrenia-spectrum disorders; all participants completed self-report questionnaires and clinician-administered interviews, and moderation hypotheses were tested with a non parametric procedure. The results indicated that motivation and pleasure-related negative symptoms moderated the relationship between social role functioning and suicide ideation; self-reported desire for social closeness and negative symptoms related to expression did not have such a moderating effect. Specifically, better social role functioning was associated with less suicide ideation only in those individuals who had low motivation and pleasure-related negative symptoms; no significant relationship was observed between social role functioning and suicide ideation among those with elevated motivation and pleasure-related negative symptoms. These findings suggest that assessing for negative symptoms and social role functioning may inform suicide risk assessments in individuals with schizophrenia, and improving social role functioning may reduce suicide ideation among those with few motivation and pleasure-related negative symptoms. (c) 2015 Elsevier B.V. All rights reserved. C1 [Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] VA Maryland Hlth Care Syst, VA Capitol Hlth Care Network VISN 5, Mental Illness Res Educ & Clin Ctr, 10 N Greene St Annex Room 723A, Baltimore, MD 21201 USA. [Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] Univ Maryland, Sch Med, Dept Psychiat, 737 W Lombard St,Suite 551, Baltimore, MD 21201 USA. [Gur, Raquel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, 10th Floor Gates Bldg, Philadelphia, PA 19104 USA. [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Jane & Terry Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90095 USA. [Horan, William P.] VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Mail Code 210A, Los Angeles, CA 90073 USA. [Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA. [Blanchard, Jack J.] Univ Maryland, Dept Psychol, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA. RP Blanchard, JJ (reprint author), Univ Maryland, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA. EM danielle.jahn@va.gov; mbennett@p.sych.umaryland.edu; stephanie.park3@va.gov; raquel@upenn.edu; horan@ucla.edu; kring@berkeley.edu; jblancha@umd.edu FU NIH [1R01MH082839]; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs FX This work was supported by NIH grant (1R01MH082839) to Dr. Blanchard. Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (Dr. Jahn and Dr. Park's time). The funding sources had no role in study design or in the collection, analysis and interpretation of data, or in the writing of this report. NR 43 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2016 VL 170 IS 2-3 BP 271 EP 277 DI 10.1016/j.schres.2015.12.011 PG 7 WC Psychiatry SC Psychiatry GA DD0LS UT WOS:000369612100006 PM 26746862 ER PT J AU Suri, P Pashova, H Heagerty, PJ Jarvik, JG Turner, JA Bauer, Z Annaswamy, M Nedeljkovic, SS Wasan, AD Friedly, JL AF Suri, Pradeep Pashova, Hristina Heagerty, Patrick J. Jarvik, Jeffrey G. Turner, Judith A. Bauer, Zoya Annaswamy, M. Nedeljkovic, Srdjan S. Wasan, Ajay D. Friedly, Janna L. TI Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis Reply SO SPINE LA English DT Letter ID TRIAL C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Dallas VA Med Ctr, Dallas, TX USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM pradeep.suri@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD FEB PY 2016 VL 41 IS 3 BP E183 EP E184 DI 10.1097/BRS.0000000000001142 PG 2 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA DD5VS UT WOS:000369993400002 ER PT J AU Suri, P Pashova, H Heagerty, PJ Jarvik, JG Turner, JA Bauer, Z Annaswamy, TM Nedeljkovic, SS Wasan, AD Friedly, JL AF Suri, Pradeep Pashova, Hristina Heagerty, Patrick J. Jarvik, Jeffrey G. Turner, Judith A. Bauer, Zoya Annaswamy, Thiru M. Nedeljkovic, Srdjan S. Wasan, Ajay D. Friedly, Janna L. TI Re: Suri, P. et al. Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis. Spine (Phila Pa 1976) 2015 May 22. Reply SO SPINE LA English DT Letter ID TRIAL C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Dallas VA Med Ctr, Dallas, TX USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM pradeep.suri@va.gov NR 4 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD FEB PY 2016 VL 41 IS 3 BP E183 EP E184 DI 10.1097/BRS.0000000000001142 PG 2 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA DD5VR UT WOS:000369993300013 ER PT J AU Monteith, LL Menefee, DS Forster, JE Bahraini, NH AF Monteith, Lindsey L. Menefee, Deleene S. Forster, Jeri E. Bahraini, Nazanin H. TI A Closer Examination of Sexual Trauma During Deployment: Not all Sexual Traumas are Associated with Suicidal Ideation SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; MENTAL-HEALTH; MILITARY PERSONNEL; OEF/OIF VETERANS; FOLLOW-UP; ASSAULT; HARASSMENT; EXPERIENCES; AFGHANISTAN AB Military personnel can be exposed to a wide range of sexual traumawhile deployed, including sexual harassment and sexual assault. We examined whether different types of sexual trauma during deployment associated with recent suicidal ideation among previously deployed OEF/OIF/OND veterans admitted to trauma-focused treatment (n=199). More severe forms of sexual trauma (e.g., sexual assault) were significantly and positively associated with suicidal ideation. In contrast, sexual trauma involving verbal remarks (e.g., sexual harassment) was not associated with suicidal ideation. Our findings suggest that sexual harassment and sexual assault during deployment may be differentially associated with suicidal ideation. C1 [Monteith, Lindsey L.; Forster, Jeri E.; Bahraini, Nazanin H.] VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. [Monteith, Lindsey L.; Bahraini, Nazanin H.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Menefee, Deleene S.] VISN 16 MIRECC, Michael F DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Menefee, Deleene S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Forster, Jeri E.] Colorado Sch Publ Hlth, Aurora, CO USA. RP Monteith, LL (reprint author), VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. EM lindsey.monteith@va.gov FU Denver Veterans Affairs Medical Center; MEDVAMC; VISN 19 MIRECC in Denver, Colorado; VISN 16 MIRECC in Houston, Texas FX This material is the result of work supported with resources and the use of facilities at the Denver Veterans Affairs Medical Center and VISN 19 MIRECC in Denver, Colorado, and the MEDVAMC and VISN 16 MIRECC in Houston, Texas. The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. Government. NR 26 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2016 VL 46 IS 1 BP 46 EP 54 DI 10.1111/sltb.12171 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DD7WS UT WOS:000370136200005 PM 26096625 ER PT J AU Saxena, V Kim, M Keah, NM Neuwirth, AL Stoeckl, BD Bickard, K Restle, DJ Salowe, R Wang, MY Steinberg, DR Mauck, RL AF Saxena, Vishal Kim, Minwook Keah, Niobra M. Neuwirth, Alexander L. Stoeckl, Brendan D. Bickard, Kevin Restle, David J. Salowe, Rebecca Wang, Margaret Ye Steinberg, David R. Mauck, Robert L. TI Anatomic Mesenchymal Stem Cell-Based Engineered Cartilage Constructs for Biologic Total Joint Replacement SO TISSUE ENGINEERING PART A LA English DT Article ID HYALURONIC-ACID HYDROGELS; ARTICULAR-CARTILAGE; POROUS TANTALUM; NUTRIENT CHANNELS; TISSUE; KNEE; REPAIR; BONE; REGENERATION; GROWTH AB Cartilage has a poor healing response, and few viable options exist for repair of extensive damage. Hyaluronic acid (HA) hydrogels seeded with mesenchymal stem cells (MSCs) polymerized through UV crosslinking can generate functional tissue, but this crosslinking is not compatible with indirect rapid prototyping utilizing opaque anatomic molds. Methacrylate-modified polymers can also be chemically crosslinked in a cytocompatible manner using ammonium persulfate (APS) and N,N,N,N-tetramethylethylenediamine (TEMED). The objectives of this study were to (1) compare APS/TEMED crosslinking with UV crosslinking in terms of functional maturation of MSC-seeded HA hydrogels; (2) generate an anatomic mold of a complex joint surface through rapid prototyping; and (3) grow anatomic MSC-seeded HA hydrogel constructs using this alternative crosslinking method. Juvenile bovine MSCs were suspended in methacrylated HA (MeHA) and crosslinked either through UV polymerization or chemically with APS/TEMED to generate cylindrical constructs. Minipig porcine femoral heads were imaged using microCT, and anatomic negative molds were generated by three-dimensional printing using fused deposition modeling. Molded HA constructs were produced using the APS/TEMED method. All constructs were cultured for up to 12 weeks in a chemically defined medium supplemented with TGF-3 and characterized by mechanical testing, biochemical assays, and histologic analysis. Both UV- and APS/TEMED-polymerized constructs showed increasing mechanical properties and robust proteoglycan and collagen deposition over time. At 12 weeks, APS/TEMED-polymerized constructs had higher equilibrium and dynamic moduli than UV-polymerized constructs, with no differences in proteoglycan or collagen content. Molded HA constructs retained their hemispherical shape in culture and demonstrated increasing mechanical properties and proteoglycan and collagen deposition, especially at the edges compared to the center of these larger constructs. Immunohistochemistry showed abundant collagen type II staining and little collagen type I staining. APS/TEMED crosslinking can be used to produce MSC-seeded HA-based neocartilage and can be used in combination with rapid prototyping techniques to generate anatomic MSC-seeded HA constructs for use in filling large and anatomically complex chondral defects or for biologic joint replacement. C1 [Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. [Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Steinberg, David R.; Mauck, Robert L.] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Kim, Minwook; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Mauck, Robert L.] Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01 EB008722]; Department of Veterans Affairs [I01 RX000700]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was funded by the National Institutes of Health (R01 EB008722), the Department of Veterans Affairs (I01 RX000700), and the Penn Center for Musculoskeletal Disorders (P30 AR050950). NR 55 TC 1 Z9 1 U1 3 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD FEB 1 PY 2016 VL 22 IS 3-4 BP 386 EP 395 DI 10.1089/ten.tea.2015.0384 PG 10 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA DD5TS UT WOS:000369987900020 PM 26871863 ER PT J AU Ismail, Z Smith, EE Geda, Y Sultzer, D Brodaty, H Smith, G Aguera-Ortiz, L Sweet, R Miller, D Lyketsos, CG AF Ismail, Zahinoor Smith, Eric E. Geda, Yonas Sultzer, David Brodaty, Henry Smith, Gwenn Agueera-Ortiz, Luis Sweet, Rob Miller, David Lyketsos, Constantine G. CA ISTAART Neuropsychiat Symptoms Pro TI Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment SO ALZHEIMERS & DEMENTIA LA English DT Article DE Dementia; FTD; Alzheimer's disease; MCI; MBI; Neuropsychiatric symptoms of dementia; NPS; Behavior; Behaviour; Agitation; Psychosis; Disinhibition; Apathy; Depression; BPSD ID ALZHEIMERS ASSOCIATION WORKGROUPS; COGNITIVE IMPAIRMENT; FRONTOTEMPORAL DEMENTIA; NATIONAL INSTITUTE; CACHE COUNTY; RISK-FACTORS; DISEASE; PROGRESSION; AGITATION; PREDICTORS AB Neuropsychiatric symptoms (NPS) are common in dementia and in predementia syndromes such as mild cognitive impairment (MCI). NPS in MCI confer a greater risk for conversion to dementia in comparison to MCI patients without NPS. NPS in older adults with normal cognition also confers a greater risk of cognitive decline in comparison to older adults without NPS. Mild behavioral impairment (MBI) has been proposed as a diagnostic construct aimed to identify patients with an increased risk of developing dementia, but who may or may not have cognitive symptoms. We propose criteria that include MCI in the MBI framework, in contrast to prior definitions of MBI. Although MBI and MCI can co-occur, we suggest that they are different and that both portend a higher risk of dementia. These MBI criteria extend the previous literature in this area and will serve as a template for validation of the MBI construct from epidemiologic, neurobiological, treatment, and prevention perspectives. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Ismail, Zahinoor] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Ismail, Zahinoor] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada. [Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Geda, Yonas] Mayo Clin, Dept Psychiat, Scottsdale, AZ USA. [Geda, Yonas] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. [Sultzer, David] VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. [Brodaty, Henry] Univ New S Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia. [Smith, Gwenn] Johns Hopkins Sch Med, Alzheimers Dis Res Ctr, Baltimore, MD USA. [Agueera-Ortiz, Luis] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, Res Unit, Madrid, Spain. [Agueera-Ortiz, Luis] CIBERSAM, Madrid, Spain. [Sweet, Rob] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Rob] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Rob] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Miller, David] Bracket Global, Wayne, PA USA. [Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. RP Ismail, Z (reprint author), Univ Calgary, Dept Psychiat, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. EM zahinoor@gmail.com FU Veterans Health Administration [BX000452]; NIH [MH071533, AG05133, AG027224, P50AG005146]; Department of Veterans Affairs FX The authors acknowledge The Alzheimer's Association ISTAART group for reading and supporting these criteria. Article supported in part by Veterans Health Administration Grant BX000452, and NIH grants MH071533, AG05133, AG027224 (R.S.), and P50AG005146 to the Johns Hopkins Alzheimer's Disease Research Center (C.G.L.) and by the Department of Veterans Affairs (D.S. and R.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 52 TC 22 Z9 22 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD FEB PY 2016 VL 12 IS 2 BP 195 EP 202 DI 10.1016/j.jalz.2015.05.017 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC9EI UT WOS:000369523500011 PM 26096665 ER PT J AU Feemster, LC Curtis, JR AF Feemster, Laura C. Curtis, J. Randall TI "We Understand the Prognosis, but We Live with Our Heads in the Clouds": Understanding Patient and Family Outcome Expectations and Their Influence on Shared Decision Making SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ADVANCED CANCER; COMMUNICATION; PREFERENCES C1 [Feemster, Laura C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Feemster, Laura C.; Curtis, J. Randall] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Curtis, J. Randall] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA. RP Feemster, LC (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.; Feemster, LC (reprint author), Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. FU NHLBI NIH HHS [HL111116, K23 HL111116] NR 14 TC 0 Z9 0 U1 4 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2016 VL 193 IS 3 BP 239 EP 241 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DC6UR UT WOS:000369355600008 PM 26829423 ER PT J AU Kellum, JA Chawla, LS Keener, C Singbartl, K Palevsky, PM Pike, FL Yealy, DM Huang, DT Angus, DC AF Kellum, John. A. Chawla, Lakhmir S. Keener, Christopher Singbartl, Kai Palevsky, Paul M. Pike, Francis L. Yealy, Donald M. Huang, David T. Angus, Derek C. CA ProCESS & ProGReSS-AKI Investigato TI The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE sepsis; septic shock; resuscitation; early goal-directed therapy; acute kidney injury ID CRITICALLY-ILL PATIENTS; CREATININE; MORTALITY; RECOVERY; CRITERIA; TRIAL; CARE AB Rationale: Septic shock is a common cause of acute kidney injury (AKI), and fluid resuscitation is a major part of therapy. Objectives: To determine if structured resuscitation designed to alter fluid, blood, and vasopressor use affects the development or severity of AKI or outcomes. Methods: Ancillary study to the ProCESS (Protocolized Care for Early Septic Shock) trial of alternative resuscitation strategies (two protocols vs. usual care) for septic shock. Measurements and Main Results: We studied 1,243 patients and classified AKI using serum creatinine and urine output. We determined recovery status at hospital discharge, examined rates of renal replacement therapy and fluid overload, and measured biomarkers of kidney damage. Among patients without evidence of AKI at enrollment, 37.6% of protocolized care and 38.1% of usual care patients developed kidney injury (P = 0.90). AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study arms (6.9% for protocolized care and 4.3% for usual care; P = 0.08). Fluid overload occurred in 8.3% of protocolized care and 6.3% of usual care patients (P = 0.26). Among patients with severe AKI, complete and partial recovery was 50.7 and 13.2% for protocolized patients and 49.1 and 13.4% for usual care patients (P = 0.93). Sixty-day hospital mortality was 6.2% for patients without AKI, 16.8% for those with stage 1, and 27.7% for stages 2 to 3. Conclusions: In patients with septic shock, AKI is common and associated with adverse outcomes, but it is not influenced by protocolized resuscitation compared with usual care. C1 [Kellum, John. A.; Pike, Francis L.; Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15261 USA. [Kellum, John. A.; Chawla, Lakhmir S.; Singbartl, Kai; Palevsky, Paul M.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA 15261 USA. [Keener, Christopher] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 930 Scaife Hall, Pittsburgh, PA 15261 USA. [Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA. [Chawla, Lakhmir S.] Vet Affairs Med Ctr, Dept Med, Div Intens Care Med, 50 Irving St NW, Washington, DC 20422 USA. [Chawla, Lakhmir S.] Vet Affairs Med Ctr, Div Nephrol, 50 Irving St NW, Washington, DC 20422 USA. [Singbartl, Kai] Penn State Hershey Med Ctr, Dept Anesthesia, Hershey, PA USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,604 Scaife Hall, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases grant [R01 DK083961]; NIH/National Institute of General Medical Sciences grant [P50 GM076659] FX Supported by National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK083961 and NIH/National Institute of General Medical Sciences grant P50 GM076659. NR 19 TC 11 Z9 11 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2016 VL 193 IS 3 BP 281 EP 287 DI 10.1164/rccm.201505-0995OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DC6UR UT WOS:000369355600013 PM 26398704 ER PT J AU Sevy, S Sher, L AF Sevy, Serge Sher, Leo TI Gender differences in the dosing of antipsychotic medications SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [Sevy, Serge; Sher, Leo] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sevy, S (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. EM sevymd@gmail.com NR 3 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD FEB PY 2016 VL 50 IS 2 SI SI BP 185 EP 186 DI 10.1177/0004867415609426 PG 3 WC Psychiatry SC Psychiatry GA DC5FQ UT WOS:000369247300022 PM 26450940 ER PT J AU Cowan, AJ Stevenson, PA Cassaday, RD Graf, SA Fromm, JR Wu, D Holmberg, LA Till, BG Chauncey, TR Smith, SD Philip, M Orozco, JJ Shustov, AR Green, DJ Libby, EN Bensinger, WI Shadman, M Maloney, DG Press, OW Gopal, AK AF Cowan, Andrew J. Stevenson, Philip A. Cassaday, Ryan D. Graf, Solomon A. Fromm, Jonathan R. Wu, David Holmberg, Leona A. Till, Brian G. Chauncey, Thomas R. Smith, Stephen D. Philip, Mary Orozco, Johnnie J. Shustov, Andrei R. Green, Damian J. Libby, Edward N., III Bensinger, William I. Shadman, Mazyar Maloney, David G. Press, Oliver W. Gopal, Ajay K. TI Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Mantle cell lymphoma; Transplantation; Minimal residual disease; Predictors; Survival ID INTERNATIONAL PROGNOSTIC INDEX; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; FLOW-CYTOMETRY; MOLECULAR REMISSION; RESPONSE ASSESSMENT; IMMUNOCHEMOTHERAPY; TOMOGRAPHY; CLASSIFICATION AB Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 238 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR. (C) 2016 American Society for Blood and Marrow Transplantation. C1 [Cowan, Andrew J.; Stevenson, Philip A.; Cassaday, Ryan D.; Graf, Solomon A.; Holmberg, Leona A.; Till, Brian G.; Chauncey, Thomas R.; Smith, Stephen D.; Philip, Mary; Orozco, Johnnie J.; Shustov, Andrei R.; Green, Damian J.; Bensinger, William I.; Shadman, Mazyar; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Fromm, Jonathan R.; Wu, David] Univ Washington, Dept Lab Med, Marrow Transplant Unit, Seattle, WA 98195 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Libby, Edward N., III] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Dept, 1124 Columbia St, Seattle, WA 98104 USA. RP Gopal, AK (reprint author), 825 Eastlake Ave E,MS G3-200, Seattle, WA 98109 USA. EM agopal@u.washington.edu FU NIH [P01CA044991, K24CA184039]; Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative Clinical Scholar Award by the Leukemia and Lymphoma Society; Mary Aileen Wright Memorial Fund; David and Patricia Giuliani Family Foundation; [5T32 CA009515-30] FX A.J.C. is supported by 5T32 CA009515-30. This work was supported by research funding from NIH P01CA044991 and K24CA184039; Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative Clinical Scholar Award by the Leukemia and Lymphoma Society, to A.K.G.; the Mary Aileen Wright Memorial Fund; the David and Patricia Giuliani Family Foundation; and philanthropic gifts from Frank and Betty Vandermeer and Don and Debbie Hunkins. NR 34 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2016 VL 22 IS 2 BP 380 EP 385 DI 10.1016/j.bbmt.2015.08.035 PG 6 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DC2JD UT WOS:000369042100027 PM 26348890 ER PT J AU ter Maaten, JM Valente, MAE Metra, M Bruno, N O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC van Veldhuisen, DJ Hillege, HL Damman, K Voors, AA AF ter Maaten, Jozine M. Valente, Mattia A. E. Metra, Marco Bruno, Noemi O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. van Veldhuisen, Dirk J. Hillege, Hans L. Damman, Kevin Voors, Adriaan A. TI A combined clinical and biomarker approach to predict diuretic response in acute heart failure SO CLINICAL RESEARCH IN CARDIOLOGY LA English DT Article DE Diuretic response; Heart failure; Biomarkers; Prediction ID BLOOD UREA NITROGEN; PROGNOSTIC VALUE; THERAPY; ATHEROSCLEROSIS; TRANSPORT; CHLORIDE; RECEPTOR AB Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood. We evaluated a combined approach using clinical characteristics and biomarkers to predict diuretic response in acute heart failure (AHF). We investigated explanatory and predictive models for diuretic response-weight loss at day 4 per 40 mg of furosemide-in 974 patients with AHF included in the PROTECT trial. Biomarkers, addressing multiple pathophysiological pathways, were determined at baseline and after 24 h. An explanatory baseline biomarker model of a poor diuretic response included low potassium, chloride, hemoglobin, myeloperoxidase, and high blood urea nitrogen, albumin, triglycerides, ST2 and neutrophil gelatinase-associated lipocalin (r (2) = 0.086). Diuretic response after 24 h (early diuretic response) was a strong predictor of diuretic response (beta = 0.467, P < 0.001; r (2) = 0.523). Addition of diuretic response after 24 h to biomarkers and clinical characteristics significantly improved the predictive model (r (2) = 0.586, P < 0.001). Biomarkers indicate that diuretic unresponsiveness is associated with an atherosclerotic profile with abnormal renal function and electrolytes. However, predicting diuretic response is difficult and biomarkers have limited additive value. Patients at risk of poor diuretic response can be identified by measuring early diuretic response after 24 h. C1 [ter Maaten, Jozine M.; Valente, Mattia A. E.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Damman, Kevin; Voors, Adriaan A.] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Metra, Marco] Univ Brescia, Brescia, Italy. [Bruno, Noemi] Univ Roma La Sapienza, Dept Cardiovasc Sci, Piazzale Aldo Moro 5, I-00185 Rome, Italy. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. RP Voors, AA (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 FU NovaCardia, Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Alere and Singulex kindly provided assays and performed biomarker measurements. NR 27 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-0684 EI 1861-0692 J9 CLIN RES CARDIOL JI Clin. Res. Cardiol. PD FEB PY 2016 VL 105 IS 2 BP 145 EP 153 DI 10.1007/s00392-015-0896-2 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DC5IM UT WOS:000369254700006 PM 26280875 ER PT J AU Hall, GM Shanmugan, S Bleier, JIS Jeganathan, AN Epstein, AJ Paulson, EC AF Hall, G. M. Shanmugan, S. Bleier, J. I. S. Jeganathan, A. N. Epstein, A. J. Paulson, E. C. TI Colorectal specialization and survival in colorectal cancer SO COLORECTAL DISEASE LA English DT Article DE Colon cancer; rectal cancer; specialization; survival ID II COLON-CANCER; HOSPITAL VOLUME; RECTAL-CANCER; UNITED-STATES; STAGE-II; ADJUVANT THERAPY; SURGERY; OUTCOMES; PREDICTORS; RECURRENCE AB AimIt is recognized that higher surgeon volume is associated with improved survival in colorectal cancer. However, there is a paucity of national studies that have evaluated the relationship between surgical specialization and survival. MethodWe used the Surveillance, Epidemiology, and End Results Medicare cancer registry to examine the association between colorectal specialization (CRS) and disease-specific survival (DSS) between 2001 and 2009. A total of 21432 colon cancer and 5893 rectal cancer patients who underwent elective surgical resection between 2001 and 2009 were evaluated. Univariate and multivariate Cox survival analysis was used to identify the association between surgical specialization and cancer-specific survival. ResultsColorectal specialists performed 16.3% of the colon and 27% of the rectal resections. On univariate analysis, specialization was associated with improved survival in Stage II and Stage III colon cancer and Stage II rectal cancer. In multivariate analysis, however, CRS was associated with significantly improved DSS only in Stage II rectal cancer [hazard ratio (HR) 0.70, P=0.03]. CRS was not significantly associated with DSS in either Stage I (colon HR 1.14, P=0.39; rectal HR 0.1.26, P=0.23) or Stage III (colon HR 1.06, P=0.52; rectal HR 1.08, P=0.55) disease. When analysis was limited to high volume surgeons only, the relationship between CRS and DSS was unchanged. ConclusionsCRS is associated with improved DSS following resection of Stage II rectal cancer. A combination of factors may contribute to long-term survival in these patients, including appropriate surgical technique, multidisciplinary treatment decisions and guideline-adherent surveillance. CRS probably contributes positively to these factors resulting in improved survival. C1 [Hall, G. M.; Shanmugan, S.; Bleier, J. I. S.; Paulson, E. C.] Univ Penn, Dept Gen Surg, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. [Jeganathan, A. N.] Univ Penn, Dept Gen Surg, Philadelphia, PA 19104 USA. [Epstein, A. J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, A. J.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Paulson, E. C.] Philadelphia VA Med Ctr, Dept Gen Surg, Philadelphia, PA 19104 USA. RP Paulson, EC (reprint author), Philadelphia VA Med Ctr, Surg Business Off, 3900 Woodland Ave,5th Floor, Philadelphia, PA 19104 USA. EM paulsone@uphs.upenn.edu NR 26 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8910 EI 1463-1318 J9 COLORECTAL DIS JI Colorectal Dis. PD FEB PY 2016 VL 18 IS 2 BP O51 EP O60 DI 10.1111/codi.13246 PG 10 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA DD2GH UT WOS:000369740200001 PM 26708838 ER PT J AU Meya, DB Manabe, YC Boulware, DR Janoff, EN AF Meya, David B. Manabe, Yukari C. Boulware, David R. Janoff, Edward N. TI The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE cryptococcus; cryptococcal meningitis; HIV; immunopathogenesis; immune reconstitution inflammatory syndrome ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-INFECTED PATIENTS; RESOURCE-LIMITED SETTINGS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; RESTORATION DISEASE; FUNGAL-INFECTIONS; PRIMARY IMMUNODEFICIENCIES AB Purpose of reviewCryptococcal meningitis causes significant mortality among HIV-infected patients, despite antifungal therapy and use of antiretroviral therapy (ART). In patients with cryptococcal meningitis, ART is often complicated by immune reconstitution inflammatory syndrome (IRIS), manifesting as unmasking of previously unrecognized subclinical infection (unmasking CM-IRIS) or paradoxical worsening of symptoms in the central nervous system after prior improvement with antifungal therapy (paradoxical CM-IRIS). We review our current understanding of the pathogenesis of this phenomenon, focusing on unifying innate and adaptive immune mechanisms leading to the development of this often fatal syndrome.Recent findingsWe propose that HIV-associated CD4(+) T-cell depletion, chemokine-driven trafficking of monocytes into cerebrospinal fluid in response to cryptococcal meningitis, and poor localized innate cytokine responses lead to inadequate cryptococcal killing and clearance of the fungus. Subsequent ART-associated recovery of T-cell signaling and restored cytokine responses, characterized by IFN- production, triggers an inflammatory response. The inflammatory response triggered by ART is dysregulated because of impaired homeostatic and regulatory mechanisms, culminating in the development of CM-IRIS.SummaryDespite our incomplete understanding of the immunopathogenesis of CM-IRIS, emerging data exploring innate and adaptive immune responses could be exploited to predict, prevent and manage CM-IRIS and associated morbid consequences. C1 [Meya, David B.] Makerere Univ, Infect Dis Inst, Kampala 22418, Uganda. [Meya, David B.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Box 736 UMHC, Minneapolis, MN 55455 USA. [Meya, David B.] Makerere Univ, Sch Med, Coll Hlth Sci, Kampala 22418, Uganda. [Manabe, Yukari C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA. [Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA. [Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Meya, DB (reprint author), Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala 22418, Uganda. EM david.meya@gmail.com OI Boulware, David/0000-0002-4715-0060 FU National Institutes of Health [R01AI078934, U01AI089244, R21NS065713, R01AI108479, T32AI055433, K24AI096925]; Welcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa [087540, AI108479]; Veterans Affairs Research Service FX This work supported by the National Institutes of Health (R01AI078934, U01AI089244, R21NS065713, R01AI108479, T32AI055433) to D.M. and D.B.; K24AI096925 to P.B.; the Welcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, grant number 087540 to D.M.; AI108479 to E.J.; and the Veterans Affairs Research Service. NR 108 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD FEB PY 2016 VL 29 IS 1 BP 10 EP 22 DI 10.1097/QCO.0000000000000224 PG 13 WC Infectious Diseases SC Infectious Diseases GA DC9NZ UT WOS:000369549600002 PM 26658650 ER PT J AU Jensen, DM Ohning, GV Kovacs, TOG Jutabha, R Ghassemi, K Dulai, GS Machicado, GA AF Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. G. Jutabha, Rome Ghassemi, Kevin Dulai, Gareth S. Machicado, Gustavo A. TI Natural history of definitive diverticular hemorrhage based on stigmata of recent hemorrhage and colonoscopic Doppler blood flow monitoring for risk stratification and definitive hemostasis SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID BLEEDING COLONIC DIVERTICULA; ENDOSCOPIC HEMOSTASIS; URGENT COLONOSCOPY; SEVERE HEMATOCHEZIA; MASSIVE HEMORRHAGE; DIAGNOSIS; MANAGEMENT; VESSEL; INJECTION; THERAPY AB Background and Aims: Few prospective reports describe the short-term natural history of colon diverticular hemorrhage based on stigmata of recent hemorrhage, and none include blood flow detection for risk stratification or as a guide to definitive hemostasis. Our purposes were to report the 30-day natural history of definitive diverticular hemorrhage based on stigmata and to describe Doppler probe blood flow detection as a guide to definitive hemostasis. Methods: Different cohorts of patients with severe diverticular bleeding and stigmata on urgent colonoscopy are reported. For 30-day natural history, patients were treated medically. If severe rebleeding occurred, they had surgical or angiographic treatment. We report natural history with major stigmata (active bleeding, visible vessel, or adherent clot) and no stigmata or flat spots after clots were washed away. We also report Doppler probe detection of arterial blood flow underneath stigmata before and after hemostasis in a recent cohort. Results: For natural history, patients with major stigmata treated medically had 65.8% (25/38) rebleeding rates, and 44.7% (17/38) had intervention for hemostasis. Patients with spots or clean bases had no rebleeding. A Doppler probe detected arterial blood flow in 92% of major stigmatadnone after hemostasisdand there was no rebleeding. Conclusions: (1) Patients with major stigmata treated medically had high rates of rebleeding and intervention for hemostasis. (2) Patients with clean diverticula or only flat spots had no rebleeding. (3) High rates of arterial blood flow were detected under major stigmata with a Doppler probe, but with obliteration by hemostasis no rebleeding occurred. C1 [Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Ulcer Res & Educ,Dept Med Ronald Reagan UCLA, Digest Dis Res Ctr,Vet Affairs Greater Los Angele, Los Angeles, CA 90095 USA. Vet Affairs West Los Angeles Med Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr DDRC, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU Clinical Veterans Affairs Merit Review Grant, NIH [P30 AM41301]; Center for Ulcer Research and Education Digestive Diseases Research Center core grant; Vascular Technologies Incorporated (VTI) FX These studies were supported partially by a Clinical Veterans Affairs Merit Review Grant (D. Jensen, PI), NIH P30 AM41301, a Center for Ulcer Research and Education Digestive Diseases Research Center core grant (human studies core), and by Vascular Technologies Incorporated (VTI), who donated colon Doppler endoscopic probes. D. Jensen is a consultant for VTI and is a speaker for BSC. All other authors disclosed no financial relationships relevant to this publication. NR 33 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2016 VL 83 IS 2 BP 416 EP 423 DI 10.1016/j.gie.2015.07.033 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AK UT WOS:000369232000021 PM 26227931 ER PT J AU Sethi, S Anzueto, A Miravitlles, M Arvis, P Alder, J Haverstock, D Trajanovic, M Wilson, R AF Sethi, S. Anzueto, A. Miravitlles, M. Arvis, P. Alder, J. Haverstock, D. Trajanovic, M. Wilson, R. TI Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease SO INFECTION LA English DT Article DE Bacteriological outcomes; Beta-lactams; Exacerbation of chronic obstructive pulmonary disease; Fluoroquinolones; Risk factors; Systemic corticosteroids ID CHRONIC-BRONCHITIS; HAEMOPHILUS-INFLUENZAE; CONTROLLED-TRIAL; GENE-EXPRESSION; COPD; MOXIFLOXACIN; INFLAMMATION; ANTIBIOTICS; INFECTIONS; COLONIZATION AB Changes in sputum microbiology following antibiotic treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), including patterns of bacteriological relapse and superinfection are not well understood. Sputum microbiology at exacerbation is not routinely performed, but pathogen presence and species are determinants of outcomes. Therefore, we determined whether baseline clinical factors could predict the presence of bacterial pathogens at exacerbation. Bacterial eradication at end of treatment (EOT) is associated with clinical resolution of exacerbation. We determined the clinical, microbiological and therapeutic factors that were associated with bacteriological eradication in AECOPD at EOT and in the following 8 weeks. Sputum bacteriological outcomes (i.e., eradication, persistence, superinfection, reinfection) from AECOPD patients (N = 1352) who were randomized to receive moxifloxacin or amoxicillin/clavulanate in the MAESTRAL study were compared. Independent predictors of bacterial presence in sputum at exacerbation and determinants for bacteriological eradication were analyzed by logistic regression and receiver operating characteristic (ROC) analyses. Significantly greater bacteriological eradication with moxifloxacin was mainly driven by superior Haemophilus influenzae eradication (P = 0.002, EOT). Baseline clinical factors were a weak predictor of the presence of pathogens in sputum (AUC(ROC) = 0.593). On multivariate analysis, poorer bacterial eradication was associated with antibiotic resistance (P = 0.0001), systemic steroid use (P = 0.0024) and presence of P. aeruginosa (P = 0.0282). Since clinical prediction of bacterial presence in sputum at AECOPD is poor, sputum microbiological analysis should be considered for guiding antibiotic therapy in moderate-to-severe AECOPD, particularly in those who received concomitant systemic corticosteroids or are at risk for infection with antibiotic-resistant bacteria. C1 [Sethi, S.] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA. [Sethi, S.] VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Miravitlles, M.] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain. [Arvis, P.] Bayer HealthCare, Loos, France. [Alder, J.; Haverstock, D.] Bayer HealthCare Pharmaceut, Whippany, NJ USA. [Trajanovic, M.] Bayer Inc, Toronto, ON, Canada. [Wilson, R.] Royal Brompton Hosp, Host Def Unit, London SW3 6LY, England. RP Sethi, S (reprint author), SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA.; Sethi, S (reprint author), VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA. EM ssethi@buffalo.edu OI Miravitlles, Marc/0000-0002-9850-9520 FU Bayer HealthCare AG, Germany FX Highfield Communication (Oxford, United Kingdom) provided editorial assistance in preparation of this manuscript. This work was supported by Bayer HealthCare AG, Germany. NR 36 TC 1 Z9 1 U1 0 U2 8 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD FEB PY 2016 VL 44 IS 1 BP 65 EP 76 DI 10.1007/s15010-015-0833-3 PG 12 WC Infectious Diseases SC Infectious Diseases GA DC5ZJ UT WOS:000369299000008 PM 26370552 ER PT J AU Zhu, JM Hamel, D Dhaliwal, G Glass, M Sharpe, B Kim, B Monash, B AF Zhu, Jane M. Hamel, David Dhaliwal, Gurpreet Glass, Marcia Sharpe, Bradley Kim, Benjamin Monash, Bradley TI Breakdown SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HEMOLYTIC-ANEMIA C1 [Zhu, Jane M.; Hamel, David; Dhaliwal, Gurpreet; Glass, Marcia; Sharpe, Bradley; Kim, Benjamin; Monash, Bradley] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Hamel, David; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Monash, B (reprint author), 533 Parnassus Ave,Box 0131, San Francisco, CA 94143 USA. EM bradley.monash@ucsf.edu NR 9 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2016 VL 11 IS 2 BP 126 EP 129 DI 10.1002/jhm.2530 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DC5VB UT WOS:000369287500008 PM 26800656 ER PT J AU Aplin, AC Kohler, T Nicosia, R AF Aplin, Alfred C. Kohler, Ted Nicosia, Roberto TI Human Plaque-Aortic Ring Co-Culture: A Novel Assay for the Study of Atherosclerosis-Induced Angiogenesis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2016 VL 96 SU 1 MA 316 BP 81A EP 81A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA DC5OQ UT WOS:000369270700317 ER PT J AU Sidani, JE Shensa, A Shiffman, S Switzer, GE Primack, BA AF Sidani, Jaime E. Shensa, Ariel Shiffman, Saul Switzer, Galen E. Primack, Brian A. TI Behavioral associations with waterpipe tobacco smoking dependence among US young adults SO ADDICTION LA English DT Article DE Addiction; dependence; hookah; measurement; scale; tobacco; waterpipe ID HOOKAH SMOKING; UNITED-STATES; UNIVERSITY-STUDENTS; CIGARETTE-SMOKING; NICOTINE EXPOSURE; PUFF TOPOGRAPHY; SMOKERS; PREVALENCE; ATTITUDES; ADDICTION AB Background and AimsWaterpipe tobacco smoking (WTS) is increasingly prevalent in the United States, especially among young adults. We aimed to (1) adapt items from established dependence measures into a WTS dependence scale for US young adults (the US Waterpipe Dependence Scale), (2) determine the factor structure of the items and (3) assess associations between scale values and behavioral use characteristics known to be linked to dependence. DesignCross-sectional survey. SettingUnited States. ParticipantsA total of 436 past-year waterpipe tobacco users ages 18-30years selected at random from a national probability-based panel. MeasurementsParticipants responded to six tobacco dependence items adapted for WTS in US populations. Behavioral use characteristics included factors such as frequency of use and age of initiation. FindingsPrincipal components analysis yielded an unambiguous one-factor solution. Approximately half (52.9%) of past-year waterpipe tobacco users received a score of 0, indicating that none of the six WTS dependence items were endorsed. Approximately one-quarter (25.4%) endorsed one dependence item and 22.7% endorsed two or more items. Higher WTS dependence scores were associated significantly with all five behavioral use characteristics. For example, compared with those who endorsed no dependence items, those who endorsed two or more had an adjusted odds ratio (AOR) of 3.90 [95% confidence interval (CI)=1.56-9.78] for having had earlier age of initiation and an AOR of 32.75 (95% CI=9.76-109.86) for more frequent WTS sessions. ConclusionsScores on a six-item waterpipe tobacco smoking dependence scale (the US Waterpipe Dependence Scale) correlate with measures that would be expected to be related to dependence, such as amount used and age of initiation. C1 [Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, UPMCMontefiore Hosp,Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Ctr Res Media Technol & Hlth, Pittsburgh, PA USA. [Shiffman, Saul] Pinney Associates, Pittsburgh, PA USA. [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat Med, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Translat Sci, Pittsburgh, PA USA. [Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Div Adolescent Med, 3420 Fifth Ave, Pittsburgh, PA 15260 USA. RP Sidani, JE (reprint author), Ctr Res Media Technol & Hlth, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA. EM sidanije@upmc.edu FU National Cancer Institute at the National Institutes of Health [R01-CA140150]; Steven Manners Memorial Fund at the University of Pittsburgh Center for Social and Urban Research FX This work was supported by the National Cancer Institute at the National Institutes of Health (R01-CA140150) and the Steven Manners Memorial Fund at the University of Pittsburgh Center for Social and Urban Research, both awarded to B.A.P. The funding agencies had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. NR 44 TC 6 Z9 6 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD FEB PY 2016 VL 111 IS 2 BP 351 EP 359 DI 10.1111/add.13163 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DC0XE UT WOS:000368940500020 PM 26417942 ER PT J AU Dupre, TV Doll, MA Shah, PP Sharp, CN Kiefer, A Scherzer, MT Saurabh, K Saforo, D Siow, D Casson, L Arteel, GE Jenson, AB Megyesi, J Schnellmann, RG Beverly, LJ Siskind, LJ AF Dupre, Tess V. Doll, Mark A. Shah, Parag P. Sharp, Cierra N. Kiefer, Alex Scherzer, Michael T. Saurabh, Kumar Saforo, Doug Siow, Deanna Casson, Lavona Arteel, Gavin E. Jenson, Alfred Bennett Megyesi, Judit Schnellmann, Rick G. Beverly, Levi J. Siskind, Leah J. TI Suramin protects from cisplatin-induced acute kidney injury SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE cisplatin; acute kidney injury; suramin; renoprotective strategies ID ACUTE-RENAL-FAILURE; EPITHELIAL-CELLS; PROXIMAL TUBULE; ER STRESS; NEPHROTOXICITY; RECEPTORS; APOPTOSIS; FIBROSIS; LIVER; MICE AB Cisplatin, a commonly used cancer chemotherapeutic, has a dose-limiting side effect of nephrotoxicity. Approximately 30% of patients administered cisplatin suffer from kidney injury, and there are limited treatment options for the treatment of cisplatin-induced kidney injury. Suramin, which is Federal Drug Administration-approved for the treatment of trypanosomiasis, improves kidney function after various forms of kidney injury in rodent models. We hypothesized that suramin would attenuate cisplatin-induced kidney injury. Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury. Furthermore, suramin attenuated cisplatin-induced expression of inflammatory cytokines and chemokines, endoplasmic reticulum stress, and apoptosis in the kidney cortex. Treatment of mice with suramin 24 h after cisplatin also improved kidney function, suggesting that the mechanism of protection is not by inhibition of tubular cisplatin uptake or its metabolism to nephrotoxic species. If suramin is to be used in the context of cancer, then it cannot prevent cisplatin-induced cytotoxicity of cancer cells. Suramin did not alter the dose-response curve of cisplatin in lung adenocarcinoma cells in vitro. In addition, suramin pretreatment of mice harboring lung adenocarcinomas did not alter the initial cytotoxic effects of cisplatin (DNA damage and apoptosis) on tumor cells. These results provide evidence that suramin has potential as a renoprotective agent for the treatment/prevention of cisplatin-induced acute kidney injury and justify future long-term preclinical studies using cotreatment of suramin and cisplatin in mouse models of cancer. C1 [Dupre, Tess V.; Doll, Mark A.; Sharp, Cierra N.; Saforo, Doug; Siow, Deanna; Arteel, Gavin E.; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. [Shah, Parag P.; Kiefer, Alex; Scherzer, Michael T.; Saurabh, Kumar; Casson, Lavona; Beverly, Levi J.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Jenson, Alfred Bennett; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Megyesi, Judit] Univ Arkansas Med Sci, Dept Internal Med, Div Nephrol, Little Rock, AR 72205 USA. [Megyesi, Judit] Cent Arkansas & Vet Healthcare Syst, Little Rock, AR USA. [Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Siskind, LJ (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, James Graham Brown Canc Ctr, 505 S Hancock St,CTRB 204, Louisville, KY 40202 USA. EM leah.siskind@louisville.edu FU National Institutes of Health (NIH) Grant [R01-DK-093462]; NIH [R01-GM-084147, UL1-RR-029882]; Small Business Innovation Research/Small Business Technology Transfer Grant [ES-023767]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Grant [1BX000851]; South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina FX This work was supported by National Institutes of Health (NIH) Grant R01-DK-093462 (to L. J. Siskind). This work was also supported by NIH Grants R01-GM-084147 (to R. G. Schnellmann), Grant UL1-RR-029882 (to R. G. Schnellmann), and Small Business Innovation Research/Small Business Technology Transfer Grant ES-023767 (to R. G. Schnellmann), Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Grant 1BX000851 (to R. G. Schnellmann), and the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina (to R. G. Schnellmann). NR 46 TC 1 Z9 1 U1 3 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD FEB 1 PY 2016 VL 310 IS 3 BP F248 EP F258 DI 10.1152/ajprenal.00433.2015 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DC2TU UT WOS:000369070400007 PM 26661653 ER PT J AU Navarro-Millan, I Yang, S DuVall, SL Chen, L Baddley, J Cannon, GW Delzell, ES Zhang, J Safford, MM Patkar, NM Mikuls, TR Singh, JA Curtis, JR AF Navarro-Millan, Iris Yang, Shuo DuVall, Scott L. Chen, Lang Baddley, John Cannon, Grant W. Delzell, Elizabeth S. Zhang, Jie Safford, Monika M. Patkar, Nivedita M. Mikuls, Ted R. Singh, Jasvinder A. Curtis, Jeffrey R. TI Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE PROTEIN; FOLLOW-UP; MORTALITY; POLYARTHRITIS; EVENTS; COHORT; VALIDATION; DATABASES AB Objective To examine the association of serum lipids, inflammation and seropositivity on coronary heart disease (CHD) and stroke in patients with rheumatoid arthritis (RA). Methods The incidence of hospitalised myocardial infarction (MI) or stroke was calculated in a cohort of patients with RA receiving care within the national Veterans Health Administration from 1998 to 2011. Cox proportional hazard models were used to examine the association between these outcomes and low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as time-varying variables, divided into quintiles. Results There were 37 568 patients with RA in the cohort with mean age of 63 years (SD 12.1); 90% were men. There was a no clear association between LDL-C and CHD/stroke. Compared with lower HDL-C (<34 mg/dL), higher HDL-C (>= 54 mg/dL) was inversely associated with MI (hazard ratio (HR)=0.68, 95% CI 0.55 to 0.85) and stroke (HR=0.69, 95% CI 0.50 to 0.96). Higher CRP >2.17 mg/dL (vs CRP <0.26 mg/dL) was associated with increased risk (HR=2.43, 95% CI 1.77 to 3.33) for MI and 2.02 (95% CI 1.32 to 3.08) for stroke. ESR >47 mm/h compared with <8 mm/h had an HR 1.87 (95% CI 1.39 to 2.52) for MI and 2.00 (95% CI 1.26 to 3.18) for stroke. The association between MI was significant for RA seropositivity (HR=1.23, 95% CI 1.03 to 1.48). Conclusions In this predominantly older male RA cohort, there was no clear association between LDL-C and CHD, whereas higher HDL-C was inversely associated with MI and stroke. CRP and ESR were similarly associated with increase MI risk and stroke, reflecting the prominent role of inflammation in CHD risk in RA. C1 [Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Singh, Jasvinder A.; Curtis, Jeffrey R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Delzell, Elizabeth S.; Zhang, Jie; Safford, Monika M.; Patkar, Nivedita M.; Singh, Jasvinder A.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA. [DuVall, Scott L.; Cannon, Grant W.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [DuVall, Scott L.; Cannon, Grant W.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. RP Curtis, JR (reprint author), Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA. EM jcurtis@uab.edu FU Agency for Healthcare Research and Quality (AHRQ) [R01HS018517]; NIH [AR 053351, R01 AR062376-S1]; Arthritis Foundation [5561] FX This work was supported by the Agency for Healthcare Research and Quality (AHRQ) (R01HS018517). Dr Curtis receives support from the NIH (AR 053351). Dr Navarro-Millan received support from the Arthritis Foundation (5561) and NIH (R01 AR062376-S1). NR 37 TC 6 Z9 7 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD FEB PY 2016 VL 75 IS 2 BP 341 EP 347 DI 10.1136/annrheumdis-2013-204987 PG 7 WC Rheumatology SC Rheumatology GA DC1CZ UT WOS:000368955700004 PM 25609412 ER PT J AU Ward, MM Deodhar, A Akl, EA Lui, A Ermann, J Gensler, LS Smith, JA Borenstein, D Hiratzka, J Weiss, PF Inman, RD Majithia, V Haroon, N Maksymowych, WP Joyce, J Clark, BM Colbert, RA Figgie, MP Hallegua, DS Prete, PE Rosenbaum, JT Stebulis, JA Van Den Bosch, F Yu, DTY Miller, AS Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Akl, Elie A. Lui, Andrew Ermann, Joerg Gensler, Lianne S. Smith, Judith A. Borenstein, David Hiratzka, Jayme Weiss, Pamela F. Inman, Robert D. Majithia, Vikas Haroon, Nigil Maksymowych, Walter P. Joyce, Janet Clark, Bruce M. Colbert, Robert A. Figgie, Mark P. Hallegua, David S. Prete, Pamela E. Rosenbaum, James T. Stebulis, Judith A. Van Den Bosch, Filip Yu, David T. Y. Miller, Amy S. Reveille, John D. Caplan, Liron TI American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA; PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY; DRUGS; GRADE AB ObjectiveTo provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). MethodsA core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework. ResultsIn patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS. ConclusionThese recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas. C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. [Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon. [Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada. [Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA. [Borenstein, David] Arthrit & Rheumatism Assoc, Washington, DC USA. [Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA. [Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA. [Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada. [Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA. [Clark, Bruce M.] RPT, Vancouver, BC, Canada. [Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA. [Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA. [Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA. [Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA. [Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA. [Van Den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium. [Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. EM wardm1@mail.nih.gov FU American College of Rheumatology; Spondylitis Association of America FX This work was supported by the American College of Rheumatology and the Spondylitis Association of America. We thank our patient representative for adding valuable perspectives. We thank Laurie Savage and Charlotte Howard of the Spondylitis Association of America for their partnership on this project. We thank Regina Parker for administrative assistance and Tamara Rader, who with Janet Joyce, developed and reviewed the literature search strategies. We appreciate the contributions of Drs. Robert Hart, Siba Raychaudhuri, and James Witter to the literature review. NR 29 TC 4 Z9 4 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2016 VL 68 IS 2 BP 151 EP 166 DI 10.1002/acr.22708 PG 16 WC Rheumatology SC Rheumatology GA DB9RT UT WOS:000368855100001 PM 26401907 ER PT J AU Ward, MM Deodhar, A Akl, EA Lui, A Ermann, J Gensler, LS Smith, JA Borenstein, D Hiratzka, J Weiss, PF Inman, RD Majithia, V Haroon, N Maksymowych, WP Joyce, J Clark, BM Colbert, RA Figgie, MP Hallegua, DS Prete, PE Rosenbaum, JT Stebulis, JA van den Bosch, F Yu, DTY Miller, AS Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Akl, Elie A. Lui, Andrew Ermann, Joerg Gensler, Lianne S. Smith, Judith A. Borenstein, David Hiratzka, Jayme Weiss, Pamela F. Inman, Robert D. Majithia, Vikas Haroon, Nigil Maksymowych, Walter P. Joyce, Janet Clark, Bruce M. Colbert, Robert A. Figgie, Mark P. Hallegua, David S. Prete, Pamela E. Rosenbaum, James T. Stebulis, Judith A. van den Bosch, Filip Yu, David T. Y. Miller, Amy S. Reveille, John D. Caplan, Liron TI American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA; PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY; DRUGS; GRADE AB Objective. To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods. A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework. Results. In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS. Conclusion. These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas. C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. [Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon. [Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada. [Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA. [Borenstein, David] Arthrit & Rheumatism Associates, Washington, DC USA. [Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA. [Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA. [Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada. [Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA. [Clark, Bruce M.] RPT, Vancouver, BC, Canada. [Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA. [Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA. [Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA. [Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA. [Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA. [van den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium. [Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. EM wardm1@mail.nih.gov FU Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH; Abbott; Amgen; Pfizer; Novartis; AbbVie; UCB; Johnson Johnson; Celgene; Iroko; Janssen; Amgen/Pfizer; GlaxoSmithKline; Janssen/Johnson & Johnson/Centocor/Ortho Biotech Products; Janssen Biotech; Augurex; Bristol-Myers Squibb; Medtronic; Ethicon; Q-Med AB; Centocor; IDEC; Xoma; Roche; Isis; Pharmacia; La Jolla Pharma; Genentech; Proctor Gamble; Genelabs; MedImmune; Human Genome Sciences; Array Biopharma; Cipher; Regeneron; Lux Biosciences; Elan; Allergan; Santen; Teva; Sanofi; Janssen/Johnson Johnson FX Drs. Ward and Colbert's work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH.; Dr. Deodhar has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Pfizer, and Novartis (less than $10,000 each) and from AbbVie and UCB (more than $10,000 each), and research grants from Novartis, UCB, Johnson & Johnson, and Amgen. Dr. Ermann has received honoraria from AbbVie (less than $10,000) for Advisory Board service. Dr. Gensler has received consulting fees, speaking fees, and/or honoraria from AbbVie, UCB, and Amgen (less than $10,000 each) and research grants from Celgene and AbbVie. Dr. Borenstein has received consulting fees, speaking fees, and/or honoraria from Iroko and Abbott (less than $10,000 each) and honoraria from Clinical Care Options (more than $10,000). Dr. Inman has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Janssen, Amgen/Pfizer, UCB, Novartis, and Celgene (less than $10,000 each). Dr. Majithia has received consulting fees, speaking fees, and/or honoraria from GlaxoSmithKline (less than $10,000). Dr. Haroon has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Amgen, Janssen/Johnson & Johnson/Centocor/Ortho Biotech Products, Janssen Biotech, Celgene, UCB, and Pfizer (less than $10,000 each). Dr. Maksymowych has received consulting fees, speaking fees, and/or honoraria from AbbVie, UCB, Pfizer, Amgen, Janssen, and Augurex (less than $10,000 each) and receives licensing fees and royalties from Augurex for the 14-3-3 biomarker. Mr. Clark has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Amgen, Janssen, and Bristol-Myers Squibb (less than $10,000 each). Dr. Figgie has received consulting fees, speaking fees, and/or honoraria from Medtronic and Ethicon (less than $10,000 each). Dr. Hallegua has received consulting fees, speaking fees, and/or honoraria from AbbVie, Q-Med AB, UCB, Bristol-Myers Squibb, Centocor, Amgen, IDEC, Xoma, Novartis, Roche, Isis, Pharmacia, La Jolla Pharma, Genentech, Proctor & Gamble, Genelabs, MedImmune, Human Genome Sciences, Array Biopharma, and Cipher (less than $10,000 each). Dr. Prete has received consulting fees, speaking fees, and/or honoraria from Abbott (less than $10,000). Dr. Rosenbaum has received consulting fees, speaking fees, and/or honoraria from UCB, Regeneron, Xoma, Lux Biosciences, Elan, Allergan, Santen, Teva, Novartis, Sanofi, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, and Genentech (less than $10,000 each) and is a contributor to UpToDate. Dr. van den Bosch has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Janssen/Johnson & Johnson, Pfizer, and UCB (less than $10,000 each). Dr. Reveille has received consulting fees, speaking fees, and/or honoraria from Abbott and UCB (less than $10,000 each). NR 29 TC 26 Z9 28 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2016 VL 68 IS 2 BP 282 EP 298 DI 10.1002/art.39298 PG 17 WC Rheumatology SC Rheumatology GA DC0XY UT WOS:000368942500005 PM 26401991 ER PT J AU Baker, JF Ibrahim, S Billig, E Michaud, K Caplan, L Cannon, GW Stokes, A Majithia, V Mikuls, TR AF Baker, Joshua F. Ibrahim, Said Billig, Erica Michaud, Kaleb Caplan, Liron Cannon, Grant W. Stokes, Andrew Majithia, Vikas Mikuls, Ted R. TI Weight loss, the obesity paradox in rheumatoid arthritis: is it a paradox? Comment on the article by Baker et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter ID OLDER-ADULTS C1 [Baker, Joshua F.; Ibrahim, Said] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.; Ibrahim, Said; Billig, Erica] Univ Penn, Philadelphia, PA 19104 USA. [Michaud, Kaleb; Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Omaha, NE USA. [Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Cannon, Grant W.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Stokes, Andrew] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Majithia, Vikas] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. RP Baker, JF (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA. FU CSRD VA [IK2 CX000955] NR 4 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2016 VL 68 IS 2 BP 553 EP 554 PG 2 WC Rheumatology SC Rheumatology GA DC0XY UT WOS:000368942500035 PM 26555220 ER PT J AU Jaffa, MA Luttrell, D Schmaier, AH Klein, RL Lopes-Virella, M Luttrell, LM Jaffa, AA AF Jaffa, Miran A. Luttrell, Deirdre Schmaier, Alvin H. Klein, Richard L. Lopes-Virella, Maria Luttrell, Louis M. Jaffa, Ayad A. CA DCC EDIC Res Grp TI Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes SO DIABETES LA English DT Article ID KALLIKREIN-KININ SYSTEM; VASCULAR SMOOTH-MUSCLE; MACROVASCULAR COMPLICATIONS; CONTACT ACTIVATION; ENDOTHELIAL-CELLS; PROLYLCARBOXYPEPTIDASE; INFLAMMATION; NEPHROPATHY; PROGRESSION; MECHANISM AB The hypothesis that plasma prekallikrein (PK) is a risk factor for the development of vascular complications was assessed in a study using the Diabetes Control and Complications Trial (DCCT)/Epidemiology and Diabetes Interventions and Complications (EDIC) cohort of subjects with type 1 diabetes. The circulating levels of plasma PK activity were measured in the plasma of 636 subjects with type 1 diabetes (EDIC years 3-5). Common and internal carotid intima-media thickness (IMT) were measured by B-mode ultrasonography in EDIC years 1 and 6. Plasma PK levels were positively and significantly associated with BMI, hemoglobin A(1c), systolic blood pressure, total cholesterol, LDL cholesterol, and triglycerides but not with age, sex, duration of diabetes, or HDL cholesterol. Univariate and multivariable statistical models after controlling for other risk factors consistently demonstrated a positive association between plasma PK and progression of internal carotid IMT. Multivariate analysis using a general linear model showed plasma PK to be significantly associated with progression of both internal and combined IMT (Wilks Lambda P value of 0.005). In addition, the mean internal carotid IMT levels were higher in subjects with plasma PK levels in the highest 10th percentile compared with subjects with plasma PK levels in the lower 10th percentile (P = 0.048). These novel findings implicate plasma PK as a risk factor for vascular disease in type 1 diabetes. C1 [Jaffa, Miran A.] Amer Univ Beirut, Fac Hlth Sci, Epidemiol & Populat Hlth Dept, Beirut, Lebanon. [Luttrell, Deirdre; Klein, Richard L.; Lopes-Virella, Maria; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Schmaier, Alvin H.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29403 USA. [Jaffa, Ayad A.] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon. RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.; Jaffa, AA (reprint author), Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon. EM aj24@aub.edu.lb FU National Institutes for Health [HL-052779, HL-055782, HL-077192, HL-087986]; Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health FX This work was supported by National Institutes for Health research grants HL-052779 (to A.H.S.), HL-055782 (to M.L.-V.), and HL-077192 and HL-087986 (to A.A.J.). The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health. NR 24 TC 1 Z9 1 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2016 VL 65 IS 2 BP 498 EP 502 DI 10.2337/db15-0930 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DC1HS UT WOS:000368968000020 PM 26603531 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI The Doppler Effect: A Century from Red Shift to Red Spot SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material ID BLOOD-FLOW; ULTRASOUND C1 [Kaunitz, Jonathan D.] VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Kaunitz, JD (reprint author), Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU BLRD VA [I01 BX001245]; Intramural VA [VA999999]; NIDDK NIH HHS [R01 DK054221] NR 12 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2016 VL 61 IS 2 BP 340 EP 341 DI 10.1007/s10620-015-3998-9 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC1XR UT WOS:000369012100006 PM 26745970 ER PT J AU Schoenfeld, P Dominitz, JA AF Schoenfeld, Philip Dominitz, Jason A. TI No Polyp Left Behind: Defining Bowel Preparation Adequacy to Avoid Missed Polyps SO GASTROENTEROLOGY LA English DT Editorial Material ID SOCIETY-TASK-FORCE; ADENOMA DETECTION RATE; AVERAGE-RISK PATIENTS; COLORECTAL-CANCER; PREPARATION SCALE; COLONOSCOPY; RECOMMENDATIONS; IMPACT; SURVEILLANCE; CLEANLINESS C1 [Schoenfeld, Philip] Univ Michigan, Sch Med, Ann Arbor Vet Hlth Care Syst, Ann Arbor, MI USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Schoenfeld, P (reprint author), Univ Michigan, Sch Med, Med, Room 111-D,2215 Fuller Rd, Ann Arbor, MI USA. NR 23 TC 0 Z9 0 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 303 EP 306 DI 10.1053/j.gastro.2015.12.024 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900010 PM 26713765 ER PT J AU Su, F Yu, L Berry, K Liou, IW Landis, CS Rayhill, SC Reyes, JD Ioannou, GN AF Su, Feng Yu, Lei Berry, Kristin Liou, Iris W. Landis, Charles S. Rayhill, Stephen C. Reyes, Jorge D. Ioannou, George N. TI Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit SO GASTROENTEROLOGY LA English DT Article DE Waitlist Outcomes; Post-Transplantation Outcomes; Transplant-Related Survival Benefit ID C VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; WAITING-LIST; NONALCOHOLIC STEATOHEPATITIS; CANDIDATES; MORTALITY; OLDER; AGE; DISEASE AB BACKGROUND & AIMS: Epidemiologic factors have generated increased demand for liver transplantation among older patients. We aimed to describe trends in age among liver transplant registrants and recipients and the effect of age on waitlist and post-transplantation outcomes and on transplant-related survival benefit. METHODS: We obtained data from the United Network for Organ Sharing on adults who were listed for liver transplantation (N = 122,606) or underwent liver transplantation (N = 60,820) from 2002 to 2014 in the United States. Competing risks analysis was used to model waitlist outcomes and Cox proportional hazards analysis to model post-transplantation survival. These models were also used to estimate 5-year transplant-related survival benefit for different age groups, calculated as the difference between waitlist and post-transplantation life expectancy. RESULTS: Between 2002 and 2014, the mean age of liver transplant registrants increased from 51.2 to 55.7 years, with a more prominent increase in hepatitis C virus-positive (50.9 - 57.9 years) than hepatitis C virus-negative (51.3 - 54.3 years) registrants. The proportion of registrants aged >= 60 years increased from 19% to 41%. In hepatitis C virus-negative patients, aging trends were driven by increasing proportions of patients with hepatocellular carcinoma or nonalcoholic steatohepatitis. Among transplant registrants, increasing age was associated with increasing mortality before transplantation and decreasing likelihood of transplantation. Among transplant recipients, increasing age was associated with increasing post-transplantation mortality. There was little difference in 5-year transplant-related survival benefit between different age groups who had the same Model for EndStage Liver Disease score. CONCLUSIONS: Dramatic aging of liver transplant registrants and recipients occurred from 2002 to 2014, driven by aging of the hepatitis C virus - positive cohort and increased prevalence of nonalcoholic steatohepatitis and hepatocellular carcinoma. Increasing age does not affect transplant-related survival benefit substantially because age diminishes both post-transplantation survival and waitlist survival approximately equally. C1 [Su, Feng] Univ Washington, Dept Med, Div Internal Med, Seattle, WA USA. [Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Rayhill, Stephen C.; Reyes, Jorge D.] Univ Washington, Dept Surg, Div Transplant Surg, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro 1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Research and Development, Veterans Affairs Puget Sound Healthcare System; Health Resources and Services Administration [231-00-0115] FX This study was funded byResearch and Development, Veterans Affairs Puget Sound Healthcare System. This work was supported in part by Health Resources and Services Administration contract 231-00-0115. NR 42 TC 4 Z9 4 U1 3 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 441 EP + DI 10.1053/j.gastro.2015.10.043 PG 19 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900031 PM 26522262 ER PT J AU Berry, K Ioannou, GN AF Berry, Kristin Ioannou, George N. TI Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details Reply SO GASTROENTEROLOGY LA English DT Letter ID HEPATOCELLULAR-CARCINOMA C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Berry, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 535 EP 537 DI 10.1053/j.gastro.2015.12.030 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900042 PM 26718174 ER PT J AU Knapp, AA Blumenthal, H Mischel, ER Badour, CL Leen-Feldner, EW AF Knapp, Ashley A. Blumenthal, Heidemarie Mischel, Emily R. Badour, Christal L. Leen-Feldner, Ellen W. TI Anxiety Sensitivity and Its Factors in Relation to Generalized Anxiety Disorder among Adolescents SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE Anxiety sensitivity; Worry; Generalized anxiety disorder; Adolescents ID REVISED CHILD ANXIETY; DSM-IV ANXIETY; EMOTIONAL DISORDERS; DEPRESSION SCALE; UNIFIED PROTOCOL; NEGATIVE AFFECT; PANIC-ATTACKS; SYMPTOMS; INDEX; WORRY AB Anxiety psychopathology, one of the most prevalent classes of disorder among youth, is linked to detrimental outcomes. Accordingly, identifying factors that influence vulnerability to anxiety disorders is important. One promising factor, given emerging evidence for its transdiagnostic nature, is anxiety sensitivity (AS); however, relatively little is known about the linkage between AS and indicators of generalized anxiety disorder (GAD), particularly among youth. The aim of the current investigation was to address this gap in the literature using a community-based sample of adolescents aged 10-17 years (n = 165; M (age) = 14.49 years, SD = 2.26). Results indicated global AS and the AS-physical concerns dimension were significantly associated with worry, generalized anxiety symptoms, and GAD diagnosis assessed via a structured clinical interview, above and beyond key theoretically-relevant covariates. These findings add to a growing body of work underscoring the relevance of AS for multiple types of anxiety-related disorders among youth. C1 [Knapp, Ashley A.; Mischel, Emily R.; Leen-Feldner, Ellen W.] Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. [Blumenthal, Heidemarie] Univ N Texas, Dept Psychol, 155 Union Circle 311280, Denton, TX 76203 USA. [Badour, Christal L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861,2nd Fl IOP South Bldg, Charleston, SC 29425 USA. [Badour, Christal L.] Ralph H Johnson VA Med Ctr, Dept Psychiat, 109 Bee St, Charleston, SC 29401 USA. RP Knapp, AA (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. EM aaknapp@uark.edu NR 70 TC 2 Z9 2 U1 6 U2 17 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 EI 1573-2835 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD FEB PY 2016 VL 44 IS 2 BP 233 EP 244 DI 10.1007/s10802-015-9991-0 PG 12 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA DC1ZF UT WOS:000369016300003 PM 25724327 ER PT J AU Walter, ND Miller, MA Vasquez, J Weiner, M Chapman, A Engle, M Higgins, M Quinones, AM Rosselli, V Canono, E Yoon, C Cattamanchi, A Davis, JL Phang, T Stearman, RS Datta, G Garcia, BJ Daley, CL Strong, M Kechris, K Fingerlin, TE Reves, R Geraci, MW AF Walter, Nicholas D. Miller, Mikaela A. Vasquez, Joshua Weiner, Marc Chapman, Adam Engle, Melissa Higgins, Michael Quinones, Amy M. Rosselli, Vanessa Canono, Elizabeth Yoon, Christina Cattamanchi, Adithya Davis, J. Lucian Phang, Tzu Stearman, Robert S. Datta, Gargi Garcia, Benjamin J. Daley, Charles L. Strong, Michael Kechris, Katerina Fingerlin, Tasha E. Reves, Randall Geraci, Mark W. TI Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SIGNATURES; EXPRESSION; MEDICINE; AFRICA AB Blood transcriptional signatures are promising for tuberculosis (TB) diagnosis but have not been evaluated among U.S. patients. To be used clinically, transcriptional classifiers need reproducible accuracy in diverse populations that vary in genetic composition, disease spectrum and severity, and comorbidities. In a prospective case-control study, we identified novel transcriptional classifiers for active TB among U.S. patients and systematically compared their accuracy to classifiers from published studies. Blood samples from HIV-uninfected U.S. adults with active TB, pneumonia, or latent TB infection underwent whole-transcriptome microarray. We used support vector machines to classify disease state based on transcriptional patterns. We externally validated our classifiers using data from sub-Saharan African cohorts and evaluated previously published transcriptional classifiers in our population. Our classifier distinguishing active TB from pneumonia had an area under the concentration-time curve (AUC) of 96.5% (95.4% to 97.6%) among U.S. patients, but the AUC was lower (90.6% [89.6% to 91.7%]) in HIV-uninfected Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 90.0% (87.7% to 92.3%) and 82.9% (80.8% to 85.1%) when tested in U.S. patients. Our classifier distinguishing active TB from latent TB had AUC values of 95.9% (95.2% to 96.6%) among U.S. patients and 95.3% (94.7% to 96.0%) among Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 98.0% (97.4% to 98.7%) and 94.8% (92.9% to 96.8%) when tested in U.S. patients. Blood transcriptional classifiers accurately detected active TB among U.S. adults. The accuracy of classifiers for active TB versus that of other diseases decreased when tested in new populations with different disease controls, suggesting additional studies are required to enhance generalizability. Classifiers that distinguish active TB from latent TB are accurate and generalizable across populations and can be explored as screening assays. C1 [Walter, Nicholas D.] Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA. [Walter, Nicholas D.; Chapman, Adam; Phang, Tzu; Stearman, Robert S.; Geraci, Mark W.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Walter, Nicholas D.; Miller, Mikaela A.; Rosselli, Vanessa; Kechris, Katerina; Fingerlin, Tasha E.; Reves, Randall] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Vasquez, Joshua; Yoon, Christina; Cattamanchi, Adithya; Davis, J. Lucian] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Weiner, Marc; Engle, Melissa] Vet Adm Med Ctr, Dept Med, San Antonio, TX USA. [Higgins, Michael; Reves, Randall] Denver Metro TB Control Program, Denver, CO USA. [Quinones, Amy M.] Denver Hlth Med Ctr, Denver, CO USA. [Canono, Elizabeth] Natl Jewish Hlth, Clin Translat Res Ctr, Denver, CO USA. [Datta, Gargi; Garcia, Benjamin J.; Strong, Michael] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Daley, Charles L.] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO USA. [Davis, J. Lucian] Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA. [Stearman, Robert S.] Indiana Univ, Dept Med, Indianapolis, IN USA. [Fingerlin, Tasha E.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Geraci, Mark W.] Indiana Univ, Dept Med, Indianapolis, IN USA. RP Walter, ND (reprint author), Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA.; Walter, ND (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.; Walter, ND (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. EM nicholas.walter@ucdenver.edu OI Garcia, Benjamin/0000-0001-5524-6946 FU Veteran's Administration Career Development Award Colorado Clinical and Translational Sciences Institute, Mucosal and Vaccine Research Colorado [CDA 1IK2CX000914-01A1]; University of Colorado Denver Division of Pulmonary Sciences and Critical Care Medicine FX The Veteran's Administration Career Development Award (CDA 1IK2CX000914-01A1) Colorado Clinical and Translational Sciences Institute, Mucosal and Vaccine Research Colorado and the University of Colorado Denver Division of Pulmonary Sciences and Critical Care Medicine provided funding. NR 24 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2016 VL 54 IS 2 BP 274 EP 282 DI 10.1128/JCM.01990-15 PG 9 WC Microbiology SC Microbiology GA DC3YD UT WOS:000369155100006 PM 26582831 ER PT J AU Zhang, Y Jenkins, AJ Basu, A Stoner, JA Lopes-Virella, MF Klein, RL Lyons, TJ AF Zhang, Ying Jenkins, Alicia J. Basu, Arpita Stoner, Julie A. Lopes-Virella, Maria F. Klein, Richard L. Lyons, Timothy J. CA DCCT EDIC Res Grp TI Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes SO JOURNAL OF LIPID RESEARCH LA English DT Article DE intensive diabetes treatment; dyslipidemia; atherosclerosis; clinical trial; high density lipoprotein; low density lipoprotein; nuclear magnetic resonance ID MAGNETIC-RESONANCE-SPECTROSCOPY; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; COMPLICATIONS TRIAL; HEART-DISEASE; CARDIOVASCULAR-DISEASE; DCCT/EDIC COHORT; FOLLOW-UP; CAROTID ATHEROSCLEROSIS; PARTICLE CONCENTRATIONS AB Our objective is to define differences in circulating lipoprotein subclasses between intensive versus conventional management of type 1 diabetes during the randomization phase of the Diabetes Control and Complications Trial (DCCT). NMR-determined lipoprotein subclass profiles (NMR-LSPs), which estimate molar subclass concentrations and mean particle diameters, were determined in 1,294 DCCT subjects after a median of 5 years (interquartile range: 4-6 years) of randomization to intensive or conventional diabetes management. In cross-sectional analyses, we compared standard lipids and NMR-LSPs between treatment groups. Standard total, LDL, and HDL cholesterol levels were similar between randomization groups, while triglyceride levels were lower in the intensively treated group. NMR-LSPs showed that intensive therapy was associated with larger LDL diameter (20.7 vs. 20.6 nm, P = 0.01) and lower levels of small LDL (median: 465 vs. 552 nmol/l, P = 0.007), total IDL/LDL (mean: 1,000 vs. 1,053 nmol/l, P = 0.01), and small HDL (mean: 17.3 vs. 18.6 mu mol/l, P < 0.0001), the latter accounting for reduced total HDL (mean: 33.8 vs. 34.8 mu mol/l, P = 0.01). In conclusion, intensive diabetes therapy was associated with potentially favorable changes in LDL and HDL subclasses in sera. Further research will determine whether these changes contribute to the beneficial effects of intensive diabetes management on vascular complications. C1 [Zhang, Ying; Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA. [Jenkins, Alicia J.] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia. [Jenkins, Alicia J.; Lyons, Timothy J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland. [Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. [Lopes-Virella, Maria F.; Klein, Richard L.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.; Klein, Richard L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Lyons, TJ (reprint author), Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA.; Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland. EM t.lyons@qub.ac.uk FU National Institutes of Health [R01DK080043]; American Diabetes Association [7-12-CT-46]; Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program; National Eye Institute, the National Institute of Neurologic Disorders and Stroke, Clinical Translational Science Center Program FX This project was supported by grants from the National Institutes of Health (R01DK080043) and the American Diabetes Association (7-12-CT-46). DCCT/EDIC has been supported by U01 Cooperative Agreement grants (1982-1993, 2011-2016) and contracts (1982-2011) from the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present). The authors have no relevant conflicts of interest to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 52 TC 2 Z9 2 U1 2 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2016 VL 57 IS 2 BP 310 EP 317 DI 10.1194/jlr.P060657 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DC3AN UT WOS:000369091600014 PM 26658239 ER PT J AU Vanderberg, RH Farkas, AH Miller, E Sucato, GS Akers, AY Borrero, SB AF Vanderberg, Rachel H. Farkas, Amy H. Miller, Elizabeth Sucato, Gina S. Akers, Aletha Y. Borrero, Sonya B. TI Racial and/or Ethnic Differences in Formal Sex Education and Sex Education by Parents among Young Women in the United States SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY LA English DT Article DE Contraception; Disparities; Parents; Race; Sex education ID REPRODUCTIVE HEALTH COMMUNICATION; UNINTENDED PREGNANCY; ADOLESCENT WOMEN; DISPARITIES; PERSPECTIVES; KNOWLEDGE; ATTITUDES AB Study Objective: We sought to investigate the associations between race and/or ethnicity and young women's formal sex education and sex education by parents. Design, Setting, and Participants: Cross-sectional analysis of a nationally representative sample of 1768 women aged 15-24 years who participated in the 2011-2013 National Survey of Family Growth. Interventions and Main Outcome Measures: We assessed 6 main outcomes: participants' report of: (1) any formal sex education; (2) formal contraceptive education; (3) formal sexually transmitted infection (STI) education; (4) any sex education by parents; (5) contraceptive education by parents; and (6) STI education by parents. The primary independent variable was self-reported race and/or ethnicity. Results: Nearly all of participants (95%) reported any formal sex education, 68% reported formal contraceptive education, and 92% reported formal STI education. Seventy-five percent of participants reported not having any sex education by parents and only 61% and 56% reported contraceptive and STI education by parents, respectively. US-born Hispanic women were more likely than white women to report STI education by parents (adjusted odds ratio = 1.87; 95% confidence interval, 1.17-2.99). No other significant racial and/or ethnic differences in sex education were found. Conclusion: There are few racial and/or ethnic differences in formal sex education and sex education by parents among young women. C1 [Vanderberg, Rachel H.; Farkas, Amy H.; Borrero, Sonya B.] Univ Pittsburgh, Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA. [Miller, Elizabeth; Sucato, Gina S.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Div Adolescent & Young Adult Med,Dept Pediat, Pittsburgh, PA 15213 USA. [Akers, Aletha Y.] Childrens Hosp Philadelphia, Craig Dalsimer Div Adolescent Med, Philadelphia, PA 19104 USA. [Borrero, Sonya B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Borrero, SB (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu FU NIH [UL1-TR-000005]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [1R21HD068736-01A1] FX The authors thank Dan Winger, at the Clinical and Translation Science Institute, University of Pittsburgh, supported by NIH Grant UL1-TR-000005, for his assistance with statistical analysis. This work was also supported by Dr. Sonya Borrero's Grant 1R21HD068736-01A1 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 24 TC 0 Z9 0 U1 18 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-3188 EI 1873-4332 J9 J PEDIATR ADOL GYNEC JI J. Pediatr Adolesc. Gynecol. PD FEB PY 2016 VL 29 IS 1 BP 69 EP 73 DI 10.1016/j.jpag.2015.06.011 PG 5 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA DC1IS UT WOS:000368970600014 PM 26143556 ER PT J AU Deo, R Shou, HC Soliman, EZ Yang, W Arkin, JM Zhang, XM Townsend, RR Go, AS Shlipak, MG Feldman, HI AF Deo, Rajat Shou, Haochang Soliman, Elsayed Z. Yang, Wei Arkin, Joshua M. Zhang, Xiaoming Townsend, Raymond R. Go, Alan S. Shlipak, Michael G. Feldman, Harold I. TI Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HEART-ASSOCIATION ELECTROCARDIOGRAPHY; OF-CARDIOLOGY-FOUNDATION; LEFT-VENTRICULAR HYPERTROPHY; SUDDEN CARDIAC DEATH; SERVICES TASK-FORCE; ARRHYTHMIAS COMMITTEE; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY; RHYTHM-SOCIETY; AHA/ACCF/HRS RECOMMENDATIONS AB Limited studies have assessed the resting 12-lead electrocardiogram (ECG) as a screening test in intermediate risk populations. We evaluated whether a panel of common ECG parameters are independent predictors of mortality risk in a prospective cohort of participants with CKD. The Chronic Renal Insufficiency Cohort (CRIC) study enrolled 3939 participants with eGFR<70 ml/min per 1.73 m(2) from June 2003 to September 2008. Over a median follow-up of 7.5 years, 750 participants died. After adjudicating the initial 497 deaths, we identified 256 cardiovascular and 241 noncardiovascular deaths. ECG metrics were independent risk markers for cardiovascular death (hazard ratio, 95% confidence interval): PR interval >= 200 ms (1.62, 1.19-2.19); QRS interval 100-119 ms (1.64, 1.20-2.25) and >= 120 ms (1.75, 1.17-2.62); corrected QT (QTc) interval >= 450 ms in men or >= 460 ms in women (1.72, 1.19-2.49); and heart rate 60-90 beats per minute (1.21, 0.89-1.63) and >= 90 beats per minute (2.35, 1.03-5.33). Most ECG measures were stronger markers of risk for cardiovascular death than for all-cause mortality or noncardiovascular death. Adding these intervals to a comprehensive model of cardiorenal risk factors increased the C-statistic for cardiovascular death from 0.77 to 0.81 (P<0.001). Furthermore, adding ECG metrics to the model adjusted for standard risk factors resulted in a net reclassification of 12.1% (95% confidence interval 8.1%-16.0%). These data suggest common ECG metrics are independent risk factors for cardiovascular death and enhance the ability to predict death events in a population with CKD. C1 [Deo, Rajat; Arkin, Joshua M.] Univ Penn, Cardiac Electrophysiol Sect, Div Cardiovasc Med, Dept Med,Perelman Sch Med, Philadelphia, PA 19104 USA. [Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27109 USA. [Townsend, Raymond R.; Feldman, Harold I.] Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. RP Deo, R (reprint author), 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19146 USA. EM Rajat.Deo@uphs.upenn.edu FU National Institutes of Health (NIH) [K23-DK089118]; National Institute of Diabetes and Digestive and Kidney Diseases [U01-DK060990, U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028, U01-DK060980, U01-DK060963, U01-DK060902]; Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/ National Center for Advancing Translational Sciences (NCATS) [UL1-TR000003]; Johns Hopkins University [UL1-TR000424]; University of Maryland [M01-RR16500]; Clinical and Translational Science Collaborative of Cleveland from the NCATS component of the NIH and NIH roadmap for Medical Research [UL1-TR000439]; Michigan Institute for Clinical and Health Research Grant [UL1-TR000433]; University of Illinois at Chicago CTSA Grant [UL1-RR029879]; Tulane University Translational Research in Hypertension and Renal Biology Grant [P30-GM103337]; Kaiser Permanente NIH/NCRR UCSF-CTSI Grant [UL1-RR024131] FX We appreciate the support of the other CRIC Study Investigators including Lawrence J. Appel, Jiang He, John W. Kusek, James P. Lash, Akinlolu Ojo, and Mahboob Rahman. The CRIC ancillary study was supported by the National Institutes of Health (NIH) grant K23-DK089118 (to R.D.). The CRIC study is supported by cooperative agreement project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK060990, U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028, U01-DK060980, U01-DK060963, and U01-DK060902).; In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/ National Center for Advancing Translational Sciences (NCATS) Grant UL1-TR000003, Johns Hopkins University Grant UL1-TR000424, University of Maryland GCRC Grant M01-RR16500, Clinical and Translational Science Collaborative of Cleveland Grant UL1-TR000439 from the NCATS component of the NIH and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research Grant UL1-TR000433, University of Illinois at Chicago CTSA Grant UL1-RR029879, Tulane University Translational Research in Hypertension and Renal Biology Grant P30-GM103337, and Kaiser Permanente NIH/NCRR UCSF-CTSI Grant UL1-RR024131. NR 33 TC 4 Z9 4 U1 2 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2016 VL 27 IS 2 BP 559 EP 569 DI 10.1681/ASN.2014101045 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DC1DS UT WOS:000368957600025 PM 26160896 ER PT J AU Gin, JL Kranke, D Saia, R Dobalian, A AF Gin, June L. Kranke, Derrick Saia, Rebecca Dobalian, Aram TI Disaster Preparedness in Homeless Residential Organizations in Los Angeles County: Identifying Needs, Assessing Gaps SO NATURAL HAZARDS REVIEW LA English DT Article DE Disasters; Residential organizations; Disaster planning; Preparedness; Homeless persons; Emergency management; Vulnerable populations ID HEALTH-CARE; COMMUNITY AB Community-based organizations (CBOs) are essential to supporting homeless populations during disasters, yet little is known about their preparedness and ability to support their vulnerable clients. This qualitative study evaluated the perceptions of Los Angeles nonprofit homeless residential service providers regarding the likely impacts of a disaster on their clients and operations, the barriers they face in disaster planning, and their suggested solutions to facilitate preparedness within their sector. Twelve semistructured interviews were conducted with executive staff and emergency planners from six organizations serving people experiencing homelessness. Respondents reported significant barriers to both postdisaster services and collaboration with emergency management. They indicated both a need for and interest in technical assistance and training to develop their disaster capabilities. These concerns suggest that a multisector effort, including homeless-service organizations, their funders, and emergency managers, is needed to strengthen the resilience of safety-net CBOs serving homeless populations. This work is made available under the terms of the Creative Commons Attribution 4.0 International license, http://creativecommons. org/licenses/by/4.0/. C1 [Gin, June L.; Kranke, Derrick; Saia, Rebecca; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. [Dobalian, Aram] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Gin, JL (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. EM June.Gin@va.gov; Derrick.Kranke@va.gov; Rebecca.Saia@va.gov; Aram.Dobalian@va.gov NR 46 TC 0 Z9 0 U1 5 U2 8 PU ASCE-AMER SOC CIVIL ENGINEERS PI RESTON PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA SN 1527-6988 EI 1527-6996 J9 NAT HAZARDS REV JI Nat. Hazards Rev. PD FEB PY 2016 VL 17 IS 1 AR 04015022 DI 10.1061/(ASCE)NH.1527-6996.0000208 PG 8 WC Engineering, Civil; Environmental Studies; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Geology; Meteorology & Atmospheric Sciences; Water Resources GA DB9LK UT WOS:000368837300016 ER PT J AU Guo, FJ Garvey, WT AF Guo, Fangjian Garvey, W. Timothy TI Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults SO OBESITY LA English DT Article ID BODY-MASS INDEX; TREATMENT PANEL-III; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MYOCARDIAL-INFARCTION; NORMAL-WEIGHT; IMPACT; WOMEN; POPULATION; OVERWEIGHT AB ObjectiveTo assess the stability of metabolic status and body mass index (BMI) status and their relative contribution to risk of diabetes, cardiovascular events, and mortality. MethodsA total of 14,685 participants from the Atherosclerosis Risk in Communities Study and 4,990 from the Coronary Artery Risk Development in Young Adults Study were included. People with healthy obesity (HO) are defined as those meeting all three indices of blood pressure, blood glucose, and blood lipids. People with unhealthy obesity crossed the risk threshold for all three criteria. ResultsIn both healthy and unhealthy subgroups, risks for coronary heart disease (CHD), stroke, and mortality were comparable among BMI status during a mean 18.7-year follow-up. When compared with HO, hazard ratios were increased for diabetes (5.56, 95% confidence interval [CI] 4.12-7.48), CHD (5.60, 95% CI 3.14-9.98), stroke (4.84, 95% CI 2.13-10.97), and mortality (2.6, 95% CI 1.88-3.61) in people with unhealthy obesity. BMI only moderately increased the risks for diabetes among healthy subjects. In the Coronary Artery Risk Development in Young Adults Study over 20 years, 17.5% of lean subjects and 67.3% of overweight subjects at baseline developed obesity during follow-up. Despite rising BMI, metabolic status remained relatively stable. ConclusionsMetabolic status is relatively stable despite rising BMI. HO had lower risks for diabetes, CHD, stroke, and mortality than unhealthy subjects but increased diabetes risks than healthy lean people. Cardiometabolic risk factors confer much higher risk than obesity per se. C1 [Guo, Fangjian] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA. [Guo, Fangjian] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA. RP Guo, FJ (reprint author), Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.; Guo, FJ (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA.; Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA. EM faguo@utmb.edu; garveyt@uab.edu OI Guo, Fangjian/0000-0003-3729-2724 FU Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH) [T32HD055163]; U.S. Department of Veterans Affairs, National Institutes of Health [DK-038765, DK-083562]; University of Alabama at Birmingham Diabetes Research Center [P60-DK079626] FX Dr. Guo is currently a postdoctoral fellow supported by an institutional training grant (National Research Service Award T32HD055163) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH). This study is supported by the Merit Review program of the U.S. Department of Veterans Affairs, National Institutes of Health (DK-038765 and DK-083562), and the University of Alabama at Birmingham Diabetes Research Center (P60-DK079626). NR 34 TC 9 Z9 9 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2016 VL 24 IS 2 BP 516 EP 525 DI 10.1002/oby.21344 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA DC3SQ UT WOS:000369139500034 PM 26719125 ER PT J AU Golier, JA Caramanica, K Michaelides, AC Makotkine, I Schmeidler, J Harvey, PD Yehuda, R AF Golier, Julia A. Caramanica, Kimberly Michaelides, Andreas C. Makotkine, Iouri Schmeidler, James Harvey, Philip D. Yehuda, Rachel TI A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Gulf War; Mifepristone; CMI; Dexamethasone; ACTH; Cortisol; Verbal learning ID POSTTRAUMATIC-STRESS-DISORDER; OPEN-LABEL TRIAL; PSYCHOTIC DEPRESSION; COGNITIVE DYSFUNCTION; ALZHEIMERS-DISEASE; HIPPOCAMPAL; MEMORY; DEXAMETHASONE; NEUROGENESIS; RU-486 AB No pharmacological treatments have been demonstrated to effectively treat chronic multisymptom illness (CMI) in Gulf War veterans (GWV). This study assessed the effect of the glucocorticoid receptor antagonist mifepristone in GWV with CMI. A randomized, double-blind, cross-over trial of mifepristone, with two six-week treatment phases separated by a one-month washout period, was conducted at a Veterans Affairs (VA) hospital between 2008 and 2011. Participants were randomized to receive either 200 mg of mifepristone per day or matched placebo first. The primary clinical outcome measure was change in self-reported physical health. Neurocognitive functioning and self-reported measures of depression, PTSD, and fatigue were secondary outcomes. Sixty-five participants enrolled, of whom 36 were randomized and 32 (mean age, 49.1 (7.2) years) completed the study. Physical and mental health status and neurocognitive functioning were poor at baseline. Mifepristone treatment was not associated with improvement in self-reported physical health (p = 0.838) or in other self-reported measures of mental health. Mifepristone treatment was significantly associated with improvements in verbal learning (p = 0.008, d = 0.508), in the absence of improvement in other cognitive measures (working memory (p = 0.914), visual learning (p = 0.643) and a global composite measure (p = 0.937). Baseline morning cortisol levels and lysozyme IC50-DEX, a measure of peripheral glucocorticoid sensitivity, displayed a significant relationship with endpoint verbal learning scores (p = 0.012 and p = 0.007, respectively). The magnitude of cortisol change during treatment mediated the improvement in verbal learning. This study was negative for the primary and secondary clinical outcomes. However, the data suggest a moderate dose of mifepristone may have circumscribed cognitive-enhancing effects in CMI. Further study is warranted to determine whether and through which mechanisms mifepristone treatment can yield clinically meaningful improvement in cognitive function in CMI or other neuropsychiatric conditions associated with HPA axis dysregulation. (C) Published by Elsevier Ltd. C1 [Golier, Julia A.; Caramanica, Kimberly; Michaelides, Andreas C.; Makotkine, Iouri; Yehuda, Rachel] James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Golier, Julia A.; Makotkine, Iouri; Schmeidler, James; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, 1428 Madison Ave, New York, NY 10029 USA. [Harvey, Philip D.] Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM julia.golier@va.gov FU Department of Defense (DoD) FX This study is registered with ClinicalTrials.gov (NCT00691067) and was solely funded by the Department of Defense (DoD). The DoD did not influence any aspects of the study design or manuscript preparation. The authors declare no conflicts of interests. The authors also acknowledge the assistance of Ahmed El-Razi, B.A. in the revising of the manuscript. NR 44 TC 2 Z9 2 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2016 VL 64 BP 22 EP 30 DI 10.1016/j.psyneuen.2015.11.001 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DB9WF UT WOS:000368867700003 PM 26600007 ER PT J AU Kline, CE Reboussin, DM Foster, GD Rice, TB Strotmeyer, ES Jakicic, JM Millman, RP Pi-Sunyer, X Newman, AB Wadden, TA Zammit, G Kuna, ST AF Kline, Christopher E. Reboussin, David M. Foster, Gary D. Rice, Thomas B. Strotmeyer, Elsa S. Jakicic, John M. Millman, Richard P. Pi-Sunyer, Xavier Newman, Anne B. Wadden, Thomas A. Zammit, Gary Kuna, Samuel T. CA Look AHEAD Res Grp TI The Effect of Changes in Cardiorespiratory Fitness and Weight on Obstructive Sleep Apnea Severity in Overweight Adults with Type 2 Diabetes SO SLEEP LA English DT Article DE apnea-hypopnea index; cardiorespiratory fitness; obstructive sleep apnea; physical activity; weight loss ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE RISK; RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; HEART-RATE RECOVERY; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; OBESE-PATIENTS; FOLLOW-UP; METABOLIC SYNDROME AB Study Objectives: To examine the effect of changes in cardiorespiratory fitness on obstructive sleep apnea (OSA) severity prior to and following adjustment for changes in weight over the course of a 4-y weight loss intervention. Methods: As secondary analyses of a randomized controlled trial, 263 overweight/obese adults with type 2 diabetes and OSA participated in an intensive lifestyle intervention or education control condition. Measures of OSA severity, cardiorespiratory fitness, and body weight were obtained at baseline, year 1, and year 4. Change in the apnea-hypopnea index (AHI) served as the primary outcome. The percentage change in fitness (submaximal metabolic equivalents [METs]) and change in weight (kg) were the primary independent variables. Primary analyses collapsed intervention conditions with statistical adjustment for treatment group and baseline METs, weight, and AHI among other relevant covariates. Results: At baseline, greater METs were associated with lower AHI (B [SE] = -1.48 [0.71], P = 0.038), but this relationship no longer existed (B [SE] = -0.24 [0.73], P = 0.75) after adjustment for weight (B [SE] = 0.31 [0.07], P < 0.0001). Fitness significantly increased at year 1 (+16.53 +/- 28.71% relative to baseline), but returned to near-baseline levels by year 4 (+1.81 +/- 24.48%). In mixed-model analyses of AHI change over time without consideration of weight change, increased fitness at year 1 (B [SE] = -0.15 [0.04], P < 0.0001), but not at year 4 (B [SE] = 0.04 [0.05], P = 0.48), was associated with AHI reduction. However, with weight change in the model, greater weight loss was associated with AHI reduction at years 1 and 4 (B [SE] = 0.81 [0.16] and 0.60 [0.16], both P < 0.0001), rendering the association between fitness and AHI change at year 1 nonsignificant (B [SE] = -0.04 [0.04], P = 0.31). Conclusions: Among overweight/obese adults with type 2 diabetes, fitness change did not influence OSA severity change when weight change was taken into account. C1 [Kline, Christopher E.; Rice, Thomas B.; Strotmeyer, Elsa S.; Jakicic, John M.; Newman, Anne B.] Univ Pittsburgh, Pittsburgh, PA USA. [Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA. [Foster, Gary D.] Weight Watchers Int, New York, NY USA. [Millman, Richard P.] Brown Univ, Providence, RI 02912 USA. [Pi-Sunyer, Xavier] Columbia Univ, New York, NY USA. [Wadden, Thomas A.; Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kline, CE (reprint author), Univ Pittsburgh, Dept Hlth & Phys Act, 32 Oak Hill Court,Room 227, Pittsburgh, PA 15261 USA. EM chriskline@pitt.edu OI Strotmeyer, Elsa/0000-0002-4093-6036; Newman, Anne B./0000-0002-0106-1150 FU Abbott; Abbvie; Actelion; Ancile; Apnex; Arena; Aptalis; Astra-Zeneca; Aventis; Banyu; Biomarin; BMS; Catalyst; Celgene; Cephalon; CHDI; Edgemont; Elan; Epix; Eisai; Elminda; Evotec; Forest; Fresca; Galderma; Genentech; Gilead; Glaxo Smith Kline; H. Lundbeck A/S; Janssen; Jazz; Johnson Johnson; King; Merck and Co.; National Institutes of Health (NIH); Neurim; Neurocrine Biosciences; Naurex; Neurogen; Novo Nordisk; Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics; Roxane; Saladax; Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor; Sunovion; Shire; Somaxon; Takeda; Takeda Pharmaceuticals North America; Targacept; Teva; Thymon; Transcept; UCB; USWorldmeds; Pharma; Ultragenyx; Vanda; Wyeth-Ayerst Research; Orexigen; Nutrisystem; Weight Watchers; Jawbone; [HL070301]; [DK60426]; [DK56992]; [DK057135]; [HL118318] FX This was not an industry supported study. Financial support was provided by HL070301, DK60426, DK56992, DK057135, HL118318. Dr. Zammit is a consultant for Acorda, Actelion, Alexza, Arena, Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Jazz, King Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon, Pfizer, Purdue, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire, Somnus, Takeda Pharmaceuticals, Vela, and Wyeth; has grant support from Abbott, Abbvie, Actelion, Ancile, Apnex, Arena, Aptalis, Astra-Zeneca, Aventis, Banyu, Biomarin, BMS, Catalyst, Celgene, Cephalon, CHDI, Edgemont, Elan, Epix, Eisai, Elminda, Evotec, Forest, Fresca, Galderma, Genentech, Gilead, Glaxo Smith Kline, Gilead, H. Lundbeck A/S, Janssen, Jazz, Johnson & Johnson, King, Merck and Co., National Institutes of Health (NIH), Neurim, Neurocrine Biosciences, Naurex, Neurim, Neurogen, Novo Nordisk, Organon, Orphan Medical, Otsuka, Pfizer, Predix, Respironics, Roxane, Saladax, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sepracor, Sunovion, Shire, Somaxon, Takeda, Takeda Pharmaceuticals North America, Targacept, Teva, Thymon, Transcept, UCB, USWorldmeds, Pharma, Ultragenyx, Predix, Vanda, and Wyeth-Ayerst Research; and has received honoraria from King Pharmaceuticals, McNeil, Merck, Neurocrine Biosciences, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, and Wyeth-Ayerst Research. Dr. Wadden serves on Scientific Advisory Boards for Orexigen, Novo Nordisk, Nutrisystem, and Weight Watchers and has received grant support, on behalf of the University of Pennsylvania, from Orexigen, Novo Nordisk, Nutrisystem, and Weight Watchers. Dr. Jakicic is a member of Weight Watchers International Scientific Advisory Board and has served as the Principal Investigator on a research grant received from Jawbone that was awarded to the University of Pittsburgh. Dr. Foster is the Chief Scientific Officer for Weight Watchers International. The other authors have indicated no financial conflicts of interest. The work was performed at: Brown University, Providence, RI; St. Luke's-Roosevelt Hospital/Clinilabs, New York, NY; Temple University, Philadelphia, PA; University of Pennsylvania, Philadelphia, PA; and University of Pittsburgh, Pittsburgh, PA. NR 62 TC 1 Z9 1 U1 2 U2 9 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD FEB 1 PY 2016 VL 39 IS 2 BP 317 EP 325 DI 10.5665/sleep.5436 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DC0WH UT WOS:000368938100008 PM 26446118 ER PT J AU Ioannou, GN AF Ioannou, George N. TI The Role of Cholesterol in the Pathogenesis of NASH SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID FATTY LIVER-DISEASE; HEPATIC STELLATE CELLS; LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM STRESS; NONALCOHOLIC STEATOHEPATITIS; LIPID DROPLETS; INSULIN-RESISTANCE; OXIDIZED LDL; HEPATOCELLULAR-CARCINOMA; CARDIOVASCULAR-DISEASE AB Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC). While the underlying molecular mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic molecule critical in the development of experimental and human NASH. In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.; Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.; Ioannou, GN (reprint author), Univ Washington, Seattle, WA 98195 USA. EM georgei@medicine.washington.edu NR 99 TC 11 Z9 12 U1 4 U2 12 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD FEB PY 2016 VL 27 IS 2 BP 84 EP 95 DI 10.1016/j.tem.2015.11.008 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DC1DE UT WOS:000368956200003 PM 26703097 ER PT J AU Kearney, DJ Simpson, TL Malte, CA Felleman, B Martinez, ME Hunt, SC AF Kearney, David J. Simpson, Tracy L. Malte, Carol A. Felleman, Benjamin Martinez, Michelle E. Hunt, Stephen C. TI Mindfulness-based Stress Reduction in Addition to Usual Care Is Associated with Improvements in Pain, Fatigue, and Cognitive Failures Among Veterans with Gulf War Illness SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Complementary and alternative medicine; Gulf War illness; Mindfulness; Veterans ID QUALITY-OF-LIFE; HEALTH-STATUS; THEORETICAL CONSIDERATIONS; ALTERNATIVE MEDICINE; PHYSICAL SYMPTOMS; FOLLOW-UP; THERAPY; QUESTIONNAIRE; DEPRESSION; DISORDER AB BACKGROUND: Many Gulf War I veterans report ongoing negative health consequences. The constellation of pain, fatigue, and concentration/memory disturbances is referred to as "Gulf War illness." Prior research suggests that mindfulness-based stress reduction may be beneficial for these symptoms, but mindfulness-based stress reduction has not been studied for veterans with Gulf War illness. The objective of this trial was to conduct a pilot study of mindfulness-based stress reduction for veterans with Gulf War illness. METHODS: Veterans (N = 55) with Gulf War illness were randomly assigned to treatment as usual plus mindfulness-based stress reduction or treatment as usual only. Mindfulness-based stress reduction was delivered in 8 weekly 2.5-hour sessions plus a single 7-hour weekend session. Pain, fatigue, and cognitive failures were the primary outcomes, assessed at baseline, after mindfulness-based stress reduction, and 6 months follow-up. Secondary outcomes included symptoms of posttraumatic stress disorder and depression. RESULTS: In intention-to-treat analyses, at 6-month follow-up, veterans randomized to mindfulness-based stress reduction plus treatment as usual reported greater reductions in pain (f = 0.33; P = .049), fatigue (f = 0.32; P = .027), and cognitive failures (f = 0.40; P < .001). Depressive symptoms showed a greater decline after mindfulness-based stress reduction (f = 0.22; P = .050) and at 6 months (f = 0.27; P = .031) relative to treatment as usual only. Veterans with posttraumatic stress disorder at baseline randomized to mindfulness-based stress reduction plus treatment as usual experienced significantly greater reductions in symptoms of posttraumatic stress disorder after mindfulness-based stress reduction (f = 0.44; P = .005) but not at 6 months follow-up (f = 0.31; P = .082). CONCLUSIONS: Mindfulness-based stress reduction in addition to treatment as usual is associated with significant improvements in self-reported symptoms of Gulf War illness, including pain, fatigue, cognitive failures, and depression. Published by Elsevier Inc. C1 [Kearney, David J.; Hunt, Stephen C.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Kearney, David J.; Hunt, Stephen C.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Simpson, Tracy L.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ C, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Felleman, Benjamin; Martinez, Michelle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov FU VA Office of Research and Development [5I01CX000313-02] FX This trial was funded by a grant from the VA Office of Research and Development (5I01CX000313-02). NR 70 TC 3 Z9 3 U1 6 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD FEB PY 2016 VL 129 IS 2 BP 204 EP 214 DI 10.1016/j.amjmed.2015.09.015 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DB2MG UT WOS:000368342300039 PM 26519614 ER PT J AU Matioc, AA AF Matioc, Adrian A. TI An Anesthesiologist's Perspective on the History of Basic Airway Management The "Preanesthetic" Era-1700 to 1846 SO ANESTHESIOLOGY LA English DT Article ID RESUSCITATION AB Basic airway management modern history starts in the early 18th century in the context of resuscitation of the apparently dead. History saw the rise and fall of the mouth-to-mouth and then of the instrumental positive-pressure ventilation generated by bellows. Pulmonary ventilation had a secondary role to external and internal organ stimulation in resuscitation of the apparently dead. Airway access for the extraglottic technique was to the victim's nose. The bellows-to-nose technique was the basic airway management technique applicable by both medical and nonmedical personnel. Although the techniques had been described at the time, very few physicians practiced glottic (intubation) and subglottic (tracheotomy) techniques. Before the anesthetic era, positive-pressure ventilation was discredited and replaced by manual negative-pressure techniques. In the middle of the 19th century, physicians who would soon administer anesthetic gases were unfamiliar with the positive-pressure ventilation concept. C1 [Matioc, Adrian A.] Univ Wisconsin, Dept Anesthesiol, Sch Med & Publ Hlth, Madison, WI USA. [Matioc, Adrian A.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA. RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA. EM aamatioc@wisc.edu FU Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois FX Support was provided by departmental sources and by a 2013 Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois, awarded in the author name for this topic. NR 61 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2016 VL 124 IS 2 BP 301 EP 311 DI 10.1097/ALN.0000000000000955 PG 11 WC Anesthesiology SC Anesthesiology GA DB5FP UT WOS:000368540300008 PM 26580835 ER PT J AU Lee, SM Takemoto, S Wallace, AW AF Lee, Susan M. Takemoto, Steven Wallace, Arthur W. TI Early Postoperative Withholding Angiotensin Receptor Blockers and 30-day Mortality after Noncardiac Surgery Reply SO ANESTHESIOLOGY LA English DT Letter ID SYSTEMS C1 [Lee, Susan M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Lee, SM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. EM susan.lee5@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2016 VL 124 IS 2 BP 513 EP 514 DI 10.1097/ALN.0000000000000965 PG 2 WC Anesthesiology SC Anesthesiology GA DB5FP UT WOS:000368540300032 PM 26785436 ER PT J AU Lee, CH Verma, P Lee, J Klaustermeyer, WB AF Lee, Christina H. Verma, Prashant Lee, Joyce Klaustermeyer, William B. TI Cost analysis of asthma maintenance medications in a veteran population SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Lee, Christina H.; Verma, Prashant; Lee, Joyce; Klaustermeyer, William B.] Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Klaustermeyer, WB (reprint author), Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM william.klaustermeyer@va.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD FEB PY 2016 VL 116 IS 2 BP 165 EP 166 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA DB5SD UT WOS:000368573000016 PM 26702545 ER PT J AU Taylor, BE McClave, SA Martindale, RG Warren, MM Johnson, DR Braunschweig, C McCarthy, MS Davanos, E Rice, TW Cresci, GA Gervasio, JM Sacks, GS Roberts, PR Compher, C AF Taylor, Beth E. McClave, Stephen A. Martindale, Robert G. Warren, Malissa M. Johnson, Debbie R. Braunschweig, Carol McCarthy, Mary S. Davanos, Evangelia Rice, Todd W. Cresci, Gail A. Gervasio, Jane M. Sacks, Gordon S. Roberts, Pamela R. Compher, Charlene CA Soc Critical Care Med Amer Soc Parenteral Enteral Nutr TI Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) SO CRITICAL CARE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY; PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC BRAIN-INJURY C1 [Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA. [Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA. [Johnson, Debbie R.] UW Hlth Univ, Wisconsin Hosp & Clin, Wound Skin Ost, Madison, WI USA. [Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA. [McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA. [Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA. [Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37212 USA. [Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA. [Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Pharm Practice, Indianapolis, IN 46208 USA. [Sacks, Gordon S.] Auburn Univ, Dept Pharm Practice, Harrison Sch Pharm, Auburn, AL 36849 USA. [Roberts, Pamela R.] Univ Oklahoma, Hlth Sci Ctr, Dept Anesthesiol, Oklahoma City, OK 73190 USA. [Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. RP Taylor, BE (reprint author), Barnes Jewish Hosp, St Louis, MO 63110 USA. EM bet1217@bjc.org FU Metagenics; Kabi USA, LLC; A.S.P.E.N. Rhoads Research Foundation - Board of Advisors; Fresenius Kabi USA, LLC; March of Dimes Foundation FX Dr. Taylor disclosed serving as an A.S.P.E.N. committee member and DNS past chair. Dr. McClave disclosed other relationships with Nestle (consulting), Abbott (Speaker), Metagenics (consulting), Covidien (consultant), and A.S.P.E.N. Dr. Martindale disclosed other relationships with Davol, LifeCell, and Metagenics (consultant) and received funding from Metagenics (research grant recipient). Dr. Warren disclosed serving as Co-chair for the Veterans Health Administration Dietary Supplement Committee and as a Chair for the Dietitians in Nutrition Support webinar planning committee. Dr. Braunschweig disclosed serving as the A.S.P.E.N. editor for clinical guidelines. Dr. McCarthy disclosed serving as an A.S.P.E.N. Committee Member for Research Committee and Abstract Review Committee, A.S.P.E.N. Nursing Section Member, and SCCM Nursing Section Member. Dr. Davanos disclosed other relationships with Baxter Healthcare (Medical Science Liaison and employee) and NY/LISPEN chapter (President Elect). Dr. Cresci disclosed other relatiosnhips with Metagenics, Advocare, and Covidien. She received funding from Metagenics (research grant, speaker) and served as a research committee member for A.S.P.E.N. and DNS (Chair - symposium planning committee). Dr. Rice disclosed other relationships with Avisa, LLC (Consultant) and GSK (DSMB). Dr. Roberts disclosed other relationships as ASA Committee Member (critical care) and as an A.S.P.E.N. Committee member (abstract reviews). Dr. Gervasio disclosed serving as an A.S.P.E.N. committee member. Dr. Sacks disclosed other relationships with Kabi USA, LLC (research grant recipient) and A.S.P.E.N. (President and member of Board of Directors, A.S.P.E.N. Rhoads Research Foundation - Board of Advisors); received funding (Research grant recipient, related to parenteral nutrition); and received funding from Fresenius Kabi USA, LLC (research grant recipient). Dr. Rice served as expert witness. Dr. Compher received funding from the March of Dimes Foundation (Research grant recipient) and disclosed other relationships with A.S.P.E.N. (Board of directors and President elect). Dr. Johnson disclosed that she does not have any potential conflicts of interest. NR 484 TC 23 Z9 30 U1 14 U2 37 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2016 VL 44 IS 2 BP 390 EP 438 DI 10.1097/CCM.0000000000001525 PG 49 WC Critical Care Medicine SC General & Internal Medicine GA DB4SO UT WOS:000368503700020 PM 26771786 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E. Leverich, Gabriele S. Nolen, Willem A. TI More illness in offspring of bipolar patients from the US compared to Europe SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Review DE Depression; Substance abuse; Anxiety disorder; Family history; Suicide attempt ID UNITED-STATES; EARLY-ONSET; N-ACETYLCYSTEINE; EARLY AGE; DISORDER; RISK; TRIAL; ADOLESCENTS; GENERATIONS; STRATEGIES AB Background: Evidence suggests that patients with bipolar disorder from the United States have an earlier age of onset and a more difficult course of illness than those from Germany and the Netherlands. These characteristics were related to a greater family burden of psychiatric illness and the experience of more psychosocial adversity in childhood. We hypothesized that this greater illness burden would extend to the offspring of the US patients. Methods: 968 outpatients (average age 41) with bipolar illness gave informed consent for participation in a treatment outcome network and filled out a detailed questionnaire about their illness and family history of illness, including whether their offspring had a diagnosis of depression, bipolar disorder, alcohol or substance abuse, suicide attempt or "other" illness. Of those with children, 356 were from the US and 132 were from Europe. Results: Compared to the Europeans, offspring of patients from the US had significantly (p < 0.001) more depression, bipolar disorder, drug abuse, and "other" illnesses. The number of illnesses in the offspring was related to the bipolar parent being from the US, having had childhood adversity, more than 20 prior episodes, and more parental psychiatric illness. Conclusions: While the findings are limited by their basis on self report, the distribution of the percentages in the US offspring are similar to those of Axelson et al. (2015) who used direct interviews. The higher burden of illness in the offspring and their in direct progenitors from the US compared to Europe warrant new attempts at better treatment and prevention. (c) 2016 The Authors. Published by Elsevier B.V. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Altshuler, Lori L.] UCLA Mood Disorders Res Program, Mood Disorders Res, Los Angeles, CA USA. RP Post, RM (reprint author), Bipolar Collaborat Network, Bethesda, MD 20814 USA. EM Robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 NR 44 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2016 VL 191 BP 180 EP 186 DI 10.1016/j.jad.2015.11.038 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DB1FL UT WOS:000368253400025 PM 26655863 ER PT J AU Halbert, CH Melvin, C Briggs, V Delmoor, E Rice, LJ Lynch, C Jefferson, M Johnson, JC AF Halbert, Chanita Hughes Melvin, Cathy Briggs, Vanessa Delmoor, Ernestine Rice, LaShanta J. Lynch, Cheryl Jefferson, Melanie Johnson, Jerry C. TI Neighborhood Satisfaction and Colorectal Cancer Screening in a Community Sample of African Americans SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Neighborhood satisfaction; Social determinants; Colorectal cancer screening; African Americans ID HEALTH; COLONOSCOPY; VALIDATION; VEGETABLES; KNOWLEDGE; COLLEGE; ACCESS; FRUITS; WOMEN AB Social determinants are important to cancer screening among African Americans. To evaluate the association between social determinants (e.g., psychological characteristics, perceived social environment, cultural beliefs such as present temporal orientation) and colorectal cancer (CRC) screening among African Americans. African American adults (n = 262) ages 50-75 completed a telephone interview. Multivariate logistic regression analysis was used to identify factors having significant independent associations with CRC screening. Only 57 % of respondents reported having CRC screening. The likelihood of screening increased with greater neighborhood satisfaction (OR = 1.38, 95 % CI = 1.01, 1.90, p = 0.04), older age (OR = 1.75, 95 % CI = 1.24, 2.48, p = 0.002), greater self-efficacy (OR = 2.73, 95 % CI = 1.40, 5.35, p = 0.003), and health care provider communication (OR = 10.78, 95 % CI = 4.85, 29.94, p = 0.0001). Community resources are important precursors to CRC screening and outcomes among African Americans. In addition to addressing psychological factors and patient-provider communication, efforts to ensure the availability of quality health care facilities that provide CRC screening in the neighborhoods where African Americans live are needed. C1 [Halbert, Chanita Hughes; Rice, LaShanta J.; Jefferson, Melanie] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Halbert, Chanita Hughes] Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Melvin, Cathy] Med Univ S Carolina, Hollings Canc Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Melvin, Cathy] Med Univ S Carolina, Dept Publ Hlth Sci, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Briggs, Vanessa] Public Hlth Management Corp, Hlth Promot Serv, 260 South Broad St, Philadelphia, PA 19102 USA. [Delmoor, Ernestine] Natl Black Leadership Initiat Canc, Philadelphia Chapter, 1415 N Broad St,Suite 221B, Philadelphia, PA 19122 USA. [Lynch, Cheryl] Med Univ S Carolina, Div Gen Internal Med, Dept Med, 135 Rutledge Ave, Charleston, SC 29425 USA. [Lynch, Cheryl] Ralph H Johnson Vet Adm Med Ctr, 135 Rutledge Ave, Charleston, SC 29425 USA. [Johnson, Jerry C.] Univ Penn, Dept Med, Div Geriatr, 3615 Chestnut St, Philadelphia, PA 19104 USA. RP Halbert, CH (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA.; Halbert, CH (reprint author), Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. EM hughesha@musc.edu FU National Cancer Institute [R01CA100254]; National Institute on Minority Health and Health Disparities Grant [R24MD001594] FX This research was supported by National Cancer Institute Grant No. R01CA100254 and National Institute on Minority Health and Health Disparities Grant No. R24MD001594. We would like to Benita Weathers, MPH for project management, Aliya Collier, BA for data management, Stacey Brown, MSW for data collection and administration, and Brenda Bryant, BA for community outreach and relations. We are very appreciative to all of the women and men who participated in this research. NR 35 TC 2 Z9 2 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD FEB PY 2016 VL 41 IS 1 BP 38 EP 45 DI 10.1007/s10900-015-0062-9 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DB6PY UT WOS:000368638400006 PM 26184107 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of cardiovascular literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 8 EP 10 DI 10.1007/s12350-015-0343-9 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300004 PM 26626784 ER PT J AU Iskandrian, AE Roth, CP Hage, FG AF Iskandrian, Ami E. Roth, Christopher P. Hage, Fadi G. TI Serial imaging and outcome prediction SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR PERFUSION; MYOCARDIAL-PERFUSION; QUANTITATIVE-ANALYSIS; ASYMPTOMATIC PATIENTS; TRIAL; ISCHEMIA; ADENOSINE; NUCLEAR; SPECT C1 [Iskandrian, Ami E.; Roth, Christopher P.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA. EM aiskand@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 21 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 117 EP 121 DI 10.1007/s12350-015-0312-3 PG 5 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300019 PM 26514576 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of cardiovascular imaging in the journal of nuclear cardiology in 2015. Part 1 of 2: Plaque imaging, positron emission tomography, computed tomography, and magnetic resonance SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review DE Vulnerable atherosclerotic plaque; myocardial perfusion imaging: PET; fluorodeoxyglucose (FDG); computed tomography (CT); magnetic resonance imaging ID CORONARY-ARTERY-DISEASE; SCREENING ASYMPTOMATIC PATIENTS; MYOCARDIAL-ISCHEMIA; CARDIAC AMYLOIDOSIS; HIV-INFECTION; MR-IMPACT; PET; ATHEROSCLEROSIS; INFLAMMATION; TRIAL AB In 2015, many original articles pertaining to cardiovascular imaging with impressive quality were published in the Journal of Nuclear Cardiology. In a set of 2 articles, we provide an overview of these contributions to facilitate for the interested reader a quick review of the advancements that occurred in the field over this year. In this first article, we focus on arterial plaque imaging, cardiac positron emission tomography, computed tomography, and magnetic resonance imaging. C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Cardiovasc Imaging, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 43 TC 1 Z9 1 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 122 EP 130 DI 10.1007/s12350-015-0319-9 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300020 PM 26542991 ER PT J AU Steverson, D Tian, L Fu, YC Zhang, W Ma, E Garvey, WT AF Steverson, Dennis, Jr. Tian, Ling Fu, Yuchang Zhang, Wei Ma, Elizabeth Garvey, William Timothy TI Tribbles Homolog 3 Promotes Foam Cell Formation Associated with Decreased Proinflammatory Cytokine Production in Macrophages: Evidence for Reciprocal Regulation of Cholesterol Uptake and Inflammation SO METABOLIC SYNDROME AND RELATED DISORDERS LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; CARDIOVASCULAR-DISEASE; NLRP3 INFLAMMASOMES; INSULIN-RESISTANCE; METABOLIC SYNDROME; DEFICIENT MICE; ATHEROSCLEROSIS; PLAQUES; TRB3 AB Background: Insulin resistance is central in the pathophysiology of cardiometabolic disease; however, common mechanisms that explain the parallel development of both type 2 diabetes and atherosclerosis have not been elucidated. We have previously shown that tribbles homolog 3 (TRB3) can exert a chronic pathophysiological role in promoting insulin resistance and also has an acute physiological role to alternatively regulate glucose uptake in fat and muscle during short-term fasting and nutrient excess. Since TRB3 is expressed in human atherosclerotic plaques, we explored its role in foam cell formation to assess its potential contribution to atherogenesis. Methods: We have used human THP-1 monocytes, which transition to lipid-laden macrophage foam cells when exposed to oxidized low-density lipoprotein (ox-LDL). Results: We first observed that TRB3 was upregulated by more than twofold (P<0.01) within 24hr of treatment with ox-LDL. To determine whether TRB3 actively participated in foam cell formation, we overexpressed TRB3 in THP-1 monocytes and found that this led to a 1.5-fold increase in cholesterol accumulation after 48hr (P<0.01), compared with controls. At the same time, TRB3 overexpression suppressed inflammation in macrophages as evidenced by reduced expression and secretion of tumor necrosis factor alpha (TNF-) and interleukin-1 beta (IL-1) (both P<0.01). Conclusions: (1) TRB3 is upregulated in macrophages upon treatment with ox-LDL; (2) TRB3 promotes lipid accumulation and suppresses cytokine expression; and (3) inflammation and foam cell formation can be reciprocally regulated, and TRB3 orients the macrophage to assume a more primary role for lipid accumulation while maintaining a secondary role as an inflammatory immune cell. C1 [Steverson, Dennis, Jr.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Steverson, Dennis, Jr.; Tian, Ling; Fu, Yuchang; Zhang, Wei; Ma, Elizabeth; Garvey, William Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, William Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Steverson, D (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM dsteversonjr@gmail.com FU National Institutes of Health [DK-038765, DK-083562]; Merit Review program of the Department of Veterans Affairs FX This work was supported by grants from the National Institutes of Health (DK-038765, DK-083562) and by the Merit Review program of the Department of Veterans Affairs. The authors also acknowledge support from core facilities of the UAB Diabetes Research Center (P30 DK079626). NR 39 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-4196 EI 1557-8518 J9 METAB SYNDR RELAT D JI Metab. Syndr. Relat. Disord. PD FEB 1 PY 2016 VL 14 IS 1 BP 7 EP 15 DI 10.1089/met.2015.0037 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DB4XT UT WOS:000368517600003 PM 26584255 ER PT J AU McGrath, JM Fisher, V Krejci-Manwaring, J AF McGrath, John M. Fisher, Valerie Krejci-Manwaring, Jennifer TI Skin Cancer Warnings and the Need for New Preventive Campaigns A Pilot Study SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID PREVALENCE C1 [McGrath, John M.] Trinity Univ, Dept Human Commun, San Antonio, TX 78212 USA. [McGrath, John M.; Krejci-Manwaring, Jennifer] Audie L Murphy Vet Hosp, San Antonio, TX USA. [Fisher, Valerie; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. RP McGrath, JM (reprint author), Trinity Univ, Dept Human Commun, One Trinity Pl, San Antonio, TX 78212 USA. EM jmcgrath@trinity.edu NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2016 VL 50 IS 2 BP E62 EP E63 DI 10.1016/j.amepre.2015.10.009 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DB1DG UT WOS:000368247600004 PM 26657182 ER PT J AU Banks, WA Dohi, K Hansen, K Thompson, HJ AF Banks, William A. Dohi, Kenji Hansen, Kim Thompson, Hilaire J. TI Assessing blood granulocyte colony-stimulating factor as a potential biomarker of acute traumatic brain injury in mice and humans SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE G-CSF; Traumatic brain injury; Biomarker; Neuroinflammation; Blood brain barrier ID INTRACEREBROVENTRICULAR INJECTION; SEVERITY SCORE; RATS; INTERLEUKIN-1-BETA; CYTOKINES; BARRIER; IMMUNE; MODEL; CARE AB Previous work has found that serum G-CSF was acutely elevated in mice 24 h but not one week after controlled cortical impact (CCI). The purpose of this study was to investigate whether blood G-CSF correlates with the elevated brain cytokines in mice after CCI and also if it correlates with traumatic brain injury (TBI) in humans. Here, we found in mice undergoing CCI, a procedure that induces direct injury to the brain, that serum G-CSF correlated directly or indirectly with several brain cytokines, indicating it is a useful marker for the neuroinflammation of TBI. A pilot study in humans (phase I, n = 19) confirmed that plasma G-CSF is acutely elevated on day I (p < 0.001) of TBI and has returned to baseline by one week. In a second human sample (phase II) (n = 80), we found plasma G-CSF peaks about 12 h after arriving in the emergency department (41.6 +/ 5.4 pg/ml). Aging was weakly associated (p < 0.05) with a less robust elevation in serum G-CSF, but there was no difference with gender. ISS, a measure of total severity of injury, correlated with the degree of elevation in serum G-CSF (r = .419; p < 0.05), but severity of head injury (via AIS) did not. The latter may have been because of the statistically narrow range of head injuries among our cases and the high number of cases diagnosed with closed head injury (a non-codable diagnosis). In conclusion, plasma G-CSF may be a useful biomarker of TBI, correlating with neuroinflammation in the animal model and in the human studies with time since injury and total severity of injury. As such, it may be useful in determining whether TBI has occurred within the last 24 h. Published by Elsevier Inc. C1 [Banks, William A.; Dohi, Kenji; Hansen, Kim; Thompson, Hilaire J.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.; Dohi, Kenji; Hansen, Kim] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. [Dohi, Kenji] Jikei Univ, Sch Med, Dept Emergency Med, Tokyo, Japan. [Thompson, Hilaire J.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Thompson, Hilaire J.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. RP Banks, WA (reprint author), VAPSHCS, Rm 1-810A,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu; kdoppy@jikei.ac.jp; nesnah@u.washington.edu; hilairet@uw.edu FU National Institutes of Health, National Center for Research Resources [KL2RR025015]; National Institute of Neurologic Diseases and Stroke [R01NS077913]; Department of Veterans Affairs; National Institute on Aging [R01AG029839, R01AG046619] FX Supported by grants from the National Institutes of Health, National Center for Research Resources KL2RR025015 (HT), the National Institute of Neurologic Diseases and Stroke R01NS077913 (HT), the Department of Veterans Affairs (WAB), and the National Institute on Aging R01AG029839 (WAB) and R01AG046619 (WAB). NR 30 TC 1 Z9 1 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD FEB PY 2016 VL 52 BP 81 EP 87 DI 10.1016/j.bbi.2015.10.002 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DB2DB UT WOS:000368317400011 PM 26441136 ER PT J AU Seltman, HJ Mitchell, S Sweet, RA AF Seltman, Howard J. Mitchell, Shaina Sweet, Robert A. TI A Bayesian model of psychosis symptom trajectory in Alzheimer's disease SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer's disease; cognitive impairment; neuropsychiatric symptoms ID LAST 2 DECADES; CARDIOVASCULAR HEALTH; COGNITIVE IMPAIRMENT; DIAGNOSIS AB ObjectivePsychosis, like other neuropsychiatric symptoms of dementia, has many features that make predictive modeling of its onset difficult. For example, psychosis onset is associated with both the absolute degree of cognitive impairment and the rate of cognitive decline. Moreover, psychotic symptoms, while more likely than not to persist over time within individuals, may remit and recur. To facilitate predictive modeling of psychosis for personalized clinical decision making, including evaluating the role of risk genes in its onset, we have developed a novel Bayesian model of the dual trajectories of cognition and psychosis symptoms. MethodsCognition was modeled as a four-parameter logistic curve with random effects for all four parameters and possible covariates for the rate and time of fall. Psychosis was modeled as a continuous-time hidden Markov model with a latent never-psychotic class and states for pre-psychotic, actively psychotic and remitted psychosis. Covariates can affect the probability of being in the never-psychotic class. Covariates and the level of cognition can affect the transition rates for the hidden Markov model. ResultsThe model characteristics were confirmed using simulated data. Results from 434 AD patients show that a decline in cognition is associated with an increased rate of transition to the psychotic state. ConclusionsThe model allows declining cognition as an input for psychosis prediction, while incorporating the full uncertainty of the interpolated cognition values. The techniques used can be used in future genetic studies of AD and are generalizable to the study of other neuropsychiatric symptoms in dementia. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Seltman, Howard J.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Mitchell, Shaina] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. RP Seltman, HJ (reprint author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. EM hseltman@stat.cmu.edu FU National Institutes of Health [AG 027224] FX This work was supported in part by the National Institutes of Health grant AG 027224. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 19 TC 1 Z9 1 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD FEB PY 2016 VL 31 IS 2 BP 204 EP 210 DI 10.1002/gps.4326 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DA8BU UT WOS:000368030100013 PM 26216660 ER PT J AU McClave, SA Taylor, BE Martindale, RG Warren, MM Johnson, DR Braunschweig, C McCarthy, MS Davanos, E Rice, TW Cresci, GA Gervasio, JM Sacks, GS Roberts, PR Compher, C AF McClave, Stephen A. Taylor, Beth E. Martindale, Robert G. Warren, Malissa M. Johnson, Debbie R. Braunschweig, Carol McCarthy, Mary S. Davanos, Evangelia Rice, Todd W. Cresci, Gail A. Gervasio, Jane M. Sacks, Gordon S. Roberts, Pamela R. Compher, Charlene CA Soc Critical Care Med Amer Soc Parenteral Enteral Nutr TI Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE nutrition; critical care; intensive care unit; enteral; parenteral; evidence-based medicine; Grading of Recommendations, Assessment, Development, and Evaluation criteria; guidelines ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY; PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC BRAIN-INJURY C1 [McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA. [Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA. [Johnson, Debbie R.] Univ Wisconsin Hosp & Clin, UW Hlth, Wound Skin Ost, Madison, WI 53792 USA. [Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA. [McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA. [Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA. [Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37235 USA. [Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA. [Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Indianapolis, IN 46208 USA. [Sacks, Gordon S.] Auburn Univ, Harrison Sch Pharm, Dept Pharm Practice, Auburn, AL 36849 USA. [Roberts, Pamela R.] Res John A Moffitt Endowed Chair, Dept Anesthesiol, Div Chief Crit Care Med, Oklahoma City, OK USA. [Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. RP Compher, C (reprint author), Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. EM stephen.mcclave@louisville.edu; compherc@nursing.upenn.edu FU Metagenics; Fresenius Kabi USA, LLC; March of Dimes Foundation FX Dr Taylor disclosed serving as an A.S.P.E.N. committee member and Dietitians in Nutrition Support past chair. Dr McClave disclosed other relationships with Nestle (consulting), Abbott (speaker), Metagenics (consulting), Covidien (consultant), and A.S.P.E.N. Dr Martindale disclosed other relationships with Davol, LifeCell, and Metagenics (consultant) and received funding from Metagenics (research grant recipient). Dr Warren disclosed serving as cochair for the Veterans Health Administration Dietary Supplement Committee and as a chair for the Dietitians in Nutrition Support Webinar Planning Committee. Dr Johnson disclosed that she does not have any potential conflicts of interest. Dr Braunschweig disclosed serving as the A.S.P.E.N. editor for clinical guidelines. Dr McCarthy disclosed serving as an A.S.P.E.N. committee member for the Research Committee and the Abstract Review Committee, an A.S.P.E.N. Nursing Section member, and a SCCM Nursing Section member. Dr Davanos disclosed other relationships with Baxter Healthcare (medical science liaison and employee) and NY/LISPEN chapter (president-elect). Dr Rice disclosed other relationships with Avisa, LLC (consultant) and GSK (Data and Safety Monitoring Board) and served as an expert witness. Dr Cresci disclosed other relationships with Metagenics, Advocare, and Covidien; received funding from Metagenics (research grant, speaker); and served as a Research Committee member for A.S.P.E.N. and Dietitians in Nutrition Support (chair of the Symposium Planning Committee). Dr Gervasio disclosed serving as an A.S.P.E.N. committee member. Dr Sacks disclosed other relationships with Fresenius Kabi USA, LLC (research grant recipient) and A.S.P.E.N. (president and member of Board of Directors, A.S.P.E.N. Rhoads Research Foundation-Board of Advisors). Dr Roberts disclosed other relationships as an American Society of Anesthesiologists committee member (critical care) and as an A.S.P.E.N. committee member (abstract reviews). Dr Compher received funding from the March of Dimes Foundation (research grant recipient) and disclosed other relationships with A.S.P.E.N. (Board of Directors and president-elect). NR 481 TC 70 Z9 90 U1 12 U2 41 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2016 VL 40 IS 2 BP 159 EP 211 DI 10.1177/0148607115621863 PG 53 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DB1TS UT WOS:000368292500002 PM 26773077 ER PT J AU Newcomb, LF Thompson, IM Boyer, HD Brooks, JD Carroll, PR Cooperberg, MR Dash, A Ellis, WJ Fazli, L Feng, ZD Gleave, ME Kunju, P Lance, RS McKenney, JK Meng, MV Nicolas, MM Sanda, MG Simko, J So, A Tretiakova, MS Troyer, DA True, LD Vakar-Lopez, F Virgin, J Wagner, AA Wei, JT Zheng, YY Nelson, PS Lin, DW AF Newcomb, Lisa F. Thompson, Ian M., Jr. Boyer, Hilary D. Brooks, James D. Carroll, Peter R. Cooperberg, Matthew R. Dash, Atreya Ellis, William J. Fazli, Ladan Feng, Ziding Gleave, Martin E. Kunju, Priya Lance, Raymond S. McKenney, Jesse K. Meng, Maxwell V. Nicolas, Marlo M. Sanda, Martin G. Simko, Jeffry So, Alan Tretiakova, Maria S. Troyer, Dean A. True, Lawrence D. Vakar-Lopez, Funda Virgin, Jeff Wagner, Andrew A. Wei, John T. Zheng, Yingye Nelson, Peter S. Lin, Daniel W. CA Canary PASS Investigators TI Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; prospective studies; watchful waiting ID RADICAL PROSTATECTOMY; RISK-ASSESSMENT; DISEASE RECURRENCE; PREDICTION; ANTIGEN; TRENDS; VALIDATION; MANAGEMENT; PATHOLOGY; MEN AB Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance. Materials and Methods: We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance. Results: At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p = 0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p = 0.76). Conclusions: Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome. C1 [Newcomb, Lisa F.; Boyer, Hilary D.; Feng, Ziding; Zheng, Yingye; Nelson, Peter S.; Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Newcomb, Lisa F.; Ellis, William J.; Tretiakova, Maria S.; True, Lawrence D.; Vakar-Lopez, Funda; Lin, Daniel W.] Univ Washington, Seattle, WA 98195 USA. [Dash, Atreya; Virgin, Jeff; Lin, Daniel W.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Brooks, James D.] Stanford Univ, Stanford, CA 94305 USA. [Carroll, Peter R.; Cooperberg, Matthew R.; Meng, Maxwell V.; Simko, Jeffry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fazli, Ladan; Gleave, Martin E.; So, Alan] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Thompson, Ian M., Jr.; Nicolas, Marlo M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanda, Martin G.; Wagner, Andrew A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lance, Raymond S.; Troyer, Dean A.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [McKenney, Jesse K.] Cleveland Clin, Cleveland, OH 44106 USA. [Kunju, Priya; Wei, John T.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Lin, DW (reprint author), Univ Washington, Dept Urol, 1959 NE Pacific St,Box 356510, Seattle, WA 98195 USA. EM dlin@uw.edu FU Canary Foundation; National Cancer Institute at the National Institutes of Health Early Detection Research Network [U01 CA086402]; National Institutes of Health [P30 CA054174]; National Institutes of Health (Pacific Northwest Prostate Cancer SPORE) [P50 CA097186] FX Supported by the Canary Foundation; the National Cancer Institute at the National Institutes of Health Early Detection Research Network (Grant U01 CA086402); and the National Institutes of Health (Grant P30 CA054174, and the Pacific Northwest Prostate Cancer SPORE P50 CA097186). NR 27 TC 17 Z9 17 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD FEB PY 2016 VL 195 IS 2 BP 313 EP 320 DI 10.1016/j.juro.2015.08.087 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DA8KZ UT WOS:000368054800023 PM 26327354 ER PT J AU Hunsberger, JG Rao, M Kurtzberg, J Bulte, JWM Atala, A LaFerla, FM Greely, HT Sawa, A Gandy, S Schneider, LS Doraiswamy, PM AF Hunsberger, Joshua G. Rao, Mahendra Kurtzberg, Joanne Bulte, Jeff W. M. Atala, Anthony LaFerla, Frank M. Greely, Henry T. Sawa, Akira Gandy, Sam Schneider, Lon S. Doraiswamy, P. Murali TI Accelerating stem cell trials for Alzheimer's disease SO LANCET NEUROLOGY LA English DT Article ID UMBILICAL-CORD BLOOD; IPSC-DERIVED NEURONS; PARKINSONS-DISEASE; A-BETA; REGENERATIVE MEDICINE; PEDIATRIC-PATIENTS; INFORMED-CONSENT; DRUG-DEVELOPMENT; MOUSE MODELS; AMYLOID-BETA AB At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and off er only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease. C1 [Hunsberger, Joshua G.; Atala, Anthony] Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA. [Rao, Mahendra] New York Stem Cell Fdn, New York, NY USA. [Kurtzberg, Joanne] Duke Univ, Med Ctr, Robertson Clin & Translat Cell Therapy Program, Durham, NC USA. [Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. [Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA. [Sawa, Akira] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [LaFerla, Frank M.] Univ Calif Irvine, Inst Memory Impairment & Neurol Disorders, Irvine, CA USA. [Greely, Henry T.] Stanford Univ, Ctr Law & Biosci, Stanford, CA 94305 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Ctr Cognit Hlth, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Natl Football League Neurol Care, New York, NY 10029 USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Alzheimers Dis Res Ctr, Los Angeles, CA 90033 USA. [Doraiswamy, P. Murali] Duke Univ, Duke Inst Brain Sci, Durham, NC USA. [Doraiswamy, P. Murali] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. RP Hunsberger, JG (reprint author), Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA. FU Accelerated Medicines Partnership [U01 AG046170]; David Werber Family Trust; Cure Alzheimer's Fund; Veterans Affairs [I01RX000684]; US National Institutes of Health; National Multiple Sclerosis Society; ALS Association; Maryland Stem Cell Research Fund; Brain & Behavior Research Foundation; Stanley Foundation; RUSK Foundation; Maryland Stem Cell Research Funds FX We acknowledge the contributions of all faculty members and participants at our meeting for the valuable discussions. We are especially grateful for the support of Marjorie Bekaert Thomas, Trustee for the Karen L Wrenn Trust, whose vision led to this conference. The meeting on stem cells and Alzheimer's disease, and the writing of this Personal View, was funded by a gift from the Karen L Wrenn Trust to PMD through Duke University. The Trust had no input in the content of this Personal View. We also acknowledge support from Accelerated Medicines Partnership/U01 AG046170, the David Werber Family Trust, the Cure Alzheimer's Fund, and Veterans Affairs (grant I01RX000684) (all to SG). JWMB, PMD, and AS have been supported by grants from the US National Institutes of Health. JWMB is also supported by the National Multiple Sclerosis Society, the ALS Association, and the Maryland Stem Cell Research Fund. AS reports receiving grants from the Brain & Behavior Research Foundation (formerly the NARSAD), Stanley Foundation, RUSK Foundation, and Maryland Stem Cell Research Funds during the writing of the manuscript. Figure 1 is courtesy of Piotr Walczak and Miroslaw Janowski, Johns Hopkins University, Baltimore, MD, USA. NR 92 TC 3 Z9 4 U1 8 U2 55 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD FEB PY 2016 VL 15 IS 2 BP 219 EP 230 DI 10.1016/S1474-4422(15)00332-4 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DA9GC UT WOS:000368116000019 PM 26704439 ER PT J AU Sher, L AF Sher, Leo TI SSRIs have a smaller benefit in paediatric when compared to adult major depressive disorder SO EVIDENCE-BASED MENTAL HEALTH LA English DT Editorial Material ID BRAIN C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA.; Sher, L (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. EM Leo.Sher@mssm.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1362-0347 EI 1468-960X J9 EVID-BASED MENT HEAL JI Evid.-Based Ment. Health PD FEB PY 2016 VL 19 IS 1 BP 26 EP 26 DI 10.1136/eb-2015-102216 PG 1 WC Psychiatry SC Psychiatry GA ET1BF UT WOS:000400000200015 PM 26729796 ER PT J AU Gardner, RC Rabinovici, GD AF Gardner, Raquel C. Rabinovici, Gil D. TI Evaluating and treating neurobehavioral symptoms in professional American football players: Lessons from a case series Respond SO NEUROLOGY-CLINICAL PRACTICE LA English DT Letter C1 [Gardner, Raquel C.; Rabinovici, Gil D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gardner, Raquel C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU American Academy of Neurology; Alzheimer's Association; Department of Veterans Affairs; NIH/NIA; UCSF Pepper Center Research Career Development Core; GE Healthcare; Rockpointe; Tau Consortium; Medscape; Avid Radiopharmaceuticals/Eli Lilly; John Douglas French Alzheimer's Foundation; Hellman Family Foundation FX R.C. Gardner has received funding for travel from the American Academy of Neurology and the Alzheimer's Association and has received research support from the Department of Veterans Affairs, NIH/NIA, and UCSF Pepper Center Research Career Development Core. G.D. Rabinovici has received funding for travel and/or speaker honoraria from Alzheimer's Association, GE Healthcare, Rockpointe, Tau Consortium, and Medscape and receives research support from Avid Radiopharmaceuticals/Eli Lilly, NIH/NIA, Alzheimer's Association, John Douglas French Alzheimer's Foundation, Hellman Family Foundation, and Tau Consortium. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD FEB PY 2016 VL 6 IS 1 BP 7 EP 8 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EI6IT UT WOS:000392599600006 ER PT J AU Kraakevik, J AF Kraakevik, Jeff TI Crafting a positive professional digital profile to augment your practice SO NEUROLOGY-CLINICAL PRACTICE LA English DT Editorial Material AB A digital profile is the sum content about a person on the Internet. A digital profile can be composed of personal or professional information shared on public Web sites posted personally or by others. One of the most effective ways to build a positive professional digital profile is through social media. It is increasingly important to maintain a positive digital profile as others mine the Internet to find out about a professional prior to meeting him or her. As the digital environment continues to grow, it will become increasingly difficult to neglect a professional digital profile without potential negative consequences. There are many benefits to creating a digital presence and using the tools available to learn about neurology and interact with other professionals and patients in ways that were not possible in the past. The spread of social media to a large part of the population makes it unlikely to go away. C1 [Kraakevik, Jeff] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. EM kraakevik@ohsu.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD FEB PY 2016 VL 6 IS 1 BP 87 EP 93 DI 10.1212/CPJ.0000000000000211 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EI6IT UT WOS:000392599600024 ER PT J AU Albergotti, WG Byrd, JK Nance, M Choi, EC Koh, YW Kim, S Duvvuri, U AF Albergotti, William G. Byrd, James K. Nance, Melonie Choi, Eun Chang Koh, Yoon Woo Kim, Seungwon Duvvuri, Umamaheswar TI Robot-Assisted Neck Dissection Through a Modified Facelift Incision SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE head and neck squamous cell carcinoma; head and neck surgery; neck dissection; surgical outcomes; treatment of head and neck tumors ID SQUAMOUS-CELL-CARCINOMA; POSTOPERATIVE MORBIDITY; RETROAURICULAR APPROACH; ORAL-CAVITY; HEAD; SURGERY; CANCER; LYMPHEDEMA; PAROTIDECTOMY; EXPERIENCE AB Objectives: The aim of this study is to describe the feasibility as well as oncologic outcomes of robot-assisted neck dissection (RAND) through a modified facelift incision in an American population. Study Design: Retrospective case series. Setting: University tertiary care hospital. Methods: All patients who underwent RAND between November 2012 and December 2014 were included. Medical records were reviewed for demographics, medical histories, staging, operative information, postoperative hospital course and complications, and oncologic outcomes. Results: There were 11 RANDs identified among 10 patients. Five patients had known nodal metastasis at the time of surgery. Two patients had been previously irradiated. The average time of surgery was 284.4 72.3 minutes, including other associated procedures. The average lymph node yield was 28.5 +/- 9.3 nodes. There were no major complications. Average follow-up was 19.4 months. There was 1 supraclavicular recurrence in a previously irradiated patient. All patients are currently alive and without evidence of disease. Conclusions: Robot-assisted neck dissection is a safe and feasible procedure that can be performed by surgeons with familiarity with neck dissection and robot-assisted surgery and who have been trained in RAND. Appropriate oncologic outcomes can be obtained in a patient wishing to avoid a noticeable scar. C1 [Albergotti, William G.; Byrd, James K.; Nance, Melonie; Kim, Seungwon; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Nance, Melonie; Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Choi, Eun Chang; Koh, Yoon Woo] Yonsei Univ, Dept Otorhinolaryngol, Coll Med, Seoul, South Korea. RP Duvvuri, U (reprint author), Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Med Ctr, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM duvuriu@upmc.edu FU Intuitive Surgical, Inc.; Department of Veterans Affairs BLRD; PNC Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Byrd was funded by a clinical robotics training and research grant from Intuitive Surgical, Inc. This work was supported in part by a Career Development Award from the Department of Veterans Affairs BLR&D and the PNC Foundation (U.D). NR 29 TC 0 Z9 0 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD FEB PY 2016 VL 125 IS 2 BP 123 EP 129 DI 10.1177/0003489415601127 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DA5NM UT WOS:000367849800004 PM 26282589 ER PT J AU Browne, KC Wray, TB Stappenbeck, CA Krenek, M Simpson, TL AF Browne, Kendall C. Wray, Tyler B. Stappenbeck, Cynthia A. Krenek, Marketa Simpson, Tracy L. TI Alcohol Consumption, Craving, and Craving Control Efforts Assessed Daily in the Context of Readiness to Change Among Individuals with Alcohol Dependence and PTSD SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Alcohol; PTSD; Craving; Motivation to change ID POSTTRAUMATIC-STRESS-DISORDER; ECOLOGICAL MOMENTARY ASSESSMENT; COMPULSIVE DRINKING SCALE; SUBSTANCE USE; CUE-REACTIVITY; PREDICTOR; DRINKERS; VALIDITY; TRAUMA; MODEL AB Research has demonstrated the positive association between alcohol craving and alcohol use and has identified craving as a central component of alcohol use disorders (AUD). Despite potential clinical implications, few studies have examined the relationship between craving and alcohol use in individuals with AUD and common psychiatric comorbidities or explored possible moderators of the craving-alcohol use relationship. The current study used daily monitoring data to: 1) replicate previous findings detecting a positive relationship between craving and alcohol use in individuals with AUD and co-occurring posttraumatic stress disorder (PTSD) and 2) extend these findings by examining the influence of initial change motivation on the craving-use relationship and within-day associations among craving, efforts to control craving, and alcohol consumption. Participants were 84 individuals with alcohol dependence and PTSD enrolled in an intervention study. Generalized estimating equations using pre-treatment baseline daily data revealed significant main effects for craving, craving control, and motivation to change alcohol use. Daily craving was positively related to alcohol use. Greater change motivation and craving control (i.e., efforts to resist craving, avoidance of thoughts and feelings related to craving) were negatively related to alcohol use. A significant interaction was detected between baseline change motivation and daily craving indicating that the association between craving and alcohol use was significantly stronger for those with low baseline change motivation. A significant interaction was also detected between craving control and daily craving, suggesting that participants were more likely to consume alcohol when experiencing high levels of craving if they reported low levels of craving control. Findings bolster the idea that efforts to prevent or ameliorate craving are critical to treatment success for individuals with AUD and PTSD who are seeking to reduce or quit drinking. Published by Elsevier Inc. C1 [Browne, Kendall C.; Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Wray, Tyler B.; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Seattle, WA 98018 USA. [Browne, Kendall C.; Stappenbeck, Cynthia A.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98018 USA. RP Simpson, TL (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,CESATE-116, Seattle, WA 98018 USA. EM tracy.simpson@va.gov FU NIH/NIAAA [R21 AA17130-01, R01 AA020252-01] FX This material is the result of work supported by NIH/NIAAA awards (GRANT R21 AA17130-01; R01 AA020252-01) to Dr. Tracy Simpson and by resources from the Center of Excellence in Substance Abuse Treatment and Education (CESATE), the Mental Illness Research, Education, and Clinical Center (MIRECC), the US Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, and the VA Puget Sound Health Care System, Seattle, WA. The views expressed in this article are those of the authors and do not represent the views of the Department of Veteran Affairs or the United States government. Dr. Tyler Wray is now affiliated with the Department of Behavioral and Social Sciences, Brown University, School of Public Health, 121 South Main St., Providence RI 02912. NR 58 TC 1 Z9 1 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD FEB PY 2016 VL 61 BP 34 EP 41 DI 10.1016/j.jsat.2015.09.005 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DA4HP UT WOS:000367761200005 PM 26597623 ER PT J AU Serafini, K Shipley, L Stewart, DG AF Serafini, Kelly Shipley, Leandra Stewart, David G. TI Motivation and substance use outcomes among adolescents in a school-based intervention SO ADDICTIVE BEHAVIORS LA English DT Article DE Stages of change; Adolescence; Substance use; Alcohol; Marijuana; Motivation; Transtheoretical Model of Change ID ALCOHOL PROBLEM INDEX; ABUSE TREATMENT; TRANSTHEORETICAL MODEL; COLLEGE-STUDENTS; DRINKING; READINESS; CONSEQUENCES; SAMPLE; SCALE; STAGE AB The stages of change (Precontemplation, Contemplation, Preparation, Action, and Maintenance) have been well studied in adult populations. However, fewer studies have examined how the stages of change are related to adolescent substance use. Furthermore, there have been no studies that have examined how the stages of change relate to outcomes in a school-based intervention. To better capture adolescent motivation, we added an additional group to the Transtheoretical Model of Change, which we titled Coerced Action, to represent adolescents that made changes to their substance use despite low problem recognition (representing the internal motivation of Precontemplation and the change behaviors of the Action group). We then examined how the stages of change were related to a thorough assessment of substance use at baseline and corresponding treatment outcomes. Our sample consisted of 264 adolescents (mean age: 16.1,44.5% Caucasian, 37.5% female) who participated in an 8-week, school-based Motivational Enhancement intervention. Results indicated significant group differences across the stages of change in substance use patterns (alcohol use, negative consequences, affective dysregulation), as well as treatment outcomes (alcohol use and negative consequences). For instance, adolescents in the Action group demonstrated more negative consequences at 16 weeks follow-up than those in Precontemplation and Coerced Action, F(1, 3) = 8.23,p <.001. The Coerced Action group reported the most alcohol use at 16 weeks follow-up, although the finding was not significant when post-hoc tests were conducted. This study provides meaningful support for the assessment of motivation among adolescent substance users within school-based settings. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Serafini, Kelly] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. [Shipley, Leandra] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Stewart, David G.] Seattle Pacific Univ, Dept Clin Psychol, Seattle, WA 98119 USA. RP Serafini, K (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. EM kelly.serafini@yale.edu FU National Institute on Drug Abuse (NIDA) [T32DA007238-23, R03DA12974-01] FX This research was supported in part through a National Institute on Drug Abuse (NIDA) grantT32DA007238-23 (Petrakis) and R03DA12974-01 (Project READY; PI: Stewart). We wish to acknowledge Michael Toohey, Ph.D., who provided feedback on this project. We also wish to thank the participants, research staff, and colleagues who participated in the original clinical trial. NR 35 TC 5 Z9 5 U1 5 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2016 VL 53 BP 74 EP 79 DI 10.1016/j.addbeh.2015.10.004 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CZ7KR UT WOS:000367278800012 PM 26458191 ER PT J AU Hiraoka, R Cook, AJ Bivona, JM Meyer, EC Morissette, SB AF Hiraoka, Regina Cook, Andrew J. Bivona, Jenny M. Meyer, Eric C. Morissette, Sandra B. TI Acceptance and Commitment Therapy in the Treatment of Depression Related to Military Sexual Trauma in a Woman Veteran: A Case Study SO CLINICAL CASE STUDIES LA English DT Article DE acceptance and commitment therapy; military sexual trauma; depression; Veterans ID AFGHANISTAN; OUTCOMES; ANXIETY; IRAQ AB Depression is commonly reported by Veterans who have experienced military sexual trauma (MST). An increasing body of literature supports the use of Acceptance and Commitment Therapy (ACT) for the treatment of depression among civilians and military Veterans; however, additional research is needed, particularly among people exposed to trauma. This clinical case study describes the application of ACT with a 21-year-old woman Veteran who sought treatment for depression related to MST. The Veteran's depression symptoms decreased substantially over the course of therapy. Moreover, she demonstrated increased ability to attend to the present moment, tolerate feelings of uncertainty, and make decisions consistent with her chosen values. Treatment implications of these findings are discussed, with an emphasis on the unique aspects of using ACT in the treatment of MST-related depression among Veterans. C1 [Hiraoka, Regina; Cook, Andrew J.; Bivona, Jenny M.; Meyer, Eric C.; Morissette, Sandra B.] Cent Texas Vet Hlth Care Syst, Waco, TX 76711 USA. [Hiraoka, Regina; Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] US Dept Vet Affairs, Washington, DC USA. [Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. RP Hiraoka, R (reprint author), Cent Texas Vet Hlth Care Syst, 4800 Mem Dr, Waco, TX 76711 USA. EM regina.hiraoka@va.gov FU Veterans Health Administration FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Veterans Health Administration. NR 26 TC 0 Z9 0 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-6501 EI 1552-3802 J9 CLIN CASE STUD JI Clin. Case Stud. PD FEB PY 2016 VL 15 IS 1 BP 84 EP 97 DI 10.1177/1534650115594004 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DA0FJ UT WOS:000367472400006 ER PT J AU Szot, P Franklin, A Miguelez, C Wang, YQ Vidaurrazaga, I Ugedo, L Sikkema, C Wilkinson, CW Raskind, MA AF Szot, Patricia Franklin, Allyn Miguelez, Cristina Wang, Yangqing Vidaurrazaga, Igor Ugedo, Luisa Sikkema, Carl Wilkinson, Charles W. Raskind, Murray A. TI Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine SO NEUROPHARMACOLOGY LA English DT Article DE Locus coeruleus; 6-Hydroxydopamine; Forced swim test; Electrophysiology; Depression ID MILD COGNITIVE IMPAIRMENT; NORADRENERGIC NERVOUS-SYSTEM; DOPAMINE-BETA-HYDROXYLASE; WISTAR-KYOTO RATS; ALZHEIMERS-DISEASE; ANTIDEPRESSANT DRUGS; PARKINSONS-DISEASE; ANIMAL-MODEL; SENILE DEMENTIA; DEFICIENT MICE AB Depression is a common co-morbid condition most often observed in subjects with mild cognitive impairment (MCI) and during the early stages of Alzheimer's disease (AD). Dysfunction of the central noradrenergic nervous system is an important component in depression. In AD, locus coeruleus (LC) noradrenergic neurons are significantly reduced pathologically and the reduction of LC neurons is hypothesized to begin very early in the progression of the disorder; however, it is not known if dysfunction of the noradrenergic system due to early LC neuronal loss is involved in mediating depression in early AD. Therefore, the purpose of this study was to determine in an animal model if a loss of noradrenergic LC neurons results in depressive-like behavior. The LC noradrenergic neuronal population was reduced by the bilateral administration of the neurotoxin 6-hydroxydopamine (6-OHDA) directly into the LC. Forced swim test (FST) was performed three weeks after the administration of 6-OHDA (5, 10 and 14 mu g/mu l), animals administered the 5 mu g/mu l of 6-OHDA demonstrated a significant increase in immobility, indicating depressive-like behavior. This increase in immobility at the 5 mu g/mu l dose was observed with a minimal loss of LC noradrenergic neurons as compared to LC neuronal loss observed at 10 and 14 mu g/mu l dose. A significant positive correlation between the number of surviving LC neurons after 6-OHDA and FST immobile time was observed, suggesting that in animals with a minimal loss of LC neurons (or a greater number of surviving LC neurons) following 6-OHDA demonstrated depressive-like behavior. As the 6-OHDA-induced loss of LC neurons is increased, the time spent immobile is reduced. Depressive-like behavior was also observed with the 5 mu g/mu l dose of 6-OHDA with a second behavior test, sucrose consumption. FST increased immobility following 6-OHDA (5 mu g/mu l) was reversed by the administration of a single dose of L-1-3-4-dihydroxyphenylalanine (DOPA) or t-threo-3,4-dihydroxyphenylserine (DOPS) prior to behavioral assessment. Surviving LC neurons 3 weeks after 6-OHDA (5 mu g/mu l) demonstrated compensatory changes of increased firing frequency, a more irregular firing pattern, and a higher percentage of cells firing in bursts. These results indicate that depressive-like behavior in mice is observed following the administration of 6-OHDA and the loss of LC noradrenergic neurons; however, the depressive-like behavior correlates positively with the number of surviving LC neurons with 6-OHDA administration. This data suggests the depression observed in MCI subjects and in the early stages of AD may due to the hypothesized early, minimal loss of LC neurons with remaining LC neurons being more active than normal. Published by Elsevier Ltd. C1 [Szot, Patricia; Franklin, Allyn; Wang, Yangqing; Raskind, Murray A.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Mental Illness Res, Seattle, WA USA. [Szot, Patricia; Wilkinson, Charles W.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Miguelez, Cristina; Vidaurrazaga, Igor; Ugedo, Luisa] Univ Basque Country, UPV EHU, Dept Pharmacol, Leioa, Spain. [Sikkema, Carl; Wilkinson, Charles W.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA USA. [Miguelez, Cristina] Univ Basque Country, UPV EHU, Dept Pharmacol, Vitoria, Spain. RP Szot, P (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM szot@uw.edu RI Ugedo, Luisa/H-4244-2015 OI Ugedo, Luisa/0000-0001-5993-0606; Miguelez, Cristina/0000-0001-6624-2932 FU Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC); Geriatric Research, Education, and Clinical Center (GRECC); University of Washington Department of Psychiatry and Behavioral Science; Basque Government [UFI 11/32]; Spanish Government [FIS PI12/00613] FX This work was supported by Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC; Patricia Szot, Allyn Franklin, Murray A Raskind), Geriatric Research, Education, and Clinical Center (GRECC; Carl Sikkema, Charles Wilkinson), University of Washington Department of Psychiatry and Behavioral Science (Patricia Szsot, Murray A Raskind) and grants form the Basque Government (UFI 11/32) and the Spanish Government (FIS PI12/00613) (Cristiria Miguelez, Luisa Ugedo). These institutions had no further competing financial interest in relation to the work described. The authors declare no conflict of interest. NR 62 TC 1 Z9 1 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD FEB PY 2016 VL 101 BP 76 EP 86 DI 10.1016/j.neuropharm.2015.09.003 PG 11 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DA0JQ UT WOS:000367483800008 PM 26362360 ER PT J AU Demissei, BG Cleland, JG O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Davison, B Givertz, MM Bloomfield, DM Dittrich, H van Veldhuisen, DJ Hillege, HL Voors, AA Cotter, G AF Demissei, Biniyam G. Cleland, John G. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Davison, Beth Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard van Veldhuisen, Dirk J. Hillege, Hans L. Voors, Adriaan A. Cotter, Gad TI Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Acute heart failure; Procalcitonin; Bacterial infection; Prognosis ID C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; TERM PROGNOSIS; DIAGNOSIS; TRIAL; OUTCOMES; ADULTS; ROLOFYLLINE; ANTAGONIST; BACTEREMIA AB Background: Bacterial infections in patients hospitalized with acute heart failure are related to worse prognosis, but they can be difficult to diagnose. In this study we evaluated the prevalence, clinical correlates and association with outcomes of significantly elevated procalcitonin levels in patients hospitalized for acute heart failure without clear signs of bacterial infection. Methods: 1781 patients from the PROTECT trial were included. Patients with a body temperature >38 degrees C, sepsis or active infection requiring IV antibiotics were excluded. Significant elevation of procalcitonin was considered present when levels exceeded 0.20 ng/mL. In-hospital and post-discharge outcomes were compared between groups of patients with and without elevated procalcitonin levels. Results: Procalcitonin >= 0.20 ng/mL was seen in 6.0% of patients (N = 104). This group of patients had lower serum albumin, lower hemoglobin, higher leukocyte count, higher C-reactive protein, higher blood urea nitrogen, higher heart rate and more pulmonary rales. Interestingly, no significant differences were observed between the two groups in terms of severity of heart failure evidenced by left ventricular ejection fraction (LVEF) or B-type natriuretic peptide (BNP) levels. Patients with significantly elevated procalcitonin levels were more often classified as treatment failure or unchanged status, and had an increased risk of 30-day all-cause mortality even after adjustment for established prognosticators; HR = 2.3 (95% CI, 1.3-4.2), (P = 0.005). Conclusion: Patients with acute heart failure and significantly elevated procalcitonin levels, indicating probable undiagnosed/untreated bacterial infection, had poorer in-hospital and post-discharge outcomes, despite similar severity of heart failure. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Demissei, Biniyam G.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Demissei, Biniyam G.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, London, England. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Davison, Beth; Cotter, Gad] Momentum Res, Durham, NC USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Brigham & Womens Hosp, Boston, MA USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard] Univ Iowa, Carver Coll Med, Abboud Cardiovasc Res C